יומן הפטנטים והמדגמים

Transcription

"
6/2010
/'
ISRAEL STATE RECORDS
November 30 ,2010
"
"
PATENTS AND DESIGNS JOURNAL
Page/
Patents
Applications filed
Applications accepted
Patents granted
Patents renewed
Patents not in force
Patents renewed for 20 years
Changes in particulars entered in
register
Corrections
Country codes
Indices of applications accepted
1
4
67
295
295
295
297
311
312
348
339
335
Designs registeredDesigns registeredDesigns
renewedDesigns renewedDesigns
canceledDesigns canceleDesigns withdranDesigns
(
withdran
November 30, 2010- "
"
:
.
'
,
5
,
,
,
,
'
#
.0-24145-2
.
GENERAL INFORMATION
Letters, documents, etc. concerning Patents and Designs should be addressed to:
The Patent Authority, Jerusalem Technology Park, Building5, Malcha., Jerusalem.
Fees to the Patent Office can be accepted only by payment to the Postal Bank Account of the
Authority, No. 0-24145-2. The receipt of the Postal Bank must be presented to the office
together with the application for the action for which the fee has been paid.
Copyright by the State of Israel. No
Extracts may be published except with the
permission of the Patent Office.
2
#
#
#
$
,
.
"
PATENTS
NOTICE UNDER SECTION 16 OF THE
PATENTS LAW, 5727-1967
In the following there are listed new
applications complying with the provisions
of rule 32(a) of the Patent Regulations, 57281968:
Particulars of the applications are given in
the following order:
Number and date of application and the first
four symbols of the International
Classification.
Title of invention (as proposed by applicant)
Applicant
Priority right:
Convention countryNumber and date of
Foreign application
International Application Number
International Publication Number
3
-$"
,
16 %
1967
( )32
:1968- "
,
: $
–
(
"
#
–
)
#
:
/
"
04/03/2010
H01Q (2010.01)
204309
TRANSMIT/RECEIVE MODULE
COMMUNICATION AND CONTROL
ARCHITECTURE FOR ACTIVE
ARRAY
RAYTHEON COMPANY
US
12/381867
17/03/2009
04/03/2010
H01Q (2010.01)
204310
SWITCHABLE 0 DEGREE/180 DEGREE
PHASE SHIFTER ON FLEXIBLE
COPLANAR ON FLEXIBLE
COPLANAR STRIP TRANSMISSION
LINE
RAYTHEON COMPANY
US
12/405132
16/03/2009
04/03/2010
/
180 /
0
A47C (2010.01)
204311
LIGHT WEIGHT STOWABLE PHASED
APPAY LENS ANTENNA ASSEMBLY
RAYTHEON COMPANY
US
12/405135
16/03/2009
04/03/2010
INFRARED SENSOR COOLED BY
STIRLING COOLER
4
–
F25B (2010.01)
204316
#
–
"
SAGEM DEFENSE SECURITE
FR
0951437
06/03/2009
07/03/2010
G01S (2010.01)
204326
INS BASED GPS CARRIER PHASE
CYCLE SLIP DETECTION AND
REPAIRING
NORTHROP GRUMMAN GUIDANCE
AND ELECTRONICS COMPANY, INC.
US
12/454580
20/05/2009
09/03/2010
5
GPS–
A62B (2010.01)
( "
204439
VEHICLE PROVIDED WITH
REVOLVING TURRET
OTO MELARA S.P.A.
14/03/2010
$
204365
POWER ASSISTANT BLOWER FOR
GAS MASK
ILAN YOGEV
11/03/2010
$
INS
)$
–
$
F41G (2010.01)
#
204476
B65H (2010.01)
"
–
TWO-STAGE DIGITAL PROGRAM
INSERTION SYSTEM
RGB NETWORKS, INC.
US
12/384278
01/04/2009
14/03/2010
B28B (2010.01)
204485
A CLOSURE COOSURE DEVICE WITH
TELESCOPIC POURING UNIT
THE AFFILIATE IMAGE HOLDING OF
THE JSC IMAGE HOLDING APS
UA
200909809
25/09/2009
15/03/2010
H01L (2010.01)
204501
GENERATOR FOR A PIEZOELECTRIC
TRANSDUCER
TIP TOP TIPS SARL
EP
09155282.8 16/03/2009
09168871.3
27/08/2009
EP
16/03/2010
$
204519
$
A01K (2010.01)
WATERING SYSTEM AND METHOD
OF IMPLEMENTING IT
YITZHAK ZINGER
6
$
#
"
16/03/2010
204559
F21V (2010.01)
MODULAR LIGHT REFLECTORS AND
ASSEMBLIES FOR LUMINAIRE
LSI INDUSTRIES, INC.
US
12/615851
10/11/2009
16/03/2010
204560
$
B08B (2010.01)
TURBINE CLEANING SYSTEM
GAS TURBINE EFFICIENCY SWEDEN
AB
US
61/164582
30/03/2009
12/633354
08/12/2009
US
17/03/2010
204568
B26D (2010.01)
ADAPTIVE ENERGY ABSORPTION
SYSTEM FOR A VEHICLE SEAT
TECHNO-SCIENCES, INC.
US
61/210326
17/03/2009
21/03/2010
204619
F24J (2010.01)
HELIOSTAT FACET
SENER, INGENIERIA Y SISTEMAS,
S.A.
ES
200901011
17/04/2009
7
"
22/03/2010
SYSTEM AND METHOD FOR
TRANSFERRING DATA OVER A
VOICE CHANNEL OF A RADIO SET
ATTOSENSE LTD
22/03/2010
/
"
"
A61B (2010.01)
204664
EPICARDIAL MAPPING AND
ABLATION CATHETER
BIOSENSE WEBSTER, INC.
US
12/384992
13/04/2009
23/03/2010
G01S (2010.01)
204654
IMPROVED LANDING SYSTEM
ISRAEL AEROSPACE INDUSTRIES
LTD.
22/03/2010
H04B (2010.01)
204649
204678
#
#
A62C (2010.01)
FIRE SUPPRESSION SYSTEM
METHOD
KIDDE TECHNOLOGIES, INC.
US
61/210842
23/03/2009
8
"
23/03/2010
G06F (2010.01)
204681
SYSTEM AND METHOD FOR QUEUE
MANAGEMENT
Q.NOMY
US
12/413625
30/05/2009
23/03/2010
B01D (2010.01)
204684
DEVICE AND METHOD FOR
COLLECTING WASTE WATER FROM
TURBINE ENGINE WASHING
GAS TURBINE EFFICIENCY SWEDEN
AB
US
61/164524
30/03/2009
12/643462
21/12/2009
US
23/03/2010
H01R (2010.01)
204688
DEVICE FOR CHARACTERIZING THE
ELECTRO - OPTICAL PERFORMANCE
OF A SEMICONDUCTOR
COMPONENT
SOCIETE FRANCAISE DE
DETECTEURS INFRAROUGESSOFRADIR
FR
0952278
08/04/2009
23/03/2010
%
204691
–
#
#
H01P (2010.01)
TUNABLE BANDPASS FILTER
RAYTHEON COMPANY
US
12/469620
20/05/2009
9
"
25/03/2010
SCRIM -ENFORCED PIPE LINER
PERMA-LINER INDUSTRIES, INC.
US
61/164006
27/03/2009
12/642229
18/12/2009
US
25/03/2010
$
#
204802
#
H04R (2010.01)
204765
ELECTROACOUSTIC UNDERWATER
ANTENNA
ATLAS ELEKTRONIK GMBH
10 2009
23/04/2009
DE
018624.7
28/03/2010
F16L (2010.01)
204748
–
–
G11B (2010.01)
POINTER DETECTION APPARATUS
AND POINTER DETECTION METHOD
WACOM CO., LTD.
200918/06/2009
JP
145880
28/03/2010
204806
G06F (2010.01)
WACOM CO., LTD.
10
"
JP
28/03/2010
2009145880
18/06/2009
G06F (2010.01)
204808
WACOM CO., LTD.
200918/06/2009
JP
145880
28/03/2010
G11B (2010.01)
204813
WACOM CO., LTD.
200918/06/2009
JP
145880
06/04/2010
APPARATUS FOR COUPLING POWER
GENERATED BY A PHOTOVOLTAIC
MODULE TO AN OUTPUT
ENPHASE ENERGY, INC.
US
61/212811
16/04/2009
12/657069
13/01/2010
US
11
H01L (2010.01)
204827
#
#
–
"
06/04/2010
H04B (2010.01)
204865
ACTIVE CHANNELIZED
INTEGRATED ANTENNA SYSTEM
RAYTHEON COMPANY
US
12/384490
06/04/2009
06/04/2010
G08G (2010.01)
204873
ASSISTING IN THE DECKING OF AN
AIRCRAFT
THALES
FR
0901645
03/04/2009
07/04/2010
$
A47L (2010.01)
204897
solid, fragrant, water-soluble substance for
use in washing machine. and
manufacturing method thereof
DROR ATUYA
08/04/2010
#
A62C (2010.01)
204927
COMBINED PASSIVE AND ACTIVE
VEHICLE FIRE PREVENTION
SYSTEM
KIDDE TECHNOLOGIES, INC.
GB
0906268.8
09/04/2009
12
#
#
"
08/04/2010
F24B (2010.01)
204943
#
SURFACE MOUNTABLE
SEMICONDUCTOR BRIDGE DIE
ENSIGN-BICKFORD AEROSPACE &
DEFENSE COMPANY
US
61/168650
13/04/2009
14/04/2010
14/04/2010
G06F (2010.01)
205074
COLLABORATIVE NAVIGATION
HONEYWELL INTERNATIONAL INC.
US
12/428358
22/04/2009
205087
#
%
B05B (2010.01)
DRIP EMITTER AND METHODS OF
ASSEMBLY AND MOUNTING
RAIN BIRD CORPORATION
US
12/436394
06/05/2009
14/04/2010
205088
A47C (2010.01)
ITEM OF SEATING FURNITURE
VOTTELER DESIGNPARTNER GMBH
10 2009 016
14/04/2009
DE
968.7
13
"
15/04/2010
B05B (2010.01)
205119
ROBOTIC WATERING UNIT
DEERE & COMPANY
US
12/427065
21/04/2009
15/04/2010
H04L (2010.01)
205120
MANAGING RESOURCE USE
DEERE & COMPANY
US
12/427043
21/04/2009
15/04/2010
MULTIBAND SUB - WAVELEGTH IR
DETECTOR HAVING FREQUENCY
SELECTIVE SLOTS AND METHOD OF
MAKING THE SAME
RAYTHEON COMPANY
US
12/433631
30/04/2009
19/04/2010
G01J (2010.01)
205132
205186
–
–
–
#
B05D (2010.01)
A SPREADING BRUSH SUITABLE
FOR TUBE OF CREAM
ILANA MALIHI
14
"
17/10/2008
B01D (2010.01)
205187
METHOD AND APPARATUS FOR THE
PURIFICATION OF SALTY STREAMS
AND THE REMOVAL OF
PARTICULATES THEREFROM
POROUS MEDIA CORPORATION
US
60/981488
20/10/2007
12/234965
22/09/2008
US
PCT/US/2008/011842
WO/2009/051773
28/11/2008
$
205188
C02F (2010.01)
METHOD FOR THE TREATMENT OF
WATER USING CHLORINE DIOXIDE
INFRACOR GMBH
DE
102007061360.3 19/12/2007
102008041081.0
07/08/2008
DE
29/09/2008
102008042424.2
DE
PCT/EP/2008/066428
WO/2009/077309
14/10/2008
205217
USE OF NORGESTIMATE AS A
SELECTIVE INHIBITOR OF TRPC3,
TRPC6 AND TRPC7 ION CHANNELS
SANOFI AVENTIS
EP
07291301.5 26/10/2007
PCT/EP/2008/008671
WO/2009/052972
14/10/2008
15
A61K (2010.01)
TRPC7 – TRPC, 6TRPC3
205218
C07K (2010.01)
"
COMPLEXES OF TRPC DOMAINS
AND SESTD1 DOMAINS AND
METHODS AND USES INVOLVING
THE SAME
SANOFI AVENTIS
EP
072913007
26/10/2007
PCT/EP/2008/008670
WO/2009/052971
22/04/2010
TRPC
SESTD1
A01J (2010.01)
205235
A MILKING TEATCUP AND METHOD
RAN SILVIANU
22/04/2010
F16C (2010.01)
205236
SEIDING HEARING
LESHINSKIY ALEXSNDER
06/11/2008
'#
NUCLEIC ACID COMPLEX AND
NUCLEIC ACID DELIVERY
COMPOSITION
OTSUKA PHARMACEUTICAL CO.,
LTD.
200708/11/2007
JP
291317
PCT/JP/2008/070642
WO/2009/061003
16
A61K (2010.01)
205237
#
#
"
31/10/2008
C12N (2010.01)
205238
#
#
DIRECTED EVOLUTION USING
PROTEINS COMPRISING
UNNATURAL AMINO ACIDS
THE SCRIPPS RESEARCH INSTITUTE
US
61/001681
02/11/2007
61/127262
08/05/2008
US
29/09/2008
61/194773
US
PCT/US/2008/012363
WO/2009/061369
19/12/2008
SM-PROTEIN BASED SECRETION
ENGINEERING
BOEHRINGER INGELHEIM PHARMA
GMBH & CO. KG
EP
07150254.6 20/12/2007
08152829.1
17/03/2008
EP
PCT/EP/2008/010882
WO/2009/080299
12/12/2007
C12P (2010.01)
205239
SM –
G02C (2010.01)
205240
INTRACORNEAL LENSES HAVING A
CENTRAL HOLE
BIOVISION AG
$
PCT/US/2007/087316
WO/2009/075685
06/05/2010
205570
MULTIPURPOSE SCRIBABLE
ARTICLE
A.R. THA GOOD GUYS ADVERTISING
SERVICES LTD
17
H01L (2010.01)
–
"
'
. .
"
06/11/2007
H01M (2010.01)
205572
TUBULAR ELECTROCHEMICAL
CELL
NANO CP. LLC
#
PCT/US/2007/023374
WO/2009/061294
22/12/2008
H04L (2010.01)
205573
METHOD AND TRANSMITTING UNIT
FOR REDUCING A RISK OF
TRANSMISSION STALLING
TELEFONAKTIEBOLAGET LM
ERICSSON (PUBL)
US
61/019910
09/01/2008
PCT/SE/2008/051552
WO/2009/088348
06/11/2008
SENSITIVE ION DETECTION DEVICE
AND METHOD FOR ANALYSIS OF
COMPOUNDS AS VAPORS IN GASES
THE ARIZONA BOARD OF REGENTS
ON BEHALF OF THE UNIVERSITY OF
ARIZONA
US
61/002121
06/11/2007
PCT/US/2008/082589
WO/2009/094059
06/11/2008
18
H01J (2010.01)
205574
205575
$
C07D (2010.01)
"
PROCESSES AND INTERMEDIATES
FOR PRODUCING
AMINOBENZIMIDAZOLE UREAS
VERTEX PHARMACEUTICALS
INCORPORATED
US
60/986141
07/11/2007
PCT/US/2008/082565
WO/2009/061875
12/11/2008
#
$
06/11/2008
205578
ALDH-2 INHIBITORS IN THE
TREATMENT OF PSYCHIATRIC
DISORDERS
CV THERAPEUTICS, INC.
US
60/985911
06/11/2007
PCT/US/2008/082643
WO/2009/061924
19
–
–
CSF–HGM
C07K (2010.01)
205577
ANTI-FACTOR B ANTIBODIES AND
THEIR USES
GENENTECH, INC.
US
61/002648
08/11/2007
PCT/US/2008/082621
WO/2009/061910
06/11/2008
C07K (2010.01)
205576
MONOCLONAL ANTIBODIES THAT BIND
TO HGM-CSF AND MEDICAL
COMPOSITIONS COMPRISING SAME
EVEC INC.
JP
2007-294945
13/11/2007
PCT/JP2008/052471 14/02/2008
JP
PCT/US/2008/012680
WO/2009/064399
$
B
–
A61K (2010.01)
ALDH–2
"
20/11/2008
A61K (2010.01)
205579
MODIFIED INSULIN POLYPEPTIDES
AND THEIR USES
AMBRX, INC.
US
60/989388
20/11/2007
PCT/US/2008/084252
WO/2009/067636
14/11/2008
LIGHT SOURCE
CERAVISION LIMITED
GB
0722548.5
0809471.6
GB
0814699.5
GB
0814701.9
GB
PCT/GB/2008/003829
WO/2009/063205
H01J (2010.01)
205580
16/11/2007
23/05/2008
12/08/2008
12/08/2008
11/09/2008
C07D (2010.01)
205581
INHIBITORS OF HUMAN
IMMUNODEFICIENCY VIRUS
REPLICATION
BOEHRINGER INGELHEIM
INTERNATIONAL GMBH
US
60/988686
16/11/2007
PCT/CA/2008/001611
WO/2009/062285
06/11/2008
METHOD FOR BORIDING OF
COATINGS USING HIGH SPEED
ELECTROLYTIC PROCESS
SERVET I. TIMUR OF
20
%
C25D (2010.01)
205582
#
#
"
07120419.2
EP
PCT/EP/2008/065065
WO/2009/060033
09/11/2007
07/11/2008
INCREASE OF IMMUNE RESPONSE
AND TARGETING BY ANTIGENS
AND/OR DRUG LINKAGE
WITTYCELL
EP
07291336.1 07/11/2007
60/996226
07/11/2007
US
PCT/EP/2008/065179
WO/2009/060086
07/11/2008
A61K (2010.01)
205583
#
/
G01S (2010.01)
205584
ENERGY EMISSION EVENT
DETECTION
DOUBLESHOT, INC.
US
60/986586
08/11/2007
PCT/US/2008/012603
WO/2009/102310
06/05/2010
INTRAOCULAR LENS (IOL)
INJECTOR APPARATUS
NULENS LTD.
21/08/2002
A61F (2010.01)
205585
(IOL)
$
"
205586
A61F (2009.01)
ACCOMMODATING LENS
ASSEMBLY
21
"
NULENS LTD.
IL
145015
PCT/IL/2002/000693
WO/2003/015669
06/11/2008
"
21/08/2001
205587
RADIO COMMUNICATION DEVICE
FOR PERFORMING
COMMUNICATION USING THE
OFDMA SYSTEM
SUMITOMO ELECTRIC INDUSTRIES,
LTD.
200709/11/2007
JP
292114
PCT/JP/2008/070200
WO/2009/060894
19/11/2008
205588
H04J (2010.01)
#
OFDMA
A61K (2010.01)
VAGINAL DELIVERY SYSTEM
BAYER SCHERING PHARMA OY
EP
07397042.8 22/11/2007
07397043.6
22/11/2007
EP
PCT/FI/2008/050670
WO/2009/066006
05/11/2008
205589
G09B (2010.01)
MOTION SIMULATION CHAIR
MONTECITO RESEARCH
US
11/936579
07/11/2007
PCT/US/2008/082493
WO/2009/061828
19/11/2008
22
205590
A01K (2010.01)
"
TOOTHED PET GROOMING TOOL
WITH FUR EJECTING MECHANISM
FURMINATOR, INC.
US
11/942231
19/11/2007
PCT/US/2008/084065
WO/2009/067537
07/11/2008
C09J (2010.01)
205591
$
INSULATING GLASS SEALANT
TREMCO ILLBRUCK
INTERNATIONAL GMBH
GB
0721958.7
08/11/2007
PCT/GB/2008/003747
WO/2009/060199
05/11/2008
METHOD AND SYSTEM FOR
HEATING AND DEHUMIDIFYING
THE STATE OF ISRAEL, MINISTRY
OF AGRICULTURE AND RURAL
DEVELOPMENT, AGRICULTURAL
RESEARCH ORGANIZATION,
VOLCANI CENTER
US
60/996266
08/11/2007
PCT/IL/2008/001449
WO/2009/060436
05/11/2008
A01G (2010.01)
205592
205593
$
,
,
A61F (2010.01)
FECAL INCONTINENCE DEVICE,
SYSTEM AND METHOD
RENEW MEDICAL INC
US
60/996275
08/11/2007
61/064374
29/02/2008
US
PCT/IL/2008/001450
WO/2009/060437
23
,
#
"
03/11/2008
C12N (2010.01)
205594
COMPOSITIONS FOR CONFERRING
TOLERANCE TO VIRAL DISEASE IN
SOCIAL INSECTS, AND THE USE
THEREOF
BEEOLOGICS, LLC
US
60/996244
07/11/2007
12/222949
20/08/2008
US
PCT/IL/2008/001440
WO/2009/060429
07/11/2008
,
A61P (2010.01)
205595
USE OF UMBILICAL CORD BLOOD IN
THE TREATMENT OF PREMATURE
BIRTH COMPLICATIONS
ANTHROGENESIS CORPORATION
US
61/002375
07/11/2007
PCT/US/2008/012540
WO/2009/061447
04/02/2005
METHODS FOR MAKING 3-OPROTECTED MORPHINONES AND 3O-PROTECTED MORPHINONE
DIENOL CARBOXYLATES
EURO-CELTIQUE S.A.
US
60/542711
06/02/2004
PCT/US/2005/003390
WO/2005/077957
12/02/2009
IMPROVED FAR END CROSSTALK
COMPENSATION
24
C07D (2010.01)
205596
#
–O–3
–O–3–
#
H01R (2010.01)
205597
#
#
"
ADC GMBH
US
61/028040
12/369543
US
PCT/US/2009/033892
WO/2009/102851
12/02/2009
12/02/2008
11/02/2009
ASYMMETRIC CROSSTALK
COMPENSATION FOR IMPROVED
ALIEN CROSSTALK PERFORMANCE
ADC GMBH
US
61/028032
12/02/2008
12/369532
11/02/2009
US
PCT/US/2009/033890
WO/2009/102849
20/08/2004
#
#
C07D (2010.01)
$
$
# HT–54
C07D (2010.01)
205600
BENZIMIDAZOLONE COMPOUNDS
HAVING 5-HT4 RECEPTOR
AGONISTIC ACTIVITY
PFIZER INC.
US
60/500144
03/09/2003
PCT/IB/2004/002741
WO/2005/021539
25
#
205599
BENZIMIDAZOLONE COMPOUNDS
HAVING 5-HT4 RECEPTOR
AGONISTIC ACTIVITY
PFIZER INC.
US
60/500144
03/09/2003
PCT/IB/2004/002741
WO/2005/021539
20/08/2004
H01R (2010.01)
205598
$
$
# HT–54
"
06/11/2008
C07D (2010.01)
205601
METHOD FOR THE PREPARATION OF
MORPHINE COMPOUNDS
SANOFI-AVENTIS
FR
0758923
09/11/2007
61/021949
18/01/2008
US
PCT/FR/2008/001558
WO/2009/092912
20/11/2008
PYRAZOLE DERIVATIVES AS 5-LO
INHIBITORS
PFIZER INC.
US
61/004261
26/11/2007
61/004236
26/11/2007
US
23/05/2008
61/055497
US
PCT/IB/2008/054873
WO/2009/069044
07/11/2008
205603
A METHOD AND APPARATUS FOR
GENERATING A TEST PLAN USING A
STATISTICAL TEST APPROACH
RAYTHEON COMPANY
US
60/986047
07/11/2007
PCT/US/2008/082731
WO/2009/061985
05/11/2008
C07D (2010.01)
205602
205604
$
LO–5
G06F (2010.01)
#
C07D (2010.01)
SUBSTITUTED CYCLOPENTANES
HAVING PROSTAGLANDING
ACTIVITY
ALLERGAN, INC.
US
60/986849
09/11/2007
12/265062
05/11/2008
US
PCT/US/2008/082469
26
$
#
"
WO/2009/061811
10/12/2008
SUBSTITUTED HYDANTOINS AS
MEK KINASE INHIBITORS
F. HOFFMANN-LA ROCHE AG
US
61/015222
20/12/2007
61/103259
07/10/2008
US
PCT/EP/2008/067221
WO/2009/080523
04/03/2005
AXL ANTIBODIES
U3 PHARMA GMBH
EP
07021931.6
PCT/EP/2008/009548
WO/2009/062690
08/12/2008
27
MEK
$
C12N (2010.01)
205606
PERFUSION CULTURES COMPRISING
A CELL CULTURE MEDIUM AND
AGGREGATING ANIMAL CELLS
DSM IP ASSETS B.V.
EP
04075703.1 05/03/2004
04075702.3
05/03/2004
EP
27/09/2004
04077656.9
EP
27/09/2004
04077657.7
EP
PCT/EP/2005/002374
WO/2005/095578
12/11/2008
C07D (2010.01)
205605
205607
#
$
C07K (2010.01)
AXL
12/11/2007
205608
C07D (2010.01)
"
TRIAZOLE -SUBSTITUTED
ARYLAMIDE DERIVATIVES AND
THEIR USE AS P2X3 AND/OR
P2X2/3PURINERGIC RECEPTOR
ANTAGONISTS
US
61/007890
17/12/2007
PCT/EP/2008/066987
WO/2009/077366
14/11/2008
–
#
X2P2/3
066
205610
/ X2P3
C07C (2010.01)
205609
BIS-(SULFONYLAMINO)
DERIVATIVES IN THERAPY 066
ASTRAZENECA AB
US
60/988164
15/11/2007
PCT/SE/2008/051307
WO/2009/064251
06/11/2008
$
(
)–
G01N (2010.01)
METHODS OF MEASURING CELL
VIABILITY WITHOUT USING
CONTROL CELLS
GENZYME CORPORATION
US
60/986751
09/11/2007
PCT/US/2008/082612
WO/2009/061905
14/11/2008
205611
QUINOXALINE-CONTAINING
COMPOUNDS AS HEPATITIS C VIRUS
INHIBITORS
ENANTA PHARMACEUTICALS, INC.
US
60/987958
14/11/2007
61/025458
01/02/2008
US
PCT/US/2008/083541
WO/2009/064975
28
A01N (2010.01)
C
#
"
05/11/2008
A61B (2010.01)
205612
$
AUSCULTATION TRAINING DEVICE
AND RELATED METHODS
LECAT PAUL JACQUES
US
11/935468
06/11/2007
PCT/US/2008/082417
WO/2009/061772
02/12/2008
TRIAZOLO [4,5-D]PYRIMIDINE
COMPOUNDS FOR TREATMENT OF
ABDOMINAL AORTIC ANEURYSMS
ASTRAZENECA AB
EP
07301616.4 03/12/2007
PCT/SE/2008/051386
WO/2009/072967
03/05/2010
A61K (2010.01)
205613
[D–5,4]
A61B (2010.01)
205614
MONITORING RENAL FUNCTION
RENALSENSE LTD
61/215580
08/05/2009
US
09/05/2010
FILTER FOR GRAY WATER
NEEDLESSLY STRUCTURE FILTER
PEL DAVID
29
$
#
"
B01D (2010.01)
205615
#
"
10/11/2008
A61K (2010.01)
205616
COMPOSITIONS FOR USE IN THE
REPAIR OR REGENERATION OF
DAMAGED MYOCARDIUM
NEW YORK MEDICAL COLLEGE
US
60/986788
09/11/2007
PCT/US/2008/082967
WO/2009/062143
24/02/2004
A61K (2010.01)
205618
INTERLEUKIN 6 ANTAGONISTS AS
MODULATORS OF NEURAL CELL
DIFFERENTIATION
KEIO UNIVERSITY
200324/02/2003
JP
046214
PCT/JP/2004/002111
WO/2004/073741
30/10/2008
6–
A61B (2010.01)
205619
INFORMATION AND PNEUMATIC
ARCHITECTURE FOR A PATIENT
CARE AND TREATMENT DEVICE
INTEGRATED MEDICAL SYSTEMS,
INC.
US
11/983567
09/11/2007
PCT/US/2008/081845
WO/2009/061665
09/05/2010
PHOTO-VOHAIC ELECTRIC PISTON
SUN TRACKING SYTEM
30
F02D (2010.01)
205620
–
,
–
"
"
MATALON ENERGY SOURCES LTD
09/11/2008
C07C (2010.01)
205621
NOVEL SYNTHETIC ANALOGS OF
SPHINGOLIPIDS
YISSUM RESEARCH DEVELOPMENT
COMPANY OF THE HEBREW
UNIVERSITY OF JERUSALEM
IL
187247
08/11/2007
PCT/IL/2008/001472
WO/2009/060457
10/11/2008
A01N (2010.01)
205622
PESTICIDAL MIXTURES
COMPRISING CYANOSULFOXIMINE
COMPOUNDS
BASF SE
US
60/988618
16/11/2007
PCT/EP/2008/065213
WO/2009/062905
07/11/2008
#
A61K (2010.01)
205623
COMPOSITIONS AND METHODS FOR
TREATMENT OF MICROBIAL
DISORDERS
GENENTECH, INC.
US
60/986170
07/11/2007
61/013620
13/12/2007
US
20/12/2007
61/015620
US
PCT/US/2008/082890
WO/2009/062102
31
$
–
"
17/11/2008
CARBOXAMIDE, SULFONAMIDE
AND AMINE COMPOUNDS FOR
METABOLIC DISORDERS
RIGEL PHARMACEUTICALS, INC.
US
60/988721
16/11/2007
60/990554
27/11/2007
US
27/11/2007
60/990558
US
29/11/2007
60/991189
US
14/12/2007
61/013924
US
PCT/US/2008/083801
WO/2009/065131
27/11/2008
C07D (2010.01)
205624
,
C07H (2010.01)
205625
ANTIVIRAL NUCLEOSIDE
COMPOUNDS
LIGAND PHARMACEUTICALS, INC.
US
60/991163
29/11/2007
61/084544
29/07/2008
US
PCT/IB/2008/054985
WO/2009/069095
26/02/2008
C22C (2010.01)
205626
LEAN AUSTENITIC STAINLESS
STEEL
ATI PROPERTIES, INC.
US
60/991016
29/11/2007
PCT/US/2008/054986
WO/2009/070345
10/11/2008
$
205627
$
–
$
G02B (2010.01)
LIGHT CONCENTRATOR
STRUCTURES AND METHODS
32
"
SUNRGI
US
60/996272
PCT/US/2008/012622
WO/2009/061502
07/11/2008
08/11/2007
COMPOSITE MATERIAL
COMPOSITIONS, ARRANGEMENTS
AND METHODS HAVING ENHANCED
THERMAL CONDUCTIVITY
BEHAVIOR
SUNRGI
US
60/996273
08/11/2007
61/071410
28/04/2008
US
28/04/2008
61/071411
US
28/04/2008
61/071412
US
23/10/2008
12/257235
US
PCT/US/2008/012611
WO/2009/061492
07/11/2008
33
,
H01L (2010.01)
205629
SOLAR CONCENTRATION AND
COOLING DEVICES,
ARRANGEMENTS AND METHODS
SUNRGI
US
60/996273
08/11/2007
61/071410
28/04/2008
US
28/04/2008
61/071411
US
28/04/2008
61/071412
US
23/10/2008
12/257158
US
PCT/US/2008/012612
WO/2009/061493
10/11/2008
F24J (2010.01)
205628
205630
,
$
A01N (2010.01)
"
USE OF SOLUTIONS OF MINT OIL OR
OF L-CARVONE FOR THE
FUNGICIDAL AND/OR ANTIGERMINATING OF BULBS AND/OR
TUBERS
XEDA INTERNATIONAL
FR
0758919
09/11/2007
PCT/FR/2008/052022
WO/2009/068803
07/11/2008
–L
/
A62C (2010.01)
205631
FIRE PROTECTION APPARATUS,
SYSTEMS AND METHODS FOR
ADDRESSING A FIRE WITH A MIST
TYCO FIRE PRODUCTS LP
US
60/987021
09/11/2007
60/989083
19/11/2007
US
03/03/2008
0803959.6
GB
PCT/US/2008/012571
WO/2009/061471
13/11/2008
–
205632
,
H04W (2010.01)
UTILIZING BROADCAST SIGNALS TO
CONVEY RESTRICTED
ASSOCIATION INFORMATION
QUALCOMM INCORPORATED
US
60/988631
16/11/2007
60/988641
16/11/2007
US
16/11/2007
60/988649
US
31/01/2008
61/025093
US
12/11/2008
12/269637
US
PCT/US/2008/083467
WO/2009/064932
12/11/2008
34
205633
A61K (2010.01)
"
TREATMENT OF UTERINE CANCER
AND OVARIAN CANCER WITH A
PARP INHIBITOR ALONE OR IN
COMBINATION WITH ANTI-TUMOR
AGENTS
BIPAR SCIENCES, INC.
US
60/987335
12/11/2007
61/012364
07/12/2007
US
03/06/2008
61/058528
US
PCT/US/2008/012757
WO/2009/644444
01/12/2005
205634
PARP
C12Q (2010.01)
METHOD FOR MEASURING
RESISTANCE OR SENSITIVITY TO
DOCETAXEL
AVENTIS PHARMACEUTICALS INC.
US
60/634298
08/12/2004
PCT/US/2005/043578
WO/2006/062811
01/12/2005
205635
C12Q (2010.01)
DOCETAXEL
US
60/634298
08/12/2004
PCT/US/2005/043578
WO/2006/062811
01/12/2005
205636
C12Q (2010.01)
DOCETAXEL
US
60/634298
08/12/2004
PCT/US/2005/043578
35
"
WO/2006/062811
01/12/2005
205637
C12Q (2010.01)
DOCETAXEL
US
60/634298
08/12/2004
PCT/US/2005/043578
WO/2006/062811
01/12/2005
205638
C12Q (2010.01)
DOCETAXEL
US
60/634298
08/12/2004
PCT/US/2005/043578
WO/2006/062811
01/12/2005
205639
C12Q (2010.01)
DOCETAXEL
US
60/634298
08/12/2004
PCT/US/2005/043578
WO/2006/062811
01/12/2005
205640
C12Q (2010.01)
DOCETAXEL
36
"
US
60/634298
08/12/2004
PCT/US/2005/043578
WO/2006/062811
01/12/2005
C12Q (2010.01)
205641
DOCETAXEL
US
60/634298
08/12/2004
PCT/US/2005/043578
WO/2006/062811
12/11/2008
A45D (2010.01)
205642
'
METERED GEL DISPENSER
ANTARES PHARMA IPL AG
US
60/987233
12/11/2007
PCT/US/2008/083196
WO/2009/064762
10/11/2008
#
METHODS FOR ADMINISTERING
CORTICOSTEROID FORMULATIONS
MAP PHARMACEUTICALS, INC.
US
61/002645
09/11/2007
61/069498
14/03/2008
US
PCT/US/2008/083059
WO/2009/062193
26/11/2008
37
A61K (2010.01)
205644
205645
H02B (2010.01)
"
$
DOUBLE-WALL HOUSING HAVING
IMPROVED HEAT-REMOVING
FUNCTION CHAMBER WALLS
ADC GMBH
DE
102007058458.1 04/12/2007
PCT/EP/2008/010010
WO/2009/071226
03/03/2009
H02B (2010.01)
205646
BASE PLATE WITH SEALING BLOCKS
BERTHOLD SICHERT GMBH
DE
102008012460.5 04/03/2008
PCT/EP/2009/052492
WO/2009/109568
10/05/2010
B65D (2010.01)
205648
$
COMBINED RECYCLING CONTAINER
SHERRY GAL
13/11/2008
POLYMORPHIC FORMS OF
ALISKIREN HEMIFUMARATE AND
PROCESS FOR PREPARATION
THEREOF
TEVA PHARMACEUTICAL
INDUSTRIES LTD.
US
60/987679
13/11/2007
61/004382
26/11/2007
US
26/12/2007
61/016650
US
14/01/2008
61/020845
US
19/02/2008
61/029752
US
25/02/2008
61/031069
US
38
C07C (2010.01)
205649
#
"
#
"
61/034229
US
61/059662
US
61/091635
US
PCT/US/2008/012816
WO/2009/064479
06/03/2008
06/06/2008
25/08/2008
10/05/2010
205650
A61C (2010.01)
205651
C07C (2010.01)
DENTAL IMPLANT SYSTEM
MIHA ROZENTAL
19/11/2008
PROCESS FOR THE
STEREOSELECTIVE PREPARATION
OF AMINO ACID DERIVATIES
BCN PEPTIDES, S.A.
ES
P200703112 19/11/2007
PCT/ES/2008/000724
WO/2009/065987
10/11/2008
205652
–
#
H04L (2010.01)
PREAMBLE DESIGN FOR A
WIRELESS SIGNAL
US
60/988720
16/11/2007
12/260826
29/10/2008
US
PCT/US/2008/083049
WO/2009/064700
09/01/2009
205653
#
H04W (2010.01)
#
SHARED RESOURCE ALLOCATION
39
$
"
US
61/020219
10/01/2008
24/03/2008
61/039082
US
29/04/2008
61/048782
US
08/01/2009
12/350690
US
PCT/US/2009/030658
WO/2009/089490
14/11/2008
H04W (2010.01)
205654
TIME SLOT RESERVATION FOR A
DOMINANT INTERFERENCE
SCENARIO IN A WIRELESS
COMMUNICATION NETWORK
THROUGH DIRECT
COMMUNICATION BETWEEN
INTERFERRED AND INTERFERING
BASE STATION
US
60/988662
16/11/2007
12/269696
12/11/2008
US
PCT/US/2008/083685
WO/2009/065075
09/12/2003
40
205656
#
H04L (2009.01)
205655
DERIVATION OF EIGENVECTORS
FOR SPATIAL PROCESSING IN MIMO
COMMUNICATION SYSTEMS
US
60/432760
11/12/2002
10/729070
04/12/2003
US
PCT/US/2003/039392
WO/2004/054191
13/10/1999
$
MIMO
C07K (2010.01)
"
THE USE OF A G PROTEIN-COUPLED
RECEPTOR TO SCREEN CANDIDATE
COMPOUNDS AS PHARMACEUTICAL
AGENTS
ARENA PHARMACEUTICALS, INC.
US
60/109213
20/11/1998
60/120416
16/02/1999
US
26/02/1999
60/121852
US
12/03/1999
60/123946
US
12/03/1999
60/123949
US
28/05/1999
60/136436
US
28/05/1999
60/137127
US
28/05/1999
60/137131
US
28/05/1999
60/136437
US
28/05/1999
60/136439
US
28/05/1999
60/136567
US
29/06/1999
60/141448
US
29/09/1999
60/157280
US
29/09/1999
60/156653
US
29/09/1999
60/156633
US
29/09/1999
60/156555
US
01/10/1999
60/157280
US
01/10/1999
60/157294
US
01/10/1999
60/157281
US
01/10/1999
60/157293
US
01/10/1999
60/157282
US
12/10/1999
09/417044
US
12/10/1999
09/416760
US
PCT/US/1999/023687
WO/2000/031258
13/10/1999
$
–
C07K (2010.01)
205657
AGENTS
US
60/109213
20/11/1998
60/120416
16/02/1999
US
26/02/1999
60/121852
US
12/03/1999
60/123946
US
12/03/1999
60/123949
US
28/05/1999
60/136436
US
28/05/1999
60/137127
US
41
G–
G–
$
–
"
60/137131
US
60/136437
US
60/136439
US
60/136567
US
60/141448
US
60/157280
US
60/156653
US
60/156633
US
60/156555
US
60/157280
US
60/157294
US
60/157281
US
60/157293
US
60/157282
US
09/417044
US
09/416760
US
PCT/US/1999/023687
WO/2000/031258
13/10/1999
28/05/1999
28/05/1999
28/05/1999
28/05/1999
29/06/1999
29/09/1999
29/09/1999
29/09/1999
29/09/1999
01/10/1999
01/10/1999
01/10/1999
01/10/1999
01/10/1999
12/10/1999
12/10/1999
AGENTS
US
60/109213
20/11/1998
60/120416
16/02/1999
US
26/02/1999
60/121852
US
12/03/1999
60/123946
US
12/03/1999
60/123949
US
28/05/1999
60/136436
US
28/05/1999
60/137127
US
28/05/1999
60/137131
US
28/05/1999
60/136437
US
28/05/1999
60/136439
US
28/05/1999
60/136567
US
29/06/1999
60/141448
US
29/09/1999
60/157280
US
29/09/1999
60/156653
US
29/09/1999
60/156633
US
29/09/1999
60/156555
US
01/10/1999
60/157280
US
01/10/1999
60/157294
US
01/10/1999
60/157281
US
42
C07K (2010.01)
205658
G–
$
–
"
60/157293
US
60/157282
US
09/417044
US
09/416760
US
PCT/US/1999/023687
WO/2000/031258
10/11/2008
01/10/1999
01/10/1999
12/10/1999
12/10/1999
H04W (2010.01)
205659
PERSISTENT INTERFERENCE
MITIGATION IN A WIRELESS
COMMUNICATION SYSTEM
US
60/988693
16/11/2007
12/262576
31/10/2008
US
PCT/US/2008/083047
WO/2009/064699
11/11/2008
G01S (2010.01)
205660
METHOD AND APPARATUS FOR
DETECTING A LAUNCH POSITION OF
A PROJECTILE
SELEX GALILEO LTD
GB
0722169.0
12/11/2007
PCT/EP/2008/065332
WO/2009/062936
12/11/2008
NEW POLYMORPHIC FORMS OF N-[4(TRIFLUOROMETHYL)BENZYL]-4METHOXYBUTYRAMIDE
LABORATORIO FARMACEUTICO C.T.
S.R.L.
EP
07120551.2 13/11/2007
PCT/EP/2008/065367
WO/2009/062949
43
C07C (2010.01)
205661
–N–[4
–4–[ $ (
#
)
"
13/11/2008
MATRIX FOR REAL-TIME AEROSOL
MASS SPECTROMETRY OF
ATMOSPHERIC AEROSOLS AND
REAL-TIME AEROSOL MALDI MS
METHOD
NEDERLANDSE ORGANISATIE VOOR
TOEGEPASTNATUURWETENSCHAPPELIJK
ONDERZOEK TNO
EP
07120550.4 13/11/2007
PCT/NL/2008/050721
WO/2009/064180
28/11/2008
$
$
MS MALDI
205664
BENZOMORPHAN COMPOUNDS
PURDUE PHARMA L.P.
US
60/991369
30/11/2007
61/077616
02/07/2008
US
PCT/IB/2008/003311
WO/2009/068989
11/12/2008
G01N (2010.01)
205662
205665
C07D (2010.01)
$
C07D (2010.01)
HETEROARYL DERIVATIVES AS
OREXIN RECEPTOR ANTAGONISTS
EP
07150294.2 21/12/2007
PCT/EP/2008/067273
WO/2009/080533
20/11/2008
205666
#
C07D (2010.01)
PYRIDINE COMPOUNDS
44
"
07122017.2
EP
PCT/EP/2008/065911
WO/2009/068468
28/11/2008
30/11/2007
A61K (2010.01)
205667
A PHARMACEUTICAL COMPOSITION
FOR TREATING OBESITY-RELATED
DISEASE COMPRISING
INSULINOTROPIC PEPTIDE
CONJUGATE
HANMI PHARMACEUTICAL CO.,
LTD.
US
11/947697
29/11/2007
10420084
26/08/2008
KR
0083194
PCT/KR/2008/007074
WO/2009/069983
22/12/2008
MULTITARGET COMPOUNDS
ACTIVE AT A PPAR AND
CANNABINOID RECEPTOR
GIULIANI INTERNATIONAL LIMITED
IE
2007/0928
21/12/2007
PCT/EP/2008/068205
WO/2009/080821
11/11/2008
PPAR–
–
F16L (2010.01)
205670
GRIP RING FOR FITTING
PLASSIM FITTINGS LTD.
60/987067
11/11/2007
US
PCT/IL/2008/001480
WO/2009/060462
45
A61K (2010.01)
205669
$
"
$
"
20/11/2008
NOVEL CYCLIC HYDROCARBON
COMPOUNDS FOR THE TREATMENT
OF DISEASES
LEO PHARMA A/S
US
60/989856
23/11/2007
61/092553
28/08/2008
US
PCT/DK/2008/000410
WO/2009/065406
14/11/2008
#
C02F (2010.01)
205672
WASTEWATER TREATMENT
PROCESS AND PLANT COMPRISING
CONTROLLING THE DISSOLVED
OXYGEN CONCENTRATION
JAVEL LIMITED
GB
0722486.8
16/11/2007
PCT/EP/2008/065624
WO/2009/063086
31/03/2008
C07C (2010.01)
205671
205673
#
$
H01P (2010.01)
FILTER ASSEMBLY
TELEFONAKTIEBOLAGET L M
ERICSSON (PUBL)
SE
0800239-6
31/01/2008
PCT/SE/2008/050370
WO/2009/096836
22/11/2007
205674
H04N (2010.01)
SECURED FACSIMILE
TRANSMISSION
PURELLA AG
PCT/EP/2007/010114
WO/2009/065423
46
"
03/12/2008
A61K (2010.01)
205675
OXAZOLIDINONES FOR THE
TREATMENT AND/OR PROPHYLAXIS
OF HEART FAILURE
JANSSEN PHARMACEUTICA, N.V.
US
61/007406
11/12/2007
PCT/EP/2008/010211
WO/2009/074249
04/12/2008
/
$
A61M (2010.01)
205676
SPIKE HAVING TWO PINS
BAYER SCHERING PHARMA
AKTIENGESELLSCHAFT
DE
102007061346.8 17/12/2007
PCT/EP/2008/010278
WO/2009/077084
12/11/2008
C01B (2010.01)
205678
A COMBUSTION PROCESS FOR THE
MANUFACTURE OF CALCIUM
PHOSPHATE AND CALCIUM
PHOSPHATE COMPOSITE PARTICLES
HKPB SCIENTIFIC LIMITED
IE
IE2007/0808 12/11/2007
PCT/EP/2008/065414
WO/2009/062973
14/11/2008
METHOD OF HYDROTHERMAL
LIQUID PHASE SINTERING OF
CERAMIC MATERIALS AND
PRODUCTS DERIVED THEREFROM
47
#
#
#
C04B (2010.01)
205679
#
#
"
RUTGERS, THE STATE UNIVERSITY
OF
NEW JERSEY
US
61/003272
15/11/2007
PCT/US/2008/083606
WO/2009/102360
20/11/2008
COMBINATIONS OF PDE4
INHIBITORS AND ANTIPSYCHOTICS
FOR THE TREATMENT OF
PSYCHOTIC DISORDERS
MEMORY PHARMACEUTICALS
CORPORATION
US
60/989221
20/11/2007
PCT/US/2008/084207
WO/2009/067607
19/11/2008
PDE4
#
C07K (2010.01)
205681
ANTI-MESOTHELIN ANTIBODIES
AND USES THEREFOR
AKTIENGESELLSCHAFT
US
61/004378
26/11/2007
PCT/EP/2008/009756
WO/2009/068204
$ –
21/11/2008
C07D (2010.01)
205682
AMINO TRIAZOLES AS PI3K
INHIBITORS
CELLZOME LIMITED
EP
07121607.1 27/11/2007
61/078006
03/07/2008
US
07/08/2008
61/086963
US
PCT/EP/2008/066001
WO/2009/068482
48
A61K (2010.01)
205680
K3PI
$
"
11/05/2010
PANEL SYSTEM FOR
STRENGTHENING STRUCTURES
WALLS AGAINST EARTHQUAKES
AND OTHER OUTSIDE
RONEN MAOZ
11/05/2010
$
–
$$
#
$
A47G (2010.01)
205684
#
MODULAR PICTURES DISPLAY UNIT
ELISHA SMALY
03/12/2008
E02D (2010.01)
205683
205685
A61B (2010.01)
COMPRESSION AND
DECOMPRESSION OF COMPUTED
TOMOGRAPHY DATA
SAMPLIFY SYSTEMS, INC.
US
11/949670
03/12/2007
PCT/US/2008/085417
WO/2009/073730
13/11/2008
205686
A SYSTEM AND METHOD FOR QUALITY
MANAGEMENT UTILIZING BARCODE
INDICATORS
VARCODE LTD.
IL
PCT/IL2007/01411 14/11/2007
61/131644
10/06/2008
US
49
G06Q (2010.01)
"
"
PCT/IL/2008/001494
WO/2009/063464
13/11/2008
G06Q (2010.01)
205687
A SYSTEM AND METHOD FOR QUALITY
MANAGEMENT UTILIZING BARCODE
INDICATORS
VARCODE LTD.
IL
PCT/IL2007/001411 14/11/2007
61/131644
10/06/2008
US
PCT/IL/2008/001495
WO/2009/063465
14/11/2008
$
A61K (2010.01)
205689
TREATMENT OF BREAST CANCER
WITH A PARP INHIBITOR ALONE OR
IN COMBINATION WITH ANTITUMOR AGENTS
BIPAR SCIENCES, INC.
US
60/987333
12/11/2007
61/012364
07/12/2007
US
03/06/2008
61/058528
US
PCT/US/2008/083147
WO/2009/064738
50
H04W (2010.01)
205688
CLASSIFYING ACCESS POINTS
USING PILOT IDENTIFIERS
US
60/988631
16/11/2007
60/988641
16/11/2007
US
16/11/2007
60/988649
US
31/01/2008
61/025093
US
12/11/2008
12/269642
US
PCT/US/2008/083632
WO/2009/065033
11/11/2008
"
PARP
"
17/07/2008
205690
F41A (2010.01)
DIRECT DRIVE RETROFIT FOR
RIFLES
JASON ADAMS
US
11/938678
12/11/2007
17/07/2008
US
PCT/US/2008/008768
WO/2009/064327
05/11/2008
205691
H04W (2010.01)
PREAMBLE DESIGN FOR A
WIRELESS SIGNAL
US
60/988665
16/11/2007
60/988720
16/11/2007
US
01/02/2008
61/025670
US
13/02/2008
61/028497
US
22/04/2008
61/047021
US
29/10/2008
12/260856
US
PCT/US/2008/082521
WO/2009/064647
14/11/2008
205692
#
H04W (2010.01)
$
SECTOR IDENTIFICATION USING
SECTOR PARAMETERS SIGNATURES
US
60/988631
16/11/2007
60/988641
16/11/2007
US
16/11/2007
60/988649
US
12/11/2008
12/269654
US
PCT/US/2008/083643
WO/2009/065041
51
"
12/11/2003
4-AMINO-6-PIPERIDINYLPYRIMIDINE COMPOUNDS AS
ANTAGONISTS OF THE
VITRONECTIN RECEPTOR, METHOD
FOR THEIR PREPARATION, THEIR
USE IN THE PREPARATION OF
MEDICINES AND PHARMACEUTICAL
COPOSITIONS CONTAINING THE
SAME
GALAPAGOS SAS
FR
02/14429
19/11/2002
PCT/FR/2003/003349
WO/2004/048375
12/11/2008
C07D (2010.01)
205693
–
H04N (2010.01)
205694
12/11/2008
52
#
C12N (2009.01)
205695
COMPOSITIONS CONTAINING DSPA
ALPHA 1 FOR THE TREATMENT OF
STROKE
PAION DEUTSCHLAND GMBH
DE
101/53/601.1 02/11/2001
01/130/006.8 17/12/2001
EP
PCT/EP/2002/012204
WO/2003/037363
205696
–4
,
MOTION ESTIMATION AND
COMPENSATION PROCESS AND
DEVICE
VRIJE UNIVERSITEIT BRUSSEL
EP
07120604.9 13/11/2007
PCT/EP/2008/065422
WO/2009/062979
31/10/2002
–6–
1
DSPA
/
C07D (2010.01)
"
HETEROCYCLIC DERIVATIVES,
COMPOSITIONS COMPRISING THE
SAME AND USES THEREOF
INCORPORATED
US
60/987490
13/11/2007
PCT/US/2008/083173
WO/2009/064752
12/11/2008
13/11/2008
PROTEASE DETECTION
53
–2–(
–
(
205699
)–2–)–3–)4
$ ( –2– $
$
)–N–( –1–
,
C07K (2010.01)
205698
METHODS FOR THE EXPRESSION OF
ACTIVE PROTEINIMMUNOGLOBULIN FUSIONS,
ACTIVE PROTEINIMMUNOGLOBULIN FUSIONS
OBTAINED T
BIOGEN IDEC MA INC.
US
60/112752
17/12/1998
PCT/US/1999/029873
WO/2000/036092
$
C07D (2010.01)
205697
4(-3-(-2-(PHENYL)MORPHOLINO)-2OXOPYRROLIDIN-1-YL)-N(THIAZOLE-2-YL)BENZENESULFONAMIDE DERIVATIVES,
COMPOSITIONS COMPRISING THE
SAME AND USES THEREOF
INCORPORATED
US
60/987485
13/11/2007
61/088141
12/08/2008
US
PCT/US/2008/083165
WO/2009/064747
16/12/1999
#
?
# LT–?–R–Ig))
B01L (2010.01)
$
"
MOLOGIC LTD
GB
0722287.0
PCT/GB/2008/003833
WO/2009/063208
03/09/2004
13/11/2007
C07D (2009.01)
205706
INTERMEDIATE PRODUCTS FOR
PRODUCING OXAZOLIDINONEQUINOLONE HYBRIDS
MORPHOCHEM
AKTIENGESELLSCHAFT FUR
KOMBINATORISCHE CHEMIE
DE
10340485.6 03/09/2003
PCT/EP/2004/009858
WO/2005/023801
12/05/2010
$
G06F (2010.01)
205707
FEED-BACK BOX
SHACHAR GLOBERSON
12/05/2010
$
CAPTURED CHILD/PASSENGER
WARNING SYSTEM FOR VEHICLES
MENASHE GANAN
13/05/2010
54
G08B (2010.01)
205708
205724
/
H04B (2010.01)
"
TECHNIQUE FOR TRAFFIC
RECOVERY IN MULTILAYER
COMMUNICATION NETWORKS
ECI TELECOM LTD.
13/05/2010
$
"
.
.
G08B (2010.01)
205727
DISTRIBUTED SENSOR NETWORK
HAVING SUBNETWORKS
PEARLS OF WISDOM RESEARCH &
DEVELOPMENT LTD,
18/10/2002
.
$
–
"
H04B (2009.01)
205729
SYSTEM AND METHOD FOR FAST
DYNAMIC LINK ADAPTATION
INTERDIGITAL TECHNOLOGY
CORPORATION
US
60/344693
19/10/2001
PCT/US/2002/033587
WO/2003/041317
10/06/2004
METER REGISTER HAVING AN
ENCODER FOR MEASURING
MATERIAL FLOW AND AN
ALGORITHM TO SELECTIVELY
BLOCK SIGNAL TRANSMISSION
ARAD MEASURING TECHNOLOGIES
LTD.
US
60/478522
13/06/2003
60/478310
13/06/2003
US
PCT/IL/2004/000498
55
G01D (2010.01)
205738
$
"
"
WO/2004/111576
13/05/2010
A61K (2010.01)
205757
HEAT-PROCESSED FOOD AS A DRUG
CARRIER AND A METHOD OF
ORALLY DELIVERING DRUGS USING
HEAT-PROCESSED FOOD AS A
CARRIER
YOCHAI ZOREA PRIEL
13/05/2010
$
$
$
A45D (2010.01)
205760
HAIR STRAIGHTENING IRON WITH
TOXIC FUMES FILTER
DANDE M&M LTD
13/05/2010
/
"
&
H04B (2010.01)
205772
TELEPHONE SWITCWING SYSTEM
YITZCHAK COHEN
06/08/2004
H01L (2010.01)
205779
APPARATUS FOR PRODUCING HIGH
ASPECT RATIO ETCH USING
MODULATION OF RF POWERS OF
VARIOUS FREQUENCIES
56
#
#
RF
#
"
LAM RESEARCH CORPORATION
US
10/645665
22/08/2003
15/12/2003
10/737022
US
PCT/US/2004/025406
WO/2005/022623
16/05/2010
D06F (2010.01)
205788
MOTOR DRIVEN CLOTHESLINE FOR
DRYING CLOTHES
ISRAEL KRITENBERG
16/05/2010
DEVICE FOR SUPERSCRIBING OF
COMPACT DISCUSES
SERGEY POPOV
09/07/2002
B43L (2010.01)
205790
CD
205792
–
C07C (2010.01)
NOVEL COMPOUNDS AS ANTIINFLAMMATORY,
IMMUNOMODULATORY AND ANTIPROLIFERATORY AGENTS USES
THEREOF AND PROCESS FO THEIR
PREPARATION
4SC AG
EP
PCT/EP01/07948 10/07/2001
PCT/EP/2002/007655
WO/2003/006425
57
,
"
02/04/1999
C12N (2010.01)
205793
VERTEBRATE PATCHED -2 PROTEIN
GENENTECH, INC.
US
09/060939
15/04/1998
PCT/US/1999/007417
WO/1999/053058
2–
18/02/2004
H04L (2009.01)
205799
COMMUNICATION RECEIVER WITH
AN ADAPTIVE EQUALIZER
US
10/368920
18/02/2003
PCT/US/2004/004706
WO/2004/075498
06/05/2004
IMMUNOCONJUGATES COMPRISING
AN IMMUNOGLOBULIN CONSTANT
REGION AND A BIOLOGICALLY
ACTIVE MOLECULE
SYNTONIX PHARMACEUTICALS, INC
US
60/469600
06/05/2003
60/487964
17/07/2003
US
26/01/2004
60/539207
US
PCT/US/2004/014064
WO/2005/001025
17/05/2010
C12N (2009.01)
205802
205811
$
#
B23C (2010.01)
MILLING TOOL AND CUTTING
INSERT THEREFOR
ISCAR LTD.
58
"
"
17/05/2010
B23K (2010.01)
205813
COMPACT COMPANION ROBOTIC
PLATFORM WITH AUTONOMOUS
TRACING CAPABILITIES
ROBO-TEAM LTD
17/05/2010
"
A47C (2010.01)
205814
A SUN-TANNING DEVICE AND
METHOD
EZRA AMRANI
17/05/2010
%$
$
G09C (2010.01)
205815
MANAGEMENT OF SECURITY RULE
SET
TUFIN SOFTWARE TECHNOLOGIES
LTD
US
61/179089
18/05/2009
17/01/2002
-
205827
"
H04W (2009.01)
DYNAMIC BANDWIDTH
ALLOCATION FOR MULTIPLE
ACCESS COMMUNICATION USING
SESSION QUEUES
TANTIVY COMMUNICATIONS, INC.
59
#
"
09/773252
US
PCT/US/2002/001512
WO/2002/061993
19/04/2005
31/01/2001
205828
MEDICAL DEVICE CONFIGURATION
BASED ON RECOGNITION OF
IDENTIFICATION INFORMATION
BAXTER INTERNATIONAL INC.
US
10/855855
27/05/2004
PCT/US/2005/013350
WO/2005/118054
15/09/2006
205840
A61M (2009.01)
#
$
C07K (2010.01)
METHOD FOR ENHANCING THE
EFFECT OF PARTICULATE BENEFIT
AGENTS
E.I. DU PONT DE NEMOURS AND
COMPANY
US
60/718035
16/09/2005
PCT/US/2006/036108
WO/2007/035531
15/09/2006
205841
C07K (2010.01)
AGENTS
COMPANY
US
60/718035
16/09/2005
PCT/US/2006/036108
WO/2007/035531
60
"
15/09/2006
C07K (2010.01)
205842
AGENTS
COMPANY
US
60/718035
16/09/2005
PCT/US/2006/036108
WO/2007/035531
17/05/2010
AIR CONDITIONER COMPRESSOR
SAFETY ARM
SHECHAKIM TECHNOLOGIES RAV
HEVEL LTD.
17/05/2010
$
HYBRID HEATING SYSTEM
PHOEBUS ENERGY LTD
61
$
"
B23Q (2010.01)
205846
A MAGNETIC SEALING CLOSURE
AND A METHOD OF
MANUFACTURING THE SAME
GOOPER HERMETIC LTD
17/05/2010
F16M (2010.01)
205845
#
"
F24D (2010.01)
205847
"
"
25/11/2003
C07K (2010.01)
205850
TREATMENT OF DISEASES AND
CONDITIONS MEDIATED BY
INCREASED PHOSPHORYLATION
DMI BIOSCIENCES, INC.
US
60/429,924
27/11/2002
PCT/US/2003/037901
WO/2004/050023
25/11/2003
#
#
C07K (2010.01)
205851
US
60/429,924
27/11/2002
PCT/US/2003/037901
WO/2004/050023
25/11/2003
#
C07K (2010.01)
205852
US
60/429,924
27/11/2002
PCT/US/2003/037901
WO/2004/050023
20/05/2010
#
#
G09B (2010.01)
205853
A METHOD, SYSTEM AND PROGRAM FOR
DELIVERING SELF INTERVENTIONS FOR
DEPRESSION BY USING THE INTERNT
JOSEPH ANSHEL BOMFELD
60/994638
21/09/2007
US
62
#
#
#
%
"
WO
PCT/IL2008/001251
20/05/2010
18/09/2008
205854
B65D (2010.01)
205871
C07D (2010.01)
BAG OF TFILIN AND TALIT
TOGETHER
BENYAMIN ISRAEL
22/09/2003
PROCESS FOR THE MANUFACTURE
OF VALSARTAN
NOVARTIS AG
GB
0222056.4
23/09/2002
PCT/EP/2003/010543
WO/2004/026847
17/10/1997
63
C07K (2010.01)
205879
INHIBITORS OF SERINE PROTEASES
PARTICULARLY HEPATITIS C VIRUS
NS3 PROTEASE, PHARMACEUTICAL
COMPOSITIONS CONTAINING
THE SAME AND THE USE THEREOF
INCORPORATED
US
60/028290
18/10/1996
PCT/US/1997/018968
WO/1998/017679
20/05/2010
#
205889
$
$
,C
#
NS3
G06F (2010.01)
"
OBJECT MANAGEMENT SYSTEM
AND METHOD
THE STANLEY WORKS ISRAEL LTD
61/180778
22/05/2009
US
21/03/2002
205897
METHOD FOR DAMAGE
PREVENTION TO CONCRETE PILES
DR BASSEM HAZZAN
64
,
"
A61K (2010.01)
205892
ROOM-TEMPERATURE STABLE
DRONABINOL FORMULATIONS
INSYS THERAPEUTICS, INC.
US
60/634474
09/12/2004
PCT/US/2005/044375
WO/2006/063109
23/05/2010
G01N (2009.01)
205890
METHODS AND KITS FOR
DETERMINING A RISK TO DEVELOP
CANCER, FOR EVALUATING AN
EFFECTIVENESS AND DOSAGE OF
CANCER THERAPY
YEDA RESEARCH AND
DEVELOPMENT CO. LTD.
US
09/815015
23/03/2001
60/303338
09/07/2001
US
PCT/IL/2002/000231
WO/2002/076280
09/12/2005
"
#
E05D (2010.01)
$
$
"
"
23/05/2010
E05B (2010.01)
205898
A LOCK OPERATION INDICATOR
AND METHOD THEREFOR
YIFTACH URI
23/05/2010
#
E05B (2010.01)
205899
A LOCKING SYSTEM AND METHOD
YIFTACH URI
06/05/2010
HAND HELD PRESSURE CONTROL
LENS
NULENS LTD.
65
A61B (2010.01)
205900
$
/
"
"
NOTICE UNDER SECTION 26 OF THE
PATENTS LAW, 5727-1967
The applications, particulars of which are set
out below, have been accepted pursuant to
Section 17 of the Patents Law. Any person
wishing to oppose the grant of a patent on any
of the applications published here, may,
within three months from the date of this
journal, give to the Commissioner of Patents
notice under Section 30 of the Patents Law, in
the manner prescribed in regulations 57 et seq
of the Patents Regulations, 5728-1968
- $"
1976
.
66
17 %
,
, $
30 %
57
.1968 – "
Particulars of the applications, where
applicable, are given in the following order:
[11] [21] Number of application
[54] Title of invention
[22] Application date
[31] [32] [33] Number and date of foreign
application – convention country.
*[51] Int.Cl.
[61] Application for patent of addition
[62] Divisional application
[71] Applicant
[72] Inventor
[87] International Publication Number
[74] Address for service
[57] Abridgement of invention (in the
language in which the specification is drawn
up)
*Note:, patent applications published in this
journal were classified according to the
International Classification version that was
in force when this journal was prepared.
26 %
,
: $
#
–/
*
%
#
'
(
)
#
#
:
.
**
$
%
"
[11][21]
[54]
ANTIVIRAL COBALT
CONTAINING IMIDAZOLE
COMPOUNDS
[22]
[31]
[51]
[71]
[74]
06.12.1992
[32] 05.12.1991
07/803259
Int. Cl.(2010.01) C07F 15//06
CHAI-TECH CORPORATION, U.S.A.
SIMON LAVIE,
21 HERZOG ST.,
JERUSALEM
[57]
103992
[33]
US
,
21
#
A compound of formula II as set forth in the specification
wherein each
A may be the same or different and is an alkyl group, a phenyl group or a substituted
derivative of a phenyl group;
Y may be the same or different and is hydrogen, an unbranched alkyl group, a
halide or group having the formula R-CO
wherein R is hydrogen, an alkoxide group, an alkyl group or OH;
B may be the same or different and each is hydrogen or an alkyl group;
Z- is a soluble, pharmaceutically acceptable negative ion, and
X may be the same or different and is an axial ligand selected from the group
consisting of moieties having the formula IIa as set forth in the specification
wherein R1, R2, R3 and R4 may be same or different and may be hydrogen or lower
alkyl having from 1 to 4 carbon atoms: with the proviso that R1, R2, R3 and R4 are of a
suitably small size so as not to prohibit the attachment of the axial ligand to the Co
atom due to steric hindrance.
35
This specification was examined in accordance
with regulation 35 of the Patent Regulations,
5728 - 1968
5
1968 – "
(
,
__________________
[11][21]
[54]
67
116114
TRANSGENIC PLANTS EXPRESSING
"
DNA CONSTRUCTS CONTAINING A
PLURALITY OF GENES TO IMPART
VIRUS RESISTANCE
[22]
[31]
[51]
[71]
[74]
[57]
DNA
23.11.1995
[32] 30.12.1994
[33] US
08/366991
07.06.1995
PCT/US95/06261
WO
Int. Cl.(2010.01) A01H 05//00, C07K 14//08, C12N 07//00, 15//10, 15//29, 15//40,
15//62, 15//82, 15//84
SEMINIS VEGETABLE SEEDS, INC.,
U.S.A.
DR. SHLOMO COHEN & CO.,
"
,'
124 IBN GABIROL ST.,
124
P.O.B. 11490,
11490 . . ,
TEL AVIV 62038
A chimeric recombinant DNA molecule comprising: at least three tandemly linked
DNA sequences, each of which comprises a promoter operably linked to a DNA
sequence which encodes a viral protein, wherein said DNA sequences are expressed in
virus-susceptible plant cells transformed with said recombinant DNA sequences to
impart resistance to infection of said cells by each of said viruses, with the proviso that
the DNA sequences encoding viral proteins do not encode potyvirus protease;
and wherein expression of said DNA sequences imparts substantially equal levels of
resistance to infection.
,195591
The applications for division
from this application have not
yet been published
(
.
__________________
[11][21]
[54]
PERSONALIZED INTERNET
INTERACTION
[22]
[31]
[51]
[71]
[74]
20.07.1998
[32] 30.01.1998
123129
Int. Cl.(2009.01) G06F 17/30
EASYNET ACCESS INC., U.S.A.
G.E. EHRLICH (1995) LTD.,
AYALON TOWER, 15TH FLOOR,
11 MENACHEM BEGIN ST.,
68
125432
[33]
IL
, "
11
(1995)
, 15
,
. .'
"
[57]
RAMAT GAN 52521
A method of a user interacting with an Internet, comprising:
tracking interactions of the user with an Internet;
analyzing said tracked interactions to determine at least a part of a user profile; and
modifying a plurality of future interactions of said user with computers on said Internet
responsive to said user profile, by modifying at least one of a presentation of
information to said user or a functional response of a computer to input from user,
wherein said plurality of modified interactions comprise interactions with the site
content of a plurality of unrelated sites.
,206271
from this application have
not yet been published
(
.
__________________
[11][21]
[54]
METHOD AND APPARATUS
FOR THE DIAGNOSIS OF
ACTUAL OR PRE-SHOCK
STATE
[22]
[51]
[71]
[72]
[74]
04.08.1999
Int. Cl.(2009.01) A61B 05/046, 05/103, A61N 01/38
CARDIOSENSE LTD.
ITTAI SHAVIT, HAIM SHANI
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
RAMAT HACHAYAL 69710
[57]
69
131245
–
, "
,
,
' 26 $
A method for the diagnosis of pre-shock state in a patient and of recovery of a patient
from actual state of shock by measuring the filling time of blood vessels subjacent to
an area of the skin of said patient, comprising acquiring an image of an area to be
gauged for color, acquiring said image to obtain a base-line color measurement, and
determining the filling time of blood vessels in said area by comparison with the color
of one or more additional images of the gauged area with said baseline measurement.
"
__________________
[11][21]
132669
–
[54]
MULTIVALENT VACCINE
COMPOSITION WITH MIXED
CARRIER
[22]
[31]
[51]
[71]
[87]
[74]
14.05.1998
[32] 14.05.1997
[33] FR
97/06210
Int. Cl.(2009.01) A61K 39/09, 39/385, 47/42, 47/48, A61P 31/10, C07K 14/315
SANOFI PASTEUR, FRANCE
WO/1998/051339
LUZZATTO & LUZZATTO,
,
#
#
INDUSTRIAL PARK, OMER,
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
[57]
The invention concerns a pharmaceutical composition for treating or preventing a
certain number of infections caused by pathogenic agents such as bacteria, comprising
as immunogen, one or several polyosides derived from one or several pathogenic
agents. The polyosides are in the form of conjugates, coupled with a carrier protein.
The composition contains at least two types of conjugates, each being at least
characterised by a different protein carrier.
,183296
(
.
__________________
[11][21]
134068
[54]
MAMMALIAN CYTOKINE:
INTERLEUKIN - B 30 AND
ISOLATED POLUNUCLEOTIDES
ENCODING THE SAME
[22]
[31]
[51]
24.07.1998
[32] 25.07.1997
[33] US
08/900905
Int. Cl.(2009.01) A61K 38/19, C07K 14/54, 16/24, C12N 01/15, 01/19, 01/21, 05/10,
15/10, 15/19, 15/24, 15/63, C12P 21/02, 21/08, C12Q 01/68, G01N 33/68
70
B 30 –
:
"
[71]
[87]
[74]
[57]
SCHERING CORPORATION, U.S.A.
WO/1999/005280
P.O.B. 11490,
TEL AVIV 62038
,'
"
124
11490 . . ,
Purified genes encoding cytokine from a mammal, reagents related thereto including
purified proteins, specific antibodies, and nucleic acids encoding this molecule are
provided. Methods of using said reagents and diagnostic kits are also provided.
,205765
(
.
__________________
[11][21]
136252
[54]
PHARMACEUTICAL AND
DIAGNOSTIC COMPOSITIONS
CONTAINING AB OR
FRAGMENTS THEREOF
[22]
[31]
30.11.1998
[32] 02.12.1997
[33] US
60/067740
60/080970
07.04.1998
US
Int. Cl.(2009.01) A61K 09/26, 33/06, 38/19, 39/00
ELAN PHARMA INTERNATIONAL
LTD., IRELAND
WO/1999/027944
WOLFF, BREGMAN AND GOLLER,
P.O.B. 1352,
JERUSALEM 91013
[51]
[71]
[87]
[74]
[57]
,
,%
1352 . . ,
The invention provides compositions and methods for treatment of amyloidogenic
diseases. Such methods entail administering an agent that induces a beneficial immune
response against an amyloid deposit in the patient. The methods are particularly useful
for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a
suitable agent is Abeta peptide or an antibody thereto.
71
AB
,205298,193245,191904
(
"
.
__________________
[11][21]
138585
[54]
VERTEBRATE PATCHED -2
PROTEIN
[22]
[31]
[51]
02.04.1999
[32] 15.04.1998
[33] US
09/060939
Int. Cl.(2010.01) C07K 14//705, 19//00, C12N 01//19, 01//21, 05//10, 15//11, 15//12,
15//62, G01N 33//68
GENENTECH, INC., U.S.A.
WO/1999/053058
REINHOLD COHN AND PARTNERS,
,
26A HABARZEL ST.,
' 26 $
[71]
[87]
[74]
[57]
2–
The present invention relates to nucleotide sequences, including expressed sequence
tags (ESTs), oligonucleotide probes, polypeptides, antibodies, vectors and host cells
expressing, immunoadhesins, agonists and antagonists to patched-2.
,205793
(
.
__________________
[11][21]
[54]
SELECTING AND PREPARING
CRUCIFEROUS PLANTS HAVING
A PREDETERMINED RATIO OF
ALKYLGLUCOSINOLATE TO
INDOLE GLUCOSINOLATE
[22]
[31]
[51]
[71]
01.07.1999
[32] 01.07.1998
60/091471
Int. Cl.(2009.01) A01H 01/04, 01/06
JOHNS HOPKINS SCHOOL OF
72
140621
[33]
US
"
[87]
[74]
[57]
MEDICINE, U.S.A.
WO/2000/001222
P.O.B. 1352,
JERUSALEM 91013
,
,%
1352 . . ,
A method for producing crucifer germplasm, in particular broccoli and cauliflower
germplasm, with high levels of cancer chemoprotectant agents which comprises
screening a population of plants for glucosinolate profiles and selecting an individual
plant with an enhanced alkyl/indole glucosinolate ratio. Subsequent breeding with a
selected plant results in varieties, lines, and plants with desirable glucosinolate
profiles. A method of growing crucifer sprouts to enhance chemoprotectant activity of
the sprouts by germinating the seeds in a limited water volume. A method for
producing crucifer germplasm which produces seeds with reduced leakage of seed
material which comprises screening a population of plants for production of seeds with
reduced leakage and selecting an individual plant which produces such seeds.
__________________
[11][21]
141800
[54]
RATE MATCHING DEVICE AND
METHOD FOR A DATA
[22]
[31]
06.07.2000
[32] 06.07.1999
[33] KR
26978/1999
27865/1999
10.07.1999
KR
Int. Cl.(2009.01) H03M 13/29, H04J 13/00, H04L 01/00
SAMSUNG ELECTRONICS CO.,
LTD., REPUBLIC OF KOREA
WO/2001/003369
SANFORD T.COLB & CO.,
P.O.B. 2273,
REHOVOT 76122
[51]
[71]
[87]
[74]
[57]
73
,'
.
,4
2273 . . ,
A device and method for matching a rate of channel-encoded symbols in a data
communication system. The rate matching device and method can be applied to a data
communication system which uses one or both of a non-systematic code (such as a
convolution code or a linear block code) and a systematic code (such as a turbo code).
The rate matching device includes a plurality of rate matching blocks, the number of
the rate matching blocks being equal to a reciprocal of a coding rate of a channel
encoder. The rate matching device can rate match the symbols encoded with a nonNovember 30, 2010- "
"
systematic code or the symbols encoded with a systematic code, by changing initial
parameters including the number of input symbols, the number of output symbols, and
the puncturing/repetition pattern determining parameter.
__________________
[11][21]
142207
[54]
ALZHEIMER'S DISEASE
SECRETASE
[22]
[31]
[51]
[71]
23.09.1999
[32] 24.09.1998
[33] US
60/101594
Int. Cl.(2009.01) C07K 14/47, C12N 09/64, 15/57, C12Q 01/37, G01N 33/68
PHARMACIA & UPJOHN
COMPANY LLC, U.S.A.
WO/2000/017369
EITAN, PEARL, LATZER AND
, #
# ,
,
COHEN ZEDEK,
7
P.O.B. 12688,
# 12688 . . ,
HERZLIYA 46733
[87]
[74]
[57]
The present invention provides the enzyme and enzymatic procedures for cleaving the
beta- secretase cleavage site of the APP protein and associated nucleic acids, peptides,
vectors, cells and cell isolates and assays.
__________________
[11][21]
[54]
74
142824
LIPOIC ACID DERIVATIVES AND
THEIR USE AS ANTI METABOLIC
"
AGENTS
[22]
[31]
[51]
[71]
[72]
[87]
[74]
[57]
26.10.1999
[32] 26.10.1998
[33] US
60/105628
Int. Cl.(2009.01) A61K 31/385, A61P 35/00, C07C 321/04, 323/52, 327/20, 327/58,
391/00, C07D 339/02, C07F 19/00
THE RESEARCH FOUNDATION OF
THE STATE UNIVERSITY OF NEW
YORK, U.S.A.
PAUL M. BINGHAM, ZUZANA
ZACHAR
WO/2000/024734
SIMON LAVIE,
,
21 HERZOG ST.,
21 #
JERUSALEM
This invention relates to the identification of a novel class of therapeutic agents which
selectively target and kill tumor cells and certain other types of diseased cells, and to
compositions comprising lipoic acid derivatives which poison the pyruvate
dehydrogenase complex specifically in such cells. This invention also provides for
methods of using therapeutically effective amounts of the lipoic acid derivatives for
the treatment of cancer and other diseases. The lipoic acid derivatives described herein
have a wide range of preventive and therapeutic applications.
__________________
[11][21]
[54]
HUMAN ANTIBODIES THAT BIND
HUMAN IL-12 AND METHODS
FOR PRODUCING THEM
[22]
24.03.2000
75
145134
LI–21–
"
[31]
[51]
[71]
[87]
[74]
[57]
[33] US
[32] 25.03.1999
60/126603
Int. Cl.(2009.01) A61K 39/395, A61P 01/04, 37/02, 43/00, C07K 16/24, C12N 15/13
ABBOTT GMBH & CO. KG,
GERMANY
WO/2000/056772
,
26A HABARZEL ST.,
' 26 $
Human antibodies, preferably recombinant human antibodies, that specifically bind to
human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity
for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the
invention can be a full-length antibody or an antigen-binding portion thereof. The
antibodies, or antibody portions, of the inveniton are useful for detecting hIL-12 and
for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in
which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for
expressing the recombinant human antibodies of the invention, and methods of
synthesizing the recombinant human antibodies, are also encompassed by the
invention.
,207029,203845
(
.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
76
145288
ISOLATED CYTOKINE
ZALPHA11 LIGAND
POLYPEPTIDE AND USES
THEREOF
ZALPHA11
09.03.2000
[32] 09.03.1999
[33] US
264908
265992
11.03.1999
US
60/142013
01.07.1999
US
Int. Cl.(2009.01) A61K 38/19, C07K 14/52, 16/24, 19/00, C12N 15/19, 15/62, 15/85
ZYMOGENETICS INC., U.S.A.
WO/2000/053761
,
26A HABARZEL ST.,
' 26 $
"
[57]
The present invention relates to zalpha11 Ligand polynucleotide and polypeptide
molecules. The zalpha11 Ligand is a novel cytokine. The polypeptides may be used
within methods for stimulating the proliferation and/or development of hematopoietic
cells in vitro and in vivo. The present invention also includes methods for producing
the protein, uses therefor and antibodies thereto.
,207424,207403
(
.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
77
METHOD FOR DIAGNOSING
PREDISPOSITIONS TO LOW HDL
CHOLESTEROL AND
APOLIPOPROTEIN AI AND
METHOD FOR DETERMINING
INHIBITION OF ENZYMOTIC
REACTION BETWEEN LIPG AND
HDL OR VLDL OR LDL
145526
HDL
24.03.2000
[32] 26.03.1999
[33]
09/277401
Int. Cl.(2009.01) C12N 09/20, G01N 33/53
THE TRUSTEES OF THE
UNIVERSITY OF PENNSYLVANIA,
U.S.A.
AVENTIS PHARMACEUTICALS
INC., U.S.A.
WO/2000/057837
26A HABARZEL ST.,
AI
HDL – LIPG
LDL
VLDL
US
,
' 26 $
Compositions and methods for raising the level of HDL cholesterol and apolipoprotein
AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in
a patient, including compositions and methods which effect the expression of a gene,
LIPG, which encodes a lipase enzyme that is a member of the tryacylglycerol lipase
family or which effect the enzymatic activity of the enzyme.
"
__________________
[11][21]
146482
[54]
TEK ANTAGONISTS
[22]
[31]
[51]
07.06.2000
[32] 07.06.1999
[33] US
60/137889
Int. Cl.(2009.01) A61K 38/17, A61P 35/00, C07K 14/71, 19/00, C12N 15/12, G01N
33/68
IMMUNEX CORPORATION, U.S.A.
WO/2000/075323
,
26A HABARZEL ST.,
' 26 $
[71]
[87]
[74]
[57]
TEK–
The present invention provides Tek antagonists and methods of inhibiting angiogenesis
in a mammal by administering Tek antagonists. The methods are particularly useful in
treating diseases or conditions mediated by angiogenesis, such as solid tumors and
diseases or conditions characterized by ocular neovascularization.
__________________
[11][21]
78
[54]
BILL MANAGEMENT
[22]
[51]
[71]
[87]
[74]
24.05.2000
Int. Cl.(2009.01) G06K 11/00
KIA SILVERBROOK, AUSTRALIA
WO/2000/072245
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
146625
,
' 26 $
"
[57]
Methods and systems are disclosed which relate to online bill management via
interface surfaces printed with information and coded data. The coded data, encoded
visibly or invisibly, may be queried by an appropriate sensing device. The sensing
device communicates with a computer system. Together, the interface surfaces,
sensing device and computer system are capable of effecting online bill management,
including bill payment, over a network.
The applications for
division from this
application have not yet
been published
,171146
(
.
__________________
[11][21]
146937
[54]
METHOD FOR PRODUCING A
PROGENY LIBRARY COMPRISED
OF POLYNUCLEOTIDE
SEQUENCES
[22]
[31]
[51]
[71]
[87]
[74]
14.06.2000
[32] 14.06.1999
[33] US
332835
Int. Cl.(2010.01) C12N 15//10, C12Q 01//68, C40B 10//00, 30//00, 50//00
VERENIUM CORPORATION, U.S.A.
WO/2000/077262
,
26A HABARZEL ST.,
' 26 $
[57]
79
The invention is directed to a process of preparing nucleic acid and poly nucleotide
libraries by cloning non-randomly generated nucleotide fragments having ligatable
ends into an expression vector. The expression of the polynucleotide provides an
"
indirect means by which to screen the polynucleotide library.
__________________
[11][21]
[54]
DETONATOR WIRE ACTUATOR
APPARATUS
[22]
[51]
[71]
[74]
13.12.2001
Int. Cl.(2010.01) F42C 15//42
ARIE SANSOLO
DEKEL PATENT LTD.,
18 MENUHA VENAHALA ST.,
REHOVOT 76209
147102
"
27
, "
, 18
,
[57]
Detonator wire actuator apparatus comprising:
an actuator comprising an at least partially hollow housing;
a cap element removably mountable on said actuator;
a coil of electrical wire disposed inside said at least partially hollow housing, a portion
of said coil of electrical wire being arranged for electrical connection with said cap
element, said coil of electrical wire being unwindable outwards from said at least
partially hollow housing; and
a control device adapted to be electrically connected to said actuator, wherein said
control device and said actuator comprise mating electrical connectors adapted to
bring said control device and said actuator into electrical communication with one
another, and wherein at least one of the mating electrical connectors is electrically
shorted until the mating electrical connectors are mated.
__________________
[11][21]
80
147889
"
[54]
HUMAN G-PROTEIN COUPLED
RECEPTOR
[22]
[31]
25.09.2000
[32] 24.09.1999
[33] EP
99203140.1
1013140
24.09.1999
NL
00202683.9
28.07.2000
EP
60/222047
31.07.2000
US
Int. Cl.(2009.01) A01K 67/00, A61K 38/17, C07K 14/705, 14/72, 16/28, C12N 15/12,
C12Q 01/68
SOLVAY PHARMACEUTICALS
B.V., THE NETHERLANDS
WO/2001/025269
,
26A HABARZEL ST.,
' 26 $
[51]
[71]
[87]
[74]
[57]
G
The polynucleotides and polypeptides of the present invention relate to the G-protein
coupled receptor family, referred to as IGS4-family. The invention also relates to
inhibiting or activating the action of such polynucleotides and polypeptides, to a vector
containing said polynucleotides, a host cell containing such vector and transgenic
animals where the IGS4-gene is either overexpressed, misexpressed, underexpressed
or suppressed (knock-out animals). The invention further relates to a method for
screening compounds capable to act as an agonist or an antagonist of IGS4-family and
the use of such IGS4 polypeptides, polynucleotides, agonists or antagonists. Preferred
uses of the invention relate to disorders of the nervous system, disorders of the
gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle
and/or of the thyroid, and/or also to lung diseases, immunological diseases and
disorders of the genitourinary system. The invention also relates to the identification of
the cognate ligand of the IGS4 polypeptides the neuropeptides known as neuromedin
U.
,196053
(
.
__________________
[11][21]
[54]
81
MESOPROGESTINS
(PROGESTERONE RECEPTOR
MODULATORS) AS A
148417
(
)
"
COMPONENT OF
COMPOSITIONS FOR HORMONE
REPLACEMENT THERAPY (HRT)
[22]
[31]
[51]
[71]
[87]
[74]
[57]
31.08.2000
[32] 31.08.1999
386140
Int. Cl.(2009.01) A61K 45/00
AKTIENGESELLSCHAFT,
GERMANY
WO/2001/034126
P.O.B. 2273,
REHOVOT 76122
[33]
US
,'
.
,4
2273 . . ,
The present invention refers to the use of mesoprogestins as pharmaceutical
components for the manufacture of a medicament for hormone replacement therapy
(HRT) and as component for the combined use together with an estrogen for the
manufacture of a medicament for HRT as well as in respective HRT-methods and
methods of treating hormone deficiency and hormone irregularity symptoms.
Mesoprogestins are defined as compounds possessing both agonistic and antagonistic
activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at
an intermediate level of agonistic and antagonistic. Corresponding functional states
cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are
the mesoprogestins preferred according to the invention.
__________________
[11][21]
149147
[54]
USE OF OXCARBAZEPINE FOR
THE PREPARATION OF
MEDICAMENTS FOR THE
TREATMENT OF SEIZURES
[22]
[31]
[51]
[71]
[87]
[74]
31.10.2000
[32] 02.11.1999
[33] GB
9925962.4
Int. Cl.(2010.01) A61K 45//06, C07D 22/3/00, 22/3/18
NOVARTIS AG, SWITZERLAND
WO/2001/032183
82
,
#
#
,
"
5352 . . ,
P.O.B. 5352,
BEER-SHEVA 84152
[57]
Oral dosage forms comprising oxcarbazepine which when administered to a patient
display no food effect.
,205504
(
.
__________________
[11][21]
149459
[54]
RECOMBINANT GELATINS
[22]
[31]
10.11.2000
[32] 12.11.1999
[33] US
60/165114
60/204437
15.05.2000
US
Int. Cl.(2010.01) A61K 08//65, 09//08, 09//14, 09//16, 09//48, 38//17, 47//42, C07K
14//78, C12N 15//12
FIBROGEN, INC., U.S.A.
WO/2001/034646
,
26A HABARZEL ST.,
' 26 $
[51]
[71]
[87]
[74]
[57]
The present invention relates to recombinant gelatins and composiitions thereof, and
methods of producing and using the same.
__________________
83
"
[11][21]
[54]
AUDIO PLAYER WITH CODE
SENSOR
[22]
[31]
[51]
[71]
27.11.2000
[32] 01.12.1999
PQ4392
Int. Cl.(2010.01) G06F 17//00
SILVERBROOK RESEARCH PTY.
LTD., AUSTRALIA
WO/2001/041047
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[87]
[74]
[57]
149959
[33]
AU
,
' 26 $
An audio player (10) is provided with an image sensor (16) capable of imaging
invisible infrared tags (78) on a substrate (70). The tags (78) encode identity data
which is directly or indirectly associated in a computer system with one or more audio
clips.The audio player (10) can be used to select and play audio clips. It acquires tag
identity data via the image sensor (16), transmits it to the computer system, and
downloads associated clip(s) for playback via a speaker (22).
__________________
[11][21]
84
[54]
SYSTEM FOR BREAST LIFTING
[22]
[51]
11.06.2002
Int. Cl.(2009.01) A61B 17/00
150151
"
[71]
[74]
[57]
-
MIM - MINIMALLY INVASIVE
MASTOPEXY LTD.
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
, "
,
' 26 $
A system for minimally invasive breast lifting and imparting a breast with natural and
lifted shape, the system comprising:
one or more anchors adapted to be fixed to a posture tissue above a desired nipple
level;
two or more readily adjustable suspension members suspended from the one or more
anchors each readily adjustable suspension member having a free end; and
a cradling portion having a first end and a second end and being configured to cradle
the breast from below, the first end and the second end of the cradling portion being
integral with and/or movably attached to the free end of a respective suspension
member, and the cradling portion having a width greater than the width of each of the
two or more readily adjustable suspension members,
wherein the system is configured to lift and thereby impart the breast with a natural
shape.
__________________
[11][21]
[54]
[22]
[51]
[71]
[74]
[57]
85
PROCESS FOR SELECTIVELY
ISOLATING IGY ANTIBODIES
FROM EGG YOLK OF AN
ANSERIFORM BIRD AND IGY
ANTIBODIES OBTAINED
THEREBY
150194
IgY
ANSERIFORM
IgY
12.06.2002
Int. Cl.(2010.01) A61K 39//395, C07K 01//14, 01//16, 16//02
GOOD BIOTECH CORPORATION,
TAIWAN R.O.C.
, " (1995)
. .'
11
, 15
,
RAMAT GAN 52521
A process for selectively isolating lgY antibodies antibodies from egg yolk of an
anseriform bird, which is characherized in
(a) absorbing yolk antibodies in a water-miscible fraction obtained from the egg yolk
"
of an anseriform bird with a water insoluble non-charged absorbent selected from the
group consisting of silicate, silicon compounds, carbonate, sulfate, phosphate, carbon,
cellulose and synthetic fiber, ceramics, and metal oxide, and wherein the water
insoluble non-charged absorbent is at an amount effective for separating the yolk
antibodies from the water-miscible fraction; and
(b) flowing the water isoluble non-charged absorbent with a buffer to obtain an
aqueous fraction containing the yolk antibodies.
__________________
[11][21]
150518
[54]
FEED MIXER FOR LIVESTOCK
[22]
[51]
[71]
[74]
02.07.2002
Int. Cl.(2010.01) A01K 05//00, A23N 17//00
DAN YOSEF
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[57]
%
,
' 26 $
A vertical feed mixer for livetock, comprising a hopper and multiple augers, each of
which adjoins at least two other augers and wherein each of said multiple augers
comprises:
a central shaft vertically extending within the hopper;
a spiral mixing blade which spirals up and out from the central shaft such that each of
said augers has an external profile that lies on a substantially conical surface;
multiple cutters disposed on an edge of the blade; and
wherein at a top elevation, peripheral most edges of adjoining augers are substantially
tangent.
__________________
[11][21]
[54]
86
151004
AUTOMATED SCREENING OF
SECURITY
"
[22]
[31]
[51]
[71]
[87]
[74]
[57]
05.02.2001
[32] 04.02.2000
60/180323
773475
02.02.2001
Int. Cl.(2010.01) H04N 07//18
CERNIUM CORPORATION, U.S.A.
WO/2001/057787
26A HABARZEL ST.,
[33]
US
US
,
' 26 $
A system (10) for automatically screening closed circuit television (CCTV) cameras
(14) for large and small scale security systems, as used for example in parking garages.
The system includes six primary software elements (30, 32, 34, 36, 38, 40), each
performing a unique function within the operation of the security system to provide
intelligent camera selection for operators, resulting in a marked decrease of operator
fatigue in a CCTV system.
__________________
[11][21]
[54]
POWER CONTROL OF
MULTIPLE CHANNELS IN A
WIRELESS COMMUNICATION
SYSTEM
[22]
[31]
13.02.2001
[32] 14.02.2000
60/182322
09/755659
05.01.2001
Int. Cl.(2009.01) H04B 07/005
QUALCOMM INCORPORATED,
U.S.A.
WO/2001/061884
[51]
[71]
[87]
87
151016
[33]
US
US
"
[74]
[57]
,'
P.O.B. 2273,
REHOVOT 76122
.
,4
2273 . . ,
Techniques to control the transmit power of multiple transmissions in wireless
communication system. A transmitting source (e.g., a base station) receives from a
receiving device (e.g., a remote terminal) a number of feedbacks of one or more
(coded or uncoded) bit streams and possibly one or more messages. The bit stream
may include one or more power control sub-channels used to send one or more metrics
(e.g., power control commands, erasure indicator bits, or quality indicator bits) for one
or more sets of channels. The bits allocated for each sub-channel may be aggregated to
form one or more lower rate feedback sub-streams having improved reliability. The
transmit power of two or more channels can be (1) independently adjusted based on
the feedbacks from respective sub-channels, or (2) adjusted together based on feedback
from one sub-channel, with the power difference being adjacent based on feedback
from another sub-channel.
__________________
[11][21]
151886
[54]
CESTRUM YELLOW LEAF
CURLING VIRUS PROMOTERS
[22]
[31]
26.03.2001
[32] 27.03.2000
[33] GB
0007427.8
0010486.9
28.04.2000
GB
01101802.5
26.01.2001
EP
60/272076
28.02.2001
US
Int. Cl.(2010.01) A01H 05//00, C07K 14//005, C12N 05//10, 05//14, 15//11, 15//33,
15//82
SYNGENTA PARTICIPATIONS AG,
SWITZERLAND
WO/2001/073087
[51]
[71]
[87]
88
"
[74]
[57]
,
P.O.B. 5352,
BEER-SHEVA 84152
#
#
,
5352 . . ,
This invention describes novel DNA sequences that function as promoters of
transcription of associated nucleotide sequences. More specifically, this invention
describes DNA sequences conferring constitutive expression to an associated
nucleotide sequence. The invention also describes recombinant sequences containing
such promoter sequences. The said recombinant DNA sequences may be used to create
transgenic plants, but especially plants expressing a nucleotide sequence of interest at
all times and in most tissues and organs.
__________________
[11][21]
[54]
IMAGE SENSOR AND AN
ENDOSCOPE USING THE SAME
[22]
[31]
[51]
[71]
04.04.2001
[32] 10.04.2000
135571
Int. Cl.(2010.01) A61B 01//00
GIVEN IMAGING LTD.
C2CURE INC., U.S.A.
WO/2001/076452
D. KLIGLER I.P. SERVICES LTD,
P.O.BOX 33111
TEL AVIV 61330
[87]
[74]
[57]
152128
[33]
IL
, "
, "
'
.
33111 . . ,
An endoscope (fig. 2, item 40) having restricted dimensions and comprising at least
one image gatherer (48), at least one image distorter and at least one image sensor (46)
shaped to fit the limited dimensions, and wherein said image distorter (fig. 13, itel 115)
is operable to distort an image receiver (fig. 2, item 40) from the image gatherer so that
the image is sensible at said shaped image sensor (fig. 2, item 46).
__________________
89
"
[11][21]
152288
,
[54]
POLYAMIDE NUCLEIC ACID
DERIVATIVES, AGENTS AND
METHODS FOR PRODUCING
THEM
[22]
[31]
[51]
07.04.2001
[32] 18.04.2000
[33] DE
10019135.5
Int. Cl.(2010.01) A61K 31//10, 38//04, 48//00, A61P 09//00, 31//04, 35//00, C07F
09//09, 09//24, 09//40, 09//547, C07H 21//00, C07K 01//16, 14//00, C12N 15//12,
C12Q 01//68, G01N 33//53
SANOFI-AVENTIS DEUTSCHLAND
GMBH, GERMANY
WO/2001/079216
, #
# ,
,
COHEN ZEDEK,
7
P.O.B. 12688,
# 12688 . . ,
HERZLIYA 46733
[71]
[87]
[74]
[57]
The invention relates to PNA derivatives that carry one or more phosphoryl groups at
the C terminus or at the C and N terminus of the PNA backbone, said phosphoryl
groups optionally carrying one or more marker groups, or groups for cross-linking, or
groups that promote the intracellular uptake, or groups that improve the binding
affinity of the PNA derivative to nucleic acids. The invention further relates to a
method for producing the above PNA derivatives and to the use thereof as a
medicament or diagnostic agent.
__________________
[11][21]
152332
[54]
ANTIBODIES FOR
SPECIFICALLY DETECTING
PATHOGENIC PRIONS OF
HUMAN ORIGIN AND
DETECTION METHODS CARRIED
OUT USING THESE ANTIBODIES
[22]
[31]
[51]
[71]
16.10.2002
[32] 19.10.2001
[33]
10152677.6
Int. Cl.(2010.01) C07K 16//18, G01N 33//68
CSL BEHRING GMBH, GERMANY
90
DE
"
[72]
[74]
[57]
MARTIN VEY, WIEGAND LANG,
ALBRECHT GROENER
PEARL COHEN ZEDEK LATZER,
, #
#
5 SHENKAR ST.,
5
' ,1 - $
P.O.B. 12704,
# 12704 . . ,
HERZLIYA 46733
Conformational epitope specific for human prion protein and only present in prion
protein under oxidizing conditions, characterized in that it is recognized by at least one
of the antibodies formed by one of the hybridoma cell lines DSM ACC 2522, DSM
ACC 2523 or DSM ACC 2524.
__________________
[11][21]
152630
[54]
IMPLANTABLE DEVICE
[22]
[51]
[71]
[74]
04.11.2002
Int. Cl.(2009.01) A61F 02/02, A61M 29/00
INNOVENTIONS LTD.
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[57]
,
,
, "
' 26 $
An implantable medical device for insertion into a body cavity, comprising an
expandable balloon having a wall and a lumen and having a steroidal shape defining a
hole, and an insert configured to be received and secured in the hole.
__________________
[11][21]
[54]
DISTRIBUTED REMOTE ASSET
AND MEDICATION
MANAGEMENT DRUG
DELIVERY SYSTEM
[22]
18.05.2001
91
152717
"
[31]
[51]
[71]
[87]
[74]
[57]
[32] 18.05.2000
60/205125
Int. Cl.(2009.01) G06F 19/00
CAREFUSION 303, INC., U.S.A.
MCKESSON AUTOMATION, INC.,
U.S.A.
WO/2001/088828
P.O.B. 1352,
JERUSALEM 91013
[33]
US
,
,%
1352 . . ,
A system and method for communicating and validating patient information including
medication delivery information in a care-giving facility is provided. A medical
transaction carrier is used to communicate information regarding medication delivery
and other patient information between a control system in communication with the
care-giving facility's other information systems and a patient specific asset such as an
infusion pump. All information carried by the medical transaction carrier is validated
both at the patient specific asset and at the control system. This validation allows for
positive control of all transactions even if a medical transaction carrier is lost. The
medical transaction carrier may be a smartcard, a PDA such as a Palm?TM¿ Pilot,
laptop computer, pager, mobile phone, or other device capable of storing and
communicating information. The system may use either wired or wireless connections
to communicate information between the components of the system.
,206282
(
.
__________________
[11][21]
[54]
92
152860
–
PURIFICATION OF DNA BY A
TRIPLE HELIX FORMATION
WITH AN IMMOBILIZED
OLIGONUCLEOTIDE
"
"
[22]
[31]
[51]
[71]
[87]
[74]
[57]
25.05.2001
[32] 26.05.2000
[33]
09/580923
Int. Cl.(2009.01) C12N 15/10, C12Q 01/68
CENTELION, FRANCE
WO/2001/092511
P.O.B. 5352,
BEER-SHEVA 84152
US
,
#
#
,
5352 . . ,
Method for double-stranded DNA purification, by which a solution containing said
DNA in a mixture with other components is passed over a support on which is
covalently coupled in oligonucleotide capable of hybridizing with a specific sequence
present on said DNA to form a triple helix.
,196444
(
.
__________________
[11][21]
153438
[54]
IMPLANTABLE AND
INSERTABLE PASSIVE TAGS
[22]
[31]
[51]
[71]
[74]
13.12.2002
[32] 21.12.2001
[33] US
029595
Int. Cl.(2010.01) A61B 05//00
BIOSENSE WEBSTER INC., U.S.A.
, "
.
P.O.BOX 33111
33111 . . ,
TEL AVIV 61330
Apparatus (20) for determining the position of an object (22) within a body of a
subject, comprising:
at least one acoustic wave generator (11, 13, 15), adapted to direct a first acoustic wave
toward the body at a first frequency; an acoustic tag (12) adapted to be fixed to the
object, the tag being wireless and comprising a shell defining a cavity therein and a
medium contained within the shell, such that responsive to incidence thereon of the
first acoustic wave, the tag emits a second acoustic wave at a second frequency,
different from the first frequency; one or more detectors, adapted to detect the second
acoustic wave and to generate signals responsive thereto; and
a signal processor, coupled to process the signals so as to determine six-dimensional
[57]
93
"
position and orientation coordinates of the object in the body.
__________________
[11][21]
154421
[54]
METHOD FOR TIMING
CONTROL
[22]
[31]
[51]
[71]
[72]
26.03.2002
[32] 29.03.2001
[33]
60/279406
Int. Cl.(2009.01) H04N 03/14, 07/18, 09/64
GIVEN IMAGING LTD.
ARKADY GLUKHOVSKY, DOV
AVNI
WO/2002/080376
5 SHENKAR ST.,
P.O.B. 12704,
HERZLIYA 46733
[87]
[74]
[57]
94
US
, "
,
5
'
, #
#
' ,1 - $
# 12704 . . ,
An imaging device (30) having an in vivo CMOS image sensor (34), at least one
illumination source (33) and a controller (36). The controller controls the illumination
source to illuminate for a first period and to be shut off for a subsequent period.
"
__________________
[11][21]
154465
[54]
IL-1BETA BINDING MOLECULES
AND USE THEREOF IN THE
PREPARATION OF
PHARMACEUTICAL
COMPOSITIONS AND
MEDICAMENTS
[22]
[31]
[51]
[71]
[87]
[74]
20.08.2001
[32] 22.08.2000
[33]
0020685.4
Int. Cl.(2009.01) C07K 16/24, C12N 15/13
WO/2002/016436
P.O.B. 5352,
BEER-SHEVA 84152
[57]
–BETA1 IL
GB
,
#
#
,
5352 . . ,
An IL-1 binding molecule, in particular an antibody to human IL-1 , especially a
human antibody to human IL-1 is provided, wherein the CDRs of the heavy and light
chains having amino acid sequences as defined, for use in the treatment of an IL-1
mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory
arthritides.
__________________
[11][21]
[54]
LABELING REAGENTS, LABELED
TARGETS, PROCESSES FOR PREPARING
LABELING REAGENTS AND PROCESSES
USING THE SAME
[22]
[31]
[51]
02.03.2003
10/096075 [32] 12.03.2002
Int. Cl.(2009.01) C12P 17/06, C12Q 01/68
95
154700
,
[33]
,
US
"
[71]
[74]
[57]
ENZO LIFE SCIENCES, INC., U.S.A.
,
#
#
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
A labeling reagent for labeling a target, said labeling reagent comprising a marker moiety
M and a reactive group R
M-R
wherein said marker moiety M and said reactive group R are covalently linked together
by a linker arm comprising a backbone which comprises one or more carbon atoms,
wherein said backbone further comprises one or more peptide bonds, said M comprising
at least one moiety that comprises a ligand, a dye, or both a ligand and a dye; and
wherein said target is labeled by forming a carbon-carbon bond between a carbon atom in
said target and a carbon atom in said labeling reagent by means of said reactive group R.
division from this
been published
,207068,206078
,195439,195438,195308,195307,195306,195305,195304,195303
(
.
__________________
[11][21]
[54]
TRANSDERMAL
ELECTROTRANSPORT DEVICE
AND METHOD FOR
MANUFACTURING SAME
[22]
[31]
[51]
[71]
[87]
[74]
10.09.2001
[32] 11.09.2000
60/231898
Int. Cl.(2010.01) A61N 01//30
ALZA CORPORATION, U.S.A.
WO/2002/022204
26A HABARZEL ST.,
[57]
96
154838
[33]
US
,
' 26 $
An electrotransport device for delivering or sampling an agent through a body surface
by electrotransport, the device having a housing including an upper, exterior housing
portion and a lower housing portion, the housing enclosing electronic components, and
at least one hydratable or hydrated reservoir containing water or an at least partially
aqueous solution of the agent. At least a portion of the housing is composed of an
"
ethylene-octene copolymer
__________________
[11][21]
[54]
DRINKING VESSEL
[22]
[31]
[51]
[71]
25.07.2001
[32] 12.09.2000
0022345.3
Int. Cl.(2009.01) A61J 11/00
JACKEL INTERNATIONAL
LIMITED, UNITED KINGDOM
WO/2002/022073
P.O.B. 2273,
REHOVOT 76122
[87]
[74]
[57]
97
154846
[33]
GB
,'
.
,4
2273 . . ,
An infant cup includes a cup body (12), a cover (16), a flexible mouthpiece (24) and a
valve element (26). The valve element (26) includes a sealing face (70) which closes
an orifice (44) in the mouthpiece in a relaxed position. The valve element includes an
angled face cooperating with an internal angled face of the mouthpiece such that when
pressure is applied to the valve element moves downwardly, opening the mouthpiece
orifice (44). The valve element is resiliently biased upwards such that when relaxed it
springs back to close the mouthpiece orifice (44) once again, and is biased upwards in
the closed position.
"
__________________
[11][21]
[54]
SYSTEM FOR MONITORING
BLOOD PRESSURE
[22]
[31]
[51]
[71]
17.05.2001
[32] 09.10.2000
200005776-0
Int. Cl.(2010.01) A61B 05//022, 05//04
HEALTHSTATS INTERNATIONAL
PTE LTD., SINGAPORE
CHOON MENG TING, NGAK HWEE
CHUA
WO/2002/030277
JMB, FACTOR & CO. LTD.,
HAR HOTZVIM HI-TECH PARK,
P.O.B. 45087,
JERUSALEM 91450
[72]
[87]
[74]
[57]
98
155300
"
[33]
SG
, "
#
,
'
,
45087 . . ,
A device for continuously monitoring a user's arterial blood pressure has a sensor
adapted to continuoulsy detect the blood pressuer and to generate signals
representative thereof by contact with an external surface of the user's body at a
location adjacent an artery. The sensor is securely held in operable contact with the
user's body at the location. A microprocessor interprets the signals generated by the
sensor to determine the actual arterial blood pressure. The sensor includes a projecting
portion for detecting and transmitting changes in blood pressure, wherein the
projecting portion is adapted to effect at least partial occlusion of the artery at the
location.
"
__________________
[11][21]
155783
–
[54]
MULTICELLULAR SYSTEMS OF
PLURIPOTENT HUMAN
EMBRYONIC STEM CELLS AND
CANCER CELLS AND USES
THEREOF
[22]
[51]
[71]
05.05.2003
Int. Cl.(2009.01) A61K 35/12, C12N 05/08, C12Q 01/00
TECHNION RESEARCH AND
, "
DEVELOPMENT FOUNDATION
LTD.
MATY TZUKERMAN, KARL
SKORECKI
WEBB & CO.,
2 PEKERIS ST., P.O.B. 2189,
REHOVOT 76121
[72]
[74]
[57]
–
,
#
,'
"
2
'
2189 . . ,
A method of producing a multicellular system of cancer cells of human origin within a
microenvironment of a normal human tissue derived from human embryonic stem
cells, comprising culturing hESC in conditions sutitable for the formation of embryoid
bodies or teratomas, and injecting cancer cells into at least one embryoid body or
teratoma, wherein the cancer cells within the multicellular system maintain their
ahnormal phenotype.
__________________
99
"
[11][21]
156597
[54]
RANDOM ANIMATED LOTTERY
SYSTEM
[22]
[31]
[51]
[71]
23.06.2003
[32] 12.08.2002
[33] US
10/218155
Int. Cl.(2009.01) A63F 13/00, G07F 17/32
SCIENTIFIC GAMES HOLDINGS
LIMITED, IRELAND
,
#
#
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
A lottery system graphically portraying a lottery result in animation, comprising:
a plurality of lottery terminals configured to provide lottery game parameters to a
plurality of players for selection; and
a game generator incluiding a random number generator and an animation drawing
subsystem, said animation drawing subsystem including a storage device,
wherein a video sequence is generated for each candidate game event, said video
sequence built of a plurality of animation segments generated for each candidate game
event and stored in said storage device of said animation drawing subsystem, wherein
at least one of said animation segments is randomly selected from a plurality of
possible appropriate segments, and after selection of the game parameters is ended at a
predetermined time, the random number generator randomly selects a plurality of
randomly selected numbers, and the animation drawing subsystem randomly selects
for at least one of the randomly selected numbers one of the appropriate stored
animation segments corresponding to the randomly selected number, and all of the
selected animation segments corresponding to the respective randomly selected
numbers into the video sequence;
wherein the animated lottery game video is made available to the plurality of players.
[74]
[57]
__________________
[11][21]
[54]
HYDROGEL WOUND DRESSING
AND METHOD OF MAKING AND
USING THE SAME
[22]
[31]
[51]
30.01.2002
[32] 30.01.2001
09/772801
Int. Cl.(2009.01) A61L 15/00, 15/26
100
157152
'
[33]
US
"
[71]
[87]
[74]
[57]
SHERWOOD SERVICES AG,
SWITZERLAND
WO/2002/060501
P.O.B. 11490,
TEL AVIV 62038
,'
"
124
11490 . . ,
A hydrogel wound dressing which is highly absorptive, contours to a wound site, and
maintains the wound in a moist state to promote healing thereof. The hydrogel wound
dressing may also contain additives to prevent bacterial and fungal infections and to
control wound odor.
__________________
[11][21]
[54]
MAGNETIC AND
ELECTROSTATIC
CONFINEMENT OF PLASMA IN A
FIELD REVERSED
CONFIGURATION
[22]
[31]
01.02.2002
[32] 01.02.2001
60/266074
60/297086
08.06.2001
10/066424
31.01.2002
Int. Cl.(2010.01) H05H 01//12
THE REGENTS OF THE
UNIVERSITY OF CALIFORNIA,
U.S.A.
NORMAN ROSTOKER, MICHL
BINDERBAUER, ARTAN QERUSHI,
HOSSANG TAHSIRI, EUSEBIO
GARATE, VITALY BYSTRITSKII
WO/2002/062112
DR. MARK FRIEDMAN LTD.,
MOSHE AVIV TOWER, 54TH
FLOOR,
7 JABOTINSKY ST.,
RAMAT GAN 52520
[51]
[71]
[72]
[87]
[74]
[57]
101
157159
[33]
7
US
US
US
'$
, "
, 54. ,
A system and method for containing plasma and forming a Field Reversed
Configuration (FRC) magnetic topology are described in which plasma ions are
"
-
"
contained magnetically in stable, non-adiabatic orbits in the FRC. Further, the
electrons are contained electrostatically in a deep energy well, created by tuning an
externally applied magnetic field. The simultaneous electrostatic confinement of
electrons and magnetic confinement of ions avoids anomalous transport and facilitates
classical containment of both electrons and ions. In this configuration, ions and
electrons may have adequate density and temperature so that upon collisions they are
fused together by nuclear force, thus releasing fusion energy. Moreover, the fusion fuel
plasmas that can be used with the present confinement system and method are not
limited to neutronic fuels only, but also advantageously include advanced fuels.
,188654
(
.
__________________
[11][21]
[54]
REFRACTIVE INTRAOCULAR
IMPLANT LENS
[22]
[31]
[51]
[71]
[72]
29.01.2002
[32] 30.01.2001
09/774127
Int. Cl.(2009.01) A61F 02/14
TIMOTHY R. WILLIS, U.S.A.
TIMOTHY R. WILLIS, LYLE E.
PAUL, JOSEPH COLLIN
WO/2002/060342
RAMAT GAN 52521
[87]
[74]
[57]
102
157177
–
[33]
US
, "
11
(1995)
, 15
,
. .'
A refractive intraocular lens (104) and method of locating the lens within the eye and
attaching the lens to the iris. The refractive intraocular lens (104) may be attached via a
staple (230), a fastener (312), anchor (412) or by the tip of the haptic (118).
"
__________________
[11][21]
157341
[54]
COMPOUNDS FOR USE IN
TREATING DEMYELINATING
DISEASES OR CONDITIONS AND
COMPOSITIONS COMPRISING
SAME
[22]
[31]
14.02.2002
[32] 15.02.2001
[33] US
60/268846
0119435.6
09.08.2001
GB
Int. Cl.(2010.01) A61K 31//4439, A61P 13//00, 25//28, C07D 40/1/12, 40/1/14
AVENTIS PHARMACEUTICALS
INC., U.S.A.
WO/2002/064126
, #
#
5 SHENKAR ST.,
5
' ,1 - $
P.O.B. 12704,
# 12704 . . ,
HERZLIYA 46733
N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of
blocking properties for both the potassium and sodium channels. These compounds are
useful for the treatment of Demyelinating Diseases and Conditions such as Multiple
Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are
also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and
Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.
[51]
[71]
[87]
[74]
[57]
,204313
(
.
__________________
103
"
[11][21]
157419
[54]
APPARATUS FOR TRAPPING
PESTS
[22]
[51]
[71]
14.08.2003
Int. Cl.(2009.01) A01M 23/00, 23/02
AMRAM OHAYON
,
MICHEL COHEN
,
,
#
#
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
An apparatus for trapping pests comprising:
(a) a housing defining an internal chamber with a floor in which an entrapped pest
remains until being released from said chamber;
(b) at least one tubular passageway spaced above the floor of said chamber, each of
said passageways being closed at a first end and open at a second end, and being
inclined so the said first end is higher than said second end;
(c) a space for receiving bait placed underneath said at least one tubular passageway;
(d) an aperture formed in the wall of each passageway and in communication with said
internal chamber, wherein the ratio of the distance between the closed end of a
passageway and the corresponding aperture to the distance between the aperture and
the open end of the passageway ranges from 25 to 60 percent; and
(e) an occluding element which is insertable and displaceable within each of said
passageways,
wherein each occluding element is upwardly displaceable upon ingress of a pest
within the corresponding passageway by pressure exerted by said pest and
downwardly displaceable by gravity upon passage of said pest through said aperture
formed in the wall of said passageway, said pest being trapped within said chamber
following displacement of said element below said aperture.
[74]
[57]
__________________
[11][21]
[54]
[22]
[31]
104
157669
NITROGEN-BASED
CAMPTOTHECIN DERIVATIVES
06.02.2002
797765
[32]
01.03.2001
[33]
US
"
[51]
[71]
[87]
[74]
[57]
Int. Cl.(2009.01) A61K 31/437, A61P 35/00, C07D 471/04, 487/04, 491/147
CATHOLIC HEALTHCARE WEST,
U.S.A.
CALIFORNIA PACIFIC MEDICAL
CENTER, U.S.A.
WO/2002/070525
, #
# ,
,
COHEN ZEDEK,
7
P.O.B. 12688,
# 12688 . . ,
HERZLIYA 46733
(20S) esters of camptothecin analogs are provided. The compounds are (20S) esters of
an aminoalkanoic acid or an imidoalkanoic acid and camptothecin, which is optionally
substituted at the 7, 9, 10, 11, and 12 positions of the camptothecin ring. The
compounds are useful for treating cancer.
__________________
[11][21]
[54]
METHOD OF DETERMINING
DIHYDROPYRIMIDINE
DEHYDROGENASE GENE
EXPRESSION
[22]
[31]
22.02.2002
[32] 02.03.2001
09/796807
09/842111
26.04.2001
09/879217
13.06.2001
Int. Cl.(2009.01) C12Q 01/68
RESPONSE GENETICS, INC., U.S.A.
KATHLEEN D. DANENBERG
WO/2002/070750
EITAN MEHULAL LAW GROUP,
10 ABBA EBEN BLVD.,
P.O. B. 2081,
HERZLIYA 46120
[51]
[71]
[72]
[87]
[74]
[57]
105
157694
[33]
US
US
US
,
#
,
10
#
2081 . . ,
The present invention relates to prognostic methods which are useful in medicine,
particularly cancer chemotherapy. The object of the invention to provide a method for
assessing Dihydropyrimidine dehydrogenase ()DPD expression levels in tissues and
prognosticate the probable resistance of a patient's tumor to treatment with 5-FU based
therapies by examination of the amount of DPD mRNA in a patient's tumor cells and
"
comparing it to a predetermined threshold expression level. More specifically, the
invention provides to oligonucleotide primer pairs DPD3A and DPD3B and methods
comprising their use for detecting levels of Dihydropyrimidine dehydrogenase (DPD)
mRNA.
,197283
(
.
__________________
[11][21]
[54]
TISSUE DISTRACTION DEVICE
[22]
[31]
08.03.2002
[32] 08.03.2001
60/274372
09/872905
01.06.2001
Int. Cl.(2009.01) A61B 17/00
SPINE WAVE, INC., U.S.A.
WO/2002/071921
P.O.B. 2273,
REHOVOT 76122
[51]
[71]
[87]
[74]
[57]
106
157768
[33]
US
US
,'
.
,4
2273 . . ,
An apparatus and method for distracting, in a given direction, and supporting two
tissue surfaces. A plurality of wafers (198, 200, 202) are consecutively inserted
between the two tissue surfaces to create a column (192) of wafers. The column of
wafers (192) is oriented between the tissue surfaces so as to expand in the given
direction as the wafers (198, 200, 202) are consecutively added to the column (192).
The apparatus is particularly suited for vertebral (60) compression fractures.
"
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
157770
USE OF A GLUCOCORTICOID
RECEPTOR ANTAGONIST IN THE
MANUFACTURE OF A
MEDICAMENT FOR
AMELIORATING THE
SYMPTOMS OF A STRESS
DISORDER
19.03.2002
[32] 23.03.2001
[33]
60/278523
Int. Cl.(2009.01) A61K 31/56, 31/57, 31/59
CORCEPT THERAPEUTICS, INC.,
U.S.A.
WO/2002/076390
P.O.B. 2273,
REHOVOT 76122
"
US
,'
.
,4
2273 . . ,
This invention generally pertains to the field of psychiatry. In particular, this invention
pertains to the discovery that agents which inhibit the binding of cortisol to its
receptors can be used in methods for treating stress disorders. Mifepristone, a potent
specific glucocorticoid receptor antagonist, can be used in these methods. The
invention also provides a kit for treating stress disorders in a human including a
glucocorticoid receptor antagonist and instructional material teaching the indications,
dosage and schedule of administration of the glucocorticoid receptor antagonist.
__________________
107
"
[11][21]
157786
[54]
PERSONALIZED COSMETICS
[22]
[51]
[71]
07.09.2003
Int. Cl.(2009.01) A61B 05/00, C12Q 01/68
AHAVA- DEAD SEA
LABORATORIES LTD.
ZEEVI MAOR, YORAM MILNER,
FRANCOIS MENAHEM
BREGEGERE
DR. EYAL BRESSLER,
11 TUVAL ST.,
RAMAT GAN 52522
[72]
[74]
[57]
"
,
,
$
'$ '$
, "
'
11
A method for designing specific dermo-cosmetic compositions that correspond to a
specific individual's skin condition comprising:
(a) sampling the skin to be treated, so as to allow the analysis of defined sets of
biomarkers relevant to at least one condition under treatment;
(b) measuring quantitatively at least one biomarker in said sampled skin, so as to
determine an individual profile of selected biomarkers that defines the individual skin
condition;
(c) analyzing said biomarker profile and designing a skin care protocol especially
adapted to the condition of said individual's skin, said skin care protocol comprising at
least one dermo-cosmetic composition corresponding to said condition of said
individual's skin;
(d) applying at least one dermo-cosmetic composition, in accordance with said skin
care protocol;
whereby a correspondence between said specific individual's skin condition and said
applied dermo-cosmetic composition is obtained.
__________________
[11][21]
[54]
108
METHODS AND KITS FOR
DETERMINING A RISK TO
DEVELOP CANCER, FOR
EVALUATING AN
EFFECTIVENESS AND DOSAGE
OF CANCER THERAPY AND FOR
CORRELATING BETWEEN AN
ACTIVITY OF A DNA REPAIR
ENZYME AND A CANCER
158003
,
"
[22]
[31]
[51]
[62]
[71]
[72]
[87]
[74]
[57]
21.03.2002
[32] 23.03.2001
[33]
09/815015
60/303338
09.07.2001
Int. Cl.(2009.01) C12Q 01/68, G01N 33/574
DIVISION FROM 158003
YEDA RESEARCH AND
DEVELOPMENT CO. LTD.
ZVI LIVNEH, TAMAR PAZ-ELIZUR,
SARA BLUMENSTEIN
WO/2002/076280
11
RAMAT GAN 52521
US
US
, "
, #
, "
-$
,
(1995)
, 15
,
#
. .'
Methods and kits for (i) determining a risk of a subject to develop cancer; (ii)
evaluating an effectiveness and dosage of cancer therapy administered to a cancer
patient; and (iii) determining a presence of correlation or non-correlation between an
activity of at least one DNA repair enzyme and at least one cancer, are disclosed.
,205890
(
.
__________________
[11][21]
[54]
DETECTION AND
AMPLIFICATION OF LIGANDS
[22]
[31]
[51]
[71]
[87]
[74]
29.03.2002
[32] 29.03.2001
09/821396
Int. Cl.(2009.01) G01N 33/53, 33/545
KENT STATE UNIVERSITY, U.S.A.
WO/2002/079755
P.O.B. 2273,
REHOVOT 76122
[57]
109
158165
[33]
US
,'
.
,4
2273 . . ,
Devices and systems for the detection of ligands comprising at least one receptor and
an amplification mechanism comprising a liquid crystalline, where an amplified signal
is produced as a result of receptor binding to a ligand are provided. Also provided are
"
methods for the automatic detection of ligands.
__________________
[11][21]
[54]
USE OF 5-LIPOXYGENASE
INHIBITORS FOR THE
PREPARATION OF A
PHARMACEUTICAL
COMPOSITION FOR TREATING
ACNE
[22]
[31]
[51]
[71]
29.04.2002
[32] 30.04.2001
10121252.6
Int. Cl.(2010.01) A61K 31//00, 31//381
CHRISTOS C. ZOUBOULIS,
GERMANY
WO/2002/089791
26A HABARZEL ST.,
[87]
[74]
[57]
110
158559
–5
[33]
DE
,
' 26 $
The invention relates to the use of lipoxygenase inhibitors for treating acne,
particularly inflammatory acne. The inventive lipoxygenase inhibitor can be used
alone or in combination with other lipoxygenase inhibitors or anti-acne active agents
in a pharmaceutically suitable composition, particularly through oral and/or local-topic
application.
"
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
158589
CARBOXYLIC ACID
SUBSTITUTED OXAZOLE
DERIVATIVES, PROCESS FOR
THEIR MANUFACTURE,
PHARMACEUTICAL
THEM AND USE THEREOF IN
THE PREPARATION OF
MEDICAMENTS FOR THE
TREATMENT AND
PROPHYLAXIS OF DISEASES
WHICH ARE MODULATED BY
PPAR-ALPHA AND -GAMMA
ACTIVATORS
,
–
,
– PPAR
06.05.2002
[32] 15.05.2001
[33] EP
01111745.4
Int. Cl.(2009.01) A61K 31/421, A61P 03/10, C07D 263/32, 413/12
F. HOFFMANN-LA ROCHE AG,
SWITZERLAND
WO/2002/092084
,
P.O.B. 5352,
BEER-SHEVA 84152
#
#
,
5352 . . ,
The present invention relates to compounds of formula (I) wherein R1 to R7 are as
defined in the description and claims, and pharmaceutically acceptable salts and esters
thereof. The compounds are useful for the treatment of diseases such as diabetes.
__________________
111
"
[11][21]
158969
[54]
MODIFIED ANTIBODIES TO
PROSTATE-SPECIFIC
MEMBRANE ANTIGEN AND USES
THEREOF
[22]
[31]
30.05.2002
[32] 01.06.2001
[33]
60/295214
60/323585
20.09.2001
60/362810
08.03.2002
Int. Cl.(2010.01) A61K 39//395, C07K 16//30
CORNELL RESEARCH
FOUNDATION, INC., U.S.A.
WO/2002/098897
SILBER, GERBER AND LEWIN,
29B KEREN HAYESOD STREET
JERUSALEM
[51]
[71]
[87]
[74]
[57]
US
US
US
,
' 29
,
Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain
of human prostate specific membrane antigen (PSMA) are provided. The modified
anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less
immunogenic compared to their unmodified counterparts to a given species, e.g., a
human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids,
recombinant expression vectors and host cells for making such antibodies and
fragments are also disclosed. Methods of using the antibodies of the invention to detect
human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing
cancer or prostatic cell, either in vitro or in vivo, are also provided.
,201274
(
.
__________________
[11][21]
[54]
[22]
[31]
[51]
112
159065
ELECTRONIC ARRAY AND
METHODS FOR FABRICATING
SAME
26.11.2003
[32] 06.12.2002
313078
Int. Cl.(2009.01) H01L 23/02
[33]
US
"
[71]
[74]
[57]
GENERAL ELECTRIC COMPANY,
U.S.A.
SELIGSOHN GABRIELI & CO.,
,'
$
31 YAVNE ST.,
31
'
P.O.B. 1426,
1426 . . ,
TEL AVIV 61013
A tileable sensor array comprising:
a substrate (14) including a front side and a back side;
a plurality of transducers (10) fabricated on said front side of said substrate,
said transducers arranged in a continuous two-dimensional array such that each
transducer is butted against at least two adjacent transducers;
a plurality of input/output connections (34) positioned on said back side of said
substrate, said input/output connections electrically coupled to said transducers;
at least one electronic device (18) comprising at least one signal processor circuit; and
a flexible metal-on-polyimide interposer (16) positioned between and against said
substrate and said electronic device, said flexible interposer comprising a multilayer
interconnect system configured to electrically connect said transducers and said
input/output connections to said electronic device.
__________________
[11][21]
159578
[54]
DIFFERENTIATED CELL
POPULATION FOR GENERATING
OSTEOPROGENITORS OR
OSTEOBLASTS
[22]
[31]
[51]
03.07.2002
[32] 06.07.2001
[33] US
60/303732
Int. Cl.(2010.01) A61K 35//12, A61L 27//38, C12N 05//071, 05//095, 05//10, C12Q
113
"
[71]
[87]
[74]
[57]
01//02
GERON CORPORATION, U.S.A.
WO/2003/004605
P.O.B. 2273,
REHOVOT 76122
,'
.
,4
2273 . . ,
This invention provides populations of mesenchymal cells obtained from pluripotent
stem cells by differentiating them ex vivo. Multipotent mesenchymal cells can in turn
be differentiated into more specialized cell types such as osteoblasts, with properties
that make them suitable for reconstituting musculoskeletal cell function in an
individual. The compositions, methods, and techniques described in this disclosure can
be used for a variety of commercially important diagnostic, drug screening, and
therapeutic applications.
__________________
[11][21]
[54]
METHOD FOR THE
PRODUCTION OF 6-(4CHLOROPHENYL)- 2,2DIMETHYL- 7- PHENYL- 2,3DIHYDRO-1H -PYRROLIZIN- 5YLACETIC ACID
[22]
[31]
[51]
[71]
[87]
[74]
21.08.2002
[32] 23.08.2001
10141285.1
Int. Cl.(2009.01) C07D 207/20, 487/04
MERCKLE GMBH, GERMANY
WO/2003/018583
26A HABARZEL ST.,
[57]
114
160047
– 2,2 – (
–5–
[33]
– 4) – 6
– 3,2
–
–7–
H1
DE
,
' 26 $
The invention relates to a method for the production of 6-(4-chlorophenyl)-2,2dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizin-5-ylacetic acid, in which 5-benzyl-3,3dimethyl-3,4-dihydro-2H-pyrrole is reacted with -bromo-4-chloroacetophenone to
give 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-lH-pyrrolizine with
introduction of the acetic acid group in the 5 position, whereby 5-benzyl-3,3-dimethyl3,4-dihydro-2H-pyrrole is obtained by hydrogenation of 2,2-dimethyl-4-oxo-5phenylvaleronitrile or a ketal. The invention further relates to methods for the
"
production intermediates occurring in the above method.
__________________
[11][21]
160157
[54]
COMBINATION MOTIF IMMUNE
STIMULATORY
OLIGONUCLEOTIDES WITH
IMPROVED ACTIVITY
[22]
[31]
19.08.2002
[32] 17.08.2001
[33] US
60/313273
60/393952
03.07.2002
US
Int. Cl.(2009.01) A61K 31/7088, A61P 31/00, 35/00, 37/04, 37/08, C12N 15/11
UNIVERSITY OF IOWA RESEARCH
FOUNDATION, U.S.A.
COLEY PHARMACEUTICAL
GMBH, GERMANY
WO/2003/015711
,'
.
P.O.B. 2273,
,4
REHOVOT 76122
2273 . . ,
[51]
[71]
[87]
[74]
[57]
A class of immunostimulatory nucleic acids having at least two functionally and
structurally defined domains is provided. This class of combination motif
immunostimulatory nucleic acids activates an immune response and is useful for
treating a variety of immune realted disorders such as cancer, infectious disease, and
allergic disorders. The nucleic acids also stimulate activation of natural killer cells and
production of type 1 interferon.
__________________
[11][21]
[54]
115
PROCESS FOR IDENTIFICATION
OF A DISPOSITION FOR A
GENETIC DISORDER RESULTING
160555
,
,
,
–
,
"
IN PHENOTYPIC OBESITY, BODY
OVERWEIGHT, ANOREXIA
NERVOSA, BULIMIA OR BODY
UNDERWEIGHT
[22]
[31]
[51]
[71]
[87]
[74]
[57]
21.08.2002
[32] 31.08.2001
01120943.4
Int. Cl.(2009.01) C12Q 01/68
GMBH, GERMANY
WO/2003/020965
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
[33]
EP
,
#
# ,
,
7
# 12688 . . ,
A process for identification of a human individual's disposition for a genetic disorder
in maintaining this individual's body weight by detecting single nucleotide
polymorphisms (SNPs) of the melanin-concentrating hormone receptor (MCH-R).
__________________
[11][21]
160762
[54]
CYCLOSPORIN ANALOGUE
MIXTURES AND THEIR USE AS
IMMUNOMODULATING AGENTS
[22]
[31]
[51]
17.10.2002
[32] 19.10.2001
[33] US
60/346201
Int. Cl.(2009.01) A61K 09/08, 09/107, 09/48, 38/13, 47/10, 47/14, 47/34, 47/42, A61P
01/00, 03/00, 07/00, 09/00, 11/00, 17/00, 19/00, 21/00, 25/00, 27/00, 29/00, 31/00,
37/00, C07K 07/64
ISOTECHNIKA INC., CANADA
WO/2003/033527
,'
.
P.O.B. 2273,
,4
REHOVOT 76122
2273 . . ,
[71]
[87]
[74]
[57]
116
The invention is directed to isomeric mixtures of cyclosporine analogues that are
structurally similar to cyclosporine A . The mixtures possess enhanced efficacy and
reduced toxicity over the individual isomers and over naturally occurring and other
presently known cyclosporines and cyclosporine derivatives. Embodiments of the
"
present invention are directed toward cis and trans-isomers of cyclosporin A analogs
referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers
exhibit a combination of enhanced potency and reduced toxicity over the naturally
occurring and presently known cyclosporins. ISATX247 isomers and alkylated,
arylated, and deuterated derivatives are synthesized by stereoselective pathways where
the particular conditions of a reaction determine the degree of stereoselectivity.
Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent
comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio
of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight
of the mixture.
__________________
[11][21]
160795
[54]
GALENIC MICROPARTICULATE
ORAL FORMULATION FOR
DELAYED AND CONTROLLED
RELEASE OF
PHARMACEUTICAL ACTIVE
PRINCIPLES
[22]
[31]
[51]
[71]
09.10.2002
[32] 09.10.2001
[33] FR
01/12999
Int. Cl.(2010.01) A61K 09//00, 09//14, 09//22, 09//50, 09//52, 09//56
FLAMEL TECHNOLOGIES,
FRANCE
WO/2003/030878
,
26A HABARZEL ST.,
' 26 $
[87]
[74]
117
"
[57]
The invention concerns a microparticulate system for delayed and controlled release of
active principles whereof the in vivo absorption window is essentially limited to the
high parts of the gastrointestinal tract, said system being designed for oral
administration. The invention aims at providing a system for reliably releasing active
principles through a double time-dependent and pH-dependent mechanism. Therefor,
the invention proposes a multiple microcapsule galenic oral formulation designed so as
to guarantee its therapeutic efficacy, and wherein the release of active principles is
controlled by a double release-triggering mechanism: time-triggering and pHtriggering. Said system consists of microcapsules (200 to 600 $g(m)m) comprising a
core of active principles coated with a coating film (not more than 40 wt. %) including
a hydrophilic polymer A (Eudradigit$m(3)L) and a hydrophobic compound B
(vegetable wax with melting point between 40 to 90°C), B/A ranging between 0.2 and
1.5. Said microcapsules have a dissolving behaviour in vitro such that at constant pH
1.4, a latent period ranging between 1 and 5 hours is observed followed by a release of
active principles and such that the shift from pH 1.4 to of pH 6.8 results in a release of
active principles without latent time in vitro.
__________________
[11][21]
160909
[54]
HALOGEN-FREE FLAME
RETARDANT COMPOUNDS AND
METHODS FOR THEIR
PREPARATION
[22]
[31]
[51]
[71]
01.10.2002
[32] 09.10.2001
[33] NL
1019144
Int. Cl.(2010.01) C07D 25/1/66, C08K 05//3492
CIBA SPECIALTY CHEMICALS
HOLDING INC., SWITZERLAND
WO/2003/031417
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[87]
[74]
[57]
118
,
' 26 $
The invention relates to a compound of the general formula: Z1-O[m(R1PO3),n(R2HPO3]-Z2, in which [m(R1PO3)] represent a copolyphosphate, with
m (R1PO3) units and n (R2HPO3) units; R3 represents an ammonium building block;
R2 represents a 1,3,5-triazine building block; Z1 and Z2 represent ammonium or 1,3,5triazine building blocks, to be chosen independently of each other; m and n represent
"
whole numbers greater than or equal to 1; and m+n numbers greater than 3. The
invention further relates to a method for the preparation of the above compound and to
flame-retardant polymer compositions in which compounds with the above formula are
applied as flame retardant, the use of the halogen-free compound in a coating
composition and a substrate containing a coating formed from the coating composition
that has been cured.
__________________
[11][21]
160938
,
[54]
CONIOSULPHIDES AND THEIR
DERIVATIVES, PROCESSES FOR
PREPARING THEM AND THEIR
USE AS PHARMACEUTICALS
[22]
[31]
[51]
[71]
06.09.2002
[32] 22.09.2000
[33] DE
10146737.0
Int. Cl.(2009.01) A61K 38/05, 38/06, A61P 25/28, C07C 323/00, C07K 05/04, 07/06
GMBH, GERMANY
WO/2003/029495
, #
# ,
,
COHEN ZEDEK,
7
P.O.B. 12688,
# 12688 . . ,
HERZLIYA 46733
[87]
[74]
[57]
119
The invention relates to compounds of formula (I), which are formed from the microorganism Coniochaeta ellipsoidea Udagawa, DSM 13856, or from one of its mutations
and/or variants during fermentation and which optionally are chemically converted
into derivatives. The invention also relates to a method for producing compounds of
formula (I) and to the use of the same as medicaments. In addition, the invention
relates to the use of a compound of formula (VI) for producing a medicament for the
treatment and prophylaxis of degenerative neuropathies or Alzheimer's disease.
"
__________________
[11][21]
160939
[54]
ENERGY ABSORBING DEVICE
FOR A VECHICLE SEAT
[22]
[51]
[71]
[74]
18.03.2004
Int. Cl.(2009.01) B60N 02/427, 02/54, F16F 03/10
PLASAN -KIBBUTZ SASA
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[57]
120
/
,
-
' 26 $
An energy absorbing device (1) for reducing acceleration transmitted to a seated
occupant in a vehicle as a result of a force of a high energy impact acting thereon in an
impact direction, the device comprising a first energy absorbing mechanism (8) having
a first dimension in the impact direction and capable of undergoing elastic
deformation of a predetermined amount in the impact direction; and a second energy
absorbing mechanism (10) having a second dimension in the impact direction, which
is smaller than the first dimension to a distance corresponding to said amount of
elastic deformation, thereby allowing the second mechanism to be loaded with said
force after the first mechanism has undergone said elastic deformation, said second
mechanism comprising a material capable of progressive deformation.
"
__________________
[11][21]
160988
[54]
PEPTIDES USEFUL IN
IMMUNOMODULATION
[22]
[31]
[51]
15.10.2002
[32] 15.10.2001
[33] IL
145926
Int. Cl.(2010.01) A61K 38//08, 38//10, A61P 35//00, 37//00, C07K 07//06, 07//08,
16//28, C12N 15//12, 15//63
CURETECH LTD.
, "
MOR RESEARCH APPLICATIONS
, "
LTD.
BRITTA HARDY, ANNAT RAITER,
,
,
LEAH KLAPPER
WO/2003/033644
WEBB & CO.,
,'
"
2
'
REHOVOT 76121
2189 . . ,
[71]
[72]
[87]
[74]
[57]
The present invention provides peptides and polynucleotides, and their use for
immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy,
and for diagnosis purposes. The immunomodulatory effect includes induction of
proliferation and activation of peripheral blood lymphocytes and induction of an antitumor effect upon administration of peptides of the invention to subjects suffering
from cancer.
__________________
121
"
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
161114
USE OF SPECIFIC DOSE OF
FONDAPARINUX SODIUM IN THE
PREPARATION OF A
MEDICAMENT FOR THE
TREATMENT OF ACS
ACS–
07.11.2002
[32] 13.11.2001
[33]
01204323.8
Int. Cl.(2009.01) A61K 31/7024, A61P 09/10
GLAXO GROUP LIMITED, UNITED
KINGDOM
WO/2003/041722
P.O.B. 2273,
REHOVOT 76122
EP
,'
.
,4
2273 . . ,
The invention relates to the use of a dose of 2.5 mg of the pentasaccharide methyl O(2-deoxy-2-sulfoamino-6-O-sulfo- -D-glucopyranosyl)-(1-4)-O-( -D-glucopyranosyl
uronic acid)-(1-4)-O-(2-deoxy-2-sulfoamino-3,6-di-O-sulfo- -D-glucopyranosyl)-(14)-O-(2-O-sulfo- -L-idopyranosyl uronic acid)-(1-4)-2-deoxy-2-sulfoamino-6-Osulfo- -D-glucopyranoside or a pharmaceutically acceptable salt thereof for the
preparation of a medicament for the treatment of Acute Coronary Syndromes (ACS).
__________________
[11][21]
161145
[54]
PROCESS FOR PREPARATION OF
GRANULATE OR POWDER FOR
PRODUCING COATING OR
BINDING AGENTS FOR
MEDICAMENTS AND
GRANULATE OR POWDER
OBTAINED BY SAID PROCESS
[22]
[31]
[51]
08.07.2003
[32] 27.08.2002
[33] DE
10239999.9
Int. Cl.(2009.01) A61K 09/00, 09/14, 09/16, 09/28, 47/10, 47/12
122
"
[71]
[87]
[74]
[57]
EVONIK ROHM GMBH, GERMANY
WO/2004/019918
26A HABARZEL ST.,
,
' 26 $
The invention relates to a method for producing a granulate or powder which is
suitable as a coating and binding agent for oral and dermal medicaments, cosmetic
products or food supplements and substantially consists of (a) a copolymer containing
radically polymerized C1 to C4 esters of acrylic acid or methacrylic acid and
additional (meth)acrylate monomers that comprise functional tertiary amino groups,
(b) 3 to 25 percent by weight relative to (a) of an emulsifier having an HLB value of at
least 14, and (c) 5 to 50 percent by weight relative to (a) of C12 to C18 monocarboxylic
acid or a C12 to C18 hydroxyl compound. Components (a), (b), and (c) are
simultaneously or successively blended or mixed by optionally adding a
pharmaceutical agent and/or other common loading agents, melted and mixed in a
heatable mixer, whereupon the melted product is cooled and comminuted into a
granulate or powder.
__________________
[11][21]
161447
[54]
SUPERCRITICAL FLUIDS
PROCESSING: PREPARATION OF
PROTEIN MICROPARTICLES
AND THEIR STABILISATION
[22]
[31]
[51]
[71]
[87]
[74]
21.10.2002
[32] 22.10.2001
[33] EP
01125048.7
Int. Cl.(2009.01) C07K 01/30, 01/32, C12N 09/96
DOMPE S.P.A., ITALY
WO/2003/035673
26A HABARZEL ST.,
[57]
123
:
,
' 26 $
A process for the co-precipitation of a substance with a stabiliser therefor, by a gas anti
solvent process comprising introducing into a particle formation vessel a supercritical
fluid pure or mixed with a modifier; and a solution comprising said substance and said
stabiliser dissolved in a solvent; so as said solvent is extracted from the solution by
said supercritical fluid and co-precipitation of the substance and stabiliser occurs. The
"
process may be carried out using an apparatus comprising a particle formation vessel
(22) and a nozzle (27) having a central orifice (39) serving to introduce a solution of
the substance and a plurality of outer orifices (41) serving to carry a flow of
supercritical fluid into the particle formation vessel (22), such that the solvent is
extracted from the solution by the supercritical fluid and precipitation of micron sized
particles of the substance/stabilizer occurs. The substance is preferably a protein of
pharmaceutical interest, which is highly stabilized for storage by this process.
__________________
[11][21]
161545
[54]
PHARMACEUTICAL AND
COSMETIC COMPOSITIONS
CONTAINING OXY GROUPBEARING AROMATIC
ALDEHYDES
[22]
[31]
16.08.2002
[32] 16.11.2001
[33] US
60/332277
60/346049
04.01.2002
US
60/368518
01.04.2002
US
60/368565
01.04.2002
US
60/384589
30.05.2002
US
60/384690
30.05.2002
US
Int. Cl.(2009.01) A61K 09/52, 31/11, C07C 47/00, 47/54
BIOFORM MEDICAL, INC., U.S.A.
WO/2003/043621
26A HABARZEL ST.,
[51]
[71]
[87]
[74]
[57]
124
,
' 26 $
Disclosed are pharmaceutical and cosmetic compositions containing oxy groupbearing aromatic aldehyde compounds or acetal derivatives thereof. Some of the
"
disclosed compositions are useful as topical therapeutics for treating inflammatory
dermatologic conditions. Some of the compositions are useful in transdermal and other
systemic dose forms for treating other inflammatory conditions in mammals.
__________________
[11][21]
161562
[54]
PSYCHOSOMATIC DIAGNOSIS
SYSTEM
[22]
[51]
[71]
11.11.2002
Int. Cl.(2010.01) A61B 05//00, G10L 17//00
ELECTRONIC NAVIGATION
RESEARCH INSTITUTE, JAPAN
MITSUBISHI SPACE SOFTWARE
CO., LTD., JAPAN
KAKUICHI SHIOMI, JAPAN
MICHIKO TAKAOKA, JAPAN
WO/2004/043259
DR. YITZHAK HESS & PARTNERS,
279 HAYARKON ST.,
P.O.B. 6451,
TEL AVIV 61063
[87]
[74]
[57]
,
279
#
"
6451 . . ,
Psychosomatic diagnosis system capable of automatically and objectively evaluating
the psychosomatic conditions of a person subjected to the diagnosis according to
replies to inquiries made to the person. The psychosomatic diagnosis system
diagnoses the psychosomatic conditions by the voice replied to the inquiries and
comprises an index database, a voice processing unit for acquiring the voice as a voice
signal, an analog!digital conversion unit for converting the voice signal into a digital
voice signal, a data processing unit for calculating a human strange attractor by using
the chaos theory and storing it in the index database, an attractor evaluation unit for
performing quantitative evaluation by using the calculated human strange attractor,
and a display unit for displaying the result of evaluation.
__________________
125
"
[11][21]
161680
[54]
PARAMETER ESTIMATOR
CONFIGURED TO DISTINGUISH
BETWEEN PEAKS AND
SIDELOBES OF CORRELATION
FUNCTION
[22]
[31]
01.11.2002
[32] 01.11.2001
[33] US
60/340100
10/060885
29.01.2002
US
Int. Cl.(2009.01) G01S 01/00, 05/14, H04B 01/707, H04J 13/04
U.S.A.
WO/2003/039021
,'
P.O.B. 2273,
REHOVOT 76122
[51]
[71]
[87]
[74]
[57]
.
,4
2273 . . ,
A parameter estimator for estimating one or more parameter(s) from a signal is
described. A correlation function is derived from the signal, and the correlation
function analyzed to determine if one or more first peak(s) (312) are present, and, if so,
distinguishable from the sidelobe(s) (318) of a second peak. If the one or more first
peak(s) (312) are present and distinguishable from the sidelobe(s) (318) of the second
peak, the one or more parameter(s) are estimated from the one or more first peak(s). If
the one or more first peak(s) are not present, or, if present, are not distinguishable from
the sidelobe(s) of the second peak, the one or more parameter(s) are estimated from the
second peak. The parameter estimator may be employed in a subscriber station to
estimate a parameter such as the time of arrival of one or more base station or sector
pilot signals in a wireless communication system. This information may be utilized in
an overall advanced forward link trilateration process for estimating the location of the
subscriber station.
__________________
[11][21]
[54]
126
161830
– 4 , 2, 1
1,2,4-THIADIAZOLIUM
DERIVATIVES AS
MELANOCORTIN RECEPTOR
MODULATORS
"
[22]
[31]
[51]
[71]
[87]
[74]
[57]
05.11.2002
[32] 08.11.2001
[33] US
60/337762
Int. Cl.(2009.01) A61K 31/433, A61P 03/00, C07D 285/08
ORTHO-MCNEIL
PHARMACEUTICAL, INC., U.S.A.
WO/2003/040118
26A HABARZEL ST.,
,
' 26 $
The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives of the
formula (I); wherein R1, R2 and R4 are ring containing radicals, R3 is H, alkyl,
alkenyl or alkynyl, useful as agonists or antagonists of the melanocortin receptor. More
particularly, the compounds of the present invention are useful for the treatement of
metabolic, CNS and dermatological disorders.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
127
161883
TRANSPORT FORMAT
COMBINATION SELECTION FOR
COMPRESSED MODE IN A WCDMA SYSTEM
12.11.2002
[32] 13.11.2001
[33]
09/993381
Int. Cl.(2009.01) H04B 07/005, H04J 13/00
U.S.A.
WO/2003/043221
P.O.B. 2273,
REHOVOT 76122
CDMA–W
US
,'
.
,4
2273 . . ,
Techniques for determining valid (i.e., supported) TFCs from among all configured
TFCs for normal and compressed modes. These techniques maintain sufficient
historical information such that 'TFC qualification' may be accurately performed. In a
first scheme, Tx_power_requirement states are maintained for different combinations
of each TFC. One combination is applicable for each TFC at each TFC interval, and
"
valid TFCs are determined from applicable combinations in the proper state(s). In a
second scheme, two Tx_power_requirement states are maintained for each TFC for the
normal and compressed modes. In a third scheme, a single Tx_power_requirement
state is maintained for each TFC for both modes based on a particular relative power
requirement. In a fourth scheme, Tx_power_requirement states are maintained for a set
of relative 'bins' that cover the total range of required transmit power for all TFCs. And
in a fifth scheme, a set of relative power requirement thresholds are maintained.
__________________
[11][21]
161926
–
[54]
SELF-LIMITING
ELECTROSURGICAL RETURN
ELECTRODE
[22]
[31]
[51]
[71]
29.04.2003
[32] 09.05.2002
[33] US
10/142253
Int. Cl.(2010.01) A61B 18//08, 18//16, A61G 13//00
MEGADYNE MEDICAL PRODUCTS,
INC., U.S.A.
BORIS GLINER
WO/2003/094766
P.O.B. 1352,
JERUSALEM 91013
[87]
[74]
[57]
128
,
,
,%
1352 . . ,
A removable semi-insulating sheet for use in self-limiting electrosurgical return
electrode for electrosurgery. Through the selection of impedance characteristics for the
electrode materials of the principal body of the semi-insulating sheet, and through
tailoring of semi-insulating sheet geometries, the return electrode of the present
invention is self-regulating and self-limiting as to current density and temperature rise
so as to prevent patient trauma. The semi-insulating sheet has an effective bulk
impedance equal to or greater than about 4,000 ohm-cm. The effective bulk impedance
"
of the sheet may rise from resistive components, capacitive components, inductive
components, or combinations thereof. The configuration of the presently described
return electrode allows the electrode to self-limit the electrode's current densities,
thereby preventing burning of a patient during surgery.
__________________
[11][21]
[54]
IMAGE IDENTIFICATION
SYSTEM
[22]
[31]
[51]
[71]
15.11.2002
[32] 16.11.2001
09/991589
Int. Cl.(2010.01) G06K 09//62
BIO-KEY INTERNATIONAL, INC.,
U.S.A.
WO/2003/044725
P.O.B. 1352,
JERUSALEM 91013
[87]
[74]
[57]
129
162003
[33]
US
,
,%
1352 . . ,
Methods and procedures for improving the performance and reliability of image
analysis within an image identification system (10) include a series of image
qualification functions designed to quickly process a fraction of available image data
and to provide feedback to a system user pertaining to image quality and authenticity.
Functions designed to produce image models based on original image data and to
catalogue such image models into a searchable database (16) are included in the
present invention. The present invention also includes functions for comparing one
image model to another. Finally, the present invention provides functions for making a
quick determination as to which, if any, of a potential thousands (or more, i.e.,
millions) of image models within a searchable database (16) exhibit a desired level of
similarity, as compared to a target image model.
"
__________________
[11][21]
[54]
INFANT SUPPORT
[22]
[51]
[71]
16.05.2004
Int. Cl.(2010.01) A47D 07//03, 15//00
AMINACH BEDDING &
FURNITURE MANUFACTURING
LTD.
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[74]
[57]
162012
, "
$
,
' 26 $
A support system for an infant or child comprising:
a mattress having a movable part that is pivotable with respect to a stationary part; and
a harness adapted for holding said infant or child, and configured to be releasably
secured to said movable portion, said system having at least one operative
configuration, wherein said harness is selectively secured to said movable part, and
said movable part is selectively pivoted with respect to said fixed part to provide a
desired inclined position to an infant or child that may be selectively secured to said
harness.
__________________
[11][21]
[54]
METHOD FOR PREPARING A
GLUCOSAMINE COMPOUND
[22]
[31]
[51]
[71]
02.12.2002
MI2001A002818 [32] 28.12.2001
Int. Cl.(2009.01) C07H 05/06
AZIENDE CHIMICHE RIUNITE
ANGELINI FRANCESCO A.C.R.A.F.
S.P.A., ITALY
WO/2003/055897
[87]
130
162272
[33]
IT
"
[74]
[57]
,
26A HABARZEL ST.,
' 26 $
Method for preparing a compound comprising protonated glucosamine and Cl ,-Na+
and SO42- ions, in which (a) glucosamine hydrochloride and a stoichiometric excess of
sodium sulphate are placed in water, (b) the mixture obtained from the preceding step
(a) is heated, (c) the mixture is cooled, and (d) the solid present in the said cooled
mixture is recovered by filtration. Compound comprising protonated glucosamine and
Cl-, Na+ and SO42- ions and having the X-ray diffraction diagram of Fig. 1.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
162409
TRANSMITTING INFORMATION
ABOUT A TARGET OBJECT
BETWEEN A PRESCANNER AND
A CT SCANNER
06.02.2003
[32] 06.02.2002
10/068459
Int. Cl.(2009.01) G01N 23/04
L-3 COMMUNICATIONS SECURITY
& DETECTION SYSTEMS, U.S.A.
WO/2003/067770
P.O.B. 2273,
REHOVOT 76122
CT
[33]
US
,'
.
,4
2273 . . ,
[57]
A method or apparatus for analyzing an object includes an X-ray prescanner (1) that
performs a prescan of the object to determine prescan information about the object.
Then, a computer tomography (CT) scanner (3) performs a CT scan on at least one
plane of the object based on the prescan information to determine CT information. In
one embodiment, if the CT scan of the object includes or is in the vicinity of metal,
then metal artifact correction of a reconstructed image from the CT scan is performed
based on the prescan information. In another embodiment, a processor (5) analyzes the
CT information and the prescan information to determine whether to update the
prescan information based on the CT information.
131
"
__________________
[11][21]
162670
,
[54]
INFORMATION DISTRIBUTION
SYSTEM AND METHOD,
PROGRAM REALIZING THE
METHOD AND INFORMATION
MEDIUM CONCERNING THE
PROGRAM
[22]
[31]
[51]
[71]
[87]
[74]
25.12.2002
[33] JP
2001-392930 [32] 25.12.2001
Int. Cl.(2010.01) G06F 15//173, G06Q 30//00, H04N 07//16, 07//173
DENTSU INC., JAPAN
WO/2003/056829
REINHOLD COHN AND
,
PARTNERS,
' 26 $
26A HABARZEL ST.,
[57]
132
The information transmission medium has become broadband and information
distribution on demand has become possible. Accordingly, there is a need for an
autonomous information distribution system satisfying a variety of client needs and
promptness of processing. An information distribution system includes number-ofdistributions management means, distribution list creation means for creating a
distribution list for selection in which the selection probability of each information
material when random selection is performed is equal to a ratio of the remaining
number (to be distributed) of each information material with respect to the total of the
remaining numbers (to be distributed) of the information materials at a moment, handy
assigning means for assigning a handy to the remaining number (to be distributed) of
each information material contained in the distribution list, and random selection
means for performing random selection of the distribution list and selecting one
information material. The information material selected is distributed from an
"
information distribution server via an information network to a distribution demand
terminal and the content of the distribution list is updated.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[72]
[87]
[74]
133
USE OF NON-NUCLEOSIDIC
INHIBITORS OF REVERSE
TRANSCRIPTASE FOR THE
PREPARATION OF
PHARMACEUTICAL
COMPOSITIONS FOR THERAPHY
AND / OR PREVENTION OF
PATHOLOGIES CHARACTERIZED
BY LOSS OF CELLULAR
DIFFERENTIATION AND
UNCONTROLLED CELL GROWTH
162680
–
/
23.12.2002
[33] IT
RM2001A000767 [32] 24.12.2001
19.08.2002
MI2002A001833
IT
Int. Cl.(2009.01) A61K 31/495, 31/536, 31/551, 38/00
ISTITUTO SUPERIORE DI SANITA,
ITALY
CORRADO SPADAFORA, PATRIZIA
LAVIA, ELISABETTA MATTEI,
GUGLIELMO PALOMBINI, RODOLFO
NELLO LORENZINI, CLARA NERVI
WO/2003/055493
EITAN, PEARL, LATZER AND COHEN
, #
# ,
,
ZEDEK,
7
P.O.B. 12688,
# 12688 . . ,
HERZLIYA 46733
"
[57]
The invention refers to the use of Reverse Transcriptase (RT) inhibitor compounds for
the preparation of pharmaceutical compositions to counteract the loss of cellular
differentiation in tumour and non tumour pathologies, said compound being able to
bind the hydrophobic pocket on the RT subunit p66. Particularly preferred for such
uses are the following compounds: nevirapine, efavirenz, delavirdine, corresponding
salts and/or pharmaceutically acceptable derivatives thereof.
__________________
[11][21]
[54]
CAPACITOR-GRADE LEAD
WIRES WITH INCREASED
TENSILE STRENGTH AND
HARDNESS
[22]
[31]
[51]
[71]
[87]
[74]
21.01.2003
[32] 24.01.2002
60/351554
Int. Cl.(2009.01) H01G 09/042
H.C. STARCK INC., U.S.A.
WO/2004/003949
26A HABARZEL ST.,
[57]
134
162966
[33]
US
,
' 26 $
A capacitor-grade wire made from powder metallurgy containing at least niobium and
silicon, wherein the niobium is the highest weight percent metal present in the niobium
wire. The wire having a controlled tensile strength at finish diameter exceeds the
strength of capacitor-grade wire formed by ingot metallurgy. Also, the powder
metallurgy wire hardness exceeds capacitor-grade wire formed from ingot metallurgy
with electrical leakage meeting the specifications normally applied to capacitor grade
tantalum, niobium or niobium-zirconium lead wire at sinter temperatures of about
"
1150°C and above.
__________________
[11][21]
163187
[54]
PROVIDING MESSAGES ON A
WIRELESS DEVICE
CONNECTING TO AN
APPLICATION SERVER
[22]
[31]
[51]
[71]
31.01.2003
[32] 31.01.2002
[33] US
10/061642
Int. Cl.(2009.01) G06F 13/00, H04B 07/26, H04L 12/56, H04M 01/725
U.S.A.
WO/2003/065596
,'
.
P.O.B. 2273,
,4
REHOVOT 76122
2273 . . ,
[87]
[74]
[57]
135
A system and method for providing a message on the graphic display of a wireless
device (12) while the wireless device (12) is connecting to an application download
server (16) across a wireless network (14). When the wireless device (12) attempts to
communicate with an application download server (16) or changes files while
navigating an application download server (16), a message is transmitted across the
wireless network (14) to the computer platform of the wireless device (12) and
displayed to the user of the wireless device (12). The message can be transmitted to the
wireless device (12) from the same application download server (16) that the wireless
device (12) is attempting to connect to or navigate, or alternately, the message can be
transmitted from another server on the wireless network (14).
"
,206111
(
.
__________________
[11][21]
163263
[54]
HEAT ENGINE
[22]
[51]
[71]
[72]
[74]
29.07.2004
Int. Cl.(2010.01) F02C 01//00
AGAM ENERGY SYSTEMS LTD.
, "
"
GAD ASSAF
%
,
,%
P.O.B. 1352,
1352 . . ,
JERUSALEM 91013
A heat engine (2), comprising:
at least one Liquid Ring Rotating Casing Compressor (LRRCC) (4) having a jacket
adapted to rotate eccentrically around a rotor core, a fluid inlet and a fluid outlet (12);
a combustion chamber (20) in fluid communication with the output of said LRRCC,
and
at least one expander (6) having a fluid inlet (24) and a fluid outlet (26), said fluid
inlet communicating with said combustion chamber;
characterized in that:
the jacket of the LRRCC is articulated to the expander so that rotation of the expander
induces rotation of the LRRCC,
the jacket is articulated to the rotor core via a mechanical transmission (10) so that
rotation of the jacket of the LRRCC by the expander induces rotation of the rotor core
of the LRRCC, and
a first heat exchanger mechanically coupled by bearings to said jacket so as to rotate
therewith and allow fluid communication between an output of the LRRCC and the
first heat exchanger for receiving water heated by the LRRCC and returning cooled
water for injection into the LRRCC so as to maintain the LRRCC isothermal.
[57]
136
"
__________________
[11][21]
163413
,
–
[54]
OXA-AND THIADIAZOLES,
THEIR USE FOR THE
PREPARATION OF A
MEDICAMENT AND PROCESS
FOR THEIR PREPARATION
[22]
[31]
[51]
20.02.2003
[32] 22.02.2002
[33] GB
0204159.8
Int. Cl.(2009.01) A61K 31/4245, 31/433, A61P 01/16, 19/00, 25/00, 29/00, 35/00,
43/00, C07D 271/06, 285/08, 413/04, 413/06, 417/04
VERNALIS (R&D) LIMITED,
UNITED KINGDOM
MERCK SERONO S.A.,
SWITZERLAND
WO/2003/070711
,
26A HABARZEL ST.,
' 26 $
[71]
[87]
[74]
[57]
Compounds of the formula (IA) or (IB), wherein W represents HO(C=O ,!(
HONH(C=O !(or H(C=O)N(OH ;!(X represents! O !or! S ;!and R ,1R ,2and R 3
are as defined in the description and claims, are inhibitors of matrix
metalloproteinases, in particular MMP9 and/or MMP12.
__________________
[11][21]
137
163637
"
,
[54]
PHARMACEUTICAL
COMBINATIONS OF
MELOXICAM, CODEINE
PHOSPHATE AND
PARACETAMOL
[22]
[31]
[51]
[71]
14.02.2003
[32] 19.02.2002
[33] ZA
2002/1395
Int. Cl.(2010.01) A61K 31//167, 31//485, 31//5415, 45//00, 45//06, A61P 29//00
ADCOCK INGRAM LIMITED,
SOUTH AFRICA
MICHAEL CHRISTIAN NORRIS
WO/2003/070251
, "
,
'
#
,
P.O.B. 45087,
45087 . . ,
JERUSALEM 91450
[72]
[87]
[74]
[57]
A pharmaceutical composition comprises a combination of a selective or specific COX
2 inhibitor or a pharmaceutically acceptable salt or derivative thereof and an opiate or
a pharmaceutically acceptable salt or derivative thereof, for example a combination of
meloxicam and codeine, as active ingredients, and a pharmaceutically acceptable
carrier. It may include a centrally-acting cyclo-oxygenase inhibitor such as
paracetamol or its pharmaceutically acceptable salts or derivatives. The pharmaceutical
compositions are used in methods of providing symptomatic relief or treatment of
pain, in an algesic and/or hyperalgesic state, with or without fever, in particular that
associated with inflammation such as that associated with trauma, osteoarthritis,
rheumatoid arthritis, non-inflammatory myalgia or dysmenorrhoea.
__________________
[11][21]
163698
)
4–(6–
[54]
METHOD FOR THE
PRODUCTION OF 4-(6BROMOHEXYLOXY)
BUTYLBENZENE
[22]
[31]
[51]
[71]
28.02.2003
[32] 05.03.2002
[33] DE
10209583.3
Int. Cl.(2009.01) C07C 43/00, 51/02, 51/41, C07F 09/141
BOEHRINGER INGELHEIM
PHARMA GMBH & CO. KG,
138
"
[87]
[74]
[57]
GERMANY
WO/2003/074458
26A HABARZEL ST.,
,
' 26 $
The invention relates to an improved method for producing 4-(6-bromohexyloxy)
butylbenzene by reacting 4-phenylbutanol with 1,6-dibromohexane in the presence of
a base and a phase transfer catalyst. 4-phenylbutanol is metered in a diluent to a
mixture consisting of 1,6-dibromohexane, a base, a phase transfer catalyst, and a
diluent. Also disclosed is the use of the resulting 4-(6-bromohexyloxy) butylbenzene
for producing salmeterol in a previously known manner.
__________________
[11][21]
163851
[54]
INTERNALIZING ANTI-CD74
ANTIBODIES AND METHODS OF
USE
[22]
[31]
[51]
[71]
[87]
[74]
03.03.2003
[32] 01.03.2002
[33] US
60/360259
Int. Cl.(2010.01) A61K 39//395, A61P 35//02, C07K 16//28, G01N 33//574
IMMUNOMEDICS, INC., U.S.A.
WO/2003/074567
,
26A HABARZEL ST.,
' 26 $
[57]
The present invention provides humanized, chimeric and human anti-CD74 antibodies,
CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind
to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii,
which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell
malignancies, other malignancies in which the cells are reactive with CD74, and
autoimmune diseases, and methods of treatment and diagnosis.
139
CD–74
,205985
(
.
"
__________________
[11][21]
164314
[54]
METHOD TO INHIBIT CELL
GROWTH USING
OLIGONUCLEOTIDES
[22]
[31]
[51]
[71]
11.04.2003
[32] 12.04.2002
[33]
10/122,630
Int. Cl.(2010.01) A61K 31//70, C07H 21//00
TRUSTEES OF BOSTON
UNIVERSITY, U.S.A.
WO/2003/087411
P.O.B. 2273,
REHOVOT 76122
[87]
[74]
[57]
US
,'
.
,4
2273 . . ,
Described are methods for treating hyperproliferative disorders, including cancers, by
administering to the affected mammal (e.g.,human) an effective amount of a
composition comprising pTT or a composition comprising one or more
oligonucleotides which share at least 50% nucleotide sequence identity with the human
telomere overhang repeat. Methods of treatment or prevention of hyperproliferative
diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, atopic
dermatitis, or hyperproliferative diseases of other epithelia and methods for reducing
photoaging, or oxidative stress or for prophylaxis against or reduction in the likelihood
of the development of skin cancer, are also disclosed.
,202597
(
.
__________________
[11][21]
[54]
140
USE OF ALPHA- BROMO OR
ALPHA-CHLORO ACRYLOYL
DISTAMYCIN DERIVATIVES IN
THE PREPARATION OF
MEDICAMENTS FOR TREATING
164356
–
–
–
–
"
CANCER
[22]
[31]
[51]
[71]
[87]
[74]
[57]
17.03.2003
[32] 02.04.2002
[33] EP
02076240.7
Int. Cl.(2009.01) A61K 31/40, 31/4025, 41/00, A61P 35/00, C07D 207/34, 403/12
NERVIANO MEDICAL SCIENCES
S.R.L., ITALY
WO/2003/082267
,
26A HABARZEL ST.,
' 26 $
The present invention provides the use of acryloyl distamycin derivatives, in particular
alpha-bromo- or alpha-chloro-acryloyl distamycin derivatives, in combination with
radiotherapy, for the treatment of tumors.
__________________
[11][21]
164383
[54]
PAYMENT TERMINAL DEVICE
FOR PAYMENT DATA
EXCHANGE
[22]
[51]
[71]
16.04.2002
Int. Cl.(2010.01) G06Q 20//00, G07F 19//00
ULTRA PROIZVODNJA
ELEKTRONSKIH NAPRAV D.O.O.,
REPUBLIC OF SLOVENIA
WO/2003/088165
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[87]
[74]
[57]
141
,
,
' 26 $
Disclosed is a terminal device (10) for payment data exchange comprising interfaces
for coupling to a point of sale devices (26), to a mobile phone (14), and to a payment
centre (1). The payment data exchange is performed on two different ways. In a first
way from the payment terminal device (10) via the mobile phone (14) and the mobile
voice network (5) to the authorisation centre (1) or, vice versa, from the payment
centre (1) via the mobile voice network (5) and the mobile phone (14) to the payment
"
terminal device (10), wherein the payment data are transferred between the payment
terminal device (10) and the mobile phone (14) on voice information. On the second
way the data are transferred directly from the terminal device (10) via e.g. the network
(5) to the authorisation centre (1) and, vice versa, from the payment centre (1) via the
network (5) to the payment terminal device (10).
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
142
DERIVATIVES OF N [PHENYL(PIPERIDIN-2 YL)METHYL]BENZAMIDE, THE
PREPARATION METHOD
THEREOF AND APPLICATION OF
SAME IN THERAPEUTICS
164400
[
(
–2–
)
]–N
,
17.04.2003
[32] 19.04.2002
[33] FR
02/04916
Int. Cl.(2009.01) A61K 31/445, 31/5375, A61P 25/00, C07D 211/26, 211/28, 401/12,
413/12
SANOFI-AVENTIS, FRANCE
WO/2003/089411
,'
.
P.O.B. 2273,
,4
REHOVOT 76122
2273 . . ,
The invention relates to compounds having general formula (I), wherein - A denotes: a
group with formula N-R1 in which R1 denotes a hydrogen atom, an alkyl group, a
cycloalkyl group, a phenylalkyl group, an alkenyl group or an alkynyl group; or a
group with formula N+ (O-) R1 in which R1 is as defined above; or a group with
formula N+ (R ) R1 in which R denotes an alkyl group and R1 is as defined above. X
denotes a hydrogen atom or one or more substituents selected from the halogen atoms
and the trifluoromethyl, alkyl and alcoxy groups. - R2 denotes a hydrogen atom, one or
"
more substituents selected from the halogen atoms and the trifluoromethyl, alkyl,
alkoxy, amino groups with formula NR3R4 in which R3 and R4 each denote a hydrogen
atom or an alkyl group or, together with the nitrogen atom bearing same, form a
pyrrolidine, piperidine or morpholine ring, or an optionally substituted phenyl group.
The invention is suitable for use in therapeutics.
__________________
[11][21]
164499
[54]
ENDOSCOPE WITH
ULTRAVIOLET ILLUMINATION
[22]
[31]
[51]
[71]
[72]
11.10.2004
[32] 16.10.2003
[33] FR
0312063
Int. Cl.(2009.01) A61B 01/00, G02B 23/24
SNECMA, FRANCE
ISABELLE BONNINGUE, JOHN LE
QUELLEC, JEAN ROVEGNO
, #
# ,
,
COHEN ZEDEK,
7
P.O.B. 12688,
# 12688 . . ,
HERZLIYA 46733
The borescope has lighting and observation units with deviating prisms (48, 30)
mounted at a distal end of a rigid tube (10). A light guiding unit (44) extends from the
tube to the prism (48) and a lens (32) extends from the prism (30) to the tube. The
prisms are placed transversally side by side in the tube and deviate a light beam from
the guiding unit, in a direction parallel to a visual axis of the prism (30).
[74]
[57]
143
–
"
__________________
[11][21]
[54]
[22]
[31]
[51]
[62]
[71]
[87]
[74]
[57]
144
164569
USE OF COMPOUNDS THAT
SELECTIVELY INHIBIT CETP
ACTIVITY FOR PREPARING
COMPOSITIONS FOR TREATING
HYPERLIPIDEMIA OR
ATHEROSCLEROSIS
CETP
10.02.1998
[32] 12.02.1997
[33] JP
9/44836
9/165085
05.06.1997
JP
10/26688
23.01.1998
JP
Int. Cl.(2010.01) A61K 31//167, 31//255, A61P 03//06, 09//10, C07C 32/3/40,
32/7/06, 32/7/22
JAPAN TOBACCO INC., JAPAN
WO/1998/035937
,
26A HABARZEL ST.,
' 26 $
CETP activity inhitors containing as the active ingredient compounds represented by
general formula (I), prodrug compounds thereof, pharmaceutically acceptable salts
"
thereof, or hydrates or solvates of these, (wherein R represents linear or branched
alkyl, linear or branched alkenyl, lower haloalkyl, optionally substitued cycloalkyl,
optionally substituted cycloalkenyl, optionally substituted cycloalkylalkyl, optionally
substitued aryl or optionally substituted heterocycle; X1, X2, X3 and X4 may be the
same or different from each other and each represents hydrogen, halogeno, lower
alkyl, lower haloalkyl, lower alkoxy, cyano, nitro, acyl or aryl; Y represents -CO- or SO¿2?-; and Z represents hydrogen or a mercapto-protective group). The compounds
represented by general formula (I) are expected to be useful as preventives or remedies
of a novel type for arteriosclerosis or hyperlipemia, since they can selectively inhibit
the CETP activity to thereby increase HDL and, at the same time, decrease LDL.
__________________
[11][21]
164572
[54]
HIGH BANDWIDTH DATA
TRANSPORT SYSTEM
[22]
[31]
30.04.2003
[32] 30.04.2002
[33] US
60/376952
09/698793
20.01.2003
US
Int. Cl.(2009.01) H04B 01/69, H04L 25/03, 27/00
LIGHTWAVES SYSTEMS, INC.,
U.S.A.
WO/2003/000094
P.O.B. 1352,
JERUSALEM 91013
[51]
[71]
[87]
[74]
[57]
145
,
,%
1352 . . ,
The present invention provides for a methods, system, and apparatus relating (1500) to
data transmission. One method of the present invention includes representing data
using at least one pulse based on a Gaussian wave form, sending the at least one pulse
over an electrically conductive guided media, and recovering the data from the at least
one pulse. The present invention can be used in conjunction with telephony
applications, cable TV applications, and data bus applications.
"
__________________
[11][21]
[54]
[22]
[51]
[71]
[87]
[74]
[57]
146
POLYMORPH OF 4-[2-[4-[1-(2ETHOXYETHYL)-1HBENZIDIMAZOLE-2-YL]-1PIPERIDINYL] ETHYL]- ALPHA,
ALPHA- DIMETHYL BENZENOACETIC ACID,
METHOD OF PREPARING THE
SAME AND USE OF THE SAME
IN THE PREPARATION OF
MEDICAMENTS
164645
1–[
–2 –
– 2 ) – 1 ] – 4] – 2] – 4
– H1 – (
–
–[
[
,
19.04.2002
Int. Cl.(2009.01) A61K 31/454, A61P 37/08, C07D 401/04
FAES FARMA ,S.A., SPAIN
WO/2003/089425
P.O.B. 2273,
REHOVOT 76122
,'
–
,
.
,4
2273 . . ,
The invention relates to polymorph 1 of acid 4-[2-[4-[1-(2-ethoxyethyl)-1Hbenzimidazole-2-il]-1-piperidinyl]ethyl-[ , -dimethyl-benzeneacetic having formula
(I), preparation methods thereof, pharmaceutical formulations containing polymorph 1
and the use of polymorph 1 for the treatment of allergic reactions and pathological
processes mediated by histamine in mammals such as humans.
"
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
147
164731
METHOD OF HANDLING PHONE
COMMUNICATIONS AND
RELATED EQUIPMENTS ON LANS
SUPPORTING VOICE AND DATA
TRANSMISSION IN AN
INTEGRATED WAY
LAN
16.10.2002
[33] IT
PI2002A000026 [32] 30.04.2002
Int. Cl.(2009.01) H04L 12/56, 29/06, H04M 11/00
GEFA S.R.L., ITALY
WO/2003/094480
26A HABARZEL ST.,
,
' 26 $
On a LAN which supports the transmission of data, including multimedial, and
digitalized telephone communications, in an integrated way, a method of handling
telephone communications and related equipments provides for the exclusive
installation in the central processing unit, or network server, specific software
dedicated to controling, monitoring and handling of telephone communications and
related equipments. The method provides for the activation of said specific software
using a standard Internet browser for sending commands and for the exchange of data
on the network, through immediate interaction on bar type graphs (21) on the
visualization means of the LAN peripheral computers. Said software enables the
continuous visual monitoring of the status of the telephone communication in progress
or other communications on arrival or on hold.
"
__________________
[11][21]
164827
[54]
TIME EFFICIENT
RETRANSMISSION USING
SYMBOL ACCUMULATION
[22]
[31]
[51]
[62]
[71]
12.11.1998
[32] 17.11.1997
[33]
08/969319
Int. Cl.(2009.01) H04J 13/00, H04L 01/18
U.S.A.
WO/1999/026371
P.O.B. 2273,
REHOVOT 76122
[87]
[74]
[57]
148
US
,'
.
,4
2273 . . ,
An efficient retransmission of data using symbol accumulation wherein the packet
received in error is retransmitted at a lower energy-per-bit level concurrently in the
same frame with the new packet. The destination device receives the data transmission
and retransmission, demodulate the signal, and separates the received data into the new
and retransmitted packet. The destination device then accumulates the energy of the
retransmitted packet with the energy already accumulated for the packet received in
error and decodes the accumulated packet. The accumulation of the additional energy
provided by the subsequent retransmissions improves the probability of a correct
decoding. The throughput rate can be improved since the packet received in error is
retransmitted concurrently with the transmission of the new data packet. The capacity
is maximized since the retransmission of the packet received in error is at a lower
energy level than that of the new packet.
"
__________________
[11][21]
165065
[54]
PHARMACEUTICAL
ROFLUMILAST FOR
TREATMENT OF EYE DISEASE
[22]
[31]
27.05.2003
[32] 28.05.2002
[33] EP
02011830.3
10223828.6
28.05.2002
DK
10311613.3
14.03.2003
DK
Int. Cl.(2009.01) A61K 31/44, A61P 29/00, C07D 213/00
NYCOMED GMBH, GERMANY
WO/2003/099278
P.O.B. 1352,
JERUSALEM 91013
[51]
[71]
[87]
[74]
[57]
,
,%
1352 . . ,
A pharmaceutical preparation comprising roflumilast for treatment of a disease of the
eye is described.
__________________
[11][21]
[54]
149
165105
DIGITAL WIRELESS POSITION
SENSOR
"
[22]
[31]
[51]
[71]
[74]
[57]
09.11.2004
[32] 11.11.2003
[33] US
10/706298
Int. Cl.(2010.01) A61B 05//00, 05//06
BIOSENSE WEBSTER, INC., U.S.A.
, "
.
P.O.BOX 33111
33111 . . ,
TEL AVIV 61330
A method is provided for tracking an object, including positioning a radio frequency
(RF) driver to radiate an RF driving field toward the object, and fixing to the object a
wireless transponder that includes a power coil and at least one sensor coil. The
method also includes receiving the RF driving field using the power coil and storing
electrical energy derived therefrom. A plurality of field generators are driven to
generate electromagnetic field at respective frequencies in a vicinity of the object that
induce a voltage drop across the at least one sensor coil. A digital output signal is
generated at the wireless transponder indicative of the voltage drop across the sensor
coil, and the generation of the digital output signal is powered using the stored
electrical energy. The digital output signal is transmitted from the wireless transponder
using the power coil, and the transmission of the digital output signal is powered using
the stored electrical energy. The digital output signal is received and processed to
determine coordinates of the object.
__________________
[11][21]
165573
[54]
PERFORMING IDLE HANDOFF IN
A MULTIPLE ACCESS
[22]
[31]
[51]
[62]
[71]
06.06.1997
[32] 07.06.1996
[33]
660436
Int. Cl.(2010.01) H04B 07//26, H04W 48//20
U.S.A.
WO/1997/047154
P.O.B. 2273,
REHOVOT 76122
[87]
[74]
[57]
150
US
,'
.
,4
2273 . . ,
A method and apparatus which permits handoffs while the mobile station (2) is in the
"
system access state. This is achieved by providing for channel assignment messages to
be sent over the paging channel of a plurality of base stations (26), which increases the
probability of one of the messages getting through. In addition, this assures the mobile
station (2) will be able to handoff to a different base station (26) and have a traffic
channel allocated to it on the new base station (26) without delay. In addition, a
method and apparatus which permits the mobile station (2) to be directly assigned into
a soft handoff state upon traffic channel assignment.
,201702,201701,201700
(
.
__________________
[11][21]
165600
[54]
BI-DIRECTIONAL WOVEN OR
KNITTED MULTI-AXIAL
FABRICS AND FABRIC
COMPOSITES
[22]
[31]
05.06.2003
[32] 07.06.2002
[33]
60/387201
10/179715
25.06.2002
Int. Cl.(2010.01) D03D 11//00, 15//00, 15//08
HONEYWELL INTERNATIONAL
INC., U.S.A.
WO/2005/028724
26A HABARZEL ST.,
[51]
[71]
[87]
[74]
[57]
151
–
US
US
,
' 26 $
Bi-directional and multi-axial woven or knitted fabrics, fabric composites, ballistically
resistant assemblies thereof, and the methods by which they are made. The fabrics are
"
comprised of sets of strong, substantially parallel, unidirectional yarns lying in parallel
planes, one above the other, with the direction of the yarns (11) in a given plane
rotated at an angle to the direction of the yarns (12) in adjacent planes; and one or
more sets of yarns (13, 14) having lower strength and higher elongation interleaved
with the strong yarns. The fabrics of the invention provide superior ballistic
effectiveness compared to ordinary woven and knitted fabrics but retain the ease of
manufacture on conventional looms and knitting machines.
__________________
[11][21]
165832
[54]
AUTOMATIC VERIFICATION OF
THE HOLDER OF AN
AUTHORISATION DOCUMENT
[22]
[31]
[51]
[71]
19.06.2003
[32] 19.06.2002
[33]
1020903
Int. Cl.(2009.01) B42D 15/10, G07C 09/00
ENSCHEDE/SDU B.V., THE
NETHERLANDS
WO/2004/017265
P.O.B. 2273,
REHOVOT 76122
[87]
[74]
[57]
152
"
,
NL
,'
.
,4
2273 . . ,
System for reading a document provided with machine-readable holder details and
establishing whether a person presenting the document has a predetermined right,
which document at least contains a chip containing biometric data on a holder as well
as data with a predetermined relationship to the holder details, and wherein the system
comprises: • a reader for reading the chip and the machine-readable holder details; • a
"
memory containing details with regard to the right of the holder; • a biometric feature
scanner; • a processing unit connected to reader, memory and scanner and equipped to:
• establish the authenticity of chip and data using public key encryption technology; •
receive the biometric data on the holder from the chip; • receive the biometric data on
the person presenting the document from the scanner and to compare these with the
data on the holder to determine whether the person presenting the document is the
holder; • receive the holder details via the reader, check the relationship between the
holder details and the data and read the right of the holder from the memory; provide a
signal to indicate the right for the person presenting the document if the chip and the
data are authentic, the relationship has been established and the person presenting the
document is the same as the holder.
__________________
[11][21]
[54]
COMPOSITION FOR REMOVING
SIDEWALL RESIDUES
[22]
[31]
[51]
[71]
[87]
[74]
27.05.2003
[32] 22.06.2002
10227867.9
Int. Cl.(2009.01) H01L 21/302
BASF SE, GERMANY
WO/2004/001834
10 ABBA EBEN BLVD.,
P.O. B. 2081,
HERZLIYA 46120
[57]
165879
[33]
DE
,
10
,
#
#
2081 . . ,
The invention relates to a composition for removing sidewall residues from metal
surfaces, particularly aluminum or aluminum-containing surfaces, especially
aluminum or aluminum-containing surfaces during the production of semiconductor
elements.
__________________
153
"
[11][21]
[54]
METHOD FOR NATURAL VOICE
RECOGNITION BASED ON A
GENERATIVE
TRANSFORMATION/PHRASE
STRUCTURE GRAMMAR
[22]
[31]
[51]
[71]
26.06.2003
[32] 28.06.2002
10229207.8
Int. Cl.(2010.01) G10L 15//00
T-MOBILE DEUTSCHLAND GMBH,
GERMANY
WO/2004/003888
P.O.B. 1352,
JERUSALEM 91013
[87]
[74]
[57]
165957
,
[33]
,
/
DE
,
,%
1352 . . ,
The invention relates to a method for natural voice recognition based on a generative
transformation/phrase structure grammar known as GT /PS grammar. According to the
invention, a spoken phrase is analyzed for triphones contained therein, words
contained in the spoken phrase are formed from the recognized triphones with the aid
dictionaries and the spoken phrase is syntactically reconstructed from the recognized
words using a grammar. The GT /PS grammar is a novel method enabling target
sentences to be placed in said grammar. It uses traditional Grammar Specification
Language (GSL), structures said sentences however in an innovative manner. It is
oriented towards the rules of phrase structure grammar and Noam Chomsky's concept
of generative transformation grammar.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
154
166030
"
CORRELATION TRACKER
BREAK LOCK DETECTION
28.07.2003
[32] 01.08.2002
10/210241
Int. Cl.(2010.01) G01S 03//786
RAYTHEON COMPANY, U.S.A.
WO/2004/013650
[33]
US
,'
.
"
,4
2273 . . ,
P.O.B. 2273,
REHOVOT 76122
[57]
System and method for detecting breaklock for correlation trackers. The inventive
system includes a first circuit (50) for computing energy EL in a residual image, a
second circuit (52) for computing energy E1 in an input image, and a third circuit (54)
for computing a residual metric RL based on the residual image energy EL scaled by the
input image energy E1. In the illustrative embodiment, the system further includes a
fourth circuit (56) for comparing the residual metric RL to a threshold TR, and a fifth
circuit (58) for setting a breaklock signal based on the output of the fourth circuit (56).
__________________
[11][21]
166038
[54]
PEGYLATED T20 POLYPEPTIDE
[22]
[31]
[51]
[71]
16.07.2003
[32] 24.07.2002
[33] US
60/398195
Int. Cl.(2010.01) A61K 38//16, 38//18, 47//48, A61P 31//18, C07K 14//16, 17//08
SWITZERLAND
WO/2004/013164
,
26A HABARZEL ST.,
' 26 $
[87]
[74]
[57]
T20
Pegylated T20 polypeptide compounds are provided. Also provided are pharmaceutical
compositions containing pegylated T20 polypeptide compounds, and processes of
making and using such compounds and compositions.
__________________
155
"
[11][21]
166438
–
[54]
METHOD FOR PURIFYING
PREPROINSULIN
[22]
[31]
[51]
[71]
18.07.2003
[32] 01.08.2002
[33]
10235168.6
Int. Cl.(2010.01) C07K 01//14, 01//16, 14//62
GMBH, GERMANY
WO/2004/013176
COHEN ZEDEK,
P.O.B. 12688,
HERZLIYA 46733
[87]
[74]
[57]
DE
,
#
# ,
,
7
# 12688 . . ,
The invention relates to a method for the chromatographic purification of
preproinsulins, according to which higher-molecular substances are separated from an
aqueous solution of the preproinsulin by means of a first chromatography on an anion
exchanger in through-flow mode and a subsequent second chromatography on a cation
exchanger in adsorption mode, and a method for the production of insulins, which
comprises the method for producing preproinsulins.
__________________
[11][21]
[54]
FLUID OPERATED PUMP
[22]
[31]
[51]
[71]
29.07.2003
[32] 29.07.2002
2002950421
Int. Cl.(2010.01) F04B 43//10, 43//113
WEIR MINERALS NETHERLANDS
B.V., THE NETHERLANDS
GORDON LEITH MORRISS,
ROBERT LESLIE WEST
WO/2004/001180
DR. DAVID AGRANOV,
P.O.B. 15,
ALONEY-ABA
36005
[72]
[87]
[74]
156
166496
[33]
AU
,
-
"
15 . . ,
"
[57]
A pumping system comprising a pump (21) for conveying a pumped fluid using an
actuating fluid. The pump comprising a rigid outer casing (25) defining an interior
space (26), a tube structure (27) accommodated in the interior space (26), the tube
structure (27) being flexible and substantially inelastic. The interior of the tube
structure (27) defines a pumping chamber (28) for receiving pumped fluid. The tube
structure (27) is movable between laterally expanded and collapsed conditions for
varying the volume of the pumping chamber (28) thereby to provide discharge and
intake strokes. The region of the interior space (26) surrounding the tube structure (27)
defines an actuating region for receiving and accommodating actuating fluid. The
pumping chamber (28) is adapted to receive pumped fluid to cause the tube structure
(27) to move towards the expanded condition and the pumping chamber (28) thereby
undergoing an intake stroke. The pumping chamber (28) undergoes a discharge stroke
upon collapsing of the tube structure (27) in response to the action of actuating fluid in
the actuating region. The pumping system also comprises a delivery means (50) for
delivering pumped fluid to the pumping chamber (28) in timed sequence for causing
the pumping chamber (28) to undergo an intake stroke, and means (70) for supplying
actuating fluid to the actuating region in timed sequence to cause the tube structure
(27) to laterally collapse whereby the pumping chamber (28) undergoes a discharge
stroke.
__________________
[11][21]
[54]
FIRE RETARDANT AND
METHOD FOR PRODUCTION
THEREOF
[22]
[31]
[51]
[71]
05.08.2003
[32] 07.08.2002
2002950614
Int. Cl.(2010.01) C09K 03//00
JENS BIRGER NILSSON,
AUSTRALIA
WO/2004/015026
[87]
157
166681
[33]
AU
"
[74]
[57]
,
26A HABARZEL ST.,
' 26 $
A fire retardant composition and a method of producing it .The composition
comprising water, a highly concentrated alkali, at least one of or a combination
thereof, of anhydrous citric acid ,citric acid, acetic acid or a related salt thereto. The
composition also includes phosphate as well as an alkali metal salt or compound from
at least one of lithium, sodium and/or potassium cation in combination with at least
one of an acetate, bicarbonate, carbonate and/or hydroxide anion. The composition is
then adjusted to a pH value around 6.5 % to 7.5 % by adjusting the amounts of highly
concentrated alkali and/or the citric acid/acetic acid respectively.
__________________
[11][21]
166747
–
[54]
WATER-SOLUBLE IRONCARBOHYDRATE COMPLEXES,
PRODUCTION THEREOF AND
MEDICAMENTS CONTAINING
SAID COMPLEXES
[22]
[31]
[51]
[71]
20.10.2003
[32] 23.10.2002
[33] DE
10249552.1
Int. Cl.(2010.01) A61K 33//26, A61P 03//02, C08B 01//00, 31//18
VIFOR (INTERNATIONAL) AG.,
SWITZERLAND
WO/2004/037865
,
26A HABARZEL ST.,
' 26 $
[87]
[74]
[57]
158
,
Disclosed is a water-soluble iron-carbohydrate complex obtained from an aqueous
iron(III)-salt solution and an aqueous solution of the product obtained by oxidizing one
or several maltodextrins with an aqueous hypochlorite solution at an alkaline pH value.
The dextrose equivalent of the maltodextrin ranges from 5 to 20 if a single
maltodextrin is used while the dextrose equivalent of the mixture of several
maltodextrins ranges from 5 to 20 and the dextrose equivalent of each individual
maltodextrin contained in the mixture ranges from 2 to 40 if a mixture of several
maltodextrins is used. Also disclosed are a method for the production of said complex
"
and medicaments for the treatment and prophylaxis of iron deficiencies.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
N - ARYL PIPERIDINE
SUBSTITUTED
BIPHENYLCARBOXAMIDES,
PHARMACEUTICAL
COMPOSIITONS COMPRISING
THEM AND METHOD FOR THEIR
PREPARATION
166795
– N–
,
05.08.2003
[32] 12.08.2002
[33] EP
02078309.8
Int. Cl.(2010.01) A61K 31//445, A61P 09//10, C07D 21/1/34, 21/1/62, 40/1/04
JANSSEN PHARMACEUTICA N.V.,
BELGIUM
WO/2004/017969
,
26A HABARZEL ST.,
' 26 $
N-aryl piperidine substituted biphenylcarboxamides compounds of formula (I)
methods for preparing such compounds, pharmaceutical compositions comprising said
compounds as well as the use of said compounds as a medicine for the treatment of
hyperlipidemia, obesity and type II diabetes. The compounds act as inhibitors of
apolipoprotein B.
__________________
[11][21]
[54]
159
166819
APPARATUS FOR DETECTING
TAMPERING WITH A UTILITY
"
METER
[22]
[31]
[51]
[71]
[87]
[74]
[57]
04.08.2003
[32] 15.08.2002
0219035.3
Int. Cl.(2010.01) G01R 11//24
POLYMETERS RESPONSE
INTERNATIONAL LTD., UNITED
KINGDOM
WO/2004/017077
26A HABARZEL ST.,
[33]
GB
,
' 26 $
An electronic utility meter to monitor magnetic fields in utility meters and to indicate
the presence of abnormally large magnetic fields. The meter comprises means for
detecting consumption of a utility, means for indicating the result of the detection and
means for detecting the presence of a magnetic field originating outside the meter.
Preferably, the magnetic field detection means includes a detection circuit, which
includes an inductance in the form of a coil wound around a ferrite core.
__________________
[11][21]
166978
[54]
VEHICLE IDENTIFICATION
MEANS DETECTION AND
EVASION SYSTEM
[22]
[31]
[51]
[71]
[72]
13.08.2003
[32] 19.08.2002
[33]
60/404450
Int. Cl.(2009.01) B60R 13/10, G08G 01/017
RON YAACOV DAVIDSON
NAUM LAUENBURG, NATHANIEL
DAVIDSON, RON YAACOV
DAVIDSON
WO/2004/017276
[87]
[74]
160
,
US
$,
,
,
, "
(1995)
. .'
"
RAMAT GAN 52521
[57]
11
, 15
,
A system for detecting and evading vehicle identification means (VIM), comprising:
locating means, control means having a plurality of I/O channels, each adapted to
receive or transmit serial or parallel data, processing means, electronic storage means
comprising at least one database of known VIM coordinates and identification
prevention device (IPD) adapted to automatically prevent identification of the vehicle's
license plate number, owner or driver.
__________________
[11][21]
167038
,
[54]
PYRAZOLE DERIVATIVES,
PHARMACEUTICAL
THE SAME, USE THEREOF IN
THE MANUFACTURE OF
MEDICAMENTS AND
INTERMEDIATE FOR
PRODUCTION THEREOF
[22]
[31]
21.08.2003
[33] JP
2002-244381 [32] 23.08.2002
2002-324076
07.11.2002
JP
Int. Cl.(2009.01) A61K 31/7056, A61P 03/04, 03/06, 03/10, 09/12, 19/06, 43/00,
C07H 17/02
KISSEI PHARMACEUTICAL CO.,
LTD., JAPAN
WO/2004/018491
,
26A HABARZEL ST.,
' 26 $
[51]
[71]
[87]
[74]
161
,
"
[57]
A pyrazole derivative represented by the general formula (I) [wherein R1 is H,
optionally substituted C1-6 alkyl, etc.; either of Q and T is the group of the formula (II)
or the formula (III) and the other is optionally substituted C1-6 alkyl, etc.; R2 is H,
halogeno, OH, optionally substituted C1-6 alkyl, etc.; X is a single bond, O, or S; Y is
optionally substituted C1-6 alkylene, etc.; Z is -RB, -CORC, etc. (RB is optionally
substituted C1-6 alkyl, etc.; and RC is optionally substituted C1-6 alkyl, etc.); R4 is H,
optionally substituted C1-6 alkyl, etc.; and R3, R5, and R6 each is H, halogeno, etc.], a
pharmacologically acceptable salt of the derivative, or a prodrug of either. They have
excellent human SGLT1 inhibitory activity and are useful as a preventive or
therapeutic agent for diseases attributable to hyperglycemia such as diabetes, impaired
glucose tolerance, fasting blood sugar abnormality, complications of diabetes, and
obesity and for diseases attributable to an increased blood galactose level such as
galactosemia.
__________________
[11][21]
167079
[54]
360 DEGREE AUTOMOBILE
VIDEO CAMERA SYSTEM
[22]
[31]
21.08.2003
[32] 26.08.2002
[33]
227270
261606
30.09.2002
Int. Cl.(2009.01) B60R 01/04, H04N 07/171
JOSEPH J. MAZZILLI, U.S.A.
WO/2004/019601
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[51]
[71]
[87]
[74]
[57]
162
°360
US
US
,
' 26 $
The present invention relates to a video camera system which has a 360o range for
"
digital video recording inside and outside of an automotive vehicle.
__________________
[11][21]
167168
[54]
INDOLINE COMPOUND IN
CRYSTALLINE FORM FOR USE
IN ORAL SOLID MEDICAMENT
AND SUCH ORAL SOLID
MEDICAMENT FOR TREATING
DYSURIA
[22]
[31]
[51]
05.09.2003
[33] JP
2002-262157 [32] 06.09.2002
Int. Cl.(2009.01) A61K 09/20, 09/48, 31/404, 45/00, 47/02, A61P 13/02, C07D
209/08
KISSEI PHARMACEUTICAL CO.,
LTD., JAPAN
WO/2004/022538
REINHOLD COHN AND
,
PARTNERS,
' 26 $
26A HABARZEL ST.,
[71]
[87]
[74]
[57]
A crystal for oral solid drug comprised of indoline compound (KMD-3213) which
exerts alpha1-adrenaline receptor shielding activity, is useful as a therapeutic agent for
dysuria and is represented by the formula: (I) wherein in the powder X-ray diffraction
pattern, the compound is characterized by main peaks of 5.5°± 0.2°, 6.1°± 0.2°, 9.8°±
0.2°, 11.1°± 0.2°, 12.2°± 0.2°, 16.4°± 0.2°, 19.7°± 0.2° and 20.0°± 0.2° as 2thetas;.
There is further provided an oral solid drug for dysuria treatment containing the crystal
as an active ingredient.
__________________
163
"
[11][21]
[54]
MULTILAYER OPTICAL DISC
HAVING A RECORDING STACK
TYPE INDICATOR
[22]
[31]
28.08.2003
[32] 11.09.2002
02078718.0
03100750.3
24.03.2003
Int. Cl.(2010.01) G11B 07//24
KONINKLIJKE PHILIPS
ELECTRONICS N.V., THE
NETHERLANDS
WO/2004/025639
26A HABARZEL ST.,
[51]
[71]
[87]
[74]
[57]
167306
[33]
EP
EP
,
' 26 $
A multilayer record carrier of a writable type has a first recording layer (40) having a
first recording stack (50,51) of a first type and a second recording layer (41) having a
second recording stack (54,55) of a second type. The first and second recording stacks
have different writing parameters. Each recording layer has a pre-formed recording
control pattern that is readable via a laser beam for indicating the track. At least one
recording control pattern comprises a recording stack type indicator for indicating the
writing parameters of the second recording stack. A recording device has a control unit
(20) for adjusting recording parameters in the device in dependence of the recording
stack type indicator retrieved from the recording control pattern.
__________________
[11][21]
164
167378
"
[54]
MIMO WLAN SYSTEM
[22]
[31]
24.10.2003
[32] 25.10.2002
60/421309
10/693419
23.10.2003
Int. Cl.(2010.01) H04L 12//28
U.S.A.
WO/2004/039011
P.O.B. 2273,
REHOVOT 76122
[51]
[71]
[87]
[74]
[57]
WLAN MIMO
[33]
US
US
,'
.
,4
2273 . . ,
A multiple-access MIMO WLAN system that employs MIMO, OFDM, and TDD. The
system (1) uses a channel structure with a number of configurable transport channels,
(2) supports multiple rates and transmission modes, which are configurable based on
channel conditions and user terminal capabilities, (3) employs a pilot structure with
several types of pilot (e.g., beacon, MIMO, steered reference, and carrier pilots) for
different functions, (4) implements rate, timing, and power control loops for proper
system operation, and (5) employs random access for system access by the user
terminals, fast acknowledgment, and quick resource assignments. Calibration may be
performed to account for differences in the frequency responses of transmit/receive
chains at the access point and user terminals. The spatial processing may then be
simplified by taking advantage of the reciprocal nature of the downlink and uplink and
the calibration.
,204180,204179
(
.
__________________
[11][21]
[54]
165
167426
PROCESS FOR THE
MANUFACTURE OF VALSARTAN
"
[22]
[31]
[51]
[71]
[87]
[74]
[57]
22.09.2003
[32] 23.09.2002
[33]
0222056.4
Int. Cl.(2010.01) C07D 25/7/00, 25/7/04
WO/2004/026847
P.O.B. 5352,
BEER-SHEVA 84152
GB
,
#
#
,
5352 . . ,
The present invention relates to a process for the manufacture of Valsartan, an
angiotensin receptor blocker (ARB; also called angiotension II receptor antagonist or
AT1 receptor antagonist) and salts thereof, to novel intermediates and process steps.
,205871
(
.
__________________
[11][21]
167829
–1 ,2 ,4
[54]
1,2,4- THIADIAZOLE
COMPOUND, COMPOSITION
FOR CONTROLLING HARMFUL
ARTHROPOD CONTAINING THE
SAME, METHOD FOR
CONTROLLING HARMFUL
ARTHROPOD USING THE SAME
AND USE OF THE SAME IN THE
PREPARATION OF THE
COMPOSITION
[22]
[51]
[71]
08.11.2002
Int. Cl.(2010.01) A01N 43//836, A01P 07//00, C07D 28/5/08
SUMITOMO CHEMICAL
COMPANY, LIMITED, JAPAN
WO/2004/041798
,
279 HAYARKON ST.,
P.O.B. 6451,
TEL AVIV 61063
[87]
[74]
[57]
166
#
"
279
6451 . . ,
1,2,4−Thiadiazole compounds represented by the general formula (1) have excellent
"
control activities against injurious arthropods: (1) wherein R1 is C3−7 alkynyl which
may be halogenated; R2 is halogeno, C1−4 alkyl, C1−4 haloalkyl, C1−4 alkoxy, C1−4
haloalkoxy, C1−4 alkylthio, cyano, or nitro, and n is an integer of 0 to 5, with the
proviso that when n is an integer of 2 or above, R2s may be the same or different from
each other; A is oxygen, sulfur, a single bond, CR3R4, or NR5; R3 and R4 are each
independently hydrogen or C1−4 alkyl and R5 is hydrogen or the like.
__________________
[11][21]
167832
[54]
SESQUITERPENE SYNTHASES AND
METHODS OF USE
[22]
[31]
02.10.2003
[32] 04.10.2002
[33] US
60/415765
02.12.2002
PCT/IB02/05070
WO
Int. Cl.(2010.01) C12N 09//88, 15//29, 15//60, C12P 05//00, 21//02
FIRMENICH SA, SWITZERLAND
MICHEL SCHALK, ANTHONY CLARK
WO/2004/031376
, #
#
5 SHENKAR ST.,
5
' ,1 - $
P.O.B. 12704,
# 12704 . . ,
HERZLIYA 46733
[51]
[71]
[72]
[87]
[74]
[57]
The invention relates to sesquiterpene synthases and methods of their production and
use. In one embodiment, the invention provides nucleic acids comprising a nucleotide
sequence as described herein that encodes for at least one sesquiterpene synthases. In a
further embodiment, the invention also provides for sesquiterpene synthases and
methods of making and using these enzymes. For example, sesquiterpene synthases of
the invention may be used to convert famesyl-pyrophosphate to various oxygenated
and aliphatic sesquiterpenes including valencene, bicyclo-germacrene, cubebol and
delta- cadinene.
__________________
167
"
[11][21]
167835
[54]
SOLID PREPARATION
COMPRISING PIOGLITAZONE
AND BIGUANIDE AND PROCESS
FOR PRODUCING THE SAME
[22]
[31]
[51]
[71]
06.10.2003
[32] 07.10.2002
[33] JP
294045/2002
Int. Cl.(2009.01) A61K 45/00, A61P 03/10, C07D 417/00, 417/12
TAKEDA PHARMACEUTICAL
COMPANY LIMITED, JAPAN
WO/2004/030700
,'
P.O.B. 2273,
REHOVOT 76122
[87]
[74]
[57]
.
,4
2273 . . ,
It is intended to provide a solid preparation containing an insulin resistance improving
drug and an active ingredient (other than the insulin resistance improving drug) which
is useful as a remedy for diabetes, etc. and excellent in the uniformity in the contents
of the insulin resistance improving drug and the active ingredient (other than the
insulin resistance improving drug) and the preparation characteristics such as elution
properties and preparation hardness.
__________________
[11][21]
168053
[54]
FOLDING DIRECTIONAL
ANTENNA
[22]
[31]
[51]
[71]
[87]
[74]
04.11.2003
[32] 04.11.2002
[33] US
10/288256
Int. Cl.(2010.01) H01Q 01//08, 01//24, 01//38, 03//26, 19//00
IPR LICENSING, INC., U.S.A.
WO/2004/042938
,
26A HABARZEL ST.,
[57]
168
' 26 $
An antenna array formed an a deformable dielectric material or substrate includes a
center element and plurality of radial elements extending from a center hub. In the
operative mode, the radial elements are folded upwardly into an approximately vertical
"
position, with the Center element at the center of the hub and the radial elements
circumferentially surrounding the center element. In one embodiment the center
element serves an active element of the antenna array and the radial elements are
controllable in a directive or reflective state to effect a directive beam pattern from the
antenna array. When not in use, the antenna elements are deformed into a plane and
can therefore be integrated into a housing for compact storage. In a phased array
embodiment, the center element is absent and the plurality of radial elements, are
controllable to steer the antenna beam.
__________________
[11][21]
168149
[54]
PROCESSING SATELLITE
COMMUNICATION DATA
[22]
[51]
[71]
[72]
[74]
20.04.2005
Int. Cl.(2009.01) H04B 07/185, H04M 03/22
ELTA SYSTEMS LTD.
BENJAMIN GILOH
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[57]
169
, "
,
' 26 $
An apparatus for intercepting and monitoring communications between target mobiles
and a main station of communication system, wherein communication between the
mobiles and the satellite is achieved by using L-band spot beams, chosen by the
mobiles and wherein communication between the satellite and the main station is
achieved by using a wideband C-band link, and wherein the network changes the
mapping scheme of the L-band frequencies to the C-band frequencies, said apparatus
comprises:
at least one RF C-band and at least one RF L-band receive antenna which transmits the
received signals to at least one RF C-band and at least one L-band receiver
"
respectively; an intermediate frequency RF distributor which receivers signals from
said RF C-band and RF L-band receivers and splits the transmission into groups of
frequencies;
a plurality of demodulators which are tuned to cover sequentially the L-band
frequency spectrum, for extracting identification codes of target mobiles and
decryption messages;
wide angle mapping unit which receives the C-band signals from said intermediate
frequency distributor, analyses and maps the received frequencies according to their
time occurrence, and correlates said frequencies with said L-band frequencies; means
for recording and monitoring said communications.
__________________
[11][21]
168266
,
,
[54]
NUCLEOSIDE DERIVATIVES,
PROCESSES FOR THEIR
PREPARATION.
PHARMACEUTICAL
THEM AND USES THEREOF FOR
THE MANUFACTURE OF
MEDICAMENTS
[22]
[31]
14.11.2003
[32] 19.11.2002
[33] US
60/427447
60/483970
01.07.2003
US
Int. Cl.(2010.01) A61K 31//70, A61P 31//14, C07H 19//167
SWITZERLAND
WO/2004/046159
26A HABARZEL ST.,
[51]
[71]
[87]
[74]
[57]
170
,
,
' 26 $
The present invention relates to nucleoside derivatives for the treatment of Hepatitis C
viral infections including compounds of formula I (I), to pharmaceutical compositions
comprising these compounds and methods for treatment or prophylaxis of Hepatitis C
Virus mediated diseases employing said compounds in monotherapy or in combination
therapy. The present invention further provides a process for preparing 1',3',4'-triacyl
pyrimidine nucleoside from a N,1',3',4'-tetraacylpyrimidine nucleoside.
"
__________________
[11][21]
[54]
PROCESS FOR PRODUCTION OF
ELECTROLYTIC CAPACITORS
[22]
[31]
[51]
[71]
[74]
03.05.2005
1020040221103 [32] 05.05.2004
Int. Cl.(2010.01) H01G 09//028
H.C. STARCK GMBH, GERMANY
26A HABARZEL ST.,
[57]
168350
[33]
DE
,
' 26 $
Process for production of an electrolytic capacitor comprising at least the following
process steps:
(A) for the formation of a solid electrolyte a mixture containing precursors for the
production of conducting polymers, one or more oxidizing agents and optionally
counter-ions is introduced into a porous electrode body of an electrode material coated
with a dielectric and optionally further layers,
(B) the electrode body impregnated with the mixture containing precursors for the
production of conducting polymers, one or more oxidizing agents and optionally
counter-ions is exposed to a relative atmospheric humidity of greater than or equal to
70%, and the precursors are polymerized to form a solid electrolyte, and
(C) for the formation of a conducting outer layer a solution or dispersion containing at
least one conducting polymer and at least one binder is applied to the porous electrode
body covered with a dielectric as well as wholly or partially with a solid electrolyte
and optionally further layers, and then is dried.
__________________
171
"
[11][21]
168477
[54]
ISOINDOLINE DERIVATIVES
AND PHARMACEUTICAL
THEM
[22]
[31]
[51]
25.11.2003
[33] JP
2002-342399 [32] 26.11.2002
Int. Cl.(2010.01) A61K 31//4035, 31//427, 31//44, 31//4439, 31//4545, 31//496, A61P
23//00, 25//20, C07D 20/9/46, 20/9/70, 40/1/04, 40/1/12, 40/1/14, 40/3/06, 40/3/14,
40/5/14, 41/7/12, 49/1/048, 49/1/056
MARUISHI PHARMACEUTICAL
CO., LTD., JAPAN
WO/2004/048332
,
# "
279 HAYARKON ST.,
279
P.O.B. 6451,
6451 . . ,
TEL AVIV 61063
[71]
[87]
[74]
[57]
A novel isoindoline compound represented by the formula (I). (I) The compound has
sedative activity. The compound leads mammals to sedation and is hence useful as a
narcotic drug.
__________________
[11][21]
[54]
172
REDUCED COMPLEXITY
CHANNEL ESTIMATION FOR
WIRELESS COMMUNICATION
SYSTEMS
168512
"
"
[22]
[31]
[51]
[71]
[87]
[74]
[57]
12.11.2003
[32] 19.11.2002
[33] US
60/427896
10/691826
22.10.2003
US
Int. Cl.(2009.01) H04L 25/02, 27/26, H04W 40/12
U.S.A.
WO/2004/047311
P.O.B. 2273,
REHOVOT 76122
,'
.
,4
2273 . . ,
Techniques to derive a channel estimate using substantially fewer number of complex
multiplications than with a brute-force method to derive the same channel estimate. In
one method, an intermediate vector B (418) is initially derived based on K sub-vectors
of a vector H for a channel frequency response estimate and at least two DFT submatrices for a DFT matrix W , where K > 1. An intermediate matrix A (420) for the
DFT matrix W is also obtained. A least square channel impulse response estimate is
then derived based on the intermediate vector B and the intermediate matrix A (422).
In one implementation, the intermediate vector B is obtained by first computing DFTs
of a matrix HTXL , which is formed based on the vector H, to provide a matrix GLXL.
Inner products between the columns of a base DFT sub-matrix W1 and the rows of the
matrix GLXL are then computed to obtain the entries of the intermediate vector B .
__________________
[11][21]
[54]
VIDEO HOLOGRAM AND DEVICE
FOR RECONSTRUCTING VIDEO
HOLOGRAMS
[22]
[31]
[51]
[71]
11.11.2003
[32] 13.11.2002
10253292.3
Int. Cl.(2010.01) G03H 01//22
SEEREAL TECHNOLOGIES GMBH,
173
168538
[33]
DE
"
[87]
[74]
[57]
GERMANY
WO/2004/044659
26A HABARZEL ST.,
,
' 26 $
The invention relates to video holograms and devices for reconstructing video
holograms, comprising an optical system that consists of a light source (1), lens (2) and
the video hologram (3) that is composed of cells arranged in a matrix or a regular
pattern with at least one opening per cell, the phase or amplitude of said opening being
controllable. The video holograms and devices for reconstructing the same are
characterised in that holographic video representations of expanded spatial objects (6)
can be achieved in a wide viewing area in real time using controllable displays,
whereby the objects are either computer-generated or created by different means. The
space-bandwidth product (SBP) of the hologram is thus reduced to a minimum and the
periodicity interval of the Fourier spectrum is used as a viewing window (5) on the
inverse transformation plane, through which the object is visible in the preceding
space. The mobility of the viewer(s) is achieved by tracking the viewing window. The
invention can be advantageously used in the television, multimedia, games and
construction fields, in military and medical technology, in addition to other economic
and social areas.
__________________
[11][21]
[54]
METHOD, SYSTEM AND
APPARATUS FOR EXPOSING
WORKBOOK RANGES AS DATA
SOURCES
[22]
[31]
[51]
[71]
17.05.2005
[32] 01.06.2004
10/858175
Int. Cl.(2010.01) G06F 12//06, 17//30
MICROSOFT CORPORATION,
U.S.A.
26A HABARZEL ST.,
[74]
[57]
174
168620
,
[33]
US
,
' 26 $
A method for exposing data objects of a workbook as a server data source, comprising:
generating metadata for the data objects by automatically identifying the metadata in
the workbook and setting properties for the identified metadata, wherein the metadata
"
is utilized by a first server computer in responding to requests for the data objects
stored in the workbook as a server data source, the server data source comprising a
multidimensional database, wherein identifying the metadata comprises analyzing the
data objects to identify the following:
data types, measures, hierarchy, and default aggregations, and wherein setting the
properties comprises indicating a first default aggregation as a count for a string data
field in the metadata and setting a second aggregation as a sum for a numeric data
field in the metadata;
publishing the workbook and the metadata to the first server computer, wherein
publishing comprises programmatically generating a spreadsheet and sending the
spreadsheet to the first server computer through a server application program interface,
wherein the workbook is parsed for ranges including the data objects by a spreadsheet
server application executing on the first server computer, and wherein user-specified
data objects from among the data objects are exposed at the first server computer as
server data sources; and
connecting to the data object exposed at the first server computer as server data
sources in a manner identical to connecting to a dedicated OLAP data source provided
by a second server computer.
__________________
[11][21]
[54]
REWINDER MACHINE FOR THE
PRODUCTION OF ROLLS OF WEB
MATERIAL
[22]
[31]
22.11.2000
FI2002A000236 [32] 03.12.2002
30.05.2003
FI2003A000157
Int. Cl.(2010.01) B65H 19//22, 67//04
FABIO PERINI S.P.A., ITALY
WO/2004/050520
5 SHENKAR ST.,
P.O.B. 12704,
HERZLIYA 46733
[51]
[71]
[87]
[74]
[57]
175
168816
[33]
IT
IT
5
, #
#
' ,1 - $
# 12704 . . ,
The rewinder machine comprises: a first winding roller (3); a second winding roller
(5), defining with said first winding roller (3) a winding cradle; a feeder (33) for
sequentially introducing winding cores to said winding cradle; an optional glue
"
applicator (21) for applying glue to said cores. The feeder (33) may include an element
(39) for applying glue to the winding cores while they are being fed to said winding
cradle. In a special embodiment, the feeder is mechanically linked to a system for
unloading the roll from the winding cradle.
__________________
[11][21]
168851
[54]
COMPOSITION COMPRISING
PSEUDOEPHEDRINE AND
DOMPERIDONE FOR
PREVENTING SNORING
[22]
[31]
[51]
[71]
01.12.2003
[32] 02.12.2002
[33] US
2760/2002
Int. Cl.(2009.01) A61K 31/135, 31/445, C07D 401/00
AUGUSTO LARRAIN ORREGO,
CHILE
WO/2004/050070
P.O.B. 2273,
REHOVOT 76122
[87]
[74]
[57]
,'
.
,4
2273 . . ,
The invention relates to the novel use of a pharmaceutical product which combines
domperidone and pseudoephedrine sulphate substances and which can be used to
reduce or stop moderate or severe snoring.
__________________
176
"
[11][21]
168896
"
[54]
RELIABILITY DETECTION OF
CHANNEL QUALITY INDICATOR
(CQI) AND APPLICATION TO
OUTER LOOP POWER CONTROL
[22]
[31]
02.12.2003
[32] 04.12.2002
[33]
60/430854
60/438560
06.01.2003
Int. Cl.(2009.01) H04B 07/005, H04L 01/20
CORPORATION, U.S.A.
WO/2004/051872
26A HABARZEL ST.,
[51]
[71]
[87]
[74]
[57]
US
US
,
' 26 $
A method for improving the reliability of a channel quality indicator (CQI) (102, 106
Fig. 3) message in a wireless communications network begins with receipt of the CQI
message. The CQI message is then decoded, and a decision metric value for each
symbol in the CQI message is computed. A largest decision metric value and a second
largest decision metric value for the CQI message are determined. The reliability of the
CQI message can be determined by comparing the two largest decision metric values.
This method may be applicable to high-speed downlink packet access in time division
duplex, frequency division duplex, or other modes of transmission.
,202323
(
.
__________________
[11][21]
177
168932
"
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
DERIVATION OF
EIGENVECTORS FOR SPATIAL
PROCESSING IN MIMO
COMMUNICATION SYSTEMS
MIMO
09.12.2003
[32] 11.12.2002
[33] US
60/432760
10/729070
04.12.2003
US
Int. Cl.(2009.01) H04B 07/04, H04L 01/02, 01/14
U.S.A.
WO/2004/054191
P.O.B. 2273,
REHOVOT 76122
,'
.
,4
2273 . . ,
Techniques for deriving eigenvectors based on steered reference and used for spatial
processing. A steered reference is a pilot transmission on one eigenmode of a MIMO
channel per symbol period using a steering vector for that eigenmode. The steered
reference is used to estimate both a matrix $ of singular values and a matrix U of left
eigenvectors of a channel response matrix H . A matrix U with orthogonalized
columns may be derived based on the estimates of $ and U, e.g., using QR
factorization, minimum square error computation, or polar decomposition. The
estimates of $ and U (or the estimate of $ and the matrix U ) may be used for matched
filtering of data transmission received via a first link. The estimate U of or the matrix
U may also be used for spatial processing of data transmission on a second link (for
reciprocal first and second links).
,205655
(
.
__________________
[11][21]
178
169149
"
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
AUTOMATED TRANSLATION OF
HIGH ORDER COMPLEX
GEOMETRY FROM A CAD
MODEL INTO A SURFACE BASED
COMBINATORIAL GEOMETRY
FORMAT
11.05.2004
[32] 19.05.2003
60/471580
Int. Cl.(2009.01) G06T 17/00
WO/2004/104870
P.O.B. 2273,
REHOVOT 76122
(
[33]
) CAD
–
US
,'
.
,4
2273 . . ,
A computer implemented process translates the high order complex geometry
embodied in CAD software to the surface based combinatorial geometry (SBCG)
format. The translation process is comprised of a set of lower-level algorithms that
operate on two data sets which are commonly available from commercial CAD
software systems. The process writes a list of trimmed surfaces (step 36) which make
up a given part. These data are typically available from one of the standard geometry
representations such as IGES, STEP, or ACIS. The process also writes a list of nodal
data (step 38) : an appropriately dense grouping of point coordinates, designated as
either inside or outside the part. These data may be obtained by discretizing solid
geometry both within and external to the part of interest using standard FE tools (e.g.
ProMechanica). The process translates these two data sets into a list of analytic
surfaces and a well-posed zoning statement (step 40) and then optimizes that statement
(step 50).
__________________
[11][21]
[54]
179
169190
"
,
REGISTERING A MEDICAL
SITUATION ASSOCIATED WITH
A FIRST COORDINATE SYSTEM,
IN A SECOND COORDINATE
SYSTEM USING AN MPS SYSTEM
[22]
[31]
[51]
[71]
[87]
[74]
[57]
18.12.2003
[32] 13.01.2003
10/341535
10/458332
09.06.2003
Int. Cl.(2009.01) A61B 05/05
MEDIGUIDE LTD.
WO/2004/062497
BOROCHOV, KORAKH & CO.,
15TH FLOOR, ATIDIM TOWER,
KIRYAT ATIDIM,
P.O.B. 58100,
TEL AVIV 61580
,
[33]
US
US
, "
,'
-
58100 . . ,
System for registering a first image with a second image, the system including a first
medical positioning system (226) for detecting a first position and orientation of the
body of a patient, a second medical positioning system (236) for detecting a second
position and orientation of the body, and a registering module (232) coupled with a
second imager and second medical positioning system, the first medical positioning
system associated with and coupled with a first imager (224), the first imager acquiring
the first image from the body, the first imager producing the first image by associating
the first image with the first position and orientation, the second medical positioning
system associated with and coupled with the second imager (234), the second imager
acquiring the second image and associating the second image with the second position
and orientation, the registering module registering the first image with the second
image, according to the first position and orientation and the second position and
orientation.
__________________
[11][21]
180
169197
"
[54]
EGG REPLACER CONCENTRATE
AND LIQUID EGG REPLACER
[22]
[31]
[51]
[71]
05.02.2004
[32] 21.02.2003
03075500.3
Int. Cl.(2009.01) A23L 01/052, 01/32
UNILEVER PLC, UNITED
KINGDOM
WO/2004/073423
26A HABARZEL ST.,
[87]
[74]
[57]
,
[33]
,
EP
,
' 26 $
An egg replacer concentrate is provided that has a low cholesterol content. It includes
40-85% protein, 10-50% vegetable oil and 0.5-15% carbohydrate. The cholesterol
content is less than 0.5%. The protein includes soy protein, milk protein and optionally
egg white protein, at least half of the protein being soy protein. The PDI is at least
60%. The concentrate is dispersed in water, and optionally egg whites, to provide a
liquid egg replacer. The liquid egg replacer includes egg white protein and has a
moisture content of 75-84%. It contains 16-28% of the egg replacer concentrate, 4582% water and optionally egg white.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
181
PROTEIN ARRAYS COMPRISING
A POLYPEPTIDE ATTACHED TO
A SOLID SUPPORT AND METHOD
FOR ATTACHING SUCH
POLYPEPTIDE TO SUCH SOLID
SUPPORT
169200
"
"
22.12.2003
[32] 22.12.2002
[33] US
60/435821
Int. Cl.(2010.01) C07K 01//00, 17//00, C40B 40//10
THE SCRIPPS RESEARCH
INSTITUTE, U.S.A.
WO/2004/058946
26A HABARZEL ST.,
,
' 26 $
"
[57]
The invention provides proteins attached to solid supports, and methods of preparing
such solid support-bound proteins are provided. The proteins are attached to solid
supports by means of an unnatural amino acid incorporated into the protein, which
unnatural amino acid includes a reactive group that can react with a second reactive
group that is attached to a solid support.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
169425
TOPICAL STABILIZED
PROSTAGLANDIN E COMPOUND
DOSAGE FORMS
31.12.2003
[32] 03.01.2003
10/336481
Int. Cl.(2009.01) A61K 09/00
NEXMED HOLDINGS, INC., U.S.A.
WO/2004/062632
P.O.B. 2273,
REHOVOT 76122
E
[33]
US
,'
.
,4
2273 . . ,
Compounds of prostaglandin E group (PGE compounds) are stabilized as non-aqueous
compositions that include the compound together with a bulking agent that can be a
non-aqueous liquid or a solid in a sheet, film or powder form. The composition can
optionally include a skin penetration enhancer. A non-aqueous, solid dosage form
comprises a PGE compound substantially uniformly distributed in a carrier sheet or
film.
__________________
[11][21]
[54]
MOUNTING/ADJUSTING
MECHANISM FOR VISION
ENHANCEMENT SYSTEM
[22]
[31]
[51]
07.07.2005
[32] 12.07.2004
10/889478
Int. Cl.(2009.01) G02B 27/01
182
169589
[33]
US
"
[71]
[72]
[74]
[57]
ITT MANUFACTURING
ENTERPRISES, INC., U.S.A.
CHARLES D. WILLEY, STEVEN A.
BRILLHART, BLAIR R. DOBBIE
YORAM TSIVION,
,
#
2 HATOCHEN ST.
,2
'
P.O.B. 3148,
3148 . . ,
CAESAREA 38900
A mounting assembly (10) for a vision enhancement device and associated vision
enhancement display, the assembly comprising:
(a) a display mount (80) for holding the vision enhancement display (82);
(b) an arm (70) extending from a fixed end to a free end positionable in front of an eye
of a user in a first position, which corresponds to an in use position;
(c) on said arm the display mount is mounted; and
(d) at least one intermediate member (20, 40, 50) for connecting the arm (70) to a
mounting platform (12) for wearing on the user's head;
characterized in that the arm (70) is invertable between the first position and a second
position, which corresponds to a non-use position, in such a manner that when the
display mount is pulled away from the first position in direction to the second position,
the arm snaps into an inverted configuration.
__________________
[11][21]
[54]
[22]
[31]
[51]
183
CRYSTALLINE MODIFICATION
OF 2-(3,5-BISTRIFLUOROMETHYL- PHENYL)N- [6 -(1,1-DIOXO- 1 LAMBDA 6 THIOMORPHOLIN-4-YL)-4-(4FLUORO-2 METHYL- PHENYL)PYRIDINE- 3- YL]- N- METHYLISOBUTYRAMIDE
169600
–
–4–
–(
– 5,3) – 2
– N –(
–
–61–
– 1,1) – 6]
–
– 2–
– 4) 4 – (
–
–N–[ –3–
23.01.2004
[32] 31.01.2003
[33] EP
03002134.9
Int. Cl.(2009.01) A61K 09/14, 09/48, 31/541, A61P 25/00, C07D 417/04
"
[71]
[87]
[74]
[57]
SWITZERLAND
WO/2004/067007
P.O.B. 5352,
BEER-SHEVA 84152
,
#
#
,
5352 . . ,
The present invention relates to a new crystalline modification of 2-(3,5-bis6
trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda- thiomorpholin-4-yl)-4(4-fluoro-2methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide characterized by the following
X-ray diffraction pattern obtained with a CUK&agr ;radiation at2 thetas; (2Theta)= 4.5,
6.4, 7.5, 7.7, 8.0, 8.2, 10.0, 10.2, 10.9, 11.1, 12.9, 13.4, 14.0, 14.5, 15.1, 15.6, 16.2,
16.5, 17.3, 17.5, 18.0, 18.9, 19.3, 19.5, 19.9, 20.1, 20.6, 21.0, 21.4, 22.7, 23.1 and 23.6
and an infrared spectrum having sharp bands at 2925, 2845, 1637, 1604, 1484, 1395,
1375, 1285, 1230, 1172, 1125, 1082, 999, 943, 893, 863, 860, 782, 705, 684 cm-1, and
wherein the extrapolated melting point (DSC) is 137.2°C.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
184
169689
–
CONJUGATES OBTAINED BY
REDUCTIVE AMINATION OF
SEROTYPE 5 PNEUMOCOCCUS
CAPSULAR POLYSACCHARIDE
16.01.2004
[32] 17.01.2003
[33]
03/00488
Int. Cl.(2010.01) A61K 39//395, C08B 37//00
SANOFI PASTEUR, FRANCE
WO/2004/067574
P.O.B. 5352,
BEER-SHEVA 84152
5
FR
,
#
#
,
5352 . . ,
The invention relates to conjugates obtained by reductive amination of serotype 5
pneumococcus capsular polysaccharide. The reductive amination conditions differ
from conventional conditions in that they avoid the creation of an undesired compound
which is harmful to the immunogenicity of the conjugates. In carbon NMR
spectrometry, the undesired compound is characterized by a resonance signal of 13 -14
ppm. The aminated polysaccharides involved in the production of the conjugates have
a carbon NMR spectrum devoid of a resonance signal of 13 -14 ppm. The reductive
"
amination conditions according to the invention are twofold. According to a first
method, the reductive amination is performed at a pH which is slightly acidic (4-6, 5)
for a maximum of 4 hours. According to a second method, the polysaccharide is
initially reduced, then fragmented and finally undergoes the reductive amination per se
in conventional or unconventional conditions. According to the method used, the
structure of the aminated polysaccharide can vary (conversion or not of the Sug
residue of the repeater unit into N-acetyl quinovosamine and N-acetyl fucosamine) but
said variations, as recorded in carbon NMR spectrometry, have no effect on
immunogenicity.
__________________
[11][21]
[54]
IDENTIFYING AND LOCATING
AN ACOUSTIC EVENT
[22]
[31]
[51]
[71]
[87]
[74]
22.01.2004
[32] 24.01.2003
10/248511
Int. Cl.(2010.01) G01S 05//30
SHOTSPOTTER, INC., U.S.A.
WO/2004/068162
31 YAVNE ST.,
P.O.B. 1426,
TEL AVIV 61013
[57]
169836
[33]
US
,'
$
31
'
1426 . . ,
A system and method for detecting, identifying, and fixing the location of the source of
an acoustic event. The inventive system includes: a plurality of sensors dispersed at
somewhat regular intervals throughout a monitored area; a communication network
adapted to deliver information from the sensors to a host processor; and a process
within the host processor for determining, from the absolute times of arrival of an
event at two or more sensors, a position of the source of the event. Acoustic events are
detected and analyzed at each sensor so that the sensor transmits over the network: an
identifier for the sensor; an identifier for the type of event; and a precise absolute time
of arrival of the event at the sensor. In a preferred embodiment, the system also
identifies the type of weapon firing a gunshot.
__________________
185
"
[11][21]
[54]
ELECTRONIC DISABLING
DEVICE
[22]
[31]
11.02.2004
[32] 11.02.2003
10/364164
10/447447
29.05.2003
Int. Cl.(2009.01) H01G 02/00
TASER INTERNATIONAL, INC.,
U.S.A.
WO/2004/073361
5 SHENKAR ST.,
P.O.B. 12704,
HERZLIYA 46733
[51]
[71]
[87]
[74]
[57]
169842
[33]
US
US
, #
#
' ,1 - $
# 12704 . . ,
5
An electronic disabling device (200) includes first and second electrodes (E1, E2) for
contact with a target animal or person. The device disables the target by providing a
current through the electrodes and consequently through the target. To assure suitable
current flow, the device imposes across the electrodes a relatively high voltage for a
relatively short time to ionize an air gap that may exist due to electrode placement.
After a short time period, a lower voltage is used to sustain disabling current flow
through the electrodes.
,185200
(
.
__________________
[11][21]
[54]
ASSAY DEVICE
[22]
26.07.2005
186
169884
"
[31]
[51]
[71]
[74]
[57]
[32] 29.07.2004
60/591964
Int. Cl.(2009.01) G01N 21/00
SAVYON DIAGNOSTICS LTD.
26A HABARZEL ST.,
[33]
US
, "
,
' 26 $
A device for carrying out a lateral flow assay on a sample comprising:
(a) a sample containing unit (4) comprising a sample container (8) said sample
container being closed off at one end by a bottom wall (9) said bottom wall having a
hole (10) sealed by a plug (11); and
(b) a housing (6) located under said sample container and adapted for holding a lateral
flow assay test strip, said sample containing unit and said housing being coupled so as
to allow rotation one relative to the other, said housing comprising a cutting
arrangement (58) capable of cutting said plug;
wherein rotation of said sample containing unit and said housing one relative to the
other results in said cutting arrangement cutting said plug, thereby unplugging the hole
in said bottom wall.
__________________
[11][21]
169885
[54]
ADAPTIVE JUNK MESSAGE
FILTERING SYSTEM
[22]
[31]
[51]
31.12.2003
[32] 25.02.2003
[33]
10/374005
Int. Cl.(2010.01) G06Q 10//00, H04L 12//58
187
US
"
[71]
[87]
[74]
[57]
MICROSOFT CORPORATION,
U.S.A.
WO/2004/079501
26A HABARZEL ST.,
,
' 26 $
The invention relates to a system for filtering messages (102) - the system includes a
seed filter (106) having associated therewith a false positive rate and a false negative
rate. A new filter (108) is also provided for filtering the messages (102), the new filter
(108) is evaluated according to the false positive rate and the false negative rate of the
seed filter, the data used to determine the false positive rate and the false negative rate
of the seed filter (106) are utilized to determine a new false positive rate and a new
false negative rate of the new filter (108) as a function of threshold. The new filter
(108) is employed in lieu of the seed filter (106) if a threshold exists for the new filter
(108) such that the new false positive rate and new false negative rate are together
considered better than the false positive and the false negative rate of the seed filter
(106).
__________________
[11][21]
[54]
SAFETY COVERS FOR ELECTRIC
SOCKETS AND THE LIKE
[22]
[31]
27.01.2004
[32] 27.01.2003
0302411.4
0302412.2
27.01.2003
0301903.1
28.01.2003
0325676.5
23.10.2003
0325677.3
23.10.2003
Int. Cl.(2009.01) H01R 13/62
DORMINA UK LIMITED, UNITED
KINGDOM
WO/2004/068647
[51]
[71]
[87]
[74]
188
169890
[33]
GB
GB
GB
GB
GB
,
"
' 26 $
26A HABARZEL ST.,
[57]
An electrical socket comprises a wall mounted faceplate (17) with pin receiving
apertures for a plug and an integral (built-in) cover having a cover panel (22) movable
between an open position allowing access to the apertures and a closed position
concealing the apertures. The cover panel (22) is secured in the closed position by
engagement of latch pins (64) with latching means within the faceplate (17). The latch
pins (64) are released by a key inserted into keyholes (66) in the side of the faceplate
(17) and opens automatically under the biasing of a spring.
__________________
[11][21]
170056
[54]
PYRAZOLE COMPOUNDS
[22]
[31]
[51]
[71]
03.02.2004
[33] JP
2003-082385 [32] 25.03.2003
Int. Cl.(2010.01) A01N 43//56, A61K 31//4468, C07D 23/1/20
SUMITOMO CHEMICAL
COMPANY, LIMITED., JAPAN
WO/2004/085405
,
279 HAYARKON ST.,
P.O.B. 6451,
TEL AVIV 61063
[87]
[74]
[57]
279
#
"
6451 . . ,
A pyrazole compound represented by the formula (a): (a) wherein R1 represents C1-4
alkyl or trifluoromethyl, R2 represents C1-4 alkyl, and R3 represents hydrogen or C1-6
alkyl; R4 represents halogeno, etc. and m is an integer of 0 to 4; R5 represents
halogeno, etc. and n is an integer of 0 to 4; R6 and R7 are the same or different and
each represents hydrogen, halogeno, or methyl; and X represents oxygen or a group
represented by R8O-N, wherein R8 represents hydrogen, C1-6 alkyl, etc. The compound
is highly active in controlling harmful arthropods.
__________________
189
"
[11][21]
[54]
COMMUNICATION RECEIVER
WITH AN ADAPTIVE EQUALIZER
[22]
[31]
[51]
[71]
18.02.2004
[32] 18.02.2003
10/368920
Int. Cl.(2009.01) H04L 25/03
U.S.A.
WO/2004/075498
P.O.B. 2273,
REHOVOT 76122
[87]
[74]
[57]
170145
[33]
US
,'
.
,4
2273 . . ,
In a wireless communication system, a method for estimating a transmitted signal is
disclosed. A wireless signal is received that includes a pilot channel and at least one
other channel. A transmitted signal is estimated using an equalizer and the received
wireless signal. The equalizer includes a filter with a plurality of taps that are adapted
through use of an adaptive algorithm that uses an estimated pilot estimated from the
received wireless signal. The pilot channel is transmitted in the wireless signal that
included the at least one other channel. The estimated pilot is extracted and provided to
the adaptive algorithm.
,205799
(
.
__________________
[11][21]
170191
[54]
MACHINE FOR INJECTING
LIQUIDS
[22]
[31]
[51]
[71]
06.02.2004
[32] 10.02.2003
[33]
10/361459
Int. Cl.(2009.01) A23B 04/00, B67D 01/00
EDWARD D. WATTS, U.S.A.
CONLY L. HANSEN, U.S.A.
WO/2004/071936
[87]
[74]
190
US
,
"
' 26 $
26A HABARZEL ST.,
[57]
A machine for injecting liquids is disclosed including use of at least one air pump (32)
in fluid communication with at least one injection head (34) having apertures (48) for
nozzles (42). High-pressure injectate flows from the air pump into the head, preferably
through a threadlessly mounted filter (72) located within the injection head. To further
minimize contamination, fluid that enters the injection head will not contact any
threading present in either the head or the nozzles. An air pressure regulator is
included to ensure a steady stream of injectate of a desired pressure is delivered to an
injection subject via each injection head and also helping to eliminate hesitation in
delivery of the fluid by the air pump. Cleaning of the machine is simplified by moving
sensitive components into a sealed enclosure, removing them from a wet working
environment.
,200201
(
.
__________________
[11][21]
170231
[54]
METHOD AND APPARATUS TO
COUNT BROADCAST CONTENT
RECIPIENTS IN A WIRELESS
TELEPHONE NETWORK
[22]
[31]
[51]
[71]
18.02.2004
[32] 18.02.2003
[33]
10/368876
Int. Cl.(2009.01) H04L 12/18, H04W 04/06
U.S.A.
WO/2004/075516
[87]
[74]
191
US
,'
.
"
,4
2273 . . ,
P.O.B. 2273,
REHOVOT 76122
[57]
A base station (110) in a wireless communications network (100) counts mobile
stations (114) receiving broadcast content via multi-user channel. The base station
broadcasts (608) a repeating message identifying at least one broadcast content stream
and, for each stream, a REGISTER (R) or DO NOT REGISTER (DNR) indicator.
Mobile stations periodically re-examine (722) contents of this message. When the
indicator is R for a broadcast content stream, mobile stations whose users have elected
to receive it send (714) the base station a registration message for that stream. When
the number of registered mobile stations reaches (612) a prescribed number, the base
station changes (614) the indicator to DNR. When the indicator is DNR for a broadcast
content stream, mobile stations refrain (712/716) from sending any registration
message for that broadcast content stream. The base station may institute a recount
(618) by resetting the indicator to R.
,203708
(
.
__________________
[11][21]
170271
[54]
TEMPERATURE RESPONSIVE
VALVE
[22]
[51]
[71]
14.08.2005
Int. Cl.(2010.01) F16K 31//64, F25B 09//02, G05D 23//00
RAFAEL - ARMAMENT
, "
#
DEVELOPMENT AUTHORITY LTD
JOSEF FLOMENBLIT, MORDEHAI
,
,
,
%
SHIMHON, DAVID GORNI,
,
LEONID RUBINSON, EILON
FARAN
YORAM TSIVION,
,
#
2 HATOCHEN ST.
,2
'
P.O.B. 3148,
3148 . . ,
CAESAREA 38900
A temperature responsive valve for controlling a gas flow, said valve comprising:
a hollow body (10) having an inlet (12), an outlet and an inner surface;
a nozzle (14) disposed at said outlet;
a shape memory alloy wire (18) having a first end (16) and a second end, said first end
attached to the inner surface of the hollow body and having an austenitic and
martensitic phase;
"
[72]
[74]
[57]
192
a stopper (20) attached to the second end of the shape memory alloy wire, said stopper
designed to be fittable into said nozzle;
wherein when the gas flows it impacts the stopper providing a stress on the wire and
tending to cool the wire to a temperature below the martensitic transition temperature
thereby allowing the wire to elongate and thus the stopper engages the nozzle and
slows or blocks flow, resulting in a temperature increase of the wire to a temperature
greater than the austenitic transition temperature thereby resulting in a contraction of
the wire retracting the stopper from the nozzle to allow gas to flow again.
__________________
[11][21]
[54]
REQUEST REDIRECTION
HANDLING IN IMC
[22]
[31]
23.03.2004
[32] 24.03.2003
03006573.4
10/633692
05.08.2003
Int. Cl.(2010.01) H04L 29//06
NOKIA CORPORATION, FINLAND
WO/2004/086723
26A HABARZEL ST.,
[51]
[71]
[87]
[74]
[57]
193
170283
IMC–
[33]
EP
US
,
' 26 $
According to an aspect of the invention a method of processing a service request in an
"
IP multimedia core network is disclosed. The method comprises the steps of receiving
a service request initiated by a first user, for a second user, forwarding the received
service request to a unit for processing the service, receiving a processing result from
the processing unit, and determining, on the basis of the received processing result,
whether service request processing for the second user is to be stopped.
__________________
[11][21]
170313
[54]
DIARYLCYCLOALKYL
DERIVATIVES AND
PHARMACEUTICAL
THEM
[22]
[31]
[51]
[71]
19.02.2004
[32] 27.02.2003
[33] DE
10308353.7
Int. Cl.(2009.01) A61K 31/421, A61P 03/08, 03/10, C07D 263/32, 413/04
GMBH, GERMANY
WO/2004/075815
, #
#
5 SHENKAR ST.,
5
' ,1 - $
P.O.B. 12704,
# 12704 . . ,
HERZLIYA 46733
[87]
[74]
[57]
194
The invention relates to diarylcycloalkyl derivatives, their physiologically compatible
salts, racemates and physiologically functional derivatives. The invention relates to
compounds of formula (I), in which the groups are defined as cited in the description,
in addition to their physiologically compatible salts and to a method for their
production. The compounds are suitable for treating and/or preventing disorders of the
fatty acid metabolism and disorders of glucose utilisation in addition to disorders, in
which insulin resistance plays a part.
"
__________________
[11][21]
170314
–4–
–
– 2)– 3) – 4
–(
,
,
[54]
4 - (3 -(2 - PHENYL - OXAZOL - 4 YLMETHOXY) CYCLOHEXYLOXY) - BUTANE
ACID DERIVATIVES AND
RELATED COMPOUNDS,
PHARMACEUTICAL
THEM AND USE THEREOF
[22]
[31]
[51]
[71]
19.02.2004
[32] 27.02.2003
10308355.3
[33] DE
Int. Cl.(2009.01) A61K 31/421, A61P 03/08, 03/10, C07D 263/32, 413/04
GMBH, GERMANY
WO/2004/076428
, #
#
5 SHENKAR ST.,
5
' ,1 - $
P.O.B. 12704,
# 12704 . . ,
HERZLIYA 46733
[87]
[74]
[57]
–(
The invention relates to aryl-cycloalkyl substituted alkane acid derivatives and the
physiologically compatible salts and physiologically functional derivatives thereof.
The invention also relates to compounds of formula (I), wherein the radicals have the
above-mentioned meanings, in addition to the physiologically compatible salts thereof
and a method for the production thereof. Said compounds can be used for example, in
the treatment and/or prevention of disorders in the metabolism of fatty acids and
disorders related to the use of glucose, in addition to insulin-related disorders.
__________________
[11][21]
[54]
195
CYCLOALKYL-METHOXY
SUBSTITUTED ACETIC ACID
DERIVATIVES AND
PHARMACEUTICAL
170316
–
"
THEM
[22]
[31]
[51]
[71]
[87]
[74]
[57]
19.02.2004
[32] 27.02.2003
[33] DE
10308355.3
Int. Cl.(2009.01) A61K 31/421, A61P 03/00, C07D 263/32, 413/04
GMBH, GERMANY
WO/2004/076427
, #
#
5 SHENKAR ST.,
5
' ,1 - $
P.O.B. 12704,
# 12704 . . ,
HERZLIYA 46733
The invention relates to cycloalkyl methoxy substituted acetic acid derivatives, in
addition to their physiologically compatible salts and physiologically functional
derivatives. The invention relates to compounds of formula (I), in which the groups are
defined as cited in the description, in addition to their physiologically compatible salts
and to a method for their production. The compounds are suitable e.g. for treating
and/or preventing disorders of the fatty acid metabolism and disorders of glucose
utilisation in addition to disorders, in which insulin resistance plays a part.
__________________
[11][21]
[54]
LIQUID ORAL DOSAGE
FORMULATIONS COMPRISING
5-METHYL-2-(2'-CHLORO-6'FLUOROANILINO)
PHENYLACETIC ACID,
METHODS FOR PREPARING
THEM AND USE THEREOF FOR
THE MANUFACTURE OF
MEDICAMENTS
[22]
[31]
[51]
[71]
[87]
[74]
11.03.2004
[32] 12.03.2003
60/454145
Int. Cl.(2009.01) A61K 09/08, 31/195
WO/2004/080451
P.O.B. 5352,
BEER-SHEVA 84152
196
170518
–5
(
[33]
– 6'–
– 2 ')–2–
,
US
,
#
#
,
5352 . . ,
"
[57]
Provided are compositions comprising aqueous suspensions of 5-methyl-2-(2’-chloro6’-fluoroanilino)phenylacetic acid suitable for oral administration. Methods for
making such compositions and methods for their stabilization are provided.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[72]
[87]
[74]
[57]
170913
USE OF AN ILEAL BILE ACID
TRANSPORT (IBAT) INHIBITOR
IN THE PREPARATION OF A
MEDICAMENT FOR THE
TREATMENT OR PROPHYLAXIS
OF CONSTIPATION
01.04.2004
[32] 05.04.2003
0307918.3
Int. Cl.(2009.01) A61K 31/00
ALBIREO AB, SWEDEN
HASSE ROLAND ABRAHAMSSON,
PER-GORAN GILLBERG
WO/2004/089350
S. HOROWITZ & CO.,
31 AHAD HAAM STREET
P.O. BOX 2499
TEL AVIV 65202
( IBAT )
[33]
GB
,'
31
/
.
2499 . . ,
The use of an IBAT inhibitor in the treatment and/or prophylaxis of constipation, in a
warm-blooded animal, such as man is described.
__________________
[11][21]
[54]
CONTACTLESS READING
SYSTEM FOR CHIP CARDS
PLACED ON OBJECTS
[22]
[31]
01.04.2004
03/04092
197
[32]
02.04.2003
170974
[33]
FR
"
[51]
[71]
[87]
[74]
[57]
Int. Cl.(2010.01) G06K 07//08
ASK S.A., FRANCE
WO/2004/090793
26A HABARZEL ST.,
,
' 26 $
A contactless reading system, wherein a chip card is fixed on a planar support of an
object such as a book (11) for identification by means of the data contained in the chip
card, and a mobile reader (16) provided with an antenna in order to read the data of the
card. The antenna of the reader (16) consists of a small-sized convolution disposed in a
series with a large-sized convolution, which are concentric and which have the same
winding direction. A maximum value is obtained for the component (H) of the
electromagnetic field produced by the antenna parallel to the antenna at a given
distance from the antenna. Maximum reception by the chip card of electromagnetic
signals emitted by the antenna is obtained when the antenna is disposed in a
perpendicular position in relation to the support of the card and at the given distance
from the card.
__________________
[11][21]
171027
[54]
TREATING URINARY TRACT
DISORDERS
[22]
[31]
[51]
[71]
[72]
[87]
[74]
16.03.2004
[32] 18.03.2003
[33]
10/389948
Int. Cl.(2010.01) A61F 07//12, A61M 25//14
ELMEDICAL LTD.
UZI ESHEL
WO/2004/082734
SOROKER-AGMON,
198
US
#
, "
,
$
"
14
14 SHENKAR ST.,
HERZLIYA PITUAH 46725
[57]
,
#
A method, device, and system for treatment of urinary tract disorders is provided. The
device includes a catheter having multiple lumens for insertion into a urinary bladder
and for providing fluid flow within the bladder and within the fluid reservoir within the
urethra. The device further includes an anchor to be placed within the bladder. A port
hub having multiple ports is connected at a proximal end of the catheter. A method of
treatment includes providing heated fluid to a urinary bladder and to a fluid reservoir
for insertion into an adjacent organ such as the urethra. Simultaneous treatment or
separate treatment may be done. Optionally, a medicated solution may be added to the
heated fluid. Additionally, pressure may be adjusted so as to optimize the therapeutic
effect
__________________
[11][21]
171040
[54]
CONVERTED HIGH MOBILITY
VEHICLE AND CONVERSION
METHOD THEREFOR
[22]
[51]
[71]
22.09.2005
Int. Cl.(2010.01) B60P 03//42, B62D 65//00
PLASAN SASA AGRICULTURAL
"
COOPERATIVE SOCIETY LTED.
TAL DAI, JAKOB BEN-ARY
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[72]
[74]
[57]
199
,
,
' 26 $
Method for manufacturing an armored high mobility vehicle (10) from an after market
4x4 produced by a manufacturer, having a chassis (12) with a frame, front axle and
rear axle (20), said chassis having a standard wheelbase, the high mobility vehicle
having increased maneuverability and on-road and/or off-road capability, relative to
the 4x4, including:
dismounting at least one of the front axle or rear axle from said frame;
shortening said frame;
mounting the dismounted axle to the shortened frame so as to obtain a shortened
chassis having a shortened wheelbase which is shorter than any standard wheelbase of
the line of models produced by said manufacturer; and protecting at least a portion of
the high mobility vehicle by armor.
"
35
This specification was examined in
accordance with regulation 35 of the Patent
Regulations, 5728 - 1968
,205969
division from this
been published
5
(
1968 – "
,
(
.
__________________
[11][21]
171255
[54]
THERMOPLASTIC STIFFENING
MATERIAL FOR USE FOR
MANUFACTURING SHOES AND A
METHOD FOR THE
PRODUCTION THEREOF
[22]
[31]
[51]
[71]
[87]
[74]
27.03.2004
[32] 11.04.2003
[33] DE
10316617.3
Int. Cl.(2010.01) C08K 03//00, C09J 12/3/08, 16/7/04
BK GIULINI GMBH, GERMANY
WO/2004/090061
DANIEL FREIMANN & CO.,
5 DROYANOV ST., 10TH FLOOR ,
10
TEL AVIV 63143
[57]
200
,
,'
5
The invention relates to a novel thermoplastic stiffening material used for
manufacturing shoes or shoe parts, and to an environmentally friendly method for the
production thereof. The inventive material is provided in the form of a hot-melt
adhesive/filler compound and is characterized in that it is comprised of one or more
hot-melt adhesives and of one or more fillers, which are provided in quantities ranging
from 50 to 15 % by weight and which do not dissolve in the hot-melt adhesive. The
hot-melt adhesive/filler compound simultaneously fulfills the following parameters: 1.
"
MVR value between 2 and 6, preferably between 3 and 5 cm3/10min; 2. Surface tack,
when measured according to DIN EN 14610 at 65 °C, ranging from at least 10 N/2 cm,
preferably 15 N/2 cm, particularly 20 N/2 cm; 3. Bonding value/peel resistance with
regard to upper materials and linings of at least 30 N/5 cm when measured according
to DIN 53357; 4. Longitudinal extension of no greater than 25 %, preferably less than
20 %, when measured at a temperature of 90 °C.
__________________
[11][21]
171356
[54]
ANTI-INTERFERON RECEPTOR
ANTIBODY FOR TREATMENT OF
INFLAMMATORY BOWEL
DISEASE
[22]
[31]
[51]
[71]
23.04.2004
[32] 23.04.2003
[33] US
60/465155
Int. Cl.(2009.01) A61K 39/395, C07K 16/18, 16/28
BRISTOL-MYERS SQUIBB
COMPANY, U.S.A.
WO/2004/093908
P.O.B. 2273,
REHOVOT 76122
[87]
[74]
[57]
201
,'
.
,4
2273 . . ,
Compositions and methods for the therapy of Inflammatory Bowel Disease (IBD),
including Celiac Disease, Crohn’s Disease, and Ulcerative Colitis, are disclosed.
Illustrative compositions comprise one or more anti-type 1 interferon antagonists, such
as anti-type 1 interferon receptor antibody antagonists and fragments thereof, as well
as polypeptides and small molecules that inhibit the interaction of type 1 interferon
with its receptor (IFNAR).
"
__________________
[11][21]
[54]
SOLAR COLLECTORS WITH
EVACUATED RECEIVER AND
NONIMAGING EXTERNAL
REFLECTORS
[22]
[31]
[51]
[71]
[87]
[74]
22.04.2004
[32] 22.04.2003
60/464429
Int. Cl.(2009.01) F24J 02/10
SOLARGENIX ENERGY LLC, U.S.A.
WO/2004/094924
P.O.B. 1352,
JERUSALEM 91013
[57]
171542
[33]
US
,
,%
1352 . . ,
A solar collector with external reflector. A solar collector includes a glass housing
having a heat pipe disposed within the housing and a light reflector disposed external
to the housing.
__________________
[11][21]
[54]
METHOD AND DEVICE FOR
ROCK BOLTING
[22]
[31]
[51]
[71]
12.05.2004
[32] 12.05.2003
0301376-0
Int. Cl.(2010.01) E21D 20//00
ATLAS COPCO ROCK DRILLS AB,
SWEDEN
202
171671
[33]
SE
"
[87]
[74]
[57]
WO/2004/099569
31 YAVNE ST.,
P.O.B. 1426,
TEL AVIV 61013
,'
$
31
'
1426 . . ,
Method and device for rock bolting, wherein a tubular bolt (2) with closed crosssection is inserted and expanded for anchoring inside a bore hole (12), wherein the
tubular bolt is expanded to contact in the inner portion of the bore hole, a tension
element (3, 7, 8, 9) which is arranged in the outer portion of the bore hole with an
inner part (7) attached to the tubular bolt (2) is pre-stressed and a settable medium is
injected into the outer portion of the bore hole (14) between (27) the tension element
and the wall of the bore hole and is allowed to set.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
203
APO2L (TRAIL) RECEPTOR
BINDING PEPTIDES AND USES
THEREOF
171733
APO2L
((TRAIL
29.04.2004
[32] 09.05.2003
[33] US
60/469436
Int. Cl.(2010.01) A61K 38//04, A61P 35//00, C07K 07//04, 07//08, 14//47, 14//525,
14//705, C12N 01//21, 05//07, 15//19, 15//63
GENENTECH, INC., U.S.A.
WO/2004/101608
,
26A HABARZEL ST.,
' 26 $
Peptides are provided that bind Apo-2L receptor molecules. These peptides can be
used for example in methods where a modulation of the biological activities of Apo-2L
and/or Apo-2L receptor molecules such as DR5 is desired.
"
__________________
[11][21]
171779
[54]
IMMUNOCONJUGATES
COMPRISING AN
IMMUNOGLOBULIN CONSTANT
REGION AND A BIOLOGICALLY
ACTIVE MOLECULE
[22]
[31]
06.05.2004
[32] 06.05.2003
[33] US
60/469600
60/487964
17.07.2003
US
60/539207
26.01.2004
US
Int. Cl.(2009.01) C07K 19/00, C12N 15/13, 15/62
SYNTONIX PHARMACEUTICALS,
INC, U.S.A.
WO/2005/001025
P.O.B. 2273,
REHOVOT 76122
[51]
[71]
[87]
[74]
[57]
,'
.
,4
2273 . . ,
The invention relates to a chimeric monomer-dimer hybrid protein wherein said
protein comprises a first and a second polypeptide chain, said first polypeptide chain
comprising at least a portion of an immunoglobulin constant region and a biologically
active molecule, and said second polypeptide chain comprising at least a portion of an
immunoglobulin constant region without the biologically active molecule of the first
chain. The invention also relates to methods of using and methods of making the
chimeric monomer-dimer hybrid protein of the invention.
,205802
(
.
__________________
[11][21]
[54]
[22]
[31]
204
171802
ELECTRONIC CONTROLLER FOR
HIGH POWER GAS DISCHARGE
LAMP
14.04.2004
200410016366.4
[32]
17.02.2004
[33] CN
"
[51]
[71]
[87]
[74]
[57]
Int. Cl.(2010.01) H05B 41//00
FANGLU LOU, CHINA
WO/2005/081588
26A HABARZEL ST.,
,
' 26 $
A electronic controller for high power gas discharge lamp, which is comprised of the
circuit of filtering, rectifying, power factor switch, driving transform power control,
startup trigger protection, output matching and auxiliary power supply, and. these
circuit are coupled to each other in this order. The filtering circuit adopts inultiple
electrode common mode and difference mode filter, which is fully according with
EMC standard, the interfere of outer track is decreased at controller, and adopts three
integrated block circuit, which has high integration degree, low element device
utilized, simple circuit, and low cost, whereas the auxiliary power supply circuit, which
supplies the integrated block working, is obtained by commercial power after voltage
transformer and voltage stabilizing tube voltage-stabilizing, and has working stability
and high reliability. In the drive circuit, straight driving switching tube Q3 by
integrated block IC2, this circuit is simple, and has little distortion, can work under
constant voltage, constant current and constant power, and has the function of work
stable in a state of short cij,,-cuit, open circuit and ordinary guide, in particular adapts
for its fix and use on high power gas discharge lamp, and has high power factor, long
performance life and high quality of lighting.
__________________
[11][21]
[54]
ENCRYPTING AND DECRYPTING
A BLOCK OF DATA
[22]
[31]
[51]
[71]
19.05.2004
[32] 23.05.2003
03011696.6
Int. Cl.(2010.01) H04L 09//06, 09//28
NAGRAVISION S.A.,
SWITZERLAND
WO/2004/105305
P.O.B. 1352,
JERUSALEM 91013
[87]
[74]
[57]
205
171933
[33]
EP
,
,%
1352 . . ,
Method to encrypt or decrypt blocks of data X to Y, based on a main key R, this
method using several serially connected modules, each module using a sub-key RA
"
derived from the main key R and comprising the steps of: - inputting at least two initial
values XOL and XOR, and mixing these values to form a mixed value X1, - obtaining
a value X2 by mixing a first part RAH of the sub-key RA with the value X1, obtaining a value X3 by applying the value X2 to a substitution layer, comprising at
least one substitution box (sbox), - obtaining a value X4 by using a diffusion box of
multi-permutation type based on the value X3, - obtaining a value X5 by mixing a
second part RAL of the sub-key RA with the value X4, - obtaining the value X6 by
applying to the value X5 a substitution layer, - obtaining a value X7 by mixing a first
part RAH of the sub-key RA with the value X6, - mixing the value X7 with the initial
at least two values XOL and XOR to obtain the at least two values X8L and X81R,
X8L and X8R representing the output value X8 of the module. This method using at
least two modules, and applies to at least one of the value X8L or X8R an
orthomorphism function before feeding them to the next module.
__________________
[11][21]
[54]
METHOD FOR GENERATING
PSEUDO-RANDOM SEQUENCE
[22]
[31]
[51]
[71]
02.09.2004
[32] 05.09.2003
03103307.9
Int. Cl.(2010.01) H04L 09//06
NAGRAVISION S.A.,
SWITZERLAND
WO/2005/025123
P.O.B. 1352,
JERUSALEM 91013
[87]
[74]
[57]
206
171934
–
[33]
,
EP
,
,%
1352 . . ,
The aim of this invention is to propose a method to generate sequences or sub-keys
based on a main key, in which each sub-key gives no information to recover the main
key or any other sub-keys. The aim is achieved with a method to generate sub-keys
based on a main key (MKEY), comprising the following steps: - obtaining a first value
"
(A1) by applying to the main key (MKEY) a linear diversification layer by mixing the
main key (MKEY) with a constant, - applying to the first value (A1) a non-linear
transformation, this transformation comprising the steps of: - obtaining a second value
(A2) by applying the first value (A1) to a substitution layer, the substitution layer
comprising at least one substitution box (sbox), each substitution box containing at
least one table of constants for which the input serves as the pointer and the pointed
constant serves as the output, - obtaining a third value (A3) by using a diffusion box of
multi-permutation type based on the second value (A2), - dividing the third value (A3)
in N blocks of same size, obtaining the output fourth value (A4) formed by N blocks,
each block of the fourth value (A4) being the result of the combination of N-1 blocks
of the third value (A3), the missing block being the block of the same index, obtaining the fifth value (A5) by applying to the fourth value (A4) a substitution layer,
- obtaining the sub-key (RKEY) by applying to the fifth value (A5) a symmetrical
encryption module, the first value (A1) serving as the key input for this module.
__________________
[11][21]
[54]
PROCESS FOR DISSOLVING
POLYVINYL CHLORIDE RESIN
FOR THE MANUFACTURE OF
PVC SOLUTION
[22]
[31]
19.05.2004
[32] 19.05.2003
10-20030031515
Int. Cl.(2010.01) C08J 03//02
E.M.A.T TECHNOLOGIES LTD
MOSHE LIPPER, WILLIAM GAY
HUGHES GAMES
WO/2004/101654
[51]
[71]
[72]
[87]
[74]
207
172034
PVC ,
PVC
[33]
KR
, "
. .
,
$
.
.
,
"
' 26 $
26A HABARZEL ST.,
[57]
The present invention relates to a process for the preparation of a PVC homopolymer
solution containing PVC in concentration greater than 5 wt %, comprising adding solid
PVC to an organic solvent containing a dissolving agent selected from phthalates,
adipates, phosphates, sebacates and azelates, and stirring the same until a clear solution
is obtained, a process for the manufacturing of the PVC sheet, comprising applying the
PVC homopolymer solution, and a PVC film, whenever manufactured by the process
of the PVC sheet. The present invention provides a process for the preparation of the
PVC homopolymer solution, the transparent solution which is stable and in which no
precipitation or gel formation occurs for long periods of time, the PVC dissolving
solution without applying any external heat, and the PVC sheet by efficient and
inexpensive method.
__________________
[11][21]
172078
–
[54]
DUAL TRACKED MOBILE
ROBOT FOR MOTION IN
ROUGH TERRAIN
[22]
[51]
[71]
21.11.2005
Int. Cl.(2009.01) B62D 55/065, 59/04
ARIEL-UNIVERSITY RESEARCH
AND DEVELOPMENT COMPANY
, "
LTD
SHRAGA SHOVAL, AMIR
,
SHAPIRO
,
#
#
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
An autonomous dual tracked mobile robot system comprising two or more tracked
driving units configured to travel in tandem and a separate mechanical linkage joining
each of said mobile units to the unit immediately preceding and following it;
wherein, each of said mechanical linkages comprises:
one connecting bar and three revolute joints on each of said units; and
a connecting beam that connects said connecting bar on one of said units with said
connecting bar on the second of said units.
said mechanical linkage enabling efficient force transmission between said two
driving units.
[72]
[74]
[57]
208
"
__________________
[11][21]
172083
[54]
CATALYST TO REDUCE CARBON
MONOXIDE AND NITRIC OXIDE
FROM THE MAINSTREAM
SMOKE OF CIGARETTE
[22]
[31]
[51]
[71]
10.06.2004
[32] 13.06.2003
[33] US
10/460303
Int. Cl.(2010.01) A24B 15//00, 15//18, 15//28, A24D 03//00, 03//06
PHILIP MORRIS PRODUCTS S.A.,
SWITZERLAND
WO/2004/110184
,
26A HABARZEL ST.,
' 26 $
[87]
[74]
[57]
Cut filler compositions, cigarettes, methods for making cigarettes and methods for
smoking cigarettes are provided, which involve the use of a catalyst capable
converting carbon monoxide to carbon dioxide and/or nitric oxide to nitrogen. Cut
filler compositions comprise tobacco and at least one catalyst. Cigarettes are provided,
which comprise a cut filler having at least one catalyst. The catalyst comprises
nanoscale metal and/or metal oxide particles supported on a fibrous support. The
catalyst can be prepared by combining a dispersion of nanoscale particles with a
fibrous support, or by combining a metal precursor solution with a fibrous support and
then heat treating the fibrous support.
__________________
209
"
[11][21]
[54]
SYSTEM AND METHOD FOR GSM
HARD HANDOFF
[22]
[31]
18.06.2004
[32] 18.06.2003
60/479777
60/531583
18.12.2003
Int. Cl.(2009.01) H04W 36/14, 52/42
U.S.A.
WO/2004/114691
P.O.B. 2273,
REHOVOT 76122
[51]
[71]
[87]
[74]
[57]
172262
GSM–
[33]
US
US
,'
.
,4
2273 . . ,
A GSM1x (206)-to-GSM (208) handoff feature allows a GSM1x subscriber with a
dual-mode (GSM1x and GSM modes) handset (204) to seamlessly roam from GSM1x
coverage areas to GSM coverage areas. This functionality is facilitated by the GSM1x
system design which integrates a CDMA RAN with a standard GSM core network.
The GSM1x system is built using standard CDMA as its air interface and an
unmodified CDMA RAN with a standard IOS interface to the MSN (304). The only
modifications are done at the MSN (304) and the MS.
__________________
[11][21]
[54]
[22]
[51]
210
172308
POOL HEATING SYSTEM AND
METHOD
01.12.2005
Int. Cl.(2009.01) F25B 13/00, 27/02, F25D 29/00
"
[71]
[74]
[57]
DAVID PERETZ
,/
GOLD PATENTS LTD.,
, " (1992)
/
15 YOHANAN HA'SANDLAR ST.
15
P.O.B 25267
25267 . . ,
HAIFA 31251
A pool heating system (10) comprising:
an immersed condenser coil (132), immersed in pool of water (136) receiving hot
refrigerant gas (141) at high pressure from an outdoor unit (12), transferring heat to
water in said pool, condensing said gas and transmitting condensed refrigerant to said
outdoors unit; and
an outdoors unit comprising:
a compressor (110) for compressing low-pressure refrigerant gas producing hot
refrigerant gas at high pressure;
an expansion valve (120) receiving and expanding condensed refrigerant from said
immersed coil for producing low-pressure cold mixture of gaseous and liquid
refrigerant;
an evaporator (142) for evaporating said low-pressure cold mixture of gaseous and
liquid refrigerant producing low-pressure refrigerant gas and transmitting said lowpressure refrigerant gas to said compressor; and
a fan (148) for blowing outside air over said evaporator for transferring heat to, and
evaporating
a low-pressure cold mixture of gaseous and liquid refrigerant.
__________________
[11][21]
[54]
211
172470
METHOD TO MONITOR
STRUCTURAL DAMAGE
OCCURRENCE AND
PROGRESSION IN MONOLITHIC
COMPOSITE STRUCTURES
USING FIBRE BRAGG GRATING
"
SENSORS
[22]
[31]
[51]
[71]
[74]
[57]
08.12.2005
[32] 28.12.2004
04107032.7
Int. Cl.(2009.01) G02B 06/34
AIRBUS ESPANA, S.L., SPAIN
26A HABARZEL ST.,
[33]
EP
,
' 26 $
A method of monitoring structural damage in a composite structure manufactured by
co-curing, co-bonding or secondary bonding of several sub-components, using fibre
optic Bragg grating sensors attached or embedded to or between (in the bonding line)
said sub-components, characterized by comprising the steps of:
(a) measuring the wavelength spectra of said Bragg grating sensors at the end of the
manufacturing of the part, and in a known load condition, considered as reference;
(b) identifying the occurrence of a failure of the structure and the progress of said
failure detecting the release of the residual stresses/strains stored during the curing
process by measuring changes with respect to said reference wavelength spectra.
__________________
[11][21]
172568
[54]
CREATING AND OPERATING
BIOMETRICALLY ENABLED
MULTI-PURPOSE CREDENTIAL
MANAGEMENT DEVICES
[22]
[31]
[51]
[71]
15.06.2004
[32] 16.06.2003
[33] US
60/478363
Int. Cl.(2010.01) G06F 21//00, G06Q 30//00, G07C 09//00
URU TECHNOLOGY,
INCORPORATED, U.S.A.
JOHN ROBERT COYNE,
CHRISTOPHER ANDREW COYNE,
WILLIAM MARK ADAMS,
RAYMOND MUNSEN WALLACE
WO/2004/114190
7
'$
FLOOR,
7 JABOTINSKY ST.,
[72]
[87]
[74]
212
–
, "
, 54. ,
"
"
RAMAT GAN 52520
[57]
A method and system used to integrate and control multiple secure credentialing
approaches including magnetic stripes, bar codes, contact and contactless SmartCard
chips (12), Short Message Systems (SMS), Global Positioning Systems (GPS), vicinity
type Radio Frequency Identification Devices (RFID) (14), and proximity-type RFID
(22), into compact, self-powered, biometrically-protected devices.
__________________
[11][21]
[54]
METHOD FOR OVERCOMING
SYSTEM ADMINISTRATION
BLOCKAGE
[22]
[31]
[51]
[71]
18.12.2005
[32] 20.12.2004
200407554-5
Int. Cl.(2009.01) G06F 09/445
TREK 2000 INTERNATIONAL LTD.,
SINGAPORE
P.O.B. 2273,
REHOVOT 76122
[74]
[57]
213
172644
[33]
SG
,'
.
,4
2273 . . ,
A method for overcoming system administrator blockage of a non-volatile memory
device newly-connected to a host computer operatively connected to a network
controllable by a system administrator, the non-volatile memory device comprising a
public memory and a private memory, the private memory being of a category for
which communication by a host computer application is able to be blocked in an
administrative privilege environment, the method comprising:
enumerating the device with the host computer application as a composite device
including a human interface device for enabling communication between the host
computer application and the private memory in a non-adminstrative privilege
environment.
"
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
NITROOXY DERIVATIVES OF
LOSARTAN, VALSARTAN,
CANDESARTAN, TELMISARTAN,
EPROSARTAN AND
OLMESARTAN AS ANGIOTENSIN
- II RECEPTOR BLOCKERS FOR
THE TREATMENT OF
CARDIOVASCULAR DISEASES
172703
,
,
,
,
II –
20.07.2004
[32] 31.07.2003
[33] EP
03102379.9
Int. Cl.(2010.01) A61K 31//4178, C07D 25/7/04, 40/3/10, 40/9/06
NICOX S.A., FRANCE
WO/2005/011646
,
26A HABARZEL ST.,
' 26 $
Nitrooxy derivatives of the angiotensin-II receptor blockers Iosartan vaalsartan,
candesartan, telmisartan, eprosartan and olmesartan and related compounds of formula
(I): R-(Y-ONO2)s wherein R is of formula (II) or (III): R0 is e.g: and R1 is: (IIa), (IIb),
(IIc), (IId) or (IIe).
__________________
[11][21]
172753
[54]
APPARATUS AND METHODS FOR
DETERMINATION OF GAIN
FACTORS FOR WIRELESS
COMMUNICATION
TRANSMISSION POWER
[22]
[31]
[51]
13.09.2004
[32] 26.09.2003
[33] US
60/506522
Int. Cl.(2010.01) H04B 07//185, H04W 52//06, 52//16
214
"
[71]
[87]
[74]
[57]
CORPORATION, U.S.A.
WO/2005/034388
26A HABARZEL ST.,
,
' 26 $
Apparatus and methods for wireless communication transmission power control are
provided. Determination of gain factors and adjustments for physical channel
reconfiguration in the context of transmission power control are addressed. Preferably,
implementation is in con unction with communication systems in which wireless
communications are conducted between wireless transmit receive units (WTRUs)
using multiple channels that are concurrently transmitted.
__________________
[11][21]
172945
[54]
THIN, STRATIFIED, REINFORCED
SLAB AND METHOD FOR THE
MANUFACTURE THEREOF
[22]
[31]
[51]
[71]
[87]
[74]
23.07.2004
[33] IT
TV03A000108 [32] 29.07.2003
Int. Cl.(2009.01) B29C 67/24, 70/02, B32B 09/04
LUCA TONCELLI, ITALY
WO/2005/014952
P.O.B. 5352,
BEER-SHEVA 84152
[57]
Between two layers (10, 12) of BretonstoneTM mix - formed by inert materials (11), a
hardening resin and a filler (13) - at least one fibrous middle layer (14) is arranged
which consists of linear elements or inorganic filaments (15), preferably made of glass
and in the form of continuous non-woven elements, pre-impregnated with a resin of
215
,
#
#
,
5352 . . ,
"
the same kind as, or compatible with that forming the said mix. The assembly is
subjected to vacuum vibro-compression before a final hardening step in a catalysis
oven. USE/ADVANTAGES : a stratified and reinforced slab is obtained which
combines a reduced thickness (even as small as 3.5 mm) to a very high impact strength
and improved mechanical properties.
__________________
[11][21]
[54]
[22]
[31]
[51]
[62]
[71]
[87]
[74]
[57]
216
PROCESS FOR THE
PREPARATION OF (4S, 5R) - N BOC - 2 - (2' 4 DIMETHOXYPHENYL) - 4 ISOBUTYL - 1 - OXAZOLIDINE - 5
- CARBOXYLIC ACID
172973
ACID CARBOXYLIC – 5 –
OXAZOLIDINE – 1 – ISOBUTYL – 4 –
(DIMETHOXYPHENYL – 4, 2) – 2 –
(BOC – N – (R5, S4
03.07.2000
[33] IT
MI99A001483 [32] 06.07.1999
Int. Cl.(2010.01) A61K 31//357, A61P 35//00, C07D 49/3/04
INDENA S.P.A., ITALY
WO/2001/002407
,
26A HABARZEL ST.,
' 26 $
A process for the preparation of (4S, 5R)-N-Boc-2-(2,4-dimethoxyphenyl)-4-isobutyl1-oxazolidine-5-carboxylic acid, which comprises the following steps:
(a) protection of the amino group of leucinol with Boc;
(b) transformation of N-R-Boc-L-leucinol into N-Boc-L-leucinal;
(c) preparation of the cyanhydrine of the product of step (b);
(d) transformation of the cyanhydrine nitrile into the corresponding carboxylic acid;
(e) formation of the carboxylic acid methyl ester;
(f) purification of the (2B, 3S)-3-(N-Boc)amino-2-hydroxy-5-methylhexanoic acid
"
methyl ester;
(g) condensation of the product of step (f) with 2,4-dimethoxybenzaldehyde dimethyl
acetal, to yield (4S, 5R)-N-Boc-2-(2,4-dimethoxyphenyl)-4-isobutyl-1-oxazolidine-5carboxylic acid methyl ester;
(h) transformation of the product of step (g) into the corresponding carboxylic acid.
__________________
[11][21]
172996
[54]
GENERATION OF ARBITRARY
MONO-CYCLE WAVEFORMS
[22]
[31]
[51]
[71]
[87]
[74]
09.07.2004
[32] 10.07.2003
[33]
10/616672
Int. Cl.(2010.01) G06F 01//02, H03B 28//00
WO/2005/008882
P.O.B. 5352,
BEER-SHEVA 84152
[57]
217
US
,
#
#
,
5352 . . ,
A waveform generator digitally synthesizes a waveform having a plurality of
successive portions that can each be as short as one mono-cycle of the waveform, or a
part of one mono-cycle. The waveform generator changes at least one of a frequency, a
phase and an amplitude of the waveform between each successive pair of the portions
thereof. A method includes digitally synthesizing a waveform having a plurality of
successive portions that can each be as short as one mono-cycle of the waveform, or a
part of one mono-cycle, including changing at least one of a frequency, a phase and an
amplitude of the waveform between each successive pair of the portions thereof.
"
__________________
[11][21]
[54]
ABRASION-RESISTANT SHEET
MATERIAL
[22]
[31]
[51]
[71]
07.07.2004
[32] 10.07.2003
10/616790
Int. Cl.(2009.01) B60V 01/16
HONEYWELL INTERNATIONAL
INC., U.S.A.
JHRG, LLC, U.S.A.
WO/2005/007478
26A HABARZEL ST.,
[87]
[74]
[57]
173055
,
[33]
US
,
' 26 $
An abrasion-resistant skirt material (15) for use with air cushion vehicles having at
least one air chamber. The sheet material comprises a fabric base (12a) comprising
yarns of an ultra-high molecular weight polyethylene. A bonding layer (12b),
comprising a thermoplastic material is bonded to the fabric base, and an outer layer
(14), comprising a rubber compound is bonded to the bonding layer.
__________________
[11][21]
[54]
218
METHOD FOR TRANSMISSION
POWER CONTROL BASED ON
EVALUATION OF A REVERSE
ACTIVITY BIT AND DATA FLOW
SPECIFIC UPWARD/DOWNWARD
173154
"
"
,
,
"
RAMPING FUNCTIONS, AND
CORRESPONDING WIRELESS
ACCESS TERMINAL
[22]
[31]
[51]
[71]
[87]
[74]
[57]
15.07.2004
[32] 15.07.2003
[33] US
60/487648
60/493782
06.08.2003
US
60/527081
03.12.2003
US
10/890719
13.07.2004
US
Int. Cl.(2009.01) H04B 07/005, H04W 52/00, 52/34, 52/50, 72/08
U.S.A.
WO/2005/011212
,'
P.O.B. 2273,
REHOVOT 76122
.
,4
2273 . . ,
An access terminal (206) is configured for wireless communication with an access
network (204) within a sector (1032). The access terminal (206) includes a transmitter
(2608) for transmitting a reverse traffic channel to the access network (204), an
antenna (2614) for receiving signals from the access network (204), a processor (2602)
and memory (2604) in electronic communication with the processor (2602).
Instructions are stored in the memory (2604). The instructions are arranged to estimate
a current value of a reverse activity bit (1444) transmitted by the access network (204).
Per flow power allocation may be decreased on increased based on an estimated
current value of the reverse activity bit.
,182656
(
.
__________________
[11][21]
[54]
219
173166
FLAME RETARDANTS WITH
"
HIGH HALOGEN CONTENT AND
LOW VISCOSITY
[22]
[31]
[51]
[71]
[87]
[74]
[57]
19.08.2004
[32] 29.08.2003
10/651823
10/849680
20.05.2004
Int. Cl.(2010.01) C08K 05//12
ALBEMARLE CORPORATION,
U.S.A.
WO/2005/023927
26A HABARZEL ST.,
[33]
US
US
,
' 26 $
A flame retardant formulation which is the combination of at least (1) at least one
bromine-containing polyol flame retardant formed from the reaction of (a)
tetrabromophthalic anhydride, (b) an aliphatic polyol, and (c) an epoxide, and (2) at
least one aliphatic diester of an alkane dicarboxylic acid, with the proviso that the
formulation has a viscosity at 25°C of about 20,000 cps or less, and a bromine content
of at least about 40 wt%. A flame retardant compound formed from A)
tetrabromophthalic anhydride; B) diethylene glycol; C) at least one alpha-omega
alkane diol, or at least one alpha-omega alkane diol and at least one aliphatic monool;
and D) at least one alkylene oxide; with the proviso that the compound has a viscosity
at 25°C of about 60,000 cps or less, and a bromine content of at least about 43 wt%.
Polymer compositions formed from (a) a polyurethane or a polyisocyanurate and (b) a
formulation of the invention. One process to make a formulation involves heating a
mixture of (a), (b), and at least one liquid aliphatic diester of a alkane dicarboxylic acid
to form an intermediate composition; and then the intermediate is contacted one or
more times with (c) thereby producing the formulation. Optionally, excess (c) is
removed.
__________________
[11][21]
[54]
220
173266
"
POWER ALLOCATION TO
CONTROL CHANNELS IN A
[22]
[31]
[51]
[71]
[87]
[74]
[57]
23.07.2004
[32] 25.07.2003
60/490338
10/643603
18.08.2003
Int. Cl.(2010.01) H04B 07//005
U.S.A.
WO/2005/013509
P.O.B. 2273,
REHOVOT 76122
[33]
US
US
,'
.
,4
2273 . . ,
An apparatus and a method for a control channel power allocation in a communication
system are disclosed. The method of control channel power allocation in an
embodiment includes sorting a plurality of access terminals in an order of increasing
required medium access control (MAC) channel power into a plurality of bins, sorting
the access terminals with equal required MAC channel power in an order of decreasing
forward link signal to interference and noise ratio (FL SINR) if two or more access
terminals have equal required MAC channel power, and determining total available
ARQ power based upon total MAC channel power, total power allocated to reverse
power control (RPC) channels, and total power allocated to reverse activity bit (RAB)
channels.
__________________
[11][21]
[54]
OTOSCOPIC TIP ELEMENT AND
RELATED METHOD OF USE
[22]
[31]
26.07.2004
60/490566
221
[32]
28.07.2003
173279
[33]
US
"
[51]
[71]
[72]
[87]
[74]
[57]
30.09.2003
60/507473
60/543858
11.02.2004
10/897455
23.07.2004
Int. Cl.(2009.01) A61B 01/227, 01/267
WELCH ALLYN, INC., U.S.A.
JOHN R. STROM, CYNTHIA A.
KUIPER, CHRIS R. ROBERTS,
MICHAEL E. BAUSCH, ALLAN I.
KRAUTER, ERIC M. ANDREASSEN,
DAVID WOODS
WO/2005/016117
P.O.B. 45087,
JERUSALEM 91450
US
US
US
, "
,
#
'
,
45087 . . ,
A tip element for an otoscopic apparatus includes engagement features that permit
selective attachment to two different tip attachment mechanisms. The tip element
includes both interior and exterior engagement features that provide interchangeability
with otoscopes having different tip attachment schemes. The tip element includes an
increased distal aperture formed from a decreased slope that enables a larger field of
view, permitting the entire tympanic membrane to be viewed at once. External
engagement features permit ejection of the tip from the otoscope, as well as
stackability of a plurality of tip elements.
__________________
[11][21]
[54]
222
173327
MIXED INTEGER LINEAR
PROGRAMMING TRAJECTORY
GENERATION FOR
AUTONOMOUS FLIGHT IN A
THREAT ENVIRONMENT
"
[22]
[31]
[51]
[71]
[74]
[57]
24.01.2006
[32] 17.02.2005
11/060347
Int. Cl.(2010.01) G06F 01//00
NORTHROP GRUMMAN
CORPORATION, U.S.A.
26A HABARZEL ST.,
[33]
US
,
' 26 $
A method of planning a path of a vehicle, the method comprising the steps:
defining a first plurality of constraints reprinting dynamics of the vehicle;
defining a second plurality of constraints reprinting collisions with obstacles;
defining a third plurality of constraints reprinting visibility to threats; and
using the first, second and third plurality of constraints with mixed integer linear
programming to generate a trajectory for the vehicle from a starting point to a
destination point in an environment containing the obstacles and the threats.
__________________
[11][21]
173331
[54]
SYNCHRONIZATION OF
MULTIPLE OPERATIONAL
FLIGHT PROGRAMS
[22]
[31]
[51]
[71]
24.01.2006
[32] 10.02.2005
[33] US
11/055753
Int. Cl.(2010.01) G06F 01//04, 01//12, 15//16, G11C 07//10, H04L 07//00
NORTHROP GRUMMAN
CORPORATION, U.S.A.
,
26A HABARZEL ST.,
' 26 $
[74]
[57]
223
A method for synchronizing frame clocks in a plurality of processors, the method
comprising the steps of:
(a) sending data packets from each of the processors to each of the other processors;
(b) each of the processors receiving the data packets and identifying two of the data
packets having the largest phase difference;
(c) using the largest phase difference to determine a target synchronization phase
angle;
(d) adjusting a period of a frame clock so that the frame clock approaches the target
synchronization phase angle; and
"
(e) repeating steps (a), (b), (c) and (d).
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
BENZIMIDAZOLE,
BENZTHIAZOLE AND
BENZOXAZOLE DERIVATIVES
AND THEIR USE AS LTA4H
MODULATORS
173372
,
LTA4H
27.07.2004
[32] 28.07.2003
[33] US
60/490710
Int. Cl.(2009.01) A61P 29/00, C07D 235/26, 263/58, 417/12
JANSSEN PHARMACEUTICA, N.V.,
BELGIUM
WO/2005/012297
26A HABARZEL ST.,
,
' 26 $
Leukotriene A4 hydrolase (LTA4H) inhibitors of Formula (I), compositions containing
them, and their use for the inhibition of LTA4H enzyme activity and the treatment,
prevention or inhibition of inflammation and/or conditions associated with
inflammation. Wherein X is selected from the group consisting of NR5, O, and S, with
R5 being on of H and CH3; Y is selected from the group consisting; W is selected from
the group consisting Of CH2 and CHR1-CH2, with R1 being one H and OH, wherein R1attached carbon member in said CHR1-CH2 is not directly attached; R4 is selected from
the group consisting of H, OCH3, CI, F Br, OH, NH2, CN, CF3 and CH3; R6 is H or F;
and R2 and R3 are each independently selected from various groups.
__________________
224
"
[11][21]
173417
[54]
METHOD OF PACKET MODE
DIGITAL COMMUNICATION
OVER A TRANSMISSION
CHANNEL SHARED BY A
PLURALITY OF USERS
[22]
[31]
[51]
[71]
29.01.2006
[32] 31.01.2005
[33] FR
0500934
Int. Cl.(2009.01) H04L 12/56
AGENCE SPATIALE EUROPEENNE
(ESA), FRANCE
ENRICO CASINI, OSCAR DEL RIO
HERRERO, RICCARDO DE
GAUDENZI, DANIEL MAURICE
ELIANE DELARUELLE, JEANPIERRE GEORGES JOSEPH
GHISLAIN CHOFFRAY
, #
#
5 SHENKAR ST.,
5
' ,1 - $
P.O.B. 12704,
# 12704 . . ,
HERZLIYA 46733
A method of transmitting data packets over a transmission channel shared by a
plurality of users (RU1,RU2), the method comprising steps of:
generating (511) at least two replicas of each packet to be transmitted; and
sending (515) said replicas over said transmission channel, separated by random time
and/or frequency shifts, the method being characterized in that it further comprises a
step (512) of inserting signaling information into each replica for enabling the other
replica(s) of the same packet to be located in the time and/or frequency domain.
[72]
[74]
[57]
225
,
"
__________________
[11][21]
[54]
CALCIUM CARBONATE
GRANULATION
[22]
[31]
[51]
[71]
[87]
[74]
14.07.2004
[32] 31.07.2003
10/631923
Int. Cl.(2009.01) C01F 11/18
DELAVAU L.L.C., U.S.A.
WO/2005/011570
P.O.B. 2273,
REHOVOT 76122
[57]
173443
[33]
US
,'
.
,4
2273 . . ,
Highly compactable granulations and methods for preparing highly compactable
granulations are disclosed. More particularly, highly compactable calcium carbonate
granulations are disclosed. The granulations comprise powdered materials such as
calcium carbonate that have small median particle sizes. The disclosed granulations are
useful in pharmaceutical and nutraceutical tableting and provide smaller tablet size
upon compression than previously available.
,184419
(
.
__________________
[11][21]
[54]
COOLING MACHINE WHICH
FUNCTIONS ACCORDING TO
THE STIRLING CYCLE
[22]
[31]
[51]
[71]
02.02.2006
[32] 03.02.2005
0501100
Int. Cl.(2010.01) F25B 09//14
SAGEM DEFENSE SECURITE,
FRANCE
REINHOLD COHN AND
[74]
226
173495
STIRLING
[33]
"
FR
,
"
' 26 $
PARTNERS,
26A HABARZEL ST.,
[57]
A cooler machine using the Stirling cycle and comprising: at least one compressor (5)
with a compressor piston (6) movable in a compression cylinder (7); a regenerator (8)
with a regenerator piston (9) movable in a regeneration cylinder (10) placed at a given
angle relative to the compression cylinder (7); a rotary drive crank (11); a compressor
connecting rod (12) possessing a first end pivotally coupled to the compressor piston
and a second end pivotally coupled to the crank; a regenerator connecting rod (13)
possessing a first end pivotally coupled to the regenerator piston and a second end
pivotally coupled to the crank; wherein at least one of the compressor and regenerator
connecting rods (a) is pivotally connected to a first end of an auxiliary link that has a
second end pivotally coupled to a structural element of the machine, and (b) is
comprised of at least two connecting rod segments pivotally connected to one another;
and where the connecting rod segments and connected auxiliary link are arranged to
move together with crank rotation so that the movement of the corresponding piston is
slowed down on passing through its top or bottom dead center.
__________________
[11][21]
[54]
STRIPPING AND CLEANING
COMPOSITIONS FOR
MICROELECTRONICS
[22]
[31]
26.07.2004
[32] 19.08.2003
60/496110
60/548976
01.03.2004
Int. Cl.(2009.01) G03F 07/42
[51]
227
173664
–
[33]
,
US
US
"
[71]
[87]
[74]
[57]
MALLINCKRODT BAKER, INC.,
U.S.A.
WO/2005/019939
10 ABBA EBEN BLVD.,
P.O. B. 2081,
HERZLIYA 46120
,
#
,
10
#
2081 . . ,
Aqueous cleaning compositions and method of using the cleaning compositions for
cleaning microelectronic substrates, which compositions are able to essentially
completely clean such substrates and produce essentially no metal corrosion of the
metal elements of such substrates. The aqueous cleaning compositions of this
invention have (a) water, (b) at least one of ammonium and quaternary ammonium
ions and (c) at least one of hypophosphite (H2PO2-) and/or phosphite (HPO32-) ions.
The cleaning compositions also may contain fluoride ions. Optionally, the composition
may contain other components such as organic solvents, oxidizing agent, surfactants,
corrosion inhibitors and metal complexing agents.
__________________
[11][21]
[54]
METHOD OF MONITORING
GLUCOSE LEVEL
[22]
[31]
[51]
[71]
09.08.2004
[32] 19.08.2003
10/643804
Int. Cl.(2009.01) A61B 05/00
A.D. INTEGRITY APPLICATIONS,
LTD.
ALEXANDER M. RAYKHMAN,
AVNER GAL, DAVID FREGER
WO/2005/017642
P.O.B. 45087,
JERUSALEM 91450
[72]
[87]
[74]
[57]
228
173695
[33]
US
, "
#
,
'
,
45087 . . ,
The method of monitoring or measuring the concentration of glucose level in human
and animal blood uses a non-invasive technique and includes measurements of the
speed of sound through the blood, the conductivity of the blood, and the heat capacity
of the blood, or by non-invasive measurement of any other parameters that can be used
to calculate the glucose level. Thereafter, the glucose level for each of the three
measurements is calculated (102,108,114) and the final glucose value is determined by
"
a weighted average of the three calculated glucose values (126).
__________________
[11][21]
[54]
HIGH DENSITY COTTON PICKER
BAR AND SPINDLE ASSEMBLY
THEREFOR
[22]
[31]
[51]
[71]
[74]
14.02.2006
[32] 15.02.2005
11/058150
Int. Cl.(2009.01) A01D 46/16
DEERE & COMPANY, U.S.A.
26A HABARZEL ST.,
[57]
173718
[33]
US
,
' 26 $
A cotton picker spindle bar assembly including an upright single spindle bar having an
arm for orienting the bar about an upright bar axis, the spindle bar mounting a plurality
of vertically spaced spindles having picking ends and gear ends, a drive shaft structure
including an upright drive shaft supported for rotation by the bar in driving
relationship with the gear ends, wherein the plurality of vertically spaced spindles on
the spindle bar include at least two sets of spindles vertically spaced on the single
spindle bar and nonaligned in the vertical direction, the arm orienting the two sets of
spindles in cotton plants during picking with the spindle ends extending generally
horizontally from one side of the spindle bar.
__________________
[11][21]
[54]
229
SYSTEM, METHOD AND
173731
,
,
"
COMPUTER PROGRAM
PRODUCT FOR CENTRALIZED
MANAGEMENT DISTRIBUTED
SYSTEM AREA NETWORK
[22]
[31]
[51]
[71]
[87]
[74]
[57]
04.08.2004
[32] 14.08.2003
10/640821
Int. Cl.(2010.01) H04L 12//24
IBM CORPORATION, U.S.A.
WO/2005/018149
IBM LABORATORIES,
HAIFA UNIVERSITY,
HAIFA 31905
[33]
US
,
A method, system, and product in a data processing system are disclosed for providing
centralized management of an InfiniBand distributed system-area network that
includes multiple end nodes. A manager application is established in one of the end
nodes. An agent application is established in one or more end nodes. Each agent
application is independent from the manager application. The manager application
maintains a current list of active agent applications and uses the list to manage the
agent applications in the end nodes.
__________________
[11][21]
173865
[54]
SYSTEM AND KIT FOR
DELIVERY OF RESTORATIVE
MATERIALS
[22]
[31]
[51]
[71]
02.09.2004
[32] 02.09.2003
[33] US
10/654543
Int. Cl.(2009.01) A61B 17/16, 17/88, A61M 05/00
ORTHOVITA, INC., U.S.A.
230
"
[87]
[74]
[57]
WO/2005/020833
P.O.B. 2273,
REHOVOT 76122
,'
.
,4
2273 . . ,
Novel kits are provided for the delivery of restorative or injectable compositions into
an intraosseous space or surgical defect comprising cannulae for accessing an
intraosseous space, mandarins insertable into the cannulae and movable therein, one or
more catheters and a system for the delivery of aliquots of restorative compositions
into the space via catheters. Independant claims relate to the catheter having a high
porosity tip (10) and to a microreamer having an expandable section comprising leaves
that flex (13).
,199702
(
.
__________________
[11][21]
[54]
APPARATUS AND METHOD FOR
REMOVING PIGMENTS FROM A
PIGMENTED SECTION OF SKIN
[22]
[31]
[51]
[71]
30.08.2004
[32] 01.09.2003
157696
Int. Cl.(2009.01) A61B 17/20
HAWK MEDICAL TECHNOLOGIES
LTD
WO/2005/020828
P.O.B. 5352,
BEER-SHEVA 84152
[87]
[74]
[57]
231
173906
[33]
#
IL
, "
'
,
#
#
,
5352 . . ,
An apparatus for removing a pigmented section of skin, comprises a) a skin puncturing
device; b) an array of one or more needles connected to said device for puncturing the
skin at said pigmented section; and c) a mediating member attached to said device and
"
to suction means, for allowing said suction means to collect the mixture of the
pigments with the cellular fluids at said punctured section of the skin.
__________________
[11][21]
174145
[54]
NOGO-A BINDING WITH
ENHANCED AFFINITY AND
PHARMACEUTICAL USE
THEREOF
[22]
[31]
[51]
[71]
17.09.2004
[32] 19.09.2003
[33] GB
0321997.9
Int. Cl.(2010.01) A61K 39//395, C07K 16//18, C12N 15//13
UNIVERSITY OF ZURICH,
SWITZERLAND
WO/2005/028508
P.O.B. 5352,
BEER-SHEVA 84152
[87]
[74]
[57]
232
A–
,
#
#
,
5352 . . ,
The present invention provides a binding molecule which is capable of binding to the
human NogoA polypeptide or human NiG or human NiG-D20 or human NogoA_342357 with a dissociation constant < 1000nM, a polynucleotide encoding such binding
molecule; an expression vector comprising said polynucleotide; an expression system
comprising a polynucleotide capable of producing a binding molecule; an isolated host
cell which comprises an expression system as defined above; the use of such binding
molecule as a pharmaceutical, especially in the treatment of nerve repair; a
pharmaceutical composition comprising said binding molecule; and a method of
treatment of diseases associated with nerve repair.
"
,203007
(
.
__________________
[11][21]
–3–(
[54]
METHOD FOR THE
PRODUCTION OF 4-(4AMINOPHENYL)-3MORPHOLINON
[22]
[31]
[51]
[71]
09.09.2004
[32] 15.09.2003
10342570.5
Int. Cl.(2009.01) C07D 265/32, 413/14
BAYER SCHERING PHARMA AG,
GERMANY
WO/2005/026135
26A HABARZEL ST.,
[87]
[74]
[57]
174194
[33]
–4)–4
DE
,
' 26 $
The invention relates to a method for the production of 4-(4-aminophenyl)-3morpholinon by reacting 4-(4-nitrophenyl)-3-morpholinon with hydrogen in the
presence of a hydrogenation catalyst. The invention is characterised in that the reaction
is carried out in an aliphatic alcohol.
__________________
[11][21]
[54]
ENERGY ABSORBING
ELEMENT FOR WALL
OPENINGS AND METHOD OF
USE THEREFOR
[22]
[51]
[71]
[74]
13.03.2006
Int. Cl.(2010.01) E06B 05//12
ARPAL ALUMINUM LTD.
REINHOLD COHN AND
PARTNERS,
233
174280
,
, ''
,
' 26 $
"
26A HABARZEL ST.,
[57]
An energy absorber (10) for use in an opening of a wall of a building, the opening
defined by a perimeter surface, the wall supporting a closure (20) substantially filling
the opening, said closure having respective edges which are substantially parallel to
said perimeter surface of the opening; the energy absorber having a planar wall
connecting portion having a first mounting aperture (12a), and a planar closure
connecting portion having a second mounting aperture (12a), said connecting portions
being connected by at least one plastically deformable deforming surface, said
mounting apertures being formed at a distance from each other along an axis, the
absorber further comprising at least one slot (14) transferring said axis and having a
length exceeding said distance, said deforming surface adapted to absorb, by plastic
deformation, a force applied to the closure.
__________________
[11][21]
174318
[54]
PROCESSING AT LEAST TWO
INPUT VALUES
[22]
[31]
[51]
[71]
28.09.2004
[32] 02.10.2003
[33] DE
10345996.0
Int. Cl.(2010.01) G06F 17//14, G06T 09//00, G10L 19//00, 19//02, H04N 07//30
FRAUNHOFER-GESELLSCHAFT
ZUR FORDERUNG DER
ANGEWANDTEN FORSCHUNG
E.V., GERMANY
234
"
[87]
[74]
[57]
WO/2005/033965
31 YAVNE ST.,
P.O.B. 1426,
TEL AVIV 61013
,'
$
31
'
1426 . . ,
In order to reduce a rounding error, a first and second non integral input value is
provided (260,262) and in a non integral state is combined (268) by addition,for
example, so that a non integral result value can be obtained, rounded and added to a
third input value (269). The rounding error can thus be reduced at an interface between
two rotations broken down into lifting steps or between a first rotation broken down
into lifting steps and a first lifting step of a subsequent multidimensional lifting
sequence.
__________________
[11][21]
[54]
OLIVE POMACE VINEGAR
[22]
[51]
[71]
15.03.2006
Int. Cl.(2009.01) C12J 01/00
CAPER NAUM VISTA OLIVE OIL
MARKET LTD
GREGORY PIPKO
DR. EYAL BRESSLER,
11 TUVAL ST.,
RAMAT GAN 52522
[72]
[74]
[57]
174320
"
# , "
$
#
, "
'
11
Vinegar derived from olive pomace, comprising olive pomace, water, a carbohydrate
source and fermenting microorganisms.
35
5
1968 – "
(
,
__________________
235
"
[11][21]
174453
[54]
PROCESS FOR THE
PREPARATION OF
POLYACRYLAMIDE BEADS
CONTAINING ENCAPSULATED
CELLS
[22]
[31]
[51]
[71]
[87]
[74]
26.10.2004
[32] 27.10.2003
[33]
03024648.2
Int. Cl.(2009.01) B01J 13/02, C12N 11/04
LONZA AG, SWITZERLAND
WO/2005/040373
P.O.B. 2273,
REHOVOT 76122
[57]
EP
,'
.
,4
2273 . . ,
Polyacrylamide beads containing encapsulated cells were prepared by a process
comprising the steps of (i) providing an aqueous solution of a mixture of acrylic
monomers, (ii) providing a suspension of cells in an aqueous solution of a persulfate
(iii) providing an emulsion of an aqueous solution of a tertiary amine in a waterimmiscible liquid, which liquid optionally contains a surfactant, (iv) mixing the
solution provided in step (i) and the suspension provided in step (ii) (v) adding the
mixture obtained in step (iv) to the stirred emulsion provided in step (iii) (vi)
polymerizing the mixture of acrylic monomers and simultaneously encapsulating the
cells to form polyacrylamide beads containing encapsulated cells.
__________________
[11][21]
174545
–
[54]
USE OF A TWO-COMPONENT
SYSTEM FOR THE
PREPARATION OF A HAIR
GROWTH INHIBITING
COMPOSITION
[22]
[31]
11.10.2004
[33] DK
PA200301500 [32] 10.10.2003
60/525967
01.12.2003
US
Int. Cl.(2009.01) A61K 06/00, 08/02, 08/66, A61Q 07/02
[51]
236
"
[71]
[87]
[74]
[57]
COSMEDICAL APS, DENMARK
WO/2005/034892
26A HABARZEL ST.,
,
' 26 $
The invention relates to the use of a composition for the preparation of a hair growth
inhibitor and furthermore to the use of a system for the preparation of a hair growth
inhibitor. The invention also relates to a composition comprising at least one enzyme,
a solvent, and a water activity reducing agent. Moreover, the invention concerns a
system for hair growth inhibition comprising a first component and a second
component, wherein the first composition of the first component comprises at least one
enzyme, a solvent and a water activity reducing agent, and wherein the second
composition of the second component comprises an enzyme-activating agent and/or a
anti-inflammatory, penetration-promoting agent and/or a preservative agent. The
invention in addition relates to a method for inhibiting hair growth and a method for
the preparation of hair growth inhibitor.
__________________
[11][21]
[54]
CAKE MIXTURE
[22]
[31]
[51]
[71]
[87]
[74]
01.04.2004
[32] 13.10.2003
03023035.3
Int. Cl.(2010.01) A21D 08//00, 10//02
NESTEC S.A., SWITZERLAND
WO/2005/034636
279 HAYARKON ST.,
P.O.B. 6451,
TEL AVIV 61063
[57]
237
174583
[33]
EP
,
#
"
279
6451 . . ,
The invention relates to a fluid cake mixture that is sufficiently refrigerated for making
"
cakes such as chocolate fondant. The inventive cake mixture is characterised by the
use of butterfat in the form of small particles of butterfat that are solid at room
temperature and dispersed in the continuous cake mixture phase. Said mixture thus
keeps its fluidity, even at the usual refrigeration temperatures at which the product can
be stored for several weeks.
__________________
[11][21]
[54]
APPARATUS AND METHOD FOR
CONTROLLING REVERSE-LINK
DATA TRANSMISSION RATE
[22]
[31]
05.03.2004
[32] 06.03.2003
10-20030014036
10-200329.04.2003
0027199
60/514383
24.10.2003
60/515897
29.10.2003
60/516232
30.10.2003
10-200331.10.2003
0076562
10/794744
05.03.2004
Int. Cl.(2010.01) H04L 12//56
LG ELECTRONICS INC., REPUBLIC
OF KOREA
WO/2005/060137
P.O.B. 1352,
JERUSALEM 91013
[51]
[71]
[87]
[74]
[57]
238
174613
[33]
KR
KR
US
US
US
KR
US
,
,%
1352 . . ,
Apparatus and method for controlling data transmission rate in a wireless
communication system during handoff comprises a terminal recognizing an active set
comprising a serving base station and at least one non-serving base station with respect
to the terminal communicating with the network at a first data transmission rate,
receiving a first rate control parameter from the serving base station (S402) and a
second rate control parameter from the at least one non-serving base station (S400),
wherein the first and second rate control parameters are associated with determination
of a second data transmission rate of the terminal during the handoff and determining
the second data transmission rate in response to the first and the second rate control
parameters, wherein the second data transmission rate is one of increased rate (S403),
decreased rate (S401, S405) and same rate (S404) from the first data transmission rate.
"
__________________
[11][21]
[54]
SYSTEMS AND METHODS USING
AN ELECTRIFIED PROJECTILE
[22]
[31]
07.10.2004
[32] 07.10.2003
60/509577
10/714572
13.11.2003
Int. Cl.(2010.01) H01T 23//00
TASER INTERNATIONAL, INC.,
U.S.A.
WO/2005/084173
5 SHENKAR ST.,
P.O.B. 12704,
HERZLIYA 46733
[51]
[71]
[87]
[74]
[57]
174777
[33]
US
US
5
, #
#
' ,1 - $
# 12704 . . ,
An apparatus (100) for immobilizing a target includes electrodes (514, 504) deployed
after contact is made between the apparatus and the target. Spacing of deployed
electrodes (514, 504) may be more accurate and/or more repeatable for more effective
delivery of an immobilizing stimulus signal.
__________________
239
"
[11][21]
174909
[54]
PHARMACEUTICAL
AN INTERLEUKIN-6
ANTAGONIST
[22]
[31]
[51]
[71]
15.10.2004
[33] JP
2003-358152 [32] 17.10.2003
Int. Cl.(2010.01) A61K 39//395, 45//00, 45//06, C07K 16//18, 16//24, 16//28
CHUGAI SEIYAKU KABUSHIKI
KAISHA, JAPAN
WO/2005/037315
,
,%
P.O.B. 1352,
1352 . . ,
JERUSALEM 91013
[87]
[74]
[57]
6–
A therapeutic agent for mesothelioma, comprising an interleukin-6 (IL-6) antagonist,
for example, an antibody against IL-6 receptor (IL-6R); and a mesothelioma cytostatic
agent comprising an IL-6 antagonist, for example, an antibody against IL-6R.
__________________
[11][21]
[54]
SOLID ELECTROLYTE, IN
PARTICULAR FOR A THIN
LAYER ELECTROCHEMICAL
CELL AND PRODUCTION
METHOD
[22]
[31]
09.11.2004
0313378
240
[32]
14.11.2003
175505
,
[33]
FR
"
[51]
[71]
[87]
[74]
[57]
Int. Cl.(2010.01) C03C 03//19, C23C 14//00, H01M 06//18
H.E.F., FRANCE
WO/2005/050764
26A HABARZEL ST.,
,
' 26 $
The invention relates to a vitreous solid electrolyte for a thin layer electrochemical cell
comprising B whose atomic content ranges from 0.001 to 0.20, P whose atomic
content ranges from 0.05 to 0.15, N whose atomic content ranges from 0.02 to 0.18, Li
whose atomic content ranges from 0.20 to 0.50 and O whose atomic content ranges
from 0.35 to 0.50, the total content being substentially equal to 100.
__________________
[11][21]
175720
[54]
NITRILE COMPOUND AND ITS
USE IN ARTHROPOD CONTROL
[22]
[31]
22.12.2004
[33] JP
2003-431908 [32] 26.12.2003
2004-036230
13.02.2004
JP
2004-283540
29.09.2004
JP
Int. Cl.(2010.01) A01N 37//34, C07C 25/5/10, 25/5/31
SUMITOMO CHEMICAL
COMPANY, LIMITED., JAPAN
WO/2005/063694
279 HAYARKON ST.,
P.O.B. 6451,
TEL AVIV 61063
[51]
[71]
[87]
[74]
[57]
,
#
"
279
6451 . . ,
The present invention provides a nitrile compound represented by the formula (I):
wherein R represents C1-C4 fluoroalkyl, Q represents halogen, C1-C11 alkyl
optionally substituted with halogen, C2-C6 alkenyl group optionally substituted with
halogen, C2-C6 alkynyl optionally substituted with halogen, C3-C7 cycloalkyl
optionally substituted with halogen or (C3-C7 cycloalkyl optionally substituted with
halogen)C1-C4 alkyl, which has excellent control effect against pests.
__________________
241
"
[11][21]
175754
–3
[54]
3-AMINOPYRROLIDONE
DERIVATIVES
[22]
[31]
[51]
16.11.2004
[32] 21.11.2003
[33] EP
03026779.3
Int. Cl.(2010.01) A61K 31//4015, 31//45, 31//55, A61P 01//00, 03//04, 13//00, 15//00,
25//00, 27//02, 29//00, C07D 20/7/273, 21/1/76, 22/3/12
NEWRON PHARMACEUTICALS
S.P.A., ITALY
WO/2005/054190
,
26A HABARZEL ST.,
' 26 $
[71]
[87]
[74]
[57]
This invention is related to compounds and use of 3-aminopyrrolidone derivatives and
analogues of the following general formula (I), wherein m is an integer from 1 to 3; X
is methylene, oxygen, sulphur or a NR6 group; R1 is a straight or branched C1-C8 alkyl
or C3-C8 alkenylene or C3-C8 alkynylene chain, optionally substituted with CF3,
phenyl, phenoxy or naphthyl, or phenyl the aromatic rings optionally substituted by
one or more C1-C4 alkyl, halogens, trifluoromethyl, hydroxy or C1-C4 alkoxy groups;
R2, R3 are independently hydrogen, a C1-C3 alkyl chain, halogen, trifluoromethyl,
hydroxy or C1-C4 alkoxy groups; R4, R5, R6 are independently hydrogen or C1-C6
alkyl; and the pharmaceutically acceptable salts thereof that are active as sodium
and/or calcium channel modulators and therefore useful in preventing, alleviating and
curing a wide range of pathologies, including, but not limited to cardiovascular,
inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the
above mechanisms have been described as playing a pathological role.
__________________
[11][21]
[54]
242
AUTHENTICATING AN
AUTHENTIC ARTICLE USING
176102
"
"
"
SPECTRAL IMAGING AND
ANALYSIS
[22]
[31]
[51]
[71]
[72]
[87]
[74]
[57]
01.12.2004
[32] 01.12.2003
[33]
60/525886
Int. Cl.(2009.01) G06K 09/00, G08B 01/00
GREEN VISION SYSTEMS LTD.
DANNY S. MOSHE
WO/2005/055155
FISHER WEILER JONES,
26 HABARZEL STREET
RAMAT HACHAYAL,
TEL-AVIV 69710
US
, "
'$ -
,
26
'
$
Authenticating an authentic article having an authentication mark. Acquiring a set of
spectral images of the authentication mark, for forming a set of single-authentication
mark spectral fingerprint data (FIG. 1). Identifying at least one spectral shift in the set
of single-authentication mark spectral fingerprint data, for forming an intraauthentication mark physicochemical region group including sub-sets of intraauthentication mark spectral fingerprint pattern data, such that data elements in each
sub-set are shifted relative to corresponding data elements in remaining sub-sets in the
same intra-authentication mark physicochemical region group (FIG. 2). Forming a set
of intra-authentication mark physicochemical properties and characteristics data
relating to the imaged authentication mark, by performing pattern recognition and
classification analysis on the intra-authentication mark physicochemical region group
(FIG. 3). Comparing and matching elements in the set of intra-authentication mark
physicochemical properties and characteristics data to corresponding reference
elements in reference set of data, thereby authenticating the authentic article.
__________________
[11][21]
176207
[54]
METHOD OF INCORPORATING A
MARK IN CVD DIAMOND
[22]
[31]
10.12.2004
[32] 12.12.2003
[33] GB
0328917.0
60/529746
17.12.2003
US
0419839.6
07.09.2004
GB
60/610223
16.09.2004
US
Int. Cl.(2010.01) C03B 29//04, C30B 25//00, 33//00
ELEMENT SIX LIMITED, UNITED
KINGDOM
[51]
[71]
243
CVD "
"
[87]
[74]
[57]
WO/2005/061400
26A HABARZEL ST.,
,
' 26 $
A method of incorporating a mark of origin, such as a brand mark, or fingerprint in a
CVD single crystal diamond material, includes the steps of providing a diamond
substrate, providing a source gas, dissociating the source gas thereby allowing
homoepitaxial diamond growth, and introducing in a controlled manner a dopant into
the source gas in order to produce the mark of origin or fingerprint in the synthetic
diamond material. The dopant is selected such that the mark of origin or fingerprint is
not readily detectable or does not affect the perceived quality of the diamond material
under normal viewing conditions, but which mark of origin or fingerprint is detectable
or rendered detectable under specialised conditions, such as when exposed to light or
radiation of a specified wavelength, for example. Detection of the mark of origin or
fingerprint may be visual detection or detection using specific optical instrumentation,
for example.
__________________
[11][21]
176232
[54]
PRINTING MOVING
SUBSTRATES
[22]
[31]
[51]
[71]
10.12.2004
[32] 12.12.2003
[33]
0328861.0
Int. Cl.(2009.01) B41J 11/00, 13/12, 13/14
INCA DIGITAL PRINTERS
LIMITED, UNITED KINGDOM
WO/2005/058603
5 SHENKAR ST.,
P.O.B. 12704,
[87]
[74]
244
GB
5
, #
#
' ,1 - $
# 12704 . . ,
"
HERZLIYA 46733
[57]
An ink jet printing apparatus for printing on a moving substrate (16) is described. The
apparatus comprises ink jet printheads (4) for printing on a surface of the substrate, a
plurality of rollers (12, 14) arranged to move the substrate (16) relative to the
printheads (4), and a pressure source (22). The pressure source (22) is arranged to
apply a negative gauge pressure (32) to the substrate (16). The application of the
pressure can hold the substrate flat and can reduce undesired movement of the
substrate relative to the rollers (12, 14). The apparatus allows for high quality full
colour images to be printed onto substrates in a single pass using an ink jet printer.
__________________
[11][21]
[54]
FLUORESCENCE MEASURING
DEVICE FOR GEMSTONES
[22]
[31]
[51]
[71]
12.01.2005
[32] 12.01.2004
10/756164
Int. Cl.(2009.01) G01N 21/87
GEMOLOGICAL INSTITUTE OF
AMERICA, INC., U.S.A.
WO/2005/067566
26A HABARZEL ST.,
[87]
[74]
[57]
245
176354
[33]
US
,
' 26 $
A gemstone fluorescence measuring device according to the invention generally
includes an ultraviolet ('UV') emission chamber, a UV radiation source, and a light
meter assembly. The UV radiation source includes an upper light emitting diode
('LED') and a lower LED that radiate a gemstone under test from both above and
below the gemstone. The UV radiation source provides both trans-radiation and direct
radiation to the gemstone, and the UV radiation source has an adjustable intensity, thus
facilitating calibration of the fluorescence measuring device. The light meter assembly
"
includes a light detector that detects the visible light emitted from the gemstone under
test in response to the UV radiation. The light detector is configured to simulate the
spectral characteristics of the human eye. The fluorescence measuring device converts
the measured visible light into a numerical lux reading, which can then be converted
into a fluorescence grade for the gemstone under test.
__________________
[11][21]
[54]
PROTECTIVE LAYER AGAINST
SHAPED CHARGES
[22]
[51]
[71]
29.12.2003
Int. Cl.(2009.01) F41H 05/02
RUAG LAND SYSTEMS,
SWITZERLAND
WO/2005/064263
P.O.B. 1352,
JERUSALEM 91013
[87]
[74]
[57]
246
176392
,
,%
1352 . . ,
The rupture disks of reactive armor that may be provided are initiated or light armor is
destroyed directly when bomblets with frontal hollow charges are dropped onto
vehicles. Previously known disrupting elements that prevent a shaped-charge jet from
forming are mostly composed of pointed parts protruding from the surface of the
vehicle or layers which are covered by a sensitive film. The disadvantages associated
with said disrupting elements can be overcome in an economic manner by using a
single protective layer (1) which consists of a high-density elastomer, is placed as a
protective roof cover in the vertical projection of a vehicle (100), and can be retrofitted
onto existing vehicles and installations. Also disclosed is a method for producing
protective layers (1), which is based on the use of a PUR high pressure system and
previously known high-density starting materials.
"
__________________
[11][21]
[54]
PROCESS FOR MAKING HIGHPERFORMANCE POLYETHYLENE
MULTIFILAMENT YARN
[22]
[31]
[51]
[71]
23.12.2004
PCT/NL04/00029 [32] 01.01.2004
Int. Cl.(2010.01) D01F 06//04
DSM IP ASSETS B.V., THE
NETHERLANDS
WO/2005/066401
P.O.B. 5352,
BEER-SHEVA 84152
[87]
[74]
[57]
247
176414
–
[33]
WO
,
#
#
,
5352 . . ,
The invention relates to a process for making high-performance polyethylene multifilament yarn comprising the steps of a) making a solution of ultra-high molar mass
polyethylene in a solvent; b) spinning of the solution through a spinplate containing at
least 5 spinholes into an air-gap to form fluid filaments, while applying a draw ratio
DRfluid; c) cooling the fluid filaments to form solvent-containing gel filaments; d)
removing at least partly the solvent from the filaments; and e) drawing the filaments in
at least one step before, during and/or after said solvent removing, while applying a
draw ratio DRsolid of at least 4, wherein in step b) each spinhole comprises a contraction
zone of specific dimension and a downstream zone of diameter Dn and length Dn with
Ln/Dn of from 0 to at most 25, to result in a draw ratio DRfluid = DRsp* DRag of at least
150, wherein DRsp is the draw ratio in the spinholes and DRag is the draw ratio in the
air-gap, with DRsp being greater than 1 and DRag at least 1. The invention further
relates to a high-performance polyethylene multifilament yarn, and to semi-finished or
end-use products containing said yarn, especially to ropes and ballistic-resistant
composites.
"
__________________
[11][21]
176476
[54]
FOLDABLE CHASSIS FOR BABY
CARRIAGES
[22]
[31]
21.06.2006
[32] 07.07.2005
[33] ES
U200501565
13.12.2005
U200502696
ES
Int. Cl.(2010.01) B62B 07//08, 07//10
JANE, S.A., SPAIN
,
# "
279 HAYARKON ST.,
279
P.O.B. 6451,
6451 . . ,
TEL AVIV 61063
This foldable chassis for baby carriages comprises two rear wheels (1) and (2), a front
rolling support (3), and a U-shaped handlebar (4) being at the end of each of its
branches (5) and (6) fitted to a respective lateral member (7) and (8) each of said
lateral members being at its upper end (9) linked in a pin-jointed connection to a
respective armrest (10) and (11), each of said armrests being in its turn linked in a pinjointed connection (12) to the respective branch of the handlebar. This chassis is
characterized in that each of the lateral members (7) and (8) inferiorly ends in a
respective bush bearing (13) and (14), said bush bearing being both fitted on the
central length of the shaft (15) being fitted to each of the wheels (1) and (2) through a
respective inflected length (16) and (17), two connecting rods (18) and (19) being
solidly secured to said central length of said shaft and articulately linked (20) to a
central support (21) making up an articulated connection with the middle length of a
U-shaped member having the end of each of its branches (24) and (25) linked in a pinjointed connection to the end region (26) of the respective branch of the handlebar and
an intermediary point (27) of each of its aforementioned branches linked in a pinjointed connection to the respective one of said lateral members (7) and (8).
[51]
[71]
[74]
[57]
248
"
__________________
[11][21]
177035
[54]
PIPE FITTING ASSEMBLY AND
A METHOD FOR FORMING IT
[22]
[51]
[71]
23.07.2006
Int. Cl.(2010.01) F16L 21//02, 21//035, 37//24, 37//26, 47//06, 47//12, 47//24
SAGIV AGUDAH SHITUFIT
/
, "
CHAKLAIT BE'AM
BLUM, GADOR & CO.,
,'
53 HASHALOM RD.,
23
,53
GIVATAYIM 53454
[74]
[57]
249
,
For use with a pipe fitting assembly (10), an adapter (12) comprising:
a hollow, substantially cylindrical sleeve formed of a polymeric material;
said sleeve defining a bore (16) on a first open end (13) for engaging a pipe fitting
assembly having an annular seal (19) thereabout and a tapered second open end (15)
for insertion into a pipe;
said bore being sized and configured to permit said sleeve to slide over and cover the
annular seal on the the pipe fitting assembly, and create thermal coupling and sealing
engagement between said pipe fitting assembly and said pipe.
"
__________________
[11][21]
177063
[54]
METHOD AND DEVICE FOR
TREATING A TEAT CANAL OF
AN ANIMAL
[22]
[31]
02.02.2005
[32] 02.02.2004
[33] US
60/540336
2004/0364
24.05.2004
IE
Int. Cl.(2009.01) A61D 01/02, 07/00, A61M 05/19
BIMEDA RESEARCH &
DEVELOPMENT LIMITED,
IRELAND
WO/2005/072644
26A HABARZEL ST.,
[51]
[71]
[87]
[74]
[57]
250
,
' 26 $
The invention relates to a method and device for treating or preventing or suppressing
a disease or condition in a non-human animal. The method comprises the steps of
providing a single delivery device containing two components for sequential delivery
from the delivery device. A first component is delivered from the single delivery
device into a teat canal of a non-human animal and subsequently the second
component is delivered from the single delivery device into the teat canal. The
"
components are delivered without substantial mixing of the components.
__________________
[11][21]
177077
,
[54]
PLATE HEAT AND MASS
EXCHANGER WITH EDGE
EXTENSION
[22]
[31]
[51]
[71]
18.02.2005
[32] 18.02.2004
[33] US
60/545672
Int. Cl.(2009.01) F24F 05/00, 06/02, F28C 03/04, F28D 03/00, 05/00, 07/00
IDALEX TECHNOLOGIES, INC.,
U.S.A.
ALAN D. GILLAN, LELAND E.
GILLAN, TIMOTHY L. HEATON,
VALERIY MAISOTSENKO, RICK J.
GILLAN
WO/2005/080881
, "
7
'$
, 54. ,
FLOOR,
7 JABOTINSKY ST.,
RAMAT GAN 52520
[72]
[87]
[74]
[57]
251
"
-
Heat exchanger plates (6) for indirect evaporative coolers, of the type having a dry side
(9) having low permeability to an evaporative liquid (22) and formed to allow a
product fluid (1) to flow over a heat transfer area of its surface, a wet side (10)
designed to have its surface wet by an evaporative liquid (22), and formed to allow a
working gas (2) to flow over its surface to evaporate the evaporative liquid, further
include edge extensions (20) formed beyond the heat exchange area of the plates to
facilitate removal of excess evaporative liquid. The edge extensions may slant or curve
away from the wet side of the plates to assist in liquid removal. The plates may be used
in a variety of configurations.
"
__________________
[11][21]
[54]
AUDIO CODING
[22]
[31]
[51]
[71]
10.02.2005
102004007191.8 [32] 13.02.2004
Int. Cl.(2010.01) G10L 19//00
FRAUNHOFER-GESELLSCHAFT ZUR
FORDERUNG DER ANGEWANDTEN
FORSCHUNG E.V., GERMANY
WO/2005/078705
31 YAVNE ST.,
P.O.B. 1426,
TEL AVIV 61013
[87]
[74]
[57]
252
177163
[33]
DE
,'
$
31
'
1426 . . ,
The aim of the invention is to encode an audio signal of a sequence of audio values
into an encoded signal. To this end, a first monitoring threshold is determined for a
first block of audio values of the sequence of audio values, and a second monitoring
threshold is determined for a second block of audio values of the sequence of audio
values; a version of a first parameterisation of a parameterisable filter is calculated
such that the transmission function thereof corresponds approximately to the inverse of
the quantity of the first monitoring threshold; a pre-determined block of audio values
of the sequence of audio values is filtered by means of the parameterisable filter, using
a pre-determined parameterisation that depends, in a pre-determined manner, on the
version of the second parameterisation, in order to obtain a block of filtered audio
values that corresponds to the pre-determined block; the filtered audio values are
quantised in order to obtain a block of quantised filtered audio values; a combination
of the version of the first parameterisation and the version of the second
parameterisation, containing at least one difference between the version of the first
parameterisation and the version of the second parameterisation, is formed; and
information containing said combination and from which the quantified filtered audio
values and a version of the first parameterisation can be derived is integrated into the
encoded signal.
"
__________________
[11][21]
177264
[54]
SOLID-STATE MAGNETIC
RESONANCE IMAGING
[22]
[31]
[51]
[62]
[71]
[87]
[74]
12.03.1999
[32] 13.03.1998
[33] US
09/041981
Int. Cl.(2010.01) A61B 05/055, G01N 24//08, G01R 33//54
SKELSCAN, INC., U.S.A.
WO/1999/045842
P.O.B. 2273,
REHOVOT 76122
[57]
253
,'
.
,4
2273 . . ,
A method for generating a magnetic resonance image of in vivo solid-state tissue, the
method comprising:
positioning the tissue in a substantially static magnetic field;
subjecting the tissue to magnetic gradients in at least two dimensions;
exciting first isotopes in the solid-state tissue using an RF excitation pluse while the
tissue is subjected to the magnetic gradients;
acquiring RF signals emitted by excited first isotopes after the first isotopes have been
excited, nd while the tissue is subjected to the magnetic gradients;
processing the RF signals to generate data representative of the distribution of the first
isotope within the solid-state tissue.
"
__________________
[11][21]
[54]
MEDICAL DEVICE
CONFIGURATION BASED ON
RECOGNITION OF
IDENTIFICATION INFORMATION
[22]
[31]
[51]
[71]
19.04.2005
[32] 27.05.2004
10/855855
Int. Cl.(2009.01) A61M 05/172, 39/00
BAXTER INTERNATIONAL INC.,
U.S.A.
WO/2005/118054
26A HABARZEL ST.,
[87]
[74]
[57]
254
177514
[33]
US
,
' 26 $
A medical delivery system (10) is provided for delivering a medicament (17) or fluid
(17) to a patient. The system comprises a disposable element such as a line set (14)
associated with a container (16) containing the fluid (17), an identifier (18) associated
with the line set (14) and having identification information associated therewith, and a
delivery device (12) configured to engage the line set (14) and deliver the fluid (17) to
the patient. The delivery device (12) includes a recognition system (20) that is capable
of obtaining the identification information associated with the identifier (18). The
identification information may include information regarding the identification of the
fluid (17), a type of line set (14), or a type of administration associated with the line set
(14). The device (12) can be capable of configuration based on the identification
information.
"
,205828
(
.
__________________
[11][21]
[54]
MEDICATION DISPENSING
APPARATUS WITH SPRINGDRIVEN LOCKING FEATURE
ENABLED BY ADMINISTRATION
OF FINAL DOSE
[22]
[31]
25.03.2005
[32] 30.03.2004
60/557545
60/638027
21.12.2004
Int. Cl.(2009.01) A61M 05/00, 05/315
ELI LILLY AND COMPANY, U.S.A.
WO/2005/097233
P.O.B. 5352,
BEER-SHEVA 84152
[51]
[71]
[87]
[74]
[57]
255
177829
–
[33]
"
US
US
,
#
#
,
5352 . . ,
A medication dispensing apparatus with a spring-driven locking feature includes a
drive member movable in a distal direction within a housing, and a fluid container with
a piston that is advanceable by the drive member (60) when such drive member is
moved distally by a driving means. The apparatus includes a latching element (180)
having a skid (190) that is slidable along a surface of the drive member as the drive
member passes distally during advancement. The drive member is arranged with the
skid so as to maintain a latching lip of the latching element against a spring force in a
first position free of the driving means during dose preparing and injecting prior to a
final dose administration. The skid-engaging surface shifts distally of the skid such
that the skid passes beyond a proximal end of that surface upon administration of a
final dose, whereby the latching lip is urged by the spring force from the first position
to a second position to physically lock the driving means to prevent further dose
preparing and injecting.
"
__________________
[11][21]
177835
[54]
LIQUID SAMPLING APPARATUS
AND METHOD OF USING SAME
[22]
[31]
[51]
[71]
07.03.2005
[32] 05.03.2004
[33] US
60/550743
Int. Cl.(2009.01) A61B 10/00, B01L 03/14, B65D 81/00
BRIAN H. RUTLEDGE, U.S.A.
PETER E. RISING, U.S.A.
WO/2005/086816
10 ABBA EBEN BLVD.,
P.O. B. 2081,
HERZLIYA 46120
[87]
[74]
[57]
,
#
,
10
#
2081 . . ,
A sampling apparatus (100) includes an ampoule barrel (101) for receiving an ampoule
(102) through a first opening, the ampoule barrel (101) comprising a second opening
(301) adapted to flow a liquid into the ampoule barrel (101) and a structure (304)
adapted break a frangible tip (104) of the ampoule (102).
__________________
[11][21]
256
178421
"
[54]
SPRAY PREVENTION DEVICE
[22]
[31]
[51]
[71]
04.04.2005
[32] 03.04.2004
0407653.5
Int. Cl.(2009.01) B62D 25/18
SPRAYDOWN LIMITED, UNITED
KINGDOM
WO/2005/095188
P.O.B. 2273,
REHOVOT 76122
[87]
[74]
[57]
[33]
GB
,'
.
,4
2273 . . ,
A device for preventing spray from emerging from the wheels of vehicles comprises a
panel (4) that is adapted to be mounted substantially vertically behind a vehicle wheel
(3) for receiving on a first side water released by the wheel (3) as it rotates. The panel
(4) includes at least one passage (6) which leads from the first side to a rear second
side of the panel (4). The or each passage (6) is other than normal to the plane of the
panel (4). There is at least one water-collecting pocket (7A, 7B, 7C) along the side of
the or each passage (6). In use, air and water enter the or each passage (6) and are
separated so that air passes through the or each passage (6) and mixes with ambient air
and water collects in the at least one water-collecting pocket (7A, 7B, 7C).
__________________
[11][21]
178825
[54]
FLUID PRESSURE SENSING
CHAMBER
[22]
[31]
[51]
[71]
[74]
23.10.2006
[32] 27.10.2005
[33] US
11/260596
Int. Cl.(2009.01) G01L 19/14
ALCON, INC., SWITZERLAND
,
#
#
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
A surgical cassette (200), adapted to be received in a cassette receiving portion (25) of
a surgical console (110), comprising:
(a) a body (220);
(b) a pressure sensing chamber (210) formed in the body; and
(c) a tubing extension (240) extending through the pressure sensing chaber, the tubing
extension defining at least one hole (260) that fluidly communicate(s) with the
pressure sensing chamber, the at least one hole being adapted to allow the purging of
"
[57]
257
"
air from the chamber during initial priming of the cassette,
characterized in that the tubing extension has a reduced diameter portion (241) in order
to create a flow restriction (242) within the tubing extension.
__________________
[11][21]
179100
[54]
SCANNING SYSTEM WITH A
STARING DETECTOR
[22]
[51]
[62]
[71]
13.06.2001
Int. Cl.(2009.01) G02B 26/10, 26/12, H04N 03/08
ISRAEL AEROSPACE
, "
INDUSTRIES LTD.
ASHER LOTTAN, TAL MAZOR,
$,
IZHACK ZUBALSKY, ZEEV
LISSAK
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[72]
[74]
[57]
258
$
# , $
,
,
' 26 $
A scanning system for scanning a field of regard (FOR) by dividing it into a plurality
of fields of view (FOVs) having different space orientations, said system having a
central axis (7) and a reference plane (x,y) perpendicular thereto and comprising:
a fixed optical system (12) having a line of sight directed along said axis;
a panoramic polygonal member (30) comprising a plurality of flat mirrors (32) having
different orientations relative to said reference plane and facing in different directions
of sight from one another and away from said reference axis to define said FOVs;
wherein said flat mirrors are fixed being spaced from said central axis;
"
each mirror having an operative state when its FOV is viewed by said optical system
and a corresponding inoperative state, and being radially spaced from said central axis
at least in the inoperative state;
a switching mechanism (40) for switching between said mirrors to successively bring
them into their operative state while keeping unchanged their said orientation and said
space orientation of the FOV, said switching mechanism comprising a folding member
(20) to perform said switching by the movement of the folding member to
successively establish a folded optical path between each flat mirror and said optical
system wherein the folding member is facing each respective mirror in turn when the
respective mirror is in its said operative state.
__________________
[11][21]
[54]
PLASTIC BAG FEATURING
OVERPRESSURE RELIEF
[22]
[31]
[51]
[71]
27.05.2005
[32] 27.05.2004
04012528.8
Int. Cl.(2009.01) B65D 33/01
JURGEN HEINEMEIER, GERMANY
BURKHARD LUCKMANN,
GERMANY
GUNTER REIMANN, GERMANY
WO/2005/115856
26A HABARZEL ST.,
[87]
[74]
259
179247
"
[33]
EP
,
' 26 $
"
[57]
The invention relates to a flexible packaging container (1) which is made of plastic and
in which a zone (4) having an inner (5) and an outer (6) wall is embodied by means of
welded or glued seams. The inner wall is provided with holes (12) which allow gas to
be discharged from the interior (14) of the container into the zone (4) located between
the inner and the outer wall while at least one subsection of the welded or glued seams
(7) that enclose said zone is configured such that gas can be discharged.
__________________
[11][21]
[54]
PROVIDING DIRECTED BANK
REFRESH FOR VOLATILE
MEMORIES
[22]
[31]
26.05.2005
[32] 27.05.2004
60/575334
10/982038
05.11.2004
Int. Cl.(2009.01) G11C 11/406
U.S.A.
WO/2005/119691
P.O.B. 2273,
REHOVOT 76122
[51]
[71]
[87]
[74]
[57]
260
179416
,
[33]
US
US
,'
.
,4
2273 . . ,
A memory system is provided. The memory system includes a volatile memory having
a number of banks and a memory controller configured to control the volatile memory
to engage in an auto-refresh mode or a self-refresh mode. The memory controller is
further configured to direct the volatile memory to perform an auto-refresh operation
on a target bank. The remaining banks are available for access while the auto-refresh
operation is being performed on the target bank.
"
,205516
(
.
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
USE OF ALEMTUZUMAB
MONOCLONAL ANTIBODY IN
FORMULATING AN HIV
MEDICAMENT
179856
HIV –
–
"ALEMTUZUMAB"
28.07.2005
[32] 30.08.2004
[33] US
60/605173
Int. Cl.(2010.01) A61K 08//00, 38//00, 39//395, A61P 01//18
AKTIENGESELLSCHAFT,
GERMANY
WO/2006/024354
REINHOLD COHN AND
,
PARTNERS,
26A HABARZEL ST.,
' 26 $
A method of treating HIV infection comprises administering to a patient a regimen that
is able to shut down the immune system in a controlled manner by using T-cell
depletion or T-cell modification such that T-cells no longer can be attacked by HIV
cells. The T-cell depletor or T-cell modifiers ate administered either alone or in
combination with 'conventional' anti-HIV drugs.
__________________
261
"
[11][21]
[54]
COMPACT RADIO FREQUENCY
TRANSMITTING AND
RECEIVING ANTENNA AND
CONTROL DEVICE EMPLOYING
SAME
[22]
[31]
[51]
[71]
20.06.2005
[32] 21.06.2004
10/873033
Int. Cl.(2010.01) H01Q 07//00
LUTRON ELECTRONICS CO. INC.,
U.S.A.
WO/2006/002145
P.O.B. 1352,
JERUSALEM 91013
[87]
[74]
[57]
[33]
US
,
,%
1352 . . ,
A compact antenna for use in a device for controlling the power delivered to an
electric load and operable to transmit or receive radio frequency signals at a specified
frequency is presented. The antenna comprises a first loop of conductive material
having a capacitance and an inductance forming a circuit being resonant at the
specified frequency, and a second loop of conductive material having two ends
adapted to be electrically coupled to an electronic circuit. The second loop is
substantially only magnetically coupled to the first loop and is electrically isolated
from the first loop. In a first embodiment of the antenna, the first and second loops are
formed on respective first and second printed circuit boards, which allow for a small,
low-cost antenna that is easy to manufacture and maximizes efficiency. When the
antenna is installed in a load control device, such as a dimmer, the first loop of the
antenna is mounted on an outer surface of the device. The second loop of the antenna
may be at a high-voltage potential such as line voltage.
262
180225
,204689
(
.
"
__________________
[11][21]
[54]
FIBROUS-COMPOSITE
MATERIAL-BASED MEMS
OPTICAL SCANNER
[22]
[31]
24.06.2005
[32] 24.06.2004
60/582405
60/659736
08.03.2005
Int. Cl.(2009.01) G02B 26/08
CORNELL RESEARCH
FOUNDATION, INC., U.S.A.
WO/2006/002388
26A HABARZEL ST.,
[51]
[71]
[87]
[74]
[57]
180244
MEMS
[33]
US
US
,
' 26 $
Mems can be fabricated from fibers without the use of a matrix material. Devices can
be built where fibers are attached only at a substrate edge (e.g. cantilevers, bridges).
Motions can be controlled by adjusting the linkage between multiple fibers with weak
coupling (e.g. base, tip, in-between). Driving mechanisms include base forcing
(magnetics, piezo, electrostatics) or tip forcing (magnetics). Mirrors may be formed on
free ends of cantilevers to form optical scanners.
__________________
[11][21]
[54]
263
180964
DRIVE ENGINE FOR A LIFT
INSTALLATION AND METHOD
"
OF MOUNTING A DRIVE ENGINE
[22]
[31]
[51]
[62]
[71]
[74]
[57]
06.08.2003
[32] 05.09.2002
[33]
02405768.9
03405297.7
29.04.2003
Int. Cl.(2009.01) B66B 11/04, B66D 01/12
INVENTIO AG, SWITZERLAND
26A HABARZEL ST.,
EP
EP
,
' 26 $
Lift insallation with cage and counterweight in a shaft, wherein the cage and the
counterweight are guided by means of cage guide rails and counterweight guide rails
respectively, and with a drive engine (20), which drives the cage and the
counterweight by way of at least two drive means, wherein the drive engine comprises
a drive shaft (4), at least two mutually spaced-apart drive zones (3;3') and components
such as a motor (1) a brake (2), wherein either the motor is arranged to the left or right
of the two drive zones and the brake is arranged on a side of the two drive zones which
is cpposite to that of the motor, or the motor as well as the brake are arranged to the
left or right of the two drive zones, and the support and drive means are arranged in
correspondence with a spacing (D) of the drive zone, characterized in that the spacing
(D) of the two drive zones, relative to one another allows an arrangement of the cage
guide rail between the two drive zones and the spacing (D) of the two drive zones or of
the support and drive means from one another corresponds with at least the width of a
rail foot of the cage guide rail and at most three times the width of the rail foot of the
cage guide rail, or the spacing (D) of the two drive zones or of the support and drive
means from one another amounts to 100 to 250 mm.
__________________
264
"
[11][21]
[54]
SYSTEMS AND METHODS FOR
UNIVERSAL IMAGING
COMPONENTS
[22]
[31]
[51]
[71]
19.07.2005
[32] 13.08.2004
10/918166
Int. Cl.(2009.01) G03G 15/00
STATIC CONTROL COMPONENTS,
INC., U.S.A.
WO/2006/020217
P.O.B. 1352,
JERUSALEM 91013
[87]
[74]
[57]
181215
[33]
US
,
,%
1352 . . ,
A cartridge chip 106 for use with an imaging cartridge installed in an imaging device,
the cartridge chip comprising a memory element 106 storing imaging cartridge data,
and a controller 104 for controlling the operation of the cartridge chip and determining
if the imaging device is a first type of imaging device or a second type of imaging
device, the controller for operating the cartridge chip in a first mode of operation if the
imaging device is the first type of imaging device, the controller for operating the
cartridge chip in a second mode of operation if the imaging device is the second type
of imaging device.
__________________
[11][21]
[54]
SEAL INSTALLATION TOOL
[22]
[31]
[51]
[71]
08.02.2007
[32] 16.02.2006
11/355420
Int. Cl.(2009.01) B23P 19/02
AIR PRODUCTS AND CHEMICALS,
265
181227
[33]
US
"
[74]
[57]
INC., U.S.A.
26A HABARZEL ST.,
,
' 26 $
A tool for installing a seal in a fitting, said tool comprising:
a sleeve having a first socket sized to receive said seal, and a second socket positioned
adjacent to said first socket, said second socket defining an open end of said sleeve and
being sized to receive said fitting:
a pusher element movable within said sleeve, said pusher element having a contact
surface engageable with said seal for moving said seal out of said first socket and into
said fitting when said pusher element is moved relatively to said sleeve, and said
pusher element comprises a shaft having said contact surface at one end thereof,
wherein said shaft has a conduit therein, and said conduit having an inlet positioned at
said one end providing filuid communication with said fitting, and an outlet providing
fluid communication with the atmosphere to allow gas to escape from said fitting to
the atmosphere when said second socket is engaged with said fitting.
__________________
[11][21]
[54]
EXTENDED DEPTH OF FIELD
USING A MULTI-FOCAL LENGTH
LENS WITH A CONTROLLED
RANGE OF SPHERICAL
ABERRATION AND CENTRALLY
OBSCURED APERTURE
[22]
[31]
11.05.2005
[32] 03.09.2004
60/607076
60/522990
30.11.2004
10/908287
05.05.2005
Int. Cl.(2010.01) G02B 13//18
AUTOMATIC RECOGNITION &
CONTROL INC., U.S.A.
WO/2006/028527
26A HABARZEL ST.,
[51]
[71]
[87]
[74]
[57]
266
181671
[33]
US
US
US
,
' 26 $
An extended depth of field is achieved by a computational imaging system that
combines a multifocal imaging subsystem for producing a purposefully blurred
"
intermediate image with a digital processing subsystem for producing a recovered
image having an extended depth of field. The multifocal imaging system preferably
exhibits spherical aberration as the dominant feature of the purposeful blur. A central
obscuration of the multifocal imaging subsystem renders point-spread functions of
object points more uniform over a range of object distances. An iterative digital
deconvolution algorithm for converting the intermediate image into the recovered
image contains a metric parameter that speeds convergence, avoids stagnations, and
enhances image quality.
__________________
[11][21]
182100
[54]
CUTTING INSERT FOR A
MILLING CUTTER
[22]
[51]
[71]
[72]
[74]
21.03.2007
Int. Cl.(2010.01) B23B 27//16, B23C 05//02, 05//20
TAEGUTEC INDIA LTD., INDIA
KEDAR SURESH BHAGATH
ISCAR LTD.,
, "
P.O.B. 11,
11 . . ,
TEFEN 24959
A double-ended indexable cutting insert comprising:
first (102) and second (104) substantially square end surfaces facing opposite
directions, each end surface having an associated abutment surface (108) and four
associated insert corners (106);
four side surfaces (112A, 112B, 112C, 112 D) connecting the first and second end
surfaces to form a total of eight edges, each edge comprising a primary cutting edge
(120), a wiper (122) and a transitive edge (124) connecting the primary cutting edge to
the wiper, at least the primary cutting edge and the wiper occupying a common plane;
a median plane (M) located mid-way between the first and second end surfaces and
passing through the four side surfaces;
wherein:
each insert corner has associated therewith:
a primary cutting edge extending from said each insert corner in a downward direction
towards the median plane; and
a wiper extending from said each insert corner in an upward direction away from the
median plane, said wiper rising above an associated abutment surface.
[57]
267
"
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
268
182290
,(AIOL)
ACCOMMODATING
INTRAOCULAR LENS (AIOL),
AND AIOL ASSEMBLIES
INCLUDING SAME
09.10.2005
[32] 13.10.2004
60/617738
Int. Cl.(2010.01) A61F 02//16
NULENS LTD.
WO/2006/040759
NULENS LTD.,
P.O.BOX 2225
MASKIT 15 ST.
HERZLIYA PITUACH 46121
(AIOL)
[33]
US
#
, "
, "
15
# 2225 . . ,
An accommodating intraocular lens (AIOL) including a biasing mechanism (79) for
elastically deforming an elastically deformable shape memory disk-like optical
element (66) for affording the AIOL a natural positive diopter strength for near vision.
The AIOL is intended to be implanted in a human eye (10) such that relaxation of its
ciliary body (19) causes its capsular diaphragm to apply an accommodation force for
overcoming the biasing mechanism to reduce the AIOL's natural positive diopter
strength for distance vision.
"
__________________
[11][21]
182524
[54]
AMORPHOUS FORM OF
CINNAMIDE COMPOUND
[22]
[31]
[51]
[71]
25.10.2005
[33] JP
2004-310909 [32] 26.10.2004
Int. Cl.(2010.01) A61K 31//454, A61P 05//28, C07D 40/1/06
EISAI R&D MANAGEMENT CO.,
LTD., JAPAN
WO/2006/046575
P.O.B. 5352,
BEER-SHEVA 84152
[87]
[74]
[57]
,
#
#
,
5352 . . ,
An amorphous form of (3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4methyl-1H-imidazol-1-yl)benzylidene]piperidine-2-one, which is represented by the
formula (1) and has Abeta-production inhibitory activity. The amorphous object has
such satisfactory properties that it has excellent solubility, is stable, does not readily
become a crystalline form, and has low hygroscopicity. It is hence suitable for use in
pharmaceutical preparations.
__________________
269
"
[11][21]
[54]
COMPRESSED SOLID DOSAGE
FORM MANUFACTURING
PROCESS WELL-SUITED FOR
USE WITH DRUGS OF LOW
AQUEOUS SOLUBILITY AND
COMPRESSED SOLID DOSAGE
FORMS MADE THEREBY
[22]
[51]
[71]
10.11.2004
Int. Cl.(2010.01) A61K 09//20
TEVA PHARMACEUTICAL
INDUSTRIES LTD.
MALI KADOSH, FANNY LESKA,
DORIT MARKO, ILAN ZALIT,
YONIT TRIGER-MESSER
WO/2006/052254
TEVA PHARMACEUTICAL
INDUSTRIES LTD.,
5 BASEL ST.,
P.O.B. 3190,
PETAH TIQVA 49131
[72]
[87]
[74]
[57]
182549
, "
#
, "
#
5 $
3190 . . ,
A pharmaceutical formulation of compounds with low aqueous solubility and method
of manufacture thereof. The formulation may include a pharmacologically active
compound having low aqueous solubility and starch in the amount of greater than
about (25) weight percent. A manufacturing method may include blending the active
compound and starch, compressing the blend into a solid, comminuting the solid into
granules, wetting the granules, drying the granules, and tabletting the dried granules to
make a solid pharmaceutical formulation.
division from this
been published
,200447
(
.
__________________
[11][21]
[54]
270
182570
ELECTROACOUSTIC METHOD
AND DEVICE FOR STIMULATION
"
OF MASS TRANSFER PROCESSES
FOR ENHANCED WELL
RECOVERY
[22]
[31]
[51]
[71]
[87]
[74]
[57]
12.11.2004
[32] 11.11.2004
10/986677
Int. Cl.(2009.01) E21B 43/00
KLAMATH FALLS, INC., BRITISH
VIRGIN ISLANDS
WO/2006/052258
P.O.B. 2273,
REHOVOT 76122
[33]
US
,'
.
,4
2273 . . ,
An electro acoustic device and related method for increasing production capacity of
wells that contains oil, gas and/or water is disclosed. The electro acoustic device
produces vibrations stimulating occurrence of mass transfer processes within the well.
The resultant acoustic flow generated in porous media, produced by superposition of
longitudinal and shear waves, is developed over a characteristic frequency threshold
value specific to water, normal oil and heavy oil, with an acoustic energy density
capable of establishing higher fluidity zones in the porous media, promoting mobility
and recovery of desired fluid and formation damage reduction in a wellbore. The down
hole electro acoustic device is a submerged unit placed in the well producing zone, and
consists of an electric generator, one or more electro acoustic transducers, and one or
more waveguide systems (sonotrodes) that include tubular type radiators which
provide transmission of elastic vibrations into the medium under treatment.
__________________
[11][21]
[54]
271
182723
COATED CUTTING INSERT AND
MANUFACTURING METHOD
THEREOF
"
[22]
[31]
[51]
[71]
[87]
[74]
[57]
20.10.2005
2004-316611 [32] 29.10.2004
Int. Cl.(2009.01) B23B 27/14
SUMITOMO ELECTRIC
HARDMETAL CORP., JAPAN
WO/2006/046462
5 SHENKAR ST.,
P.O.B. 12704,
HERZLIYA 46733
[33]
JP
5
, #
#
' ,1 - $
# 12704 . . ,
An edge replacement type cutting tip (1) and a method of manufacturing the cutting
tip. The cutting tip (1) comprises a body (8), a base layer formed on the body (8), and a
use state indicating layer formed on the base layer. The body (8) is characterized in
that at least one face thereof is formed in a face (2) and the other at least one face is
formed in a flank (3), ridges where the face (2) crosses the flank (3) are formed in edge
ridge lines (4), the base layer presents a color different from that of the use state
indicating layer, and the use state indicating layer is formed on the base layer in the
entire surfaces or parts of the surfaces of areas (A2) on the flank (3) excluding areas
(A1) vertically extended by a distance of 0.2 to less than 3.0 mm from the edge ridge
lines (4).
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[72]
[87]
[74]
272
182795
– 2, 3 –
PROCESS FOR THE PREPARATION
OF 1,4-DIALKYL-2, 3-DIOL-1, 4BUTANEDIONE
27.10.2005
PCT/IB2004/003631 [32] 02.11.2004
Int. Cl.(2010.01) C07C 45//72, 49//17
FIRMENICH SA, SWITZERLAND
FERDINAND NAEF, RENE DECORZANT
WO/2006/048795
– 1, 4
– 1, 4 –
[33]
WO
, #
#
"
5
5 SHENKAR ST.,
P.O.B. 12704,
HERZLIYA 46733
[57]
'
#
,1 - $
12704 . . ,
The present invention relates to a process for the preparation of compounds of a 1,4dialkyl-2,3-diol-1,4-butanedione by a catalytic aldol condensation between an alkyl
glyoxal and an a-hydroxy ketone.
__________________
[11][21]
[54]
SHARING CELLULAR
COMMUNICATION SERVICES
AMONG MOBILE STATIONS OF
DIFFERENT NETWORKS
[22]
[51]
[62]
[71]
[74]
27.03.2002
Int. Cl.(2010.01) H04W 08//10, 08//28
CELLCOM ISRAEL LIMITED
REINHOLD COHN AND
PARTNERS,
26A HABARZEL ST.,
[57]
273
182840
,
, "
' 26 $
A Home Location Register (HLR) operative in a wireless network and configured to
support, at least, Interim Standard 41 (IS-41), said HLR operatively coupled to a first
Visitor's Location Register (VLR) configured to support communication with a first
single-protocol mobile station over protocol IS-41 and to a second VLR configured to
support communication with a second single-protocol mobile station over a protocol
other than IS-41; wherein the first mobile station and the second mobile station are
bearing different inherent telephone numbers, and said HLR is configured to receive
an incoming call addressed to either the first or the second mobile stations; said HLR
is further configured to accommodate a configuration comprising a Calling Line
Identity (CLI) common to the first and the second mobile stations, said CLI associated
with the inherent telephone number of the first mobile station and the inherent
telephone number of the second mobile station.
"
__________________
[11][21]
183107
[54]
TRIPEPTIDE AND
TETRAPEPTIDE THIOETHERS
[22]
[31]
[51]
[71]
[87]
[74]
04.01.2006
[32] 06.01.2005
[33] US
60/641932
Int. Cl.(2010.01) A61K 38//06, 38//07, A61P 31//00, C07K 05//08, 05//10
TELIK, INC., U.S.A.
WO/2006/074249
,
26A HABARZEL ST.,
' 26 $
[57]
–
Tripeptide and tetrapeptide thioethers, pharmaceutical compositions containing them,
their pharmaceutical use, and their preparation. The compounds are useful in
potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively
exerting toxicity in tumor cells, elevating the production of GM progenitors in bone
marrow, stimulating the differentiation of bone marrow, mitigating the
myelosuppressive effects of chemotherapeutic agents, and modulating hematopoiesis
in bone marrow.
__________________
[11][21]
274
183145
"
[54]
CONTROLLED-VOLUME
INFUSION DEVICE
[22]
[31]
[51]
[71]
[87]
[74]
18.11.2005
[32] 19.11.2004
60/629795
Int. Cl.(2009.01) A61M 05/178
CURLIN MEDICAL INC., U.S.A.
WO/2006/055834
P.O.B. 1352,
JERUSALEM 91013
[57]
[33]
US
,
,%
1352 . . ,
An infusion device capable of administering liquid medication at a continuous flow
rate, and upon user demand delivers a controlled volume dosage of liquid medication
at a higher dosage flow rate. The dosage reservoir (200) remains empty until the user
actuates it by selectively and temporarily removing the pressure source, such as a
spring (230). During actuation, fluid rapidly flows from the medication reservoir (100)
to fill the dosage reservoir (200). After actuation, the pressure source (230) exerts a
higher pressure on the dosage reservoir (200) than the medication reservoir pressure
(100), which results in a temporary higher bolus flow rate. Thus, two distinct flow
rates are achieved with one flow restrictor element (700).
__________________
[11][21]
183147
[54]
TOROIDAL PISTON INTERNAL
COMBUSTION ENGINE
[22]
[51]
[71]
13.05.2007
Int. Cl.(2010.01) F01C 09//00, F02B 53//00
EFIM LAPATIN
OLGA LAPATIN
EFIM LAPATIN,
42/1 UZIEL ST.,
RAMAT GAN 52382
[74]
[57]
275
,
1
42
,
,
$
'
A toroidal piston internal combustion engine comprising:
a stator,
"
a piston assembly and its stopping device,
a reversible mechanism,
a driveshaft rotatably set in bearings disposed in the stator,
a fly wheel attached to the driveshaft,
at least two pairs of toroidal cylinders connected with combustion chambers and
symmetrically disposed in the stator on both sides of the driveshaft,
feed channels disposed in the stator and connected with the combustion chambers by
controlled admission valves,
exhaust channels disposed in the stator and connected with the combustion chambers
by controlled exhaust valves,
the piston assembly having at least two pairs of toroidal pistons, slidably set in the
toroidal cylinders and connected by a connecting rod,
split seal rings, fitted to the toroidal cylinders, disposed in external ring grooves of the
toroidal pistons,
the stopping device including stopping toroidal cylinders, disposed in the stator on
both sides of the driveshaft, and stopping toroidal pistons fitted to the said cylinders
and connected to the piston assembly,
the stopping toroidal cylinder, having a buffer, set on its bottom, and formed on its
wall a hole and a chamel, connected with a throttle and set between the said buffer and
the said hole,
the reversible mechanism, disposed in the stator including: two conical gear wheels
rotatably put on the driveshaft, opposite set to each other and engaged with driven
conical gear wheels, rotatably set in the stator on an axis
perpendicular to the driveshaft; circular profile surfaces formed on the conical gear
wheels, disposed opposite to each other; projections and hollows evenly disposed on
the circular profile surfaces, the projection set after the near hollow in the direction of
the driveshaft rotation and displaced from the said hollow on an arc conforming to
calculated angle 0 of the piston assembly turn; a spline slider slidably set on the
driveshaft between the circular profile surfaces and having two cams, adjoining to the
circular profile surfaces and rotatably set on axles, attached to the spline slider and
perpendicular to the driveshaft, the projections, formed on one of the circular profile
surfaces, disposed opposite the hollows formed on other of the circular profile surfaces
or, on the contrary, the hollows formed on one of the circular profile surfaces,
disposed opposite of the projections, formed on other of the circular profile surfaces,
a lever, connecting one of the conical gear wheel with the connecting rod.
__________________
[11][21]
[54]
276
183924
USE OF A COMBINATION OF
ACTIVE AGENTS IN THE
PREPARATION OF
PHARMACEUTICAL
"
COMPOSITIONS
[22]
[31]
[51]
[71]
[72]
[87]
[74]
[57]
20.12.2005
[32] 22.12.2004
[33] US
60/638674
04106910.5
22.12.2004
EP
Int. Cl.(2009.01) A61K 31/7076, 39/395, A61P 37/02, C07K 16/18, 16/28
MERCK SERONO S.A.,
SWITZERLAND
GIAMPIERO DELUCA
WO/2006/067134
INTERPHARM LABORATORIES
, "
LTD.,
18
18 HAKISHON ST.,
151 . . ,
P.O.B. 151,
YAVNE 81101
This invention is directed towards treatments for multiple sclerosis comprising
administering to a patient in need thereof a first agent, such as 2-chloro-2'deoxyadenosine (2-CdA), that reduces the number of lymphocytes in combination with
a second agent, such as an anti-alpha-4 integrin antibody, that blocks the adhesion of
monocytes and leukocytes to endothelial cells. The use of 2-CdA combined with an
anti-alpha-4 integrin antibody may be more effective than either treatment alone for
MS. Furthermore, the combination treatment may allow for a lowering or altering the
dose of one or more of the agents in order to limit any adverse effects associated with
the individual agents, but maintaining the same therapeutic efficacy.
__________________
[11][21]
184284
[54]
MODIFIED BETA THYMOSIN
PEPTIDES
[22]
[31]
17.01.2006
[32] 14.01.2005
[33]
60/643684
60/643686
14.01.2005
60/643687
14.01.2005
60/643688
14.01.2005
Int. Cl.(2010.01) A61K 38//00, C07K 14//575
REGENERX
BIOPHARMACEUTICALS, INC.,
U.S.A.
FRIEDRICH-ALEXANDERUNIVERSITAT ERLANGEN-
[51]
[71]
277
–
US
US
US
US
"
[72]
[87]
[74]
[57]
NURNBERG, GERMANY
EWALD HANNAPPEL, THOMAS
HUFF, ALLAN L. GOLDSTEIN,
DAVID CROCKFORD
WO/2006/076523
WEBB & CO.,
REHOVOT 76121
,'
"
2
'
2189 . . ,
A composition including an oxidized or superoxidized methionine-containing beta
thymosin peptide, isoform thereof, fragment thereof, isolated R-enantiomer thereof or
isolated S-enantiomer thereof, other than racemic thymosin beta 4 sulfoxide, or a
modified beta thymosin peptide, isoform or fragment thereof with an amino acid
substituent substituted for at least one methionine of an amino acid sequence of a
normally methionine-containing beta thymosin peptide, isoform or fragment thereof,
and method for forming same.
__________________
[11][21]
[54]
INHALATOR CAPSULES
[22]
[31]
[51]
[71]
17.05.2006
102005022862.3 [32] 18.05.2005
Int. Cl.(2009.01) A61K 09/48
GMBH & CO. KG, GERMANY
WO/2006/122790
279 HAYARKON ST.,
P.O.B. 6451,
TEL AVIV 61063
[87]
[74]
[57]
278
187278
,
[33]
DE
,
#
279
"
6451 . . ,
The invention relates to a capsule, which is used, in particular, in the form of a package
for inhalation formulations and comprises at least one cavity encased by a wall. Said
invention is characterised in that at least one part of the wall comprises a polymer
composition containing at least one type of absorber. The preferred use thereof, an
inhalator and a secondary packing means containing said capsule are also disclosed.
"
__________________
[11][21]
[54]
[22]
[31]
[51]
[71]
[87]
[74]
[57]
279
188164
PHARMACEUTICAL
FORMULATION OF THE
TUBULIN INHIBITOR INDIBULIN
FOR ORAL ADMINISTRATION
WITH IMPROVED
PHARMACOKINETIC
PROPERTIES AND PROCESS FOR
THE MANUFACTURE THEREOF
07.06.2006
[32] 14.06.2005
[33]
11/151459
Int. Cl.(2010.01) A61K 09//16, 31//4439
ZIOPHARM ONCOLOGY, INC.,
U.S.A.
WO/2006/133835
26A HABARZEL ST.,
,
US
,
' 26 $
The present invention relates to a pharmaceutical formulation for oral administration
of the poorly soluble and therefore hardly bioavailable tubulin inhibitor Indibulin and a
process for its manufacture. In particular, there is provided a pharmaceutical
formulation of lndibulin for oral administration comprising a granulate containing
micronized lndibulin having a particle size of less than 20 µm for at least 99 vol.-% of
the particles, at least one hydrophilic surfactant, and one or more capsulation
excipients.
__________________
"
[11][21]
188457
[54]
USE OF ANTI-HISTAMINICS FOR
ACUTE REDUCTION OF
ELEVATED INTRACRANIAL
PRESSURE
[22]
[31]
[51]
[62]
[71]
22.11.2002
[32] 23.11.2001
[33] EP
01204574.6
Int. Cl.(2010.01) A61K 45//06, A61P 07//02, 07//08, 09//10, C07D 51/9/00
JANSSEN PHARMACEUTICA, N.V.,
BELGIUM
WO/2003/044023
,
26A HABARZEL ST.,
' 26 $
[87]
[74]
[57]
280
–
"
The invention concerns a novel histamine receptor antagonist and the use of an
histamine receptor antagonist for the reduction of intracranial pressure (ICP), in
particular for the prevention and treatment of elevated intracranial pressure and/or
secondary ischaemia, in particular caused by brain injury, more in particular caused by
traumatic (TBI) and non-traumatic brain injury. The novel compounds comprise
compounds according to the general Formula (I) the pharmaceutically acceptable acid
or base addition salts thereof, the stereochemically isomeric forms thereof and the Noxide form thereof. In particular, the preferred compound is 3-[2-[4-(11,12-dihydro6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenylmethyl)-1-piperidinyl]ethyl]2,10-dimethyl pyrimido[1,2-a]benzimidazol-4(10H)-one, the pharmaceutically
acceptable acid or base addition salts thereof, the stereochemically isomeric forms
thereof and the N-oxide form thereof. Also claimed is the novel use of commercially
available histamine H1-and H2-receptor antagonists for the reduction of intracranial
pressure (ICP).
"
__________________
[11][21]
[54]
SALIX EXTRACT, ITS USE AND
FORMULATIONS CONTAINING IT
[22]
[31]
[51]
[71]
[87]
[74]
14.06.2006
MI2005A001349 [32] 14.07.2005
Int. Cl.(2009.01) A61K 36/185, 36/76
INDENA S.P.A., ITALY
WO/2007/006384
26A HABARZEL ST.,
[57]
188706
,
[33]
IT
,
' 26 $
The present invention relates to an extract of Salix spp obtainable by fractioning on a
resin and to the process for its preparation. The extract of the invention is characterized
by an high content in salicin derivatives, reduced content in high molecular tannins and
a content in proanthocyanidins sufficient to inhibit some tissue metal proteases. The
product is formulated in oils rich in &ohgr;-3 and &ohgr;-6 acids which provide a
better absorption of the extract active principles, also increasing synergetically their
action.
__________________
[11][21]
189071
[54]
SUPPORT OF MULTIUSER
DETECTION IN THE DOWNLINK
[22]
[31]
[51]
[62]
[71]
02.02.2001
[32] 04.02.2000
[33] US
60/180402
Int. Cl.(2010.01) H04B 01//707, H04J 03//00, 11//00, 13//00, H04W 16//14
CORPORATION, U.S.A.
WO/2001/058041
,
26A HABARZEL ST.,
' 26 $
[87]
[74]
281
"
"
[57]
A wireless time division duplex base station, the base station comprising:
means for assigning at least one channelization code to a user equipment;
a mapping between midamble codes and channelization codes, where at least one
midamble code is mapped to a plurality of channelization codes having a same
spreading factor; and
means for selecting the midamble code mapped to the at least one channelization code
to the user equipment; and
means for forming a communication burst with the assigned at least one channelization
code and the selected midamble code.
__________________
[11][21]
189470
[54]
DETACHABLE SHEET
[22]
[31]
[51]
[71]
[72]
[87]
[74]
02.11.2006
[32] 15.11.2005
[33] US
60/736333
Int. Cl.(2010.01) B26F 01//18, B42D 05//00, 13//00, B42F 03//00
DAVID A. GLUCK
DAVID A. GLUCK
WO/2007/057882
DAVID A. GLUCK,
18 HATIVAT HAREL
20
93
AP. 93, 20TH FLOOR
MODI'IN 71721
[57]
282
,
.
.
,
.
18
In one aspect, the present invention is directed to a sheet comprising: a first section on
one side of the sheet; and a second section on the other side of the sheet and parallel to
the first section; wherein the distance between the tip of the first section and the tip of
the second section being substantially greater than zero, thereby upon applying a force
along the tips, detaching the sheet between the tips. In another aspect, the present
invention is directed to a sheet comprising: a section on one side of the sheet in which
the shortest distance between the tip of the section and the un-sectioned edge of the
sheet is substantially greater than zero, thereby upon applying a force along the
section, detaching the sheet between the tip and the edge.
"
35
5728 - 1968
5
1968 – "
(
,
__________________
[11][21]
[54]
[22]
[31]
[51]
[62]
[71]
[87]
[74]
[57]
283
POLYNUCLEOTIDE SEQUENCES
TO A STREPTOMYCES
AVERMITILIS AVEC ALLELE
PRODUCING A REDUCED CLASS
2:1 RATIO OF AVERMECTINS
192371
aveC
2:1
31.01.2003
[32] 12.02.2002
[33] US
60/356222
Int. Cl.(2010.01) C12N 15//00
PFIZER PRODUCTS, INC., U.S.A.
WO/2003/068955
,
#
#
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
A polynucleotide molecule comprising a nucleotide sequence that is otherwise the
same as the Streptomyces avermetiils aveC allele, the S. avermetilis AveC gene
product-encoding sequence of plasmid pSE 186 (ATCC 209604) or the nucleotide
sequence of the aveC ORF of S. avermetilis as presented in SEQ ID IN: 1, or a variant
thereof which includes one or more silent changes to the nucleotide sequence
according to the degeneracy of the genetic code, but which nucleotide sequence further
comprises mutations encoding a combination of amino acid substitutions at amino acid
residues to the amino acid positions of SED ID IN: 2, such that cells of S. avermetilis
strain ATCC 53692 in which the wild-type aveC allel has been inactivated and that
Sexpress the polynucleotide molecule comprising the mutated nucleotide sequence are
capable of producing a class 2:1 ratio of avermectins that is reduced compared to the
"
ratio produced by cells of S. avermetilis strain ATCC 53692 that instead express only
the wild-type aveC allele, wherein when the class 2:1 avermectins are cyclohexyl
132:cyclohexyl B1 avermectins the ratio of class 2:1 avermectins is 0.2:1 or less, and
wherein the combinations of amino acid substitutions comprise substitutions at both
D48 and G179, and wherein the combination of amino acid substitutions comprises a
combination selected from the group as set forth in the specification.
__________________
[11][21]
193631
[54]
HUMANIZED ANTIBODIES THAT
SEQUESTER AMYLOID BETA
PEPTIDE
[22]
[31]
26.02.2001
[32] 24.02.2000
[33] US
60/184601
60/254465
08.12.2000
US
60/254498
08.12.2000
US
Int. Cl.(2009.01) A61K 39/395, A61P 25/28, C07K 16/18, C12N 05/10, 15/13, C12R
01/91
ELI LILLY AND COMPANY, U.S.A.
WASHINGTON UNIVERSITY,
U.S.A.
WO/2001/062801
,
#
#
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
[51]
[62]
[71]
[87]
[74]
[57]
284
A method to treat conditions characterized by formation of amyloid plaques both
prophylactically and therapeutically is described. The method employs humanized
antibodies which sequester soluble A peptide from human biological fluids or which
"
preferably specifically bind an epitope contained within position 13-28 of the amyloid
beta peptide A .
__________________
[11][21]
194204
[54]
PARABOLIC SOLAR TROUGH
SYSTEMS WITH ROTARY
TRACKING MEANS
[22]
[51]
[71]
[87]
[74]
28.03.2006
Int. Cl.(2010.01) F24J 02//14, 02//18, 02//38, 02//54
CAPAN, RAHMI, OGUZ, TURKEY
WO/2007/110713
279 HAYARKON ST.,
P.O.B. 6451,
TEL AVIV 61063
[57]
285
,
#
279
"
6451 . . ,
The inventive solar trough field system (A) comprises multiple parabolic reflectors
(1), support circles (3) of which the center coincides with the focus of the parabolic
reflector (1 ) and which are used in order to support the reflector (1 ), core
mechanisms (2) which are located on the center of the circles (3), guy wires (4) which
connect the circle (3) and the core mechanism (2) to each other, side support units
(5,5J) which bear the support circles (3) from their outer surfaces, lightweight filling
materials (6) which support the reflectors (1 ) from their lower parts, thermal receiver
tubes (11) which pass through the center axis of the circles (3). The parabolic
reflectors (1) are rotated around the center axis of the circles (3), which is the focus
thereof, and directed towards the sun. Thus, the parallel beams coming from the sun
are concentrated in the thermal receiver tubes (11) which are located in the focus of
the reflectors (1).
"
__________________
[11][21]
195435
[54]
PROCESSES FOR PREPARING
LABELING REAGENTS
[22]
[31]
[51]
[62]
[71]
[74]
02.03.2003
[32] 12.03.2002
[33] US
10/096075
Int. Cl.(2010.01) C07D 41/3/00, 41/7/00
,
#
#
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
A process for preparing a cyanine dye labeling reagent, said process comprising the
steps of:
(a) providing:
(i) a first intermediate compound of formula I as set forth in the specification
wherein, X1 comprises carbon, oxygen, nitrogen or sulfur; and
(ii) a second intermediate compound of formula II as set forth in the specification
wherein X2 comprises carbon, oxygen, nitrogen or sulfur,
wherein at least one of R1 through R10 comprises a reactive group capable of forming a
carbon-carbon linkage with a target, and
(iii) linking reagents suitable for link said first intermediate compound and said second
intermediate compound;
(b) forming a reaction mixture comprising said first intermediate compound (I), said
second intermediate compound (II), and said linking reagents under conditions to link
(I) and (II) to form a compound of formula III as set forth in the specification
wherein at least one of R1 through R10 comprises a reactive group capable forming a
carbon-carbon linkage with a target, wherein said reactive group comprises an alkene
group, an alkyne group or a metallo-organic compound, and wherein n is an infeger of
1,2 or 3, and wherein X1 and X2 independently comprises carbon, oxygen, nitrogen or
sulfur.
[57]
__________________
[11][21]
[54]
LABELING REAGENTS
[22]
02.03.2003
286
195436
"
[31]
[51]
[62]
[71]
[74]
[57]
[33] US
[32] 12.03.2002
10/096075
Int. Cl.(2010.01) C07D 31/1/26
,
#
#
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
A labeling reagent comprising an aphemylic analog of a rhodamine dye, said analog
comprising at least one reactive group for attaching said labeling reagent to a target,
said at least one reactive group being attached directly to sid analog or indirectiy
through a linker arm.
__________________
[11][21]
195437
[54]
LABELING REAGENTS AND
LABELED TARGETS
[22]
[31]
[51]
[62]
[71]
[74]
02.03.2003
[32] 12.03.2002
[33] US
10/096075
Int. Cl.(2010.01) C07D 48/7/22
,
#
#
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
A labeling reagent comprising a nometallic porphyrin, said reagent comprising a
compound of formula I as set forth in the specification
wherein R0 is a reactive group and is attached directly or indirectly to any one of the
four non-pyrrole positions of said nonmetallic porphyrin, and R1 through R8
independently comprise hydrogen, aliphatic, unsaturated aliphatic, cyclic, beterocyclic,
aromatic, heteroaromatic, charged or polar groups, or any combinations of the
foregoing, wherein said reactive group R0 comprises sulfhydryl, hydroxyl, amine,
isothiocyanate, isocyanate, monochlorotriazine, dichlorotriazine, mono- or di-halogen
substituted pyridine, mono- or di-halogen substituted diazine, maleimide, aziridine,
sulfonylhalide, acid halide, hydroxysuccinimide ester,
hydroxysulfosuccinimide ester, imidoester, hydrazine, azidonitrophenyl, azide, 3-(2pyridyldithio)-propionamide, glyoxal, an alkene group, an alkyne group or a
halogenated compound.
[57]
287
"
__________________
[11][21]
195440
[54]
FLUORESCENT DYE
COMPOSITION AND TARGET
LABELED THEREWITH
[22]
[31]
[51]
[62]
[71]
[74]
02.03.2003
[32] 12.03.2002
[33] US
10/096075
Int. Cl.(2010.01) C09B 62//00, C12Q 01//68, G01N 33//00
,
#
#
,
P.O.B. 5352,
5352 . . ,
BEER-SHEVA 84152
A dye composition of the formula
R-Fluorescent Dye
wherein R comprises a reactive group covalently linked to said Fluorescent Dye
wherein said Fluorescent Dye comprises a combination of two or more members
selected from:
(a) unsaturated aliphatic groups comprising an alkene or alkyne;
(b) unsaturated heterocyclic goups;
(c) aromatic groups;
(d) and wherein R provides a conjugated system or an electron delocalized
system with said Fluorescent Dye and said composition optionally comprises
a charged or polar R' group and wherein said composition further comprises a
reactive group Rx attached to either said fluorescent dye, said R group or said
polar R' group, wherein sid reactive group Rx comprises sulfhydryl, hydroxyl,
amine, isothiocyanate, isocyanate, monochlorotriazine, dichlorotriazine,
mono- or di-halogen substituted pyridine, mono- or di-hlogen substituted
diazine, maleimide, aziridine, sulfonylhalide, acid halide,
hydroxysuccinimide ester, hydroxysulosuccinimide ester, imidoester,
hydrazine, azidonitrophenyl, azide, 3-(2-pyridyl dithio)-proprionamide,
glyoxal or aldehyde.
[57]
__________________
[11][21]
[54]
288
195538
DYNAMIC BANDWIDTH
"
ALLOCATION FOR MULTIPLE
ACCESS COMMUNICATION
USING SESSION QUEUES
[22]
[31]
[51]
[62]
[71]
[87]
[74]
[57]
17.01.2002
[32] 31.01.2001
[33] US
09/773252
Int. Cl.(2009.01) H04J 03/16, 13/00, H04W 72/04
TANTIVY COMMUNICATIONS,
INC., U.S.A.
WO/2002/061993
26A HABARZEL ST.,
,
' 26 $
A code division multiple acess (CDMA) user device comprising:
a transceiver configured to receive data traffic from at least one data buffer over a data
traffic channel and to receive control data indicative of a data rate associated with the
data traffic channel over a control channel wherein the transceiver is dynamically
assigned additional data traffic channels for receiving data traffic based on an urgency
factor indicative of the urgency of the data traffic; and wherein the urgency factor is
used to determine channel allocation based on a data type of the data traffic.
,207057,205827
(
.
__________________
[11][21]
[54]
MOISTURE BARRIER SEALING
OF FIBER OPTIC COILS
[22]
15.08.2003
289
195688
"
[31]
[51]
[62]
[71]
[87]
[74]
[57]
[33]
[32] 15.08.2002
10/219412
Int. Cl.(2010.01) B21J 05//06
NORTHROP GRUMMAN
CORPORATION, U.S.A.
WO/2004/066009
HENRY SINAI,
IP-PARTNERSHIP
P.O.B 669
RAANANA 43350
US
,
4
669 . . ,
A system for applying a moisture barrier seal to a fiber optic coil, comprising:
mounting means for mounting a fiber optic coil in a vacuum deposition chamber, so as
to expose a large exterior surface area of the fiber optic coil to an interior portion of
the deposition chamber; means for reducing air pressure within the chamber to a value
less than ambient pressure outside of the chamber; and means for introducing a vapor
form of a non-porous material into the chamber wherein the vapor form of the nonporous material changes into a solid state upon contact with the fiber optic coil, so as
to form a conformal coat on the fiber optic coil.
166806
The parent application from which
this application has been divided has
(
__________________
[11][21]
[54]
GENES ENCODING FLAVONE
SYNTHASE PROTEINS
[22]
[31]
28.01.2000
11-22427
290
[32]
29.01.1999
195808
[33]
JP
"
[51]
[62]
[71]
[87]
[74]
[57]
19.07.1999
11-205229
JP
Int. Cl.(2009.01) A01H 05/00, C12N 09/02, 15/53, 15/82
SUNTORY LIQUORS LIMITED,
JAPAN
WO/2000/044907
P.O.B. 1352,
JERUSALEM 91013
,
,%
1352 . . ,
A DNA encoding an enzyme capable of converting flavanone directly into flavone
which is obtained from, for example, antirrhinum and torenia, and utilization thereof.
The amino acid sequences of this DNA and the enzyme encoded thereby are
represented by, for example, SEQ ID NOS: 1, 2, 3 and 4. Transfer of this gene into a
plant makes it possible to, for example, change the flower color of the plant.
__________________
[11][21]
197482
,
[54]
VALIDATING DETECTED
RATES OF RECEIVED VARIABLE
RATE SPEECH FRAMES
[22]
[31]
[51]
[62]
[71]
29.11.2001
[32] 04.12.2000
[33] US
09/730147
Int. Cl.(2009.01) H04B 01/707, 07/26, H04L 01/00, 01/08, 29/08
U.S.A.
WO/2002/047316
,'
P.O.B. 2273,
REHOVOT 76122
[87]
[74]
[57]
291
.
,4
2273 . . ,
A method for detecting rate errors in a variable rate receiver, comprising:
receiving an encoded speech signal;
performing a rate determination algorithm on the speech signal to provide a rate for a
current frame;
providing a set of illegal rate transitions which are based upon knowledge of speech
classification and phonetic character of conversational speech; and detecting errors in
the provided rate by determining whether a rate transition from a rate for a previous
frame to the rate for the current frame is within the set of illegal rate transitions.
"
__________________
[11][21]
[54]
[22]
[31]
[51]
[62]
[71]
[87]
[74]
[57]
292
197704
SYSTEM FOR EFFICIENT
RECOVERY OF NODE B
BUFFERED DATA FOLLOWING
SERVING HIGH SPEED
DOWNLINK SHARED CHANNEL
CELL CHANGE
HS–DSCH–
02.04.2003
[32] 05.04.2002
[33] US
60/370740
10/334489
30.12.2002
US
Int. Cl.(2009.01) H04B 01/69, 07/26, H04L 12/56
CORPORATION, U.S.A.
WO/2003/087978
26A HABARZEL ST.,
,
' 26 $
A user equipment (UE) comprising:
a reordering buffer of a medium access control (MAC-hs) circuity, wherein the
reordering buffer is flushed in response to receiving a radio resource control RRC)
requested message associated with a high speed-downlink shared channel (HS-DSCH)
cell change; and
at least one acknowledge mode (AM) radio link control (RLC) instance mapped to the
HS-DSCH which generates a status report, the status report indicating HS-DSCH
packet data units (PDUs) missed by the (UE) in response to the reordering buffer
having been flushed.
"
,205946
(
.
__________________
[11][21]
[54]
199377
EXPANDABLE DEVICES FOR
DISPLACING THE
SCHNEIDERIAN MEMBRANE
[22] 09.05.2001
[31] 09/567471
[32] 09.05.2000
[51] Int. Cl.(2010.01) A61C 08//00
[62] DIVISION FROM 152732
[71] BEN ZION KARMON
[72] BEN-ZION KARMON
[87] WO/2001/085062
5728 - 1968
[33]
US
,
35
#
#5
(
1968 – "
,
__________________
[11][21]
[54]
SELF-OBSERVATION SYSTEM
AND METHOD
[22]
[51]
[71]
23.12.2009
Int. Cl.(2010.01) G02B 27//02
ELI ZAKEN
KFIR SASSON
ELI ZAKEN,
109/3 HARISHONIM STREET
MEVASERET ZION 90805
[74]
[57]
293
202910
#
, $
#-
,
, $
109/3
#
A self-observation system (10), comprising:
"
a semi-transparent mirror (44) disposed in front of a user (48);
a display device (46) disposed behind said semi-transparent mirror;
at least one video camera (12), for providing a video of the body of said user to said
display device; and
a user interface (58) for turning said display device to ON, for transmitting said video
from said display device through transparency of said said semi-transparent mirror to
the eyes of said user, and
for turning said display device off, thereby reflecting the body of said user through
reflectance of said semi-transparent mirror to said user's eyes,
thereby providing selection of the viewed picture through said semi-transparent
mirror.
35
5
1968 – "
(
,
__________________
294
"
PATENTS
PATENTS GRANTED
131481
148880
161179
161794
162508
163367
164307
165178
166154
190634
156678
157884
159258
159913
160711
144361
152112
153700
173469
174725
179989
167872
170206
171953
132533
149698
161185
162041
162782
163492
164322
165292
166169
192393
156715
158179
159362
159998
160914
144755
152231
154150
173668
174905
180016
167893
170263
172079
146491
150124
161318
162058
162884
163867
164801
165382
166285
138665
156720
158514
159485
160015
160953
145615
152268
154266
173708
175558
136055
168261
170872
172432
146703
150295
161347
162126
162920
163873
164966
165469
166353
142155
156820
158646
159507
160038
181042
151441
152302
154271
174017
176456
136684
168381
170898
172608
147536
150622
161360
162132
163011
164073
165073
165500
166358
156250
156994
158763
159525
160084
183364
151585
152605
154933
174058
176516
166781
169094
170948
172784
148317
150692
161498
162205
163042
164246
165117
165559
166528
156438
157380
158827
159619
160286
185118
151807
152615
155124
174559
177018
166929
169583
171132
172841
148679
161107
161636
162286
163237
164275
165119
165695
166563
156553
157757
158854
159827
160335
143767
151940
152732
155315
174662
177241
167019
169673
171431
173038
148836
161124
161702
162424
163243
164296
165167
165766
166743
156641
157880
158912
159834
160695
143832
152054
153078
173388
174686
177908
167824
170197
171703
102289
102398
102460
102531
102609
102758
118682
118797
118860
118919
102297
102399
102464
102567
102643
102915
118709
118801
118872
118931
PATENTS RENEWED
100385
102310
102407
102465
102579
102659
106199
118747
118805
118876
295
100696
102354
102413
102468
102585
102665
116847
118753
118825
118883
101850
102379
102417
102486
102590
102673
117388
118777
118836
118890
102189
102382
102451
102491
102593
102687
117389
118778
118837
118898
102200
102394
102456
102519
102594
102695
118403
118791
118844
118914
102215
102395
102457
102525
102599
102712
118546
118792
118857
118917
"
118955
120558
122325
122584
122705
122853
122940
123189
127776
137099
137292
137507
137762
141636
141935
143768
146386
146851
147015
147181
147254
147347
147413
147494
147533
147625
147682
147744
147810
147931
149261
151225
152686
153528
153725
154574
156858
158161
161034
162450
162799
162980
163288
164709
166687
166875
168041
296
118959
122118
122402
122594
122733
122870
122942
123278
134966
137123
137296
137521
138659
141643
142025
143889
146450
146889
147027
147194
147261
147355
147418
147495
147537
147628
147699
147755
147826
147962
149325
151671
152955
153620
153727
155476
157176
158162
161045
162511
162830
163010
163373
165314
166720
166890
168175
118966
122120
122405
122606
122747
122880
122960
123333
136702
137133
137316
137522
139824
141743
142070
143952
146636
146903
147052
147195
147267
147371
147425
147499
147563
147632
147704
147756
147830
148058
149616
151772
153430
153625
153728
155568
157269
159017
161611
162512
162882
163015
163950
165380
166721
166897
168177
118968
122161
122408
122607
122754
122889
122991
123616
136725
137139
137342
137586
141194
141752
142319
144182
146746
146916
147069
147198
147268
147387
147440
147511
147577
147639
147705
147759
147840
148305
149804
151858
153432
153664
153801
155656
157588
159815
161643
162522
162905
163104
164093
165895
166722
167269
168186
118973
122162
122434
122617
122755
122894
122992
123617
136849
137151
137364
137594
141461
141761
142408
144323
146783
146928
147089
147214
147282
147388
147445
147513
147582
147655
147706
147761
147855
148406
150768
152239
153433
153714
153804
155801
157591
160015
161657
162575
162916
163135
164199
166283
166724
167337
168187
118974
122243
122437
122618
122756
122905
123077
123822
136915
137224
137381
137615
141585
141787
142409
145145
146791
146931
147119
147215
147293
147401
147461
147514
147604
147663
147724
147785
147876
148470
150873
152372
153434
153722
154078
156556
157592
160407
161994
162626
162935
163136
164323
166420
166725
167495
168472
118977
122290
122463
122665
122757
122907
123120
126433
137046
137268
137447
137676
141619
141932
143172
145676
146812
146938
147142
147227
147302
147403
147467
147522
147616
147669
147732
147801
147894
148700
150972
152576
153526
153723
154538
156579
157651
160643
162092
162676
162969
163209
164363
166421
166769
167673
169252
118986
122312
122517
122704
122837
122910
123131
126993
137078
137269
137455
137728
141620
141934
143481
145795
146848
146955
147163
147242
147346
147409
147482
147527
147620
147675
147736
147809
147916
149169
151141
152604
153527
153724
154560
156764
157902
160951
162152
162718
162970
163287
164592
166422
166781
167968
169328
"
169351
171613
173018
179576
169478
171664
173158
179865
169515
171883
173202
186993
169585
171947
173304
187551
169612
171953
175454
187652
170387
172597
175538
170424
172839
177348
171598
172929
177349
PATENTS NOT IN FORCE DUE TO NON-PAYMENT OF RENEWAL
FEES
138888
142337
115895
115971
116019
116105
116268
153805
139796
143276
115896
115981
116020
116108
116275
153852
140934
167357
115902
115988
116034
116110
116277
154637
159105
168109
115915
115990
116035
116123
116305
155355
159276
115875
115920
115991
116073
116167
116531
161924
159905
115879
115930
115992
116092
116215
151933
164963
160757
115890
115951
115994
116099
116218
152880
165668
160801
115892
115967
116011
116100
116236
152987
165960
PATENTS RENEWED FOR 20 YEARS
126626
161337
#
EXTENSION ORDERS RENEWED
79336
297
84863
88363
"
NOTICE
Under section 60 of the
Patent Law, 5727-1967
Application has been filed
for the restoration of the
patent recorded below,
which has lapsed through
non-payment of the
prescribed renewal fees:
No. of Patent
Acceptance published in
journal no:
Proprietors:
60 %
,
1967-$"
$
,
:
118049
11/2000
'
:'
:
DOMETIC GMBH
Title of invention:
: !" !
METHOD FOR OPERATING AN ABSORPTION REFRIGERATION UNIT AS WELL
AS AN ABSORPTION REFRIGERATION UNIT
Any person may oppose the
said application within three
months from the date of this
Patents Journal, as
, $
prescribed by section 61 of
92
61 %
the law and by regulation 92
- "
,
of the Patent Regulations,
1968
5728-1968
298
"
NOTICE
non-payment of the
No. of Patent
journal no:
Proprietors:
1967-$"
$
60 %
,
,
:
128361
12/2000
'
:'
:
DROR BACHAR
: !" !
8
RAG CLAMPING DEVICE FOR FLOOR-WASHING WIPERS
Patents Journal, as
, $
92
61 %
"
,
1968
5728-1968
Title of invention:
299
"
NOTICE
non-payment of the
No. of Patent
journal no:
Proprietors:
1967-$"
$
60 %
,
,
:
137579
10/2006
'
:'
:
"
ORBOTECH MEDICAL SOLUTIONS LTD.
: !" !
(4
GAMMA-RAY DETECTOR FOR COINCIDENCE DETECTION
Patents Journal, as
, $
92
61 %
"
,
1968
5728-1968
Title of invention:
300
"
NOTICE
non-payment of the
No. of Patent
journal no:
Proprietors:
1967-$"
$
60 %
,
,
:
177522
2/2008
'
:'
:
"
YAD KONENA LTD.
: !" !
8
8
SYSTEM AND METHOD FOR POWER GENERATION BY HYDROTHERMAL
MEANS
Patents Journal, as
, $
92
61 %
"
,
1968
5728-1968
Title of invention:
301
"
NOTICE
Under section 66 of the Patents
Law, 5727-1967
This is to notify that permission
has been granted to the owner of
Patent Application No.
Acceptance published in journal
To amend the specification of the
said Patent Application.
Any person may oppose such
grant of permission within three
Patents Journal, as prescribed by
section 67 of the Law and by
regulation 99 of the Patent
Regulations, 5728-1968.
302
,
66 %
1967-$"
$
141912
'
9/2006
, $
- "
67 %
,
99
.1968
"
NOTICE
Law, 5727-1967
303
,
66 %
1967-$"
$
157584
'
4/2008
, $
- "
67 %
,
99
.1968
"
NOTICE
Law, 5727-1967
304
,
66 %
1967-$"
$
161707
'
8/2008
, $
- "
67 %
,
99
.1968
"
NOTICE
Law, 5727-1967
305
,
66 %
1967-$"
$
169243
'
8/2008
, $
- "
67 %
,
99
.1968
"
CHANGES IN PARTICULARS ENTERED IN REGISTER
306
"
Gournal Corrections
Patent application No
173309
No. of Patent:
112009
DELETE PRIORITY NUMBER
US 15.7.2004 10/891953
307
'
:
5
US 15.07.2004 10/891953
"
DESIGNS
DESIGNS REGISTERED
Class
47227 ,47226 ,47225
25(02)
08.02.2009
RESHAFIM SECURITY DOORS
Door
Class
46890
13(03)
27.11.2008
$
DAVID ZILBERBERG
Socket's cover
Class
45812
24(03)
09.04.2008
"
A.B. DENTAL DEVICES LTD.
. .
Dental implant
Class
46298
25(01)
23.07.2008
MOSHE SELES
Profile
308
"
Class
46405
9(01)
05.08.2008
NOMS DE CODE
Flask
Convention date (OHIM)
07.02.2008
Class
(
)
46821
9(03)
05.11.2008
LABORATOIRES LA PRAIRIE SA
Container
Class
46839
9(03)
12.11.2008
LABORATOIRES LA PRAIRIE SA
$
Container
Class
46851
24(04)
18.11.2008
.OTSUKA PHARMACEUTICAL CO.LTD
Inhaler
23.05.2008
Convention date (JAPAN)
(
Class
KETER PLASTIC LTD.
%
)
46860
6(04)
20.11.2008
"
Storage cabinet
309
"
Class
46930
23(02)
07.12.2008
ARMAND SERFATY
Dispenser for wet and dry paper
Convention date (U.S.A.)
Class
(
06.06.2008
#
)
46934
24(02)
07.12.2008
SULZER MIXPAC AG
Coupling
Class
(
12.06.2008
47042
6(04)
29.12.2008
"
KETER PLASTIC LTD.
Storage cabinet
Class
)
(
04.12.2008
)
47047
7(01)
31.12.2008
.STRAUSS
COFFEE B.V
Cup
Class
310
47182 ,47181
25(01)
"
02.02.2009
DOMA MARKETING FOR
BUILDING AND TRADE (1996)
LTD.
"
(1996)
Building unit
311
"
Class
47223
12(02)
08.02.2009
Class
47424
3(01)
15.03.2009
DAVID SHISH
RAFI GEVA
Shopping cart
"
HADAR ROSEN LTD.
$
Bag
Class
47430 ,47429 ,47428
26(05)
15.03.2009
.LSI INDUSTRIES,
Lighting
Class
29.09.2008
INC
(
#
)
47619
19(02)
30.04.2009
. .
"
C.I.Q LTD.
EHUD AMIR
#
Connector for office equipment
Class
47664
28(03)
13.05.2009
YA'ACOV MOSHEH
312
"
Massage appliance
313
"
Class
47499
8(08)
05.04.2009
"
AMISHAY MARKETING
COMPANY (1980) LTD.
(1980)
Door apparatus
Class
47850 ,47849
6(01)
15.06.2009
KEREN SHTEIMBERG
Seating system
Class
48876
25(01)
17.01.2010
Class
47808
11(01)
03.06.2009
ARNON BARAK
Profile
GERALDO LTD.
"
'
"
'
Ring
Class
47809
11(01)
03.06.2009
GERALDO LTD.
Gemstone sphere
314
"
Class
47946
9(01)
07.07.2009
BEAUTE PRESTIGE INTERNATIONAL
Bottle
Class
(
07.01.2009
)
48061
3(02)
27.07.2009
BENELLI ARMI S.P.A
#
A case for a shotgun
Class
48125
6(01)
05.08.2009
"
KETER PLASTIC LTD.
Furniture set
Class
.H.
16.02.2009
(
)
48140
11(01)
06.08.2009
STERN COMERCIO E INDUSTRIA S.A
Jewel
Class
48182
7(06)
16.08.2009
ISRAEL HAY GURMAN
315
"
$
Napkins packaging
316
"
Class
48246
19(08)
30.08.2009
Class
48299
11(01)
09.09.2009
HENIAL PELED
Label
AYELET FEINBERG
Ornament
48323
23(01)
15.09.2009
Class
ADITAL ELA
ODED DAVIDOVITCH
/
Dew and rain collector
48326
24(03)
14.09.2009
Class
"
A.B. DENTAL DEVICES LTD.
. .
Implant
Class
48364
23(02)
01.10.2009
EFRAIM ECKHAUS
Sink
317
08.04.2009
(
#
)
"
Class
.H.
48384 ,48383 ,48382
48386 ,48385
11(01)
11.10.2009
Jewel
Class
48414
23(02)
13.10.2009
"
KETER PLASTIC LTD.
Bath device
Class
48419 ,48418
24(02)
14.10.2009
$
MORIS TOPAZ
#
Wound closure devices
Class
.H.
48471 ,48469 ,48467
11(01)
25.10.2009
Jewel
Class
48487
20(03)
01.11.2009
LARS HAMMAR
Sign support
318
04.05.2009
(
)
"
Class
48515
14(01)
11.11.2009
"
MOREL ACOUSTIC LTD.
Loudspeaker
Class
48554
11(01)
17.11.2009
"
ROTHEM COLLECTION LTD.
Gemstone
Class
48561
28(03)
22.11.2009
$
EYA SIEGELSTEIN
ALBERT PULATOV
$
Ear protector
Class
48858
21(01)
13.01.2010
YAIR VIENER
TZAFRIR MILLER
#
Casual game
Class
SUNWAY SUN PROTECTIVE
SWIMWEAR LTD.
319
48887
27(02)
19.01.2010
"
"
Swimsuit
320
"
48888
2(03)
19.01.2010
Class
"
SUNWAY SUN PROTECTIVE
SWIMWEAR LTD.
Hat
48217
25(01)
20.08.2009
Class
"
KLIL INDUSTRIES LTD.
Profile
48308 ,48307 ,48306
48309
11(01)
13.09.2009
Class
.H.
Jewel
48519
2(07)
12.11.2009
Class
"
RETRO J. AMRANI LTD.
.
Belt
Class
47813
23(01)
04.06.2009
VICTAULIC COMPANY
#
Flexible pipe coupling
321
"
322
04.12.2008
(
#
)
"
Class
IDEAS MANUFACTURING &
IMPORT OF PAPER PRODUCTS
LTD.
47701
6(01)
21.05.2009
"
#
#
Chair
323
"
DESIGNS RENEWED
33542
33788
40866
41032
41289
324
33543
33884
40906
41033
41340
33544
33932
40953
41034
41365
33546
33934
40954
41098
33687
33936
40956
41277
33693
33937
40991
41281
33698
34046
40992
41283
33784
40791
41031
41285
"
DESIGNS VOID
24561
24589
32695
325
24562
24590
32696
24565
24616
39863
24566
24634
24568
24662
24573
32579
24582
32613
24588
32621
"
$
WITHDRAWN DESIGNS
44795
46857
46916
46992
47011
45212
46859
46919
46994
47012
Dr. Meir Noam
Commissioner of Patents,
Designs and Trade Marks
326
45695
46879
46921
46995
47013
45696
46889
46937
47004
47071
45697
46896
46938
47006
47823
46280
46897
46944
47008
47939
46844
46898
46986
47009
48493
,
46855
46913
46990
47010
48626
"
"
INDICES OF APPLICATIONS ACCEPTED
NAME INDEX
183147 163263 - "
157786 - "
202910 169190 - "
- "
155783
160988 - "
157419 182290 - "
169884 - "
182840 - "
150151 - "
$
183147 172034 - "
. . .
.
172034 - " . . . .
152630 - "
202910 - $
171027 - "
168149 - "
150151 - "
172078 - "
147102 174280 - ''
162012
161926 199377 -
157419 160939 -
/
-
"
171040 -
154421 , 152128 - "
176102 - "
- "
'
170271
'$ -
179100
177035
327
'
173906 - "
'
"
155783 - "
- "
- "
#
172308 - /
189470 .
150518 - %
160988 - "
131245 - "
199377 - "
166978 #
"
-
$
#
182549 - "
#
158003 - "
"
174320
A.D. INTEGRITY APPLICATIONS, LTD.
- 173695
ABBOTT GMBH & CO. KG - 145134
ADCOCK INGRAM LIMITED - 163637
ADI SHFARAM - 150151
AGAM ENERGY SYSTEMS LTD. 163263
AGENCE SPATIALE EUROPEENNE
(ESA) - 173417
AHAVA- DEAD SEA LABORATORIES
LTD. - 157786
AIR PRODUCTS AND CHEMICALS,
INC. - 181227
AIRBUS ESPANA, S.L. - 172470
AIRSEC S.A.S. - 187278
ALBEMARLE CORPORATION - 173166
ALBIREO AB - 170913
ALCON, INC. - 178825
ALZA CORPORATION - 154838
AMINACH BEDDING & FURNITURE
MANUFACTURING LTD. - 162012
AMRAM OHAYON - 157419
ARIE SANSOLO - 147102
ARIEL-UNIVERSITY RESEARCH AND
DEVELOPMENT COMPANY LTD 172078
ARPAL ALUMINUM LTD. - 174280
ASK S.A. - 170974
ASTRAZENECA AB - 170913
ATLAS COPCO ROCK DRILLS AB 171671
AUGUSTO LARRAIN ORREGO - 168851
AUTOMATIC RECOGNITION &
CONTROL INC. - 181671
AVENTIS PHARMACEUTICALS INC. 145526
AVENTIS PHARMACEUTICALS INC. 157341
AZIENDE CHIMICHE RIUNITE
ANGELINI FRANCESCO A.C.R.A.F.
S.p.A. - 162272
BASF SE - 165879
BAXTER INTERNATIONAL INC. 328
177514
BAYER
BETEILIGUNGSVERWALTUNG
GOSLAR GMBH - 168350
BAYER SCHERING PHARMA AG 174194
AKTIENGESELLSCHAFT - 148417
AKTIENGESELLSCHAFT - 179856
BEN ZION KARMON - 199377
BIMEDA RESEARCH &
DEVELOPMENT LIMITED - 177063
BIOFORM MEDICAL, INC. - 161545
BIO-KEY INTERNATIONAL, INC. 162003
BIOSENSE WEBSTER INC. - 153438
BIOSENSE WEBSTER, INC. - 165105
BK GIULINI GMBH - 171255
GMBH & CO. KG - 163698 , 187278
BORIS GLINER - 161926
BRIAN H. RUTLEDGE - 177835
BRISTOL-MYERS SQUIBB COMPANY 171356
BURKHARD LUCKMANN - 179247
C.D.C. S.R.L. - 164731
C2CURE INC. - 152128
C2CURE INC. - 152128
CALIFORNIA PACIFIC MEDICAL
CENTER - 157669
CAPAN, RAHMI, OGUZ - 194204
CAPER NAUM VISTA OLIVE OIL
MARKET LTD - 174320
CARDIOSENSE LTD. - 131245
CAREFUSION 303, INC. - 152717
CATHOLIC HEALTHCARE WEST 157669
CELLCOM ISRAEL LIMITED - 182840
CENTELION - 152860
CERNIUM CORPORATION - 151004
CHAI-TECH CORPORATION - 103992
CHRISTOS C. ZOUBOULIS - 158559
"
CHUGAI SEIYAKU KABUSHIKI
KAISHA - 174909
CIBA SPECIALTY CHEMICALS
HOLDING INC. - 160909
COLEY PHARMACEUTICAL GMBH 160157
COLEY PHARMACEUTICAL GROUP,
INC. - 160157
COMBINED RESOURCE ENGINEERING
PTY LTD. - 166496
CONLY L. HANSEN - 170191
CORCEPT THERAPEUTICS, INC. 157770
CORNELL RESEARCH FOUNDATION,
INC. - 158969
CORNELL RESEARCH FOUNDATION,
INC. - 180244
COSMEDICAL APS - 174545
CSL BEHRING GMBH - 152332
CURETECH LTD. - 160988
CURLIN MEDICAL INC. - 183145
CUTANIX CORPORATION - 161545
DAN YOSEF - 150518
DAVID A. GLUCK - 189470
DAVID PERETZ - 172308
DEERE & COMPANY - 173718
DELAVAU L.L.C. - 173443
DENTSU INC. - 162670
DEVTEK PTY LTD. - 166496
DOMPE S.P.A. - 161447
DORMINA UK LIMITED - 169890
DSM IP ASSETS B.V. - 176414
E.M.A.T TECHNOLOGIES LTD - 172034
E.M.A.T. LTD, - 172034
EASYNET ACCESS INC. - 125432
EDWARD D. WATTS - 170191
EFIM LAPATIN - 183147
EISAI R&D MANAGEMENT CO., LTD. 182524
ELAN PHARMA INTERNATIONAL
LTD. - 136252
ELECTRONIC NAVIGATION
RESEARCH INSTITUTE - 161562
ELEMENT SIX LIMITED - 176207
ELI LILLY AND COMPANY - 177829 ,
329
193631
ELI ZAKEN - 202910
ELMEDICAL LTD. - 171027
ELTA SYSTEMS LTD. - 168149
ENSCHEDE/SDU B.V. - 165832
ENZO LIFE SCIENCES, INC. - 154700 ,
195435 , 195436 , 195437 , 195440
EVONIK ROHM GMBH - 161145
F. HOFFMANN-LA ROCHE AG - 158589
, 166038 , 168266 , 169600
FABIO PERINI S.P.A. - 168816
FAES FARMA ,S.A. - 164645
FANGLU LOU - 171802
FIBROGEN, INC. - 149459
FIRMENICH SA - 167832 , 182795
FLAMEL TECHNOLOGIES - 160795
FRAUNHOFER-GESELLSCHAFT ZUR
FORDERUNG DER ANGEWANDTEN
FORSCHUNG E.V. - 174318 , 177163
FRIEDRICH-ALEXANDERUNIVERSITAT ERLANGENNURNBERG - 184284
GEFA S.R.L. - 164731
GEMOLOGICAL INSTITUTE OF
AMERICA, INC. - 176354
GENENTECH, INC. - 138585 , 171733
GENERAL ELECTRIC COMPANY 159065
GENETICS INSTITUTE, LLC. - 145134
GERON CORPORATION - 159578
GIVEN IMAGING LTD. - 152128 , 154421
GLAXO GROUP LIMITED - 161114
GOOD BIOTECH CORPORATION 150194
GREEN VISION SYSTEMS LTD. 176102
GUNTER REIMANN - 179247
H.C. STARCK INC. - 162966
H.C. STARCK GMBH - 168350
H.E.F. - 175505
HAWK MEDICAL TECHNOLOGIES
LTD - 173906
HEALTHSTATS INTERNATIONAL PTE
LTD. - 155300
"
HONEYWELL INTERNATIONAL INC. 165600 , 173055
IBM CORPORATION - 173731
IDALEX TECHNOLOGIES, INC. 177077
IMMUNEX CORPORATION - 146482
IMMUNOMEDICS, INC. - 163851
INCA DIGITAL PRINTERS LIMITED 176232
INDENA S.P.A. - 172973 , 188706
INNOVENTIONS LTD. - 152630
CORPORATION - 168896 , 172753 ,
189071 , 197704
INVENTIO AG - 180964
IPR LICENSING, INC. - 168053
ISOTECHNIKA INC. - 160762
ISRAEL AEROSPACE INDUSTRIES
LTD. - 179100
ISTITUTO SUPERIORE DI SANITA 162680
ITT MANUFACTURING ENTERPRISES,
INC. - 169589
JACKEL INTERNATIONAL LIMITED 154846
JANE, S.A. - 176476
JANSSEN PHARMACEUTICA N.V. 166795
JANSSEN PHARMACEUTICA, N.V. 173372 , 188457
JAPAN TOBACCO INC. - 164569
JENAPHARM GMBH & CO.KG - 148417
JENS BIRGER NILSSON - 166681
JHRG, LLC - 173055
JOHN ANTHONY DOWNES - 178421
JOHNS HOPKINS SCHOOL OF
MEDICINE - 140621
JOSEPH J. MAZZILLI - 167079
JURGEN HEINEMEIER - 179247
KAKUICHI SHIOMI - 161562
KENT STATE UNIVERSITY - 158165
KFIR SASSON - 202910
KIA SILVERBROOK - 146625
KISSEI PHARMACEUTICAL CO., LTD. 330
167038 , 167168
KLAMATH FALLS, INC. - 182570
KONINKLIJKE PHILIPS ELECTRONICS
N.V. - 167306
L-3 COMMUNICATIONS SECURITY &
DETECTION SYSTEMS - 162409
LG ELECTRONICS INC. - 174613
LIGHTWAVES SYSTEMS, INC. - 164572
LONZA AG - 174453
LUCA TONCELLI - 172945
LUTRON ELECTRONICS CO. INC. 180225
MALLINCKRODT BAKER, INC. 173664
MARUISHI PHARMACEUTICAL CO.,
LTD. - 168477
McKESSON AUTOMATION, INC. 152717
MEDIGUIDE LTD. - 169190
MEGADYNE MEDICAL PRODUCTS,
INC. - 161926
MERCK PATENT GESELLSCHAFT MIT
BESCHRANKTER HAFTUNG - 165879
MERCK SERONO S.A. - 163413 , 183924
MERCKLE GMBH - 160047
MICHEL COHEN - 157419
MICHIKO TAKAOKA - 161562
MICROSOFT CORPORATION - 168620 ,
169885
MIM - MINIMALLY INVASIVE
MASTOPEXY LTD. - 150151
MITSUBISHI SPACE SOFTWARE CO.,
LTD. - 161562
MOR RESEARCH APPLICATIONS LTD.
- 160988
NAGRAVISION S.A. - 171933 , 171934
NERVIANO MEDICAL SCIENCES S.R.L.
- 164356
NESTEC S.A. - 174583
NEURALAB LIMITED - 136252
NEWRON PHARMACEUTICALS S.P.A. 175754
NEXMED HOLDINGS, INC. - 169425
NICOX S.A. - 172703
"
NOKIA CORPORATION - 170283
NORTHROP GRUMMAN
CORPORATION - 173327 , 173331
NORTHROP GRUMMAN
CORPORATION - 195688
NOVARTIS AG - 149147 , 154465 ,
167426 , 170518 , 174145
NULENS LTD. - 182290
NYCOMED GMBH - 165065
OLGA LAPATIN - 183147
ORTHO-MCNEIL PHARMACEUTICAL,
INC. - 161830
ORTHOVITA, INC. - 173865
PETER E. RISING - 177835
PFIZER ITALIA S.R.L. - 164356
PFIZER PRODUCTS, INC. - 192371
PHARMACIA & UPJOHN COMPANY
LLC - 142207
PHILIP MORRIS PRODUCTS S.A. 172083
PLASAN -KIBBUTZ SASA - 160939
PLASAN SASA AGRICULTURAL
COOPERATIVE SOCIETY LTED. 171040
POLYMETERS RESPONSE
INTERNATIONAL LTD. - 166819
QUALCOMM INCORPORATED - 151016
, 161680 , 161883 , 163187 , 167378 ,
168512 , 168932 , 170145 , 170231 ,
172262 , 173154 , 173266 , 197482
RAFAEL - ARMAMENT
DEVELOPMENT AUTHORITY LTD 170271
RAPPAPORT FAMILY INSTITUTE FOR
RESEARCH IN THE MEDICAL
SCIENCES - 155783
RAYTHEON COMPANY - 166030 ,
169149 , 172996
REGENE EX LTD. - 199377
REGENERX BIOPHARMACEUTICALS,
331
INC. - 184284
RESPONSE GENETICS, INC. - 157694
RKW SE - 179247
RON YAACOV DAVIDSON - 166978
RUAG LAND SYSTEMS - 176392
SAGEM DEFENSE SECURITE - 173495
SAGIV AGUDAH SHITUFIT CHAKLAIT
BE'AM - 177035
SAMSUNG ELECTRONICS CO., LTD. 141800
SANOFI PASTEUR - 132669
SANOFI PASTEUR - 169689
SANOFI-AVENTIS - 161114 , 164400
GMBH - 152288
GMBH - 160555 , 160938 , 166438 ,
170313 , 170314 , 170316
SAVYON DIAGNOSTICS LTD. - 169884
SCHERING CORPORATION - 134068
SCIENTIFIC GAMES HOLDINGS
LIMITED - 156597
SCIENTIFIC GAMES INTERNATIONAL,
INC. - 156597
SEEREAL TECHNOLOGIES GMBH 168538
SEMINIS VEGETABLE SEEDS, INC. 116114
SHERWOOD SERVICES AG - 157152
SHOTSPOTTER, INC. - 169836
SILVERBROOK RESEARCH PTY. LTD.
- 149959
SKELSCAN, INC. - 177264
SNECMA - 164499
SOLARGENIX ENERGY LLC - 171542
SOLVAY PHARMACEUTICALS B.V. 147889
SPINE WAVE, INC. - 157768
SPRAYDOWN LIMITED - 178421
STATIC CONTROL COMPONENTS,
INC. - 181215
SUMITOMO CHEMICAL COMPANY,
LIMITED - 167829
SUMITOMO CHEMICAL COMPANY,
LIMITED. - 170056 , 175720
SUMITOMO ELECTRIC HARDMETAL
"
CORP. - 182723
SUNTORY FLOWERS LIMITED - 195808
SUNTORY LIMITED - 195808
SUNTORY LIQUORS LIMITED - 195808
SYNGENTA PARTICIPATIONS AG 151886
SYNTONIX PHARMACEUTICALS, INC
- 171779
TAEGUTEC INDIA LTD. - 182100
TAKEDA PHARMACEUTICAL
COMPANY LIMITED - 167835
TANTIVY COMMUNICATIONS, INC. 195538
TASER INTERNATIONAL, INC. - 169842
, 174777
TECHNION RESEARCH AND
DEVELOPMENT FOUNDATION LTD. 155783
TELECOM PRODUCTIONS INC. 156597
TELIK, INC. - 183107
TEVA PHARMACEUTICAL
INDUSTRIES LTD. - 182549
THE REGENTS OF THE UNIVERSITY
OF CALIFORNIA - 157159
THE RESEARCH FOUNDATION OF
THE STATE UNIVERSITY OF NEW
YORK - 142824
THE SCRIPPS RESEARCH INSTITUTE 169200
THE TRUSTEES OF THE UNIVERSITY
OF PENNSYLVANIA - 145526
TIMOTHY R. WILLIS - 157177
T-MOBILE DEUTSCHLAND GMBH -
165957
TREK 2000 INTERNATIONAL LTD. 172644
TRUSTEES OF BOSTON UNIVERSITY 164314
ULTRA PROIZVODNJA
ELEKTRONSKIH NAPRAV D.O.O. 164383
UNILEVER PLC - 169197
UNIVERSITY OF IOWA RESEARCH
FOUNDATION - 160157
UNIVERSITY OF ZURICH - 174145
URU TECHNOLOGY, INCORPORATED
- 172568
VERENIUM CORPORATION - 146937
VERNALIS (R&D) LIMITED - 163413
VIFOR (INTERNATIONAL) AG. - 166747
WASHINGTON UNIVERSITY - 193631
WEIR MINERALS NETHERLANDS B.V.
- 166496
WELCH ALLYN, INC. - 173279
YEDA RESEARCH AND
DEVELOPMENT CO. LTD. - 158003
ZIOPHARM ONCOLOGY, INC. - 188164
ZYMOGENETICS INC. - 145288
SUBJECT MATTER INDEX
A01D - 173718
A01H - 140621
332
A01M - 157419
A21D - 174583
"
A23L - 169197
A23N - 150518
A24D - 172083
A47D - 162012
A61B - 150151, 157768, 157786,
169190, 173279, 173695,
173865, 173906
A61B - 152128, 153438, 155300,
161562, 161926, 165105
A61C - 199377
A61F - 157177
A61F - 171027, 182290
A61J - 154846
A61K - 136252, 148417, 157770,
161114, 161145, 162680,
164356, 164400, 167835,
168851, 169425, 170518,
170913, 171356, 174545,
183924, 187278, 188706
A61K - 157341, 158559, 160795,
163637, 174909, 179856,
182549, 184284, 188164,
188457
A61L - 157152
A61M - 152630, 177063, 177514,
177829, 183145
A61N - 131245
A61N - 154838
B01J - 174453
B21J - 195688
B23B - 182723
B23C - 182100
B23P - 181227
B29C - 172945
B41J - 176232
B42F - 189470
B60N - 160939
B60R - 166978, 167079
B60V - 173055
B62B - 176476
B62D - 171040
B62D - 172078, 178421
B65D - 177835, 179247
B65H - 168816
B66B - 180964
B67D - 170191
333
C01F - 173443
C03C - 175505
C07C - 142824,
163698
C07C - 164569,
C07D - 149147,
167829,
172703,
182524,
195437
C07D - 157669,
161830,
165065,
170313,
173372,
C07F - 103992
C07H - 162272,
C07H - 164314,
C07K - 132669,
154465,
C07K - 150194,
163851,
169200,
C08B - 166747,
C08J - 172034
C08K - 160909,
C09J - 171255
C09K - 166681
C12J - 174320
C12N - 116114,
151886,
160988,
192371
C12N - 134068,
146482,
160157,
193631,
C12P - 167832
C12Q - 154700,
C12Q - 195440
C30B - 176207
C40B - 146937
160938, 161545,
175720,
166795,
168477,
172973,
195435,
182795
167426,
170056,
175754,
195436,
158589,
163413,
167168,
170314,
174194
160047,
164645,
169600,
170316,
167038
168266
145134, 147889,
160762
152332, 158969,
166038, 166438,
183107
169689
173166
138585, 149459,
152288, 159578,
171733, 174145,
142207, 145288,
152860, 155783,
161447, 171779,
195808
157694, 160555
D01F - 176414
D03D - 165600
"
E06B - 174280
E21B - 182570
E21D - 171671
G06T - 174318
G07C - 165832
G07F - 156597
G07F - 164383
G08B - 176102
G10L - 165957, 177163
G11B - 167306
G11C - 179416
F01C - 183147
F02C - 163263
F04B - 166496
F16K - 170271
F16L - 177035
F24J - 171542
F24J - 194204
F25B - 173495
F25D - 172308
F28C - 177077
F41H - 176392
F42C - 147102
G01L - 178825
G01N - 145526,
162409,
G01N - 177264
G01R - 166819
G01S - 166030,
G02B - 164499,
179100,
G02B - 181671,
G03F - 173664
G03G - 181215
G03H - 168538
G06F - 125432,
172644
G06F - 149959,
172996,
G06K - 146625
G06K - 162003,
G06Q - 169885
G06T - 169149
334
158003, 158165,
169884, 176354
169836
169589, 172470,
180244
202910
152717, 163187,
H01G - 162966, 169842
H01G - 168350
H01L - 159065, 165879
H01Q - 168053, 180225
H01R - 169890
H01T - 174777
H04B - 151016, 168149, 168896
H04B - 165573, 172753, 173266,
189071
H04J - 161680, 161883
H04L - 141800, 164572, 164731,
164827, 168932, 170145,
173417, 197482, 197704
H04L - 167378, 170283, 171933,
171934, 173731, 174613
H04N - 151004, 162670
H04N - 154421
H04W - 168512, 170231, 172262,
173154, 195538
H04W - 182840
H05B - 171802
H05H - 157159
168620, 172568,
173327, 173331
170974
"
COUNTRY CODES APPEARING IN THIS JOURNAL
Code
AR
AT
AU
BA
BE
BR
CA
CH
CN
CU
CZ
DE
DK
EC
EP
ES
FI
FR
GB
GE
GR
GT
HR
HU
IE
IL
IN
IT
JP
KR
LK
LU
LV
335
Country or Organization
Argentina
Austria
Australia
Herzegovina
Belgium
Brazil
Canada
Switzerland
China
Cuba
Czech Republic
Germany
Denmark
Ecuador
European Patent Office
Spain
Finland
France
United Kingdom
Georgia
Greece
Guatemala
Croatia
Hungary
Ireland
Israel
India
Italy
Japan
Republic of Korea
Sri Lanka
Luxembourg
Latvia
Code
MX
MY
NL
NO
NZ
PL
PT
RU
SE
SG
SI
SK
TH
TR
TW
UA
US
UY
UZ
WO
ZA
Country or Organization
Mexico
Malaysia
The Netherlands
Norway
New Zealand
Poland
Portugal
Russian Federation
Sweden
Singapore
Slovenia
Slovakia
Thailand
Turkey
Taiwan
Ukraine
United States of America
Uruguay
Uzbekistan
World Intellectual Property
Organization (W.I.P.O.)
South Africa
"
,
,
" #
,
EDITED BY THE PATENT OFFICE, MINISTRY OF JUSTICE, JERUSALEM
PRINTED BY THE GOVERNMENT PRINTER
336
"

יומן הפטנטים והמדגמים

Transcription

Similar documents

cpe power supplies - PCT International, Inc.

amateur-satellite service

Product Information

Poster SPLLift

class notes

books1-2 label.ai